var title_f19_28_19904="Takayasu arteritis";
var content_f19_28_19904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Takayasu arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Angiogram of a child with Takayasu arteritis showing massive bilateral carotid dilation, stenosis, and poststenotic dilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Behrman, RE. Nelson textbook of pediatrics, 16th ed, WB Saunders, Philadelphia 2000. Copyright &copy;2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19904=[""].join("\n");
var outline_f19_28_19904=null;
var title_f19_28_19905="Patient information: Retinopathy of prematurity (ROP) (The Basics)";
var content_f19_28_19905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Retinopathy of prematurity (ROP) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/retinopathy-of-prematurity-rop-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H108791168\">",
"      <span class=\"h1\">",
"       What is retinopathy of prematurity?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Retinopathy of prematurity (also called &ldquo;ROP&rdquo;) is an eye condition that happens in babies who are born very early or are very small. In ROP, extra blood vessels grow inside the eye. They can damage the tissue at the back of the eye, called the &ldquo;retina.&rdquo; This part of the eye contains the cells that react to light. Damage to the retina can cause vision problems and even blindness.",
"     </p>",
"     <p>",
"      ROP usually goes away as a baby grows. But if ROP is severe, a baby might need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H108791183\">",
"      <span class=\"h1\">",
"       What are the symptoms of ROP?",
"      </span>",
"      &nbsp;&mdash;&nbsp;ROP does not usually cause symptoms. But if a baby is born very early or is very small, doctors will check for signs of ROP. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H108791198\">",
"      <span class=\"h1\">",
"       Is there a test for ROP?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. An eye doctor with special training in caring for newborn babies can do an exam to check for ROP. A baby might not need this exam until he or she is 4 to 8 weeks old.",
"     </p>",
"     <p>",
"      After the first exam, an eye doctor will probably check your baby&rsquo;s eyes every 1 to 3 weeks. He or she can check to see if the ROP is getting worse or better. If it gets worse, your baby might need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H108791213\">",
"      <span class=\"h1\">",
"       How is ROP treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some babies do not need any treatment for ROP. But severe ROP needs treatment. If severe ROP is not treated, it can cause blindness.",
"     </p>",
"     <p>",
"      Doctors usually treat ROP with a procedure called &ldquo;photocoagulation.&rdquo; This treatment uses a powerful light called a &ldquo;laser&rdquo; to seal or destroy the extra blood vessels.",
"     </p>",
"     <p>",
"      Sometimes, ROP pulls the retina out of its normal place in the eye. When this happens, it is called a &ldquo;retinal detachment.&rdquo; Doctors can do surgery to put the retina back in place. But there might be too much damage for surgery to fix it completely. If this happens to your baby, he or she might not see well from that eye. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H108791228\">",
"      <span class=\"h1\">",
"       Can ROP be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Right now, doctors do not have a good way to keep babies from getting ROP. But if your baby needs eye exams to check for ROP, make sure you go to all the appointments. If you do this, your baby can get treatment for ROP if he or she needs it. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H108791243\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/28/19905?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83444 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19905=[""].join("\n");
var outline_f19_28_19905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108791168\">",
"      What is retinopathy of prematurity?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108791183\">",
"      What are the symptoms of ROP?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108791198\">",
"      Is there a test for ROP?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108791213\">",
"      How is ROP treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108791228\">",
"      Can ROP be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108791243\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_28_19906="Endosc gastric carcinoids";
var content_f19_28_19906=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric carcinoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 370px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFyAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKWjFADhyK7Dwh4cNwyX94mbUHMUbf8tD6n/ZH61U8J6Ab8i6u1Is0PfjzSO309a9Ks1AbcANgACgDAA+lYVqnLotzvwmG53zz27dydIndHLfexgYHQY6U+3imWAhOnUgdafcKVh+8y9zjjNPtDL9lUsCFPb1rj31PUTsrFe4nlUhUOCexFVnkkk3+avzA1dkHlozPjcTgGqcl4SDCFHsxoUrjj5ImIdkWKMHpnJPU1Zs4vnAdfnxyT2qCF5n2NHtAB54xUjzSbiANzZ5IpNal3b0Jrl8ROMjAHb1qCzuMxZI9s0klyUi2lMu3UHnNQ20ckrbI0ODzz0pWKS01Le4Q72YAs3GBTIpGAy42qOx70820kjBpsAKOB9KkMKNKN7Bk9u1GgNoasiIWkIQ7+AKw/Eqm4s14yyHg9a1p7bqyFtoPGKrzJvt2iK8nIpp21RnKKkmji/NLsQwBIFQg88sRzzT5oikssW4ArmowVZT8xDfnXemnqjwpx5dCSNuhYruPAqwpCgHIBHBNVg205Zd2OMGpRvIyBznOKq/kZO7Qruyx8DIJ6gdKazgkg/qBTTuO5R8oPTnvUZ+7k4bB5Jo0JY2SXjaMjnFSWzZ5OCfTrUD4K8McnnFPhIz1IYdsdaTSSLi9TXtJjCYvmYLuxjpXQRXiBOQBu6GuZRirocfxY5rahIaArsPmDB68CuWauezQlZI1opGf5AflbnOOlMGc4DE1DFIWC8kYGPrUoA655PpXO0d0NCRmfIXdnnmrKZBxtz6mo41STb8pyvNTLL5RbAGD1zStcpy0LVtDmQkY54xVhFWMk7eR6jvWdHLJvPlhS/f2qysrYU53D696LCle9xWI83LYLHPbvVlIvMg3AfOOQPSp9P1RbexvrJrOBzdADznUlo8f3T2qN5QgTy8DjHHenZdDJz1tYgO8fKX6jpUJiZI+Tu2nceetSjOQckk880rMXVt2ATStfQpNrY6jVL/RL74e7YdFht9YEqRrOoGSAeWz15GR6VhXcSPCi7XVgM9c44qkhETrzkdPYU57gq25juX+6aq7ZhGnyXSfW5A0aRJuyevTPWqDXJE2XJx04qzqE24EqBg9MVj5IyGP507a6juWhL5gcHIHPJ9KreaAcqDxTJJSFYHDY4qONSeOVAPX0qvMhsm/eYd2xz2JqMMTIAxAOO9EsxLEKwbj72aWGB59wQnryad9dibXBZD5gGNy561cl8q8int7mISW8q7GR+h+nofftU+n6aEA3qWY1ZktFwqKpyrZyRSb1uilFW5WeL+KvD8ui3gzua1lyY5PX2PvWAQK9/1DTLbUbSa0vI96OPxB9R6EV414j0KfRb/yJxujb5opR9119f8AH3rtpVedWZ5mKw3s3zR2MOinkY6jFIRWpxDaKKKACiilA5oAUDNdB4V8Pvq9x5kmUsoz+8c8bv8AZHuf0qHw7okmrz8ZW2jx5sgGSAew9WPpXpdp5FtEsEUYjtowAiqe3v65rKrUUFZbnZhMK6z5pfCWpUWG1jigijEcYwiDoB6UluSjlnzsxnkYFO8zzT84wvQAdqtG1LfNnK8Vw3tue0laIG6WaIk4K9hUse+VIwCeDgAHiqE0buTtIVR2FMDSR7AGI+lJJBZItyKu5vOOHxx6ConRZcOCPk4wO9V5JnUMxUE9jRFOBEXzj5uR60/QlNplkShAUyVQ96iQsrbopGJzUkASRMnHqeamt4JBLubBjPPHGKZSaS1IRJOH3Fcuf4h2FP8AtDbvlDZxxzVtypjYxkDHABNQSyru2kBmx1FTcak2RC+uEcLJtwfxwKe87yIu9gq5yGHWkMAaJmJG4fw9c0yLDOVK7B90bh1oaSKTRI8kjFctlQfTrRPLH16SDoDT2gZgQepHAFVZIxuZX6r0Jp77k3ic34jhEdx5o4RhnHSskFedqkEjPWul162WWz3bcleetc0RhDlhkdPyrqpyVjycXBKV0C4LLuY1PH8sYLEncTiq6HzABk7h1qcMxXbgbV+7jrWvU42gYgE5yFHPbk1CvDBlGPUdjTyOGU5H93pzTDuCgnJwecUzN6EbA7eRj14p0JAcMQeehFR4G1txJJ9afApBU9gMUNaFxRfyihS3Qv3rWtpSXC7+MY9KxpHXy03jlWBGBV6Mg4Izu9TXNJM9Si1dGzbL1PJHoTVyNnRfu8kVRhyqZGTkdKuITyBnI61zta6nqx2LAJJBDEY61YEMci/OxAPSoYcsecYB6VcBX5PlwCeTUPQT0FiiKLhCW4xnFTW0bBcEAd6dCFXDkggcGnL1POFI70OTJEcAYyvTgGmqctyD8vcmpF8vrngZwKGRnlJBAHpVak+oxQxkwo+UdcmpCF5zgcVHvdfvD5icCkJAcqTzjr6UEtleWXYcZ7cZqCWbEfztkHlqbcSKso3c9aoXk4VSF43DFNK5DYS3fmsFiHGMcUyNWKELnJPB9KbAVjGe5HNPeQYyRtTsetWZt2ESMJIFGXI6mrT2wdQZH2gdh0qvl2UbSAueQR1q9p1q15wRsiPfHWnewlFyehBBaLOfLX5QvBJ71t6ZYpapwCxPcmr9vYxwn+8gHHFPG8uFAJQdT71EpWNIrsIN7RlWUDHQ1XdDtyCT7gVsRWEssAYuFU9qdHYEDcxHTAqblaLcwfs7TqMDBPc8ZqvrWg2mraa9ndIcHmOVRlo29R/h0NdUbVQMhcYqJ7YvnaRnHHHenF2fMiJSTVnsfM3iXRLrQdTks76MBl5SRclZF7MPY1jEV9KeLfDlv4h0z7JfYS4UZhnAyYm9PdT3FfPus6Xc6RqE9nexGKeM4wehHZh6g9jXoUqqmvNHjV6Dpu62Zl0U7pxSH1rQ5wHrWpoWlTateCCEYHV3x90f4+1Q6VYTajdJb2ybiTlieij1Neq6LpUOmWYgt1yOC8hHLN6/4VnUqKCOrDYd1nd7EumafFZ2K28CbYV7HGST1JPrVr7OJVCp9S3rRd7mCxwj8qeiyIyhiE47muGTb1Z7UI8qtsTWtkEUM3B9cUslyodVRsnGM1EJHCkBiT1zVSZfLCuG3zE8AVNtSmu5aNwI0O9VLN0qnvLEswLA+nanLG3ms0oDPnj2qQJIoKqpznoKewuuo0BANpJJPNRNbbQCDlTzyavPC7ZYqM4x1xiqMrSRk7vyoTBk6Sxwxn7uemKu2lwJjt34AA6VkQyIsjNKAwJziryFCm5cKx6gelMlxsXZUSR2VCAO4qOCzMZcE5Yn5T608SomZvlZdvSm2l0jkcZIPC1KVhxuiYQAyBlIWQDBHY1WuIZ5G3sy4z2qS4unaZlijy4HQVBFLcojMU5J5B9KSQ1fdj7eQoGV9xYZxmmPHkNt4UkZJFQSSM+SQAM4H0qSJx0IHTHTpVi1Ww28i3WzpjJOQOK4aSMxSMHGFzgAiu9Eu5cSAjHy5xXIazAYrt1AyPvK1XT3OXFRcoXM4Alsg+wGKl8wqMZCnGBgZqvhickkY/nSxnKqQ271IrrR5diYMGdjL8pIxxxUe8bCeR1pz8csAc8YNMPCnGcU09TOVxhGB2yRzkUKoyFzu5qNuqszcngDtUkSOTkc4OeKfQcFqWrgE2ZyMHcMGpLWQmRIm46NnNQT5+zNuJKlhxSo582BtoyODWNtDuhK0onVQsQuQcnHerceBjaOf51TtXLKGZVPbirUTZBJDDH61ySR7UC5GB3Yhup9KtwyIYwACSOaowHKYZdq9s8k1ajcgNxkVmU9S1uXIOSPX3pPM/vHaOwzVfltp7A9/wDCpBw/OdjD070W7hypFmFVyWb8MVKgaM/MxNRRZPRhnNSsV/eFzyBx70JGbaIJ5OOc5HOB3rPkucMepz19qddThThsk/yrMkkAfJIycCtEjJ2HzzqXIydxqtkMx3tuJ6c9KZjfKxYnjPQVPbxiSVUHOTzV2MrsIUZ2HlozL6kVN5BX7+S6npjirqtl2RAFRTgAd6u6fasxLSkEnrUt9Cow5tyO0s1lPmMMA+o6Vs21uIlTYoC/SnwWoVBt69ga0re0kEQaTHTgDrUNml1HYYFjUKrdW6YHSntbKFIyQM5zV4RRxMNidR/EBQ6gsVwCD3NTcSdthCkaRqAWz1BzUiJvTAOR71D5bNICeFB6Z5NX4UZVV9nyk0asmS0GRW5cYyNvQ9KiuINqDYMVcCYBNOWNWIcrnIx1poz3MaSE5A25Y9xXI+OfCsXiOxZSoS/iBEEzD/x1vb09O1eieWRkqpyORWddxsxJB+Y9Riqg3F3QOMZrlfU+TNRtJ7G6ltrqJop4mKOjDBBHrVM9Mdq9/wDH/gz/AISC0e6t0SPU4FwjdPOUA/Kff0NeD3MLwyvFKjJIhIZWGCCOuRXo06nOrnk4ig6UvI9X8O6NFpFp5Q2tKeZJP7x9vYVpTsWQ7G+UcZxjNRWwLfewBnnmpHkLzLGR7AGuBtyd2e3CKpxtEii3J95iWPQHrUj5eVQQXfHGKeyMbnaqcjAJNNmY20g8s7mPBpGqJGiMCCSeUZx93GaigjMqNJnv6YpLaGSe4BcsVx3rQkiMXCgHd1HpRdImRnESwEeWMndzkVLI1wZFVwMZznbzSyyNNceVFHtCnJIHGatpkkh85HXmkDaW5GxK7ASDGpyciqmoEXG4EAMBlcVfeMjsAT0HWs++VijHYARTWhKfMZ1tiRFJUgg4I61oQE+ZtZRt6AmqURNuyyFcFu+a144DcLkkgDoacpLoPzYLb+ZGFjIznB4pqo6yODxtGAQKlnWSFVEf8Pp3qaAjySZGyx5weDSuTexSiyBuLcnqcc1Y3Yh3b9v1FVZdxYsrYBHSoxMypsYEHHNMdrj7naWGGzkA56VHG/3uAce/So5pAVB6kdhTI2YEnAx3A60wSLatvQYPU5zWLr8QKJMASy8H3rcVQEHXnsap38BeCSMg7ccYpxdmRUjeLOOkTB4zjqaFCspywGBxgVKyBVOQfl7ZzmogSGwAFOO/aupanjTjyjpBlGJbBB/OomOUIVmwSe3WpOMbio5PTrTGJ4HAHP51cUQ7iAblUKASDSxHbMFbep45FMLYUY3YHXHrU8fDq/UgcA1O10Edx0+dpCnEe7+Ko3YKsYHYg5HHNRuzCEnqSwxx0oDKXAIycgZ980LzNnLWx11rjyl2nORnNXojjABx9aydPfEcakBRjr6mrZfDqnVif0rklFo9ujPmimace7cMZODnNWIpgxIY9uOKhhwqZwCOuKcwGc/dB7VludOhZjlOXVgCOxzRcTEKoHTrUCsVBLYINKjDzMNjA6UWE31LttIQB5mAetQXM437geBwOahknO0kHg8VQvbklAABhPQflQtTCXcinmy7Et+fNRKAxzkbP51HGdzjd69KmAYsmFwC2OPStLdEYt9yVfmyOBgYq1awGIM+FDEelJbRryoBLKc5Pc1o28DOSxwR2IpN2KjG+o6ytRhWHU9zWnBu3FUQkjjOOtT2tmyRqOo61pxW4jiwv32PXFTY191DLS0lkUnlcHOa2IIikCmVjzxUIcoqxqD15IpZJpQPL8skA/ePep0RjK8tEOn3sV8vjnnNLDBLPNsiHzdSc04bi6s69Ow71ehEUIL/AHpWHAHamrMV3sQwWXzbXPzA+laHlmJkic9vwqBpS2N2AcVOsilQGDEgZNUmRJS3IkgGWXccnvUqWxjXaOQetP3Euv8AdNN8xjIRu4BofkJXbIZ4nDx7fxqjdwFCxXkZ6VvCMugwdpPrVLUIWjwUGexxSURqSvYw7i2L25VOucnFeYfEvwWdUhfUdMjA1CMZkUD/AFwH/s3869jWHcMqe3I71nGHfcx47OOo96qnPl1RE4qd4S2PJUwlqzYIb0zVmFfLi3HDOUzg81VV1e5VAw4bJ9xmtOyX7ZcsyqGSIcL0o2OlNrcLMGFA7jdJ1ORwKpLmS+JZh5Y5yB39Klv72V1aDaI3Y9B6U6wgiAAflupyTSS6lFlA0kSLGAADkEDrUpjJIU845JxT0RXAEfBH6VHcKxbCyAMec0k+pO7KPkzSX0qROFUdyea1Liyew+SaZJHZQ3ynIxWUIjBeNGsrHIyzYzU3mRLIsW0mQ/xHuKaCaelmI0hMrmLYcVUuVkXJ3biCMj2qwwgjUgnax71Tj82Zyse5gCeSKauxpLcs3catboSByc49KWylZozCg4NQSmUYjmyVxxjtTIQEZthJI5FFieXuWRdSBXDKfOU4ApMK6eZOMSdc4qzDCjSbpFzxkkU+4jiA3A9OqmlfoVoZsrCPABO4jkelTSkeWgKEnbgsQac1uZVyNuQOtRBSkflSN260xMoupDEhc96dEcSAtjGOafkMCufnHAz0piY+6Rz0NA46mlAdwwF4PWkuVUf7uOM96IBsQfNxxxmp5xuQhThev0qS3E4nUI1inkIXg1myjKnPJI69K6DXrd4385OUP3uM1hP5bRDdyTwK66bvsePiYcsmRgYJ55x60MoCKVyT05oUBG3EcE9alLMw5AOK2v1OVqxAeD908Dk1N9wjbg8ZzTGwVPBBbtmhd0rrBArSTNwipyTUsIrUSIO7SY9eSeaf5G2dUYYz1rT1bTxolvb6fPKpv52Elwo/5Zei/Wql5KjXsQRgxB5wetPV6ItNG1ZrGlu4mK4A4Jq54fs57q4Xy4pJ5pDtjiQEk1StLZr6NS64iB7DGa6fR7y70W+t73TJPIuYDlGPIBxjpXJUavY9fC05pc/3Ine3+zySWt4j28yZ3xuvzIfQjtVMEEhiSQOOKS+vLi+1Ke9vrh57u4YtI55yaVE+TCnAPOKxOzW2u4u472AGB71HKzNwOCOnFOLYOTz+NR+aVVi2MZyMii3cnmsRXbBYdowCKzGbc65ORnJ5zUl7MZXKrz3OOahXy/tUceBkjnBrSKMJSuTCMyMOGHHBJrQtlyUDA8dMVFbRhnAA6Vp28R42hd2cHnpQ2OMLkljb/vN3PXJBratoWULgY9sVHp8CxqGdhk81pw5ByAQe3vWZV7Fu3QYG8MeeauoixIdoJ78mo4WH3nJ4HNW2USx7doANDM27kEW6UFwpx9KvwW7yEtJhR2FNtgAViRcKOtW4U3uwyeOc0khSdkQCNt7F8YHAz3pkQDzEg/N7elaEioE3E8+lVoogV/dYX1bvVtEwluWEhAQu5yOwpsaHLhVx9RU6qNg5LEdKdEj43YIz2NFiebQjgTER3HJBqRowQrKo+lShNpwy8mnsm8KASvvRYV+o2Nyudw6Hg0yc732n+LvippAVUc8VWebdv29qbVhRV3chjt9u4cFs8GqEihb9BtAO8fzq9IjBHbk45FQvse6gfp8wBP41HkXy9TwqI/OzJ8xzit61cWtqruoXcOeetYEaOJHZG+YnOAOKvPP5yKu0jA6Vb1Nbjra2M1y9xICFB4PatHy1DGRsYz93pVZLgbY0O5QvUEEVo28SzKzou5mA59KmXYvVK41HiJLHKL0Gaq2ZSeeVId0krEBcnAA6VJqJtrea0S5+aEyqHA9M4P8AOuy+Ieh6b4c8XRW9gkaafe2gmhCvyjdOT79RSV7XIdWMbLqzjAkX2yRYd4dF2yBh3zVQOPOkk4KqOMU22mlj1C+zMWAz05zVApLOMwghGPOKa0NLdySeSS7xHGpJzyQOlTRJJAwjB4xk+tWLLMcLIgIfPU96lWJ5Lhnbkc5NO9tidtCrcKAiB8l931OKqspjwV57cVZugUV5CDUNuxlXcpAAHegSstzR0u6iWRSVVivVWHBqxd2c0lq12ttIlvuIDY4z6ZqlaKiENJ8rdzWld3sj28cCuzRqP9WWyKLEPe8TGJkjXbuw/qxqiTkZcjcD2q9dbncqm0t3IqCRCm08YHWi5t0KMbYy3Qk96cp7ArgHkiklAMgfI2n1pU5jKgYBqtLEovQygZAPWrcEin5OynJrNhJVFD8d6tQsVDHBx9Kg2ZeWRonzHsKnghgDmsW98KQX7eZpE6QTk5MEx4z7NWih7MPrVkta8ebuEZIzt6/hTU3HYxq0Y1Fqcde+EfEsEmP7KedmOEMIDg++RU114I8XQ3ptxol3JJgHKx5BHselenanb6Pp+m2V/wCEfEly14zjzLSb5fLHqTn1+ta+v2/jlrW0vh4ohurm8RfLs7aTLhccnFdfteRPnW2tzyZYe7Ti7J6a3Wp5lY/CjxFPEbnXpLXR7MctJO4yB/ujmtOe68PeB4Rb+FIzrWvSJ82oSgeVEp44U96q3Fhd6hM7ahPPcSqcPuYnB/OiGxjTCRRgt1wvOazdZL4dfM2hl7ekpfccquhXN7cvc6hcs00rbmI5Oa17XQ7SAofLJYDhic1qbNm0sOe/NOeSP+EEA9s9KydRy6noUcNTp/CgjURkHACggAetLO/zZ71WeUZ9+3FPXvwx49KzaOi+oqoqnORlvU047wFYdq6rT4LXT/DUF9Pa2t3NPKyKDKS8Yx3WsK/2ozY4LZwF6VTjyq5gqnM7WM64lHJ6HpVG5mIXbu49qfcvy28EKO9UZPmbPb9acUmKUhwHG7GCerY7VPCiABtozj72M1FH8yrGhOT2IxWjDAxkVFI6YwKbJjqXdMtd/wA2Tj1rbaJYol4wTTtMtxFAGDAsOxNWHiaedAfmH8XpUtopy1C3jZo2DD6VqWyHy/kyW7E1TWPzJdgBG30rTskXaBnBAxjNSOWxPb248nY7Fj7VetLfanLH1waoR7gGCbuPWrto0hQF1CY9e9Ihp23Lhi+ZXQYx2HerVsAFPr0qMFHQ5OAO9SxsqrkD5cdqtGEriTqAp3emODUMILpsRsAVZeMSfMM8D9KrzKkexNxBPIIpjguhcjRfL25yetWo4xs8xM59Kq229FGMk464qwiGPDZzSTJmtBJNwYFs4PUUzzBlgwx6c0hfexXHOeKZciOFgWOc9Oacn2HGOtixH+9jdXOFXvVNEAkYdUPT3qxC4kwAe9NlRQQy9qlNstKzsIQfKzxiqewLOGX5kLjPfFWtymORWzxzTVjUPBgcMy8/jQxpWZ4VBCCQVPXirRja3VbuNl3wsCAcGqtlKEKqwzuP5VYt4/NkkWQkR5IFUjTlezLsVw1y73U6hzJnOBwK3vDvh6+1o3lvp0iIbeEygnnec8Ln3PFc7bZgcpnapOME8Gt3SfEU3hu/jkimb7JJMj3MSnBkjU5IFS1zO17L+v1HU5owfLv0MH7HeR6lJFqVtturWQedC5+6c9MjpU/izW5vFPitpERFmnjS3jiVshVAAAyaveINb0/X/HV/fJM1hZag8Y3umTEAMFsD86t69ZaXBoGmaXZabN9pjud0Wt4IW9UZLYHXuPyq0nFNP79r27fmlr1M+ZNwnJWlb7r739PvMB9OOhajYzQyRSXUT5mV/nAcHkEdMVNemT7bNcERqJmLlUXao+g7UvlW6eaJIykhYnk5yabcuqbGdQWbgAVF77FO97kEz7TjjdjIqBZnfIibn+P3qxdOquoUAHace9QhWaPzFXb1BpJ9ASXKQvCDJjcdgHzU1tiyBUBxj0pqhirHccUwlyw+YbcfnVLQGn3JmZSgRWHy85NLbb7mTy0cYPU1RZ8ufl+ZhjpWrp+wOFk+Xb/d9aG7It+6i5PaokG1VQsBwRWHMhwQcqT0zXR2ls15crFbqzOx2YI4H40vjLQr7QZ7eDUYUWSaPfHsYHI9eKm63IjLXlbOOkjZH9RxgDvT40Ch2JxjoKlmUN8ufmHJGeKg3KYygBHOTWnqirak0Sl0yxGB3J7VNA25DnPXFRxruVdhH1xUqrtJOaRqhwYZBI44qUFSgb6/KR1qIRK2G5bNPPBCjOB6dBUssj8tAxZY1y3B9TToFmguC8Ukkcq8Blbke1SZyOmSPahMv8p27velfoGosbNGJNzYZjn60kLNDllZlzxxQ3JOBgUxm4CYI6073E7jGchuoANIQZHG8DPbnrSyKrJ/Fu64pA6YB28+vpQtRIfDEGYgHnvWjHGIozgncRzVCDBUbh7+9XkkCKBggnnPtS2Ik+xYEMMezDFjjPTvVC+YFRk5PXGOhqdZjkYOR1P0qhfzIx2qDtHQ+tO3YhuxnTOTlWJH9aYVRIlYudxpMFzgkc/nU9sShRkVGUcbSM5rRLTUhi2cLecrDBY8V0FlaiM4bBPqKZpNvtUvKg3N0HpWssJwCo564FQ32NIxLVtanAY/cx0NEe8bgQOv6U6SbZbpGgPPUmmKzMm1QcDoRWeo0nfUuacyszFAWK8HvWlbKolwgwaqWKOsBAG3d96teJQIl2ryR1qokz0JLWBiTvYdM81Ltdht4BHH4U0yKkZyGORxjvSm5TyxnIb61V0Qrg4ZAU5Iqa1cxYJJZWPQ0xP33IBA70oGXVVbAU/nS0Bq5aUysZCfu9sU23DPxIvzdcY7Uwvtck5NOgJMoOTuI4zS62Hy2TNa2WPYoyAfrTi+CUIxngEVW2sSHIAA9ql3hgue54rXY57X1Y6YGOLjG/rxVaaMmIOUJI7GrUsHzq0jnb6CnSHByOmOhpepUXbVFCyUrEG6HOatSIJGAI7cU62T5uQAatwwEAtjP9KSj2HOavdmYYUViGHzCq0cjPdxRjlRIuPzrZv4VVN6fex0rHhkX7RExXb+8GfzpNKxVKXMrnhJUmbbH1FdBaWHl2J/vPz75rGQbpQ3TJyK6jT7kwoXC7mj5PpSbaWhUpNO5gXUbSTRo2SsZBbaOcV2sGkfDrV9LS6l1W+tNQhhPmxt3kA7A/41ylkZL3XhHDjdO+0E9Mnit3xJ8OdU0i7llQW92FkSN0T72XGcY6n6ihOKXvq+nnp/kTUfM0uflb2/yOY0vyJPJgt7WSSaVyq5Xpk4GT2HvW5qWs6pO8GlX0yG40VmihRcEL9CPvcd66D4c3WoeF/iHPpc6abEkseyU3LbVj284B9a43U5kv7zX9RZIYzcXLtH5XQc4+U+lUoWjzdHps/z+QSmqlTltoldPffRFJr5GkklupQzk4Y+lNl1G2aaIoS6qOMCo7S0jeBXZAc8E1Pe21tDGstvF5bcDbnOfeloaOKvYrf2iivHMImkZX+6RxipZtTS5nkKRCHk/L2qWKJZkLuqoB1461VuIFVxyAWGR8tJNXsOyQx32xlYyNzdSTUMkwCgEkEH060iQOTvbO3O3C1L5EaqSSCemDVA1ZiWcYlzI457CtyyRYTuwoLDvWCjBXBKlWzgGrcZlbLyMyL27VLuOSbOg/t14LN7RJ1WAvuIVRuz9azfENxb3EsKW9zPP8gBeXgA+gqXT7W3gO+TDKx5zg1Dq0YkZDEgEac9MZo5iIRipaGXJY+SpOS28c+1VFQK2Rk44NakTckOnAxzVKWLc7gjAOO1MrW+o9YtigJkZ5zVgoFjyPmx7VDGQAMkYA6ZqyQpGQ2QentSZomVxLgg/NtbsB0qY7OBltpGaRIRhdwPp1xTZoXVztztx93Oancu6JETbKpBwAOR605o8tvQAZ/Ooo1c7VPBx9aWSSSFT3HTFMYpIVmHU/SlGzavHPrUAO4DOQc04DjAY9aExO4r4BJyPSmBBIVGcA4z7UojyDjcOe9SRo2DgZVTgUbEjVIVsL8zdM4qVpeAGPA9KCAAW4Vh0A7cVXB+bJORnkCmiWroeXEZJGc8DNZt1IGZgO3JJq5JLtTLDg9gKzJpflO3Prj0qkjOWg2Bd8jE4CjjOa0rKMTTJGoKqnpUMELvAWIAA5z0rT0uMs3myjK9uKqTS0FBX1N+0jEQUHHAqWF38wsmMZwRTYAZJFycA8Crk0casoQc9Tz1rG9zXRfMhnxu9N3YVPYRli5Iwq8j3pqQ7iXB78CraRBIx8zbvSgFZF23YOpwDhatxyKIzuyBk9ao2imMsWO1D3PFVrrU4oXYBgTzwOaV7bicbuyNhJ1UAI2fwpLZfOnJbGRnrWB/aRkf5cgeoqzbXPlrgsS570XLVJnUuuIgCwHb60sYAyR96sSKdnbk5Uc1oQTM/K8r3Bp8zM3TaHzLIXwMnnJq3ErReXgdu/Wn2p3KScZHahnZyMLxnHTFVbqJyvpYnWWQKCcbc9K0Y8fZxIFyR0zVSOPKhM/MBkmryMFVUdcjPYVcTnqWFRi4GQM5qG7QgfKM+tTO+DwAo9cU0MzOoGSMVRC0dyKzUllJzz2xWsudjoBkHoaqoFQ5GferIfy1yDwRxRFWZFRuTM67DMGGOOgrLjTbJEGXJ8wZ/OtuVxJEUPfmqZh/0mIDruH86l2extSlbRngVoo8tRjJHXNacdwRAURgFYYNYxbMe5OOgIzUxeQIIYgcEcH0/Glp1NHG7LOmwKl2Mv8AOCdhBI+ldhpPjPxH4dv7oWMkV0k2DILgFip9QfpXG6YyWt8hlO5h6810M0/ms5jR2d+gUc0KtOjdxdl+Hzvox1oRm0pq5T1K7e+vWuL63glebcWRflyxz8361k2Ufl2zRAKsaE5HWtvU9Duo9CttYe4tys83krCr/vEIHVhWZBbbonjYDjkmslolbZfIIyTi1F3/AK/4JVtZ/s0s0YQMknYDOKW8jMqhlU/L8wyOM09EUXj7WwVGMAVI6O4KGQ+gqm+xd0nchhuN6p+6+buMVJd7R82wEgcDFVZGeCRCBk4xkVYd2aPdIBnp0oXdky3uQWZAlcNkZGduOhpkkMYck55OcetTeQFBGfmYccc0NB5MR85ySO/cU7g3re5RhI+2EsPlHYitF/LlXnGOw9Kyrg+WeMkbqlRQDkHjrimrJXNGr9TcslRiDnIHG2kvmBtmLZXaPlGKhtHx9zAFLqcyvFgrgnGMdKjTchJ8xXhkMkIbFVJOSGbH0/Gr6RxxxjDAqecDsaoT7FYlcZHb0p3uU0r6DWVTjk5I9KcjCLdgBwBx61Hbnz2J4VgOtWI4GJHzU1uVtuOi2S7csVbOcVK/zEkAL6ZHWq80G05OPanBWUjLDnj6UvQtE6KELAkAY/OiQRCMk4LE8DP61HIXJ3NkhehFKIQzAoQW7g96Q0u5BMmGyoHHemxIrtnoM5xV0RIMBhg+1SvFGH6YOM0IL2K7qVzgZXPTFWFZI4nKgF24wKbFGZSUSInJ6kUro0b+XwcHPHahPXUTsV7jakXI2k+9Z0zckhSTnjFad2iDcWJZh93ArLZCPnP8R4FUmTcgnJAUMMEc8VVhT7VdRwAjJYZIHQVYmJON559MVJoqk6mkj7c54GKtIxqM29Rt1VlgjwRj6ZqxBEVgSNSMjqBUKuJ7x8Z44/CryqNuBww6GpkzSmlFFm1HCMQTj26VcYDjse3FVV+RFU5G7vUjFndUDc+orNlyVy1Eu0nGSc96VZSC8hYYUgAYqdlK4BIBIznpWJqd6I3EMeGPU89KHpuKHvaD7/U5ppPLh4jB655qza6aZSJZQWPUDNUtBspLqZihJf72O1dto2lu0BlmIVFJAJ/rRGDZ0S5aa1M630pAR8md3YVflsVhG3YA2OvWtNpYIoP3T5mzkVSuJHnYKckn72ap2WiM05Sd+hVgt3PGDjucVeW0IAaNzsx6UtmdxZc/N6Cr8NrJ5fykAUoxuKo7DLNNpO9gMDjjrUqxt5gYgnaefrU9rYNNeRxu6qu0sz9lAphYEfIcqePr71drI5b3ehZtyzJkrtJqaIEvgngCqkEjJgO2SemasRq2CWq12REolgnDfNggjGBUTzGN+DkU6OTCncFxTPLLK+GG49DR5EpK+o+KQS5AySTV2QMY1APAqhaW5hkz7datyMwUk9+BkURutyaiV1YqOXEpHoe9TWygzwgn5vMXP50yVd3JOMdatWaDzoTxy4/nRpfQJPQ+a9+VVQACcA1JHLyVBGRxzT1VFuU+UlT1pZI1luX+UquMde9SmdfqUxI4lkweR0JHeuu8I+JLnQ7iK9tYoZZ4wQEkGVOa4sb1duoIOPrW1HB5diJQ2JRyB601pr/w3zJklKPLI0lhmmW4nkwJriV5mQdAzEk49KZbLNE7oHUluue1SWtx5kIfI3Y9e9OeNS6uOJD1AqJXISaumZd4slpd+aNvz9angIQs7puAGc56mo9VePaF77geDyasS4mt1Ea7U6gZ71Nn0Ll8KM69VleF0YknsasRZcmRlJUUxU33ZkuCuyNeBmpZZ0RFELfuzikKWqsipevkhl4YHIzTpSDb+ZnMh6inTxknzAeD1HrVd5VWJ1Y8gcDsavcOiKDyO8pB6HqDzitOGFJDyvy7fvZqjbKRcM6JkEdMVbi3PhHG1c844pvQ0ky4kZAVRg+nNQM++9SM5AjGT6Gpsqi554wASetQQMDN5rnK5x17VNmRB63H3UI8vlTgnoaoSom48YNbEjRlCZJV6ZHtWTc3CAARHeCevWhalRd9BkMaEhQcY71agDKpBZjj0Gaqw7iDyOfSpklWKMbgDgYY9TTaL1sWgwWPBUMSMcjpSW0JdDznnOagEpkYfIQvT61oWjyLhgFCKcAGoHsh625CjYyj1J5qs4ZJCUjyfY1elKqvm78Z4xUM19HGoEQJJ4OOaATK8IMhPm/LzxzV/TrIyykBhvLYBY4pPClppOq6ykOr6mbKAZLSY9uBWmmlNcNK+mCW7iMu2L5CC69qpRbTktl/wRSmlLk2ZAsX2PPmgF++Kz7p0jdpedxHSpNVlmjle2eOSNoThg/VT6EVjXz5kLGYEkdzSjG+4ctldkV9ITIDknPuarOTwR90dKeSTHuJ56DiqsxO/wCUHd0+vrWiRDetiGQ5GN2Tnr6VascRTZX7w5BzVIAPtXndnBFa1lDmQE9Kb0RMVdmpp0DljJkD1rQaPJUknB/Wo7YYiGO54q6is2cjOPSs2aolYoIx3wMDNWLCHC78HBzziqU67rkRqDtIB25rbiTyooo3BU7c8HOaQpS5UU9WmEce8HkcZNZWmWAubgy3HCnuRU+pky38UPVS2TWooVcxrjj0HWlJ3OjDw93mLthPFZSLHZRAMy7SwHQetWbnUDbkxAksw3YU8Gs621BdMuzOrbZFwACMg+xqKeSScmVVVQ3PNS5LbqbRouUry2Ohs/8ASkWR9inHyg1Y3eXtLrkc8dqxtLhknIMjEIowCK3bYtM6WkURklbhFXqauMm1dmNWKg7iRGNfnRMueeKuh/tEYZQykDkdKqxgPFIQpVo2KMD/AAkdqqvcOJtiOwXHPoauV4XXyMXDnNSFyCNw3KOMH+VLcqSQwAUDoBVaKM74j5mR/s1oXS4TIbt6daI6mL0kQINyLIRgCrkD70zg4qvAxkjMZQYGcVZhACZOPTA7VUbETHEKcqp59PWmqSrbR09aYCfMyBwDxUqljKWKggU9xWsSLOd6qefWrBfcVDZPfFZrApJnOOeKtQkyyRuGxtGDSTsyJQW46X5j0qW1B86HHB3r/Omunzs2SD6VJZKRcwk8jev86poh/CfOSzHbuC4IPH51OqK67jks3OOtV9/yEqQc/wCNSRytBtGCAe4rLVaHZcqz/NjCHIPJNXdKljkULKc7TioDLvMhC/KOhHeohE8bh0J9SPWmvMl6F2/wl0rRgiMnkCtS2njUKwUlu+DWLHeGRAsgwCeDitBGVY1ZTjjk570mhP4R2oxJJGZJsqxzsAqHTlMQxy4UZxVS+vS07tuYqo44zTUe4kiRkkIHXnvTUA6D7qHzr9sg4I+7nqas20UccEo2Z54welZZM7XKu45x16UqyXTb1ZgM9OKfKHvNFkyPLGVI2oPRqoCPzZlAXIU8HNSbLox4yq8854zUaR3C4AICnJJAoshp6llDKhIjwQvvmpYmmEe8jEeckms8O6bijkMOMHvTWNxLHwQBQ0mORcedHcKc7c5yBxRb+Y/7qFflcjGOKqraSbFO5d3bmpoXuY9p2EFeaXoOOm5JcI8bPC6kFTg5FIbcRoAF3DHGOKRL6WV2d13sW5z1qVLiSTKqMH0pW7l3fQgBwCB1PH0qa3Hl/fAYN3qIRzAEqCQT6dakjEpkA2AgdqQFuNGl2AbQRyMVOyTK2WAb1Ap1qjEASIF5zxVwSBIWwcDnrzikQ5WHWy+dbMXiGAOpFJpGoWOmatbXd3Zm6toGJaN03KT+NQxTOqAKC2eD6Vr2XjRtG8P3WjtpVve+dIGEjjkdOP0oSUmruy8yJ89nyq9+l7EniTX9I1y4SKw0G2025MhfzFGCQegPb3rb8SXF3oGlW3hwXFuk7AXHnQPnk9ie1c/r/iSDW9Tt7230WDT1hhCMi9GIrEu7wJI887MXfpuPbHFU3q7r7tjJUtIpqyXR6/iRa3ctGWZ2LySHLs3Vj7/jWEvzysSMDHHpSvIbqUu7ZGeOaTBwcklarbc2ctCIqZCXB/dj0aoixyZCPUipJWIjVDjy+oqKY4QjJx2Aql2F0uMjbfdKoGCTznmughk/dxRFAADnOKo2FrvjM5eMeUAShPzN9BV21GT1JOelKXYqlvc2dNjSSVd0ioB0yeK040Ug4IHNYtlF+9wTWzkYUjJx6VlfuaSQtrEZ7t2DhSqEgEfePpVuR2SJT5ZQgYI9TVGNUju/3hJVxg4qa5YJDtGdoyfemjKSZmIWl1B3Jx2WujtLcgorMCzelYOmKJJ1d8gluDXW2A3FuM7R+tZ3Vz0n7kEipeachnyV3tjgelMbTJc5IGB2BrorfGCdo34psyrHMrMpBYHpWiimrkRryWgyxty2nM23YBwBir2i3v8AZV7BczoskqZKqODzxWdFcoFK+ZgZ+6DViJzLJuKhmHAwealL3WjKacr82zNC4iaZ5ZItsYuHLsD1JPJqCSzLfJIm1ug9KJbghMtuBXAX2NS3N80CqPvMQNp65NaOV23JGCUopKJXgtzbSgNkj0q6wLsqcnPVTVZZmm+YDH94elWbU7vnJ4BwDQrX0RMr7sl8pkO0jG2nFinGODVhMMQx6fzqtM+HLA5X0rR2SujFe87MaUJfjI5qaKWNn2qD6dars52t1BxwahinCbVzufuazbNOXmRPcSDgOh46cVZVhHCmAAWPSlt8SAhhgjuac5AwhIzxt9qpW3M5NfCKZMKCwAIHNW7HbJNCyHnzF/nWeTvcxN+hrU0xQLm3I6B1/nTMqitE+WbeX94IypA9avKTNEVLd+Rnms6RHTnPAxkmrNpLxuzjHUDvUnUW3QCPag5X72BRAxeJiQBxjPrTPtO2Nht4PFEUmY9qhfl5AqV0B3aInVgucjaGzgU9Ve62FiVjz2pnmB3MYU7uvA71ct5A8oQKOnUdBVkJPYILNA0ofJBHHpVuTTHiihezY3SFS0saKcxAdzVi3KgkNtwRgDPNV4gQJJUmdGU42jjINSnrqNN9CG3uoZ5ELlRkcVLOrKUKqCM5LVUmw04URfKPbpUs1s/3oXdWAzgjIpNIvTRliZAxfjGRxjvUUiiSNFA2EfrUC3c9tsa8Q7DwGAqV5orpx5TDrwaTQ0nchksHJlfbuAOetQIm3EeF65rWKMg2OQpYdapTpj5B1A6ii4JsW3tTG6sW3e1acMXmROdgyOlU0KxwqA2WHrVuCfbErcFu4pO5MkzI1C2+zu74wPbrUUOnzrbNdxY2E4OTz+VWNYumkmVQMFvrRp0cgiOWx7DpTu7GkW7akBE7AI24DGcjtTIrhoJAhU9OpFa3l4T5m3ZPpUc1ukmMJz6+tCYKXRjRdyKOhC+uOKY8ksnORs/nV6CxnuIWihV3XALbRUUluq7ED7WI5FLmS3GuW5Uivp4N6hNqryM1bstl0pduWPOadPDuCJkcjJxWRPd3FurImNvI4o30B2exo3t0sEZXcrFeKw97XbZbPByKbskZd8rjDDJq7bBI1yFxnjNXaxlJ2DyERSFwO+SKikO4MrNz2pJpfmw3B7VUYl3ZSckDg4qkZpXJYkge4SOQ5iLAE5ov7ZYL+SNGWTZ0YHINRZAVVGD3zimQfvHyGIGe4oW5VjU04xtC25Rk8Zqwu1Jsx8K3OKr2AKq+0ZGcfjVhS0smSo681EjWC0NG2+Xa47HrWxbsMAPzmsuGJRGF655xWlaglwuBzUs0eqBYZJ79YolaRycKiKST+VO1KRlaa3kt5Ip1Hzo4wQfoamSSaw1GG5tZRFMnKMDyD2p+q3GoX88tzqUyzXLpw2ADinG3bUys279DK04Hai9zzWrY6hLFM6vyDxisrTmOxAc9OtXI1BYuTgM2AKwZ7XKnozr7CVfJVixBIx1zzVt1TyiHbc5FYdirCL5HyOtaNuSAVL7pD69q0jKyscM6dndFu0toZpETHlgEK2R0z3rptb0Sy0cWclvdbnkO0hsHI9axtN0281B2jt4t74y5zjA7VBNbSGd4WYl4jg7+3tXRGM1Fu2hxTbnUSU7W3RJc4eaRcLj1qOMn7Uv7vcqLheOAalijMbsnynI5NWooSV4JVepx0qGrjclFWKqKDPtUHeeWPatrwxpcOoXLLMSI0GSFPU1lSSRo5EQ4XqRT9Nu5raYzW0nlntT62XcyqxlKDUHZm7q9klhftHATs2hgrckZrGuI+Tu6FulSm6lmZpppTJO3UmkXljn6g1tOam7pWMaUZQSUndkaqMkFQc8YpFijRFVkAf1okEgcOnOOMVZiAfaX5YelZs0cmtRgjPKp/Fzn0p8oGVLDoMdOatlQgDHgDtVZ5Q8nTINNqxCk5O5DaAuWIBz6mtDTp1S5jTsJF/nUMCFcgjC1NaQ4v4Qfu71/nStoTNqV7nzLLCWLlgMccetU2LRfNtO3HK9a2Z1KFQ6/K3pVGRSkZD4IJ6D0qEzpaSY61ZGiy7DGOBUQdV4UHn07VFIGtthQb0798U9GR8Mo4BOcUbBHcA2JCduCOvvVwyMzBoUww4IFVVUl8jn61cglEJEmwNjAK0a3G/Mvx3SNtbyxhOOnNPikVpcGPgdQazoH/wBIZnAVWOQAcVoW5EpLo3OcBPak0JpLUZdbgdxjODzgVNAWlUMScgdDSSKYszSHI6Y9Kg8p1kVoHI3c4PSi/caV42H3BaSaMSpujzzx0pk9pDKZNgKgc5FWi0jKGDKMHpQkZ3BicAdcd6LjRnxwySAEyE7egJpI450SQs24deeCKvSgCdXUArnk1POvUKAUYdRyaH5FcxlQJJJCSxCoTzWhaxiSLC7Tgcc9aaLUbViDMDjPSpoAIYsIpLqe/FQ1cptPYp3MCIqmVCvPXGar2CsjuZcGM9zWtd5ltyWA/AVoeFrG1vYLwajBcSRx27NGYBkhx0z7UK70RDlyxbfQyxHhWZT8nanwkXC9QMcA4qtp8E0sZjjbLehqy9reWYRp02NKMp7ipd76mjgixYyTWrhoLgxtuG7B61v6Vr9haXcpvNJW6DREBiMnee9cipYZMuQwPQVJLe+QjjGc9D3FOLszKpR5tH+BWkmdTJ5i7ckkHHTnpWZMsksuDgc1YLSyS53CTJz0qOdWbJzgAk+hrW/M7j+HQhZQp25BJ60zzC42AZHHPpSSZUYH8XAz1oVAqKCcAUzNojkwBk9qYqk4JHJ6n2qV+uBwD7U9trA7eMDFBVitKREpKnGe1OgjPlFiO3X3pksecIM4z1qyy4hOM5xjmjRIXUv2yBYgM87fSkjZsgAAAHnOaW1fNqgHLe1N6u7Nnb6d6TNIm3bKNobjp1q/brtAOTkH9Kz4DuiC9ABV4b2jwwKkY6VEi9bD78l7hVIx3zU/LFc9lxnvUE2UuIyy8kYyan3bUAycseCaQpR00Mizj2s8ZJAVz9a1oo4woAGD1FZs6+XqBx6c5qxNJuhWQnbsOCBWclqetSl7SCZvWmIxGQN2e1bdicMWAUADO6sWwYIYGmjJVhlfetpUVgxc+XGTwKqGuqOWv2N7R9autM+0XECrOHAGGB4NUfOuZJpJpj+9ncs3GBzSxwqLHy4846j1PvUqJtt0VslweDXQ1dW6Hn2gpOSWotmhjLuxyAOKX7TIYmLRg4/IU25leGMKnDdyR1pkJVCBK555xUvRCtfVkdqpuZCrBmZsnaorS0LTre/1FYLiQxqMkgHB47VlQXRtpp5YHCyYIUin6c5eSRpMjA65xUN9B1ISadtNDa1y1gsNRkjgbdGqg+pHtVCGTzR8xPpzTZ5FkyEByeaLIBVZh6455NdE5c8r7GUIONO0ndl5EU4HYc02aZEb73JOAKbG4ZyozkjmoHiIuADhlA60m7oiMddTSLrJFtI7VXZCq/Kpx61LbDcW4IH86seV5iBCOPanFXWpnfkdkOjw6Lx25qzAoW5gOcnev86jVPKjTA3MOKTeI7yMN13r/Omk4owb5nofM8dwGkKk4z2NQTFWkcA4zxjrUKMwl2soJ9c06RnEe4YwPasfQ9ISJRkoxzxVWL9xKEIzG44JqRSS24MSfrTbpS0a4XlTkc1SZNizEeTzTnRzvw34GqtpKoIODk/pV4AEhmLFW6Gk9GNO5HbqrgrIWBX071LAJYZsxufm5AxxUWF3mXJB6EYrQUqsSyIC2OODSZdySG6SYeSxIfupHWrGELpj5doqnc2pkdZIR8wHJ9KhM7qQkuRg4yDip0Y+XsaTvHvCj5g3OQKdI8YkAQnH1rM+17QBCpKjuasRIrsJHAD8fLmhuw1F9S/sWUMpUjpx61JEgUGNhgjtSpuVg0i4DDjHSl4j3MeeM9c4oT7kNdCdmBYFQM46VnXqOtwjx9BwwFWoWLRrjBZj24qSVFYEMNvqaGwh7rKrOpjUg59c1Faaje29zLFYTvEJV2NtOMg9RSI0fnOByo/WpJDLGEuIYHG1uHAOM0tjVxVtR1taCFzHkq3oOoq7dxuFiEkryFeFLHOBV7WdV/tC5iup4oo5vLC/ugFDcdTWaJnkBUrz2rOSdyVdpOS1Kd+vl5YMDtFZVxHLJ8zfcYda0LgkKVbO89c1HJltiA8+lWrlOdtDPgSRH/djnpkU+a1IhVxITIfvDFaJjY7gmM459qhnc+V5YAJPGfSqRjzGQ6ebLsbPTOc04qAAvVieMelWUtNuVJO/H3s00plkCLlvaq3DdkBTAxkk5xTGwBgnBFWQg8zc/LH9KrzEEbQAcCga1IogpYAZ9anLDzMcYAqO2jZnx0Pf2qSVQHxkHA7UwW5atARHkjH8qhy0jeVEwMhNTQqwg+UHGOhqTREUzSyOQMnA56VD0ZtFXlZGpYQssQySX7/Wta2RioEvOO9VrWGTGVHy/wB71q1C+0FcHA4qC5JJDwPNjO4fMDRLCHA+U/LyMd6dHIoYIVOTT7t5IWQxjIP8qaMrtOyMq+BjeOQcAgZzRkvEY5AuxjnOOav3cKzqu4gccE1QRvLKrIeh4JHFKSvqdeHq8rszodHdgI0k+ZUXCknlRXSQmFmiCnJ6c1yumy5fKYBPX3rct7kbx+75HfFEXYK8bs3ZWbJERAwKYjKgLOxJ6/jUEMwJ4H1IzSyugxuLZrTmT2OG3Ri3UwmVVTLMTVLVbmSOMRNtRu2O9WBeQjIjG0jvUE6LcOryEOVGQaV76GkEk1fYp714xuyf1Nadqhht9jH53PJ68VUVDv3OoCjoK0LcFyOO2aUY2ZVWWlkXV2xxhkXJx0NJC5I4AGTnikdjuCKM+9RIsgck8LmtTlWq1LVqhjkZgSWc8+lWdoJIPU1UiuCQMDIzirUTZlGOaaaZlJSvqWowA6gHIHBq6i7egx3qKCMBSScVM7gKATk1qtDknK70HI4cnNROiPPGxGCHX+dLHsCnaCc1AMm5ROuXX+dCYorU8Bksba6uEMLhdw5xwKz9Q0ua1JVl3RjkFDVlrcrIpBPB7VNFcyKrJKd4bpmudNHqOD3RzEsbo5OOQcEUDDAggkjsa3bi1ikDFflY89ax7i32hs5zjgg000TYozoyklRtOM4J71JFO6hVL9Oop5R2Cj7x4znvTGQMCF+9603qJJ9C+WEkeePen2kgAeNSAvSspZJYm6tjuPepknCsCOCTgnNKy3KizpLMKsbbnzJn7o7iq2qhHKKnyk4zxTtOuI2Kq5Oc4JxnAqa5VPOjQncC2c47VBpF66lYWv2dkkYboycYPakbZI+YCw+lbHlsIxGSTD9Oc1RFmschkCls9/SpKUk9xEumVFFwD6CpjcFYiOo6mqTSB5vKdDmpkYq5UK5Q4oafQuy3NGEu8EYj+739qlut7RttIKgdutVY7tY32x/Kw7Gp/MWVVxye/PFTruzNrW5UngZYBLGRu9D3rStPE19Z6RLpiRRSwTgthkHykjGc1Xk8vygDxmo4IIRPuIzntWkXy6oJqM1aS0Gxxbgskp+ZeevSpJ/MCptI+Y1ceGLbgsC2OBVC/QjaE5P8qm99w5kytIczjqeSKiXaLosyEBR61M4xgA/MKS4O1CRlmGCapLsQ2Esu4ZjjC+5NQpE773/i9KWKMzEKB8p5p+/yS6rg0yHpsV5RtVOpcjFV1bypCQfmxjFSJIxl+ZSCemKgPz3GCWyOvvQl1HHcfjhsjtwcVRnXd7E9PatGeRmARcbj021VYdA6k85yOaaaC46zXy4f3mMtxmmlSZyegx271ajACgduT6YqMJmYnOcUNjJFG2NscjHQ0ulgPGV6HdyBSkfI2cnAOcGk0pla3ZujhsYqZbHRQ+JmzFeS2rLCBuUg8ntWnHhlA/jbms6AfKFcjHXNWCudxjJOPunFZpm9SKZaQoAFLHdV1hE6gZJ4wPasr55JQ7H58dO1Xrd9kib+M9MU7nNUg1qhJ4wY9gboetRXdmHiCEjA54q1KN77T359CTTAjNJsLcr1JprQUdjNi8+3BeBi2085rVsdXSUok+YpMcA9D+NNhtjG5BddjcjFWZ9PSYcgcdD3o9mm7GntGtDZhuHwpSVNuPSpgSdjSNjPI965q2iZH8hycL901u6ZBNdXAS4BjtY0ODmiMWZzlbUn/dltw5z+lSqME7TgegqLymWRhGSRnjIqQDyyGZNx74q7Mly7j7aBixLcknir6B0IGOCKjtk81S2DtHYVoW+VHzDketaKNjGdQarKgACZPfNN3DaSVwAealkISMsq5yecioPPiD7Od5HTFMzjrqJDEMlwfkboD2p4Xdcq24hDUsIAGcHjtVmyiUlt4+lHKmrClPuTxM7rgNx3qSZCFPXNKuFX5egNI77wRn6VS0OW93oRxyeXb5JO6ptPIe6hY4Pzrkn61XeISoBnv0zUtimLuBeB865/Ok7obtZ9zxGWDlt4wPWqUsDeWeMD6V1MtqM54bPBqGSx3AgAc1y3PWujk/L2jAPB5ziopYlZSRnceMV0d1ppXOATxxWbNbFWO4dKpSTC1znpoMSfQVUaP5TjqDXRTRksOB+FUpoTg9u3FUmiXAx3jO8g/XrUDROCTwV+lackBX5gcn271A3ydWwPaqIcSC3uWhII71owXH2lAd/zA+vOazpoty4U49/WoYvMtXU7COc5pWuCfKdvp91JImxl+YdmFaPkhwAAAuM8VyFtqOVLNy575roNMvugzuTHOamS7ikr6obc2BL+bH1qKNZShLLwOK1TkhtjZB6VTWIwyEsx59ah+TLjN2syjNCJJFVFJdqcqPbvIkkbIRxg9qszbUlUqWDDkYpZ33ylpWy7Z+91oXZml7orMj4UBvlJ5qdYTIw2fnUJjXDB25zxz0qbT5mRGzlRjv3oegm3YttZypGHVyVJ6d8Vnyo0cjFzw3Ga0VVpCXWTgDpmqV+3yhmPC9zTWpldvQz70sknyn5e9KIpGj3hmwevHWmSM0hyF4zkZHWn/aXRggjYr654rTfYTuWjGI4shsMBms+SKQtvBY5q4zAphsZPvTZidgDnH0o2IV09SKSBVjX5vm9qgeHYFKE7mPNTuACCTnjvTyNrL/Fx3pdSr2K6JsOdo5qEJ8zZ4A9+KtkZDYOefypiKCCT0bg09AjrqV2HlnJJKnpSxj5Szd/0p854bGSAO4p0SeYgKnJB5HTFSixflBO8e2c1WswVu2wAATwRV5wCvI+XHaqQRlIdeNvIPrQ9UawfK7m/bIx6hlXHBI61bjEiAgBcEZxVe3ufMtkQMBlep7VdgKDbuOff1qFY3nMdCCY1c43Vcs1Qzodu8Lk4xVdSCTgdulaFg6xYZV5Iwc07I5pvS5FMiE/KB97P0qP5VLgfe7kHtT5VYM3yEHtzUduoQknjI59c0ChsWomEU1vIQpCsDgjIrYCyzSPO0BjiY/KQODWXDteIAqDng+xrbtrud7NLeWZ2jT7qdQKqLV7EVG+hmTRbpgw6r61pWMhdSOMDiotodjnqO9Os22s47jpTaaY90XyMIzbQpHTmoogcMzjBb3qcFmwQPzoYlACxBPTpWttDNMs2eFyFPFWgNsm7II9MVFbsuwEkZpGnXlcc0J6GDvcncFh8vSojEuzII3VFDI7W7kgqc8UxGYuqg5J5NK5aTLSOFAUglj6VdQAAEZx/WqkKfNk9emDV1V2xjAwKpamVTsPVwEx+dRZC55xxmiMk57ikP8Wep9KLmaRHHPyG75qzb4F1E+csXX8OapBcPj+EVatlLXkDfw71H6il1sXJI4VY1J6GpPJULnBGalhQE8/z61Y8r8B6VzpHc9DPe19gc1RuLEHcSOvtW/sOPWkMWcetO1hczRxN1YYxxj6VkzWpjOccGvQbmzB5IrGudPO5mUZz2otYtTvucLJD1GQPoKp3EHGVP1zXWX2n4HI5rIubYL8wHAFCdyrX2MB1KjpyKchMoxKeBVyVAU3McDsDUbwLgcgPjg54qr3JkrFKe2eMvLbOCp7elPstQaCX5hhh1UnrUyM8B8uUspPO7sadcWyTDLjLEdc5p3XUy1Wxu2l8JwGyqnIxzV6SaGUF2kztNcGFmsJgXJKNwD7Vp2N1Fv5kPI6HpUOF9UONmdM+dy4TcoHWpdR1JbuxtbdLBI5YmOZQeXqtbzxkDYRjHINPXa82V5JqVdO5WnUzLmYwSs8gIUjrTbeaQqzg5yRge1XNatpBA7Y5HIrPtriMQKecjtVpWNLpxui7azzb8MOOnWq2puZmSHYQc9RUq73OR0Izx/WnojDe2MNjFC8iZOzI7QdFYYCjpTo4la4yxwoz3pqBoW5yw9adYsrXEjMSoBzg07tGD3FltwZN24qoGQCKjkYPE24YPr6Vdvp4tvYnOBVQyKiHIGW4p2JUnbUp3EhyuwnYBip4Ecruk6nnrSxiJFO453DipSFWBVzkUbmstUQkDkE9MGlA/uZA9jQ54wQp+lInyFgF49O1LlElYrzqQ/3iUI5qa1U7S205PFRz4BOTgEVZtgMKeSOg4o0He6GfdOCvGOc0m0bmRuh6cVadCvqKAuXzg7vU1N9TW6GWwVQsfOK07QkM7MMqOneqkEQZwGIVick1cBWIsCfl6etJs05uhetgXTcvf1rQRQsYC5461Vs1VY1yDk8jirfyrKvzc9xSZjN6hOwMYbac1HNuIVo1X5eDVl2TgnGBSMQi4AGG5qiIysQwM+4KRwe9a1oxVlBxg+tZykZORxV6MDcCvzEUI0lqXX+Qf7RqSzTdlttRjdIF67j7Zq2sbI+32zWyRg3oW7dV2l8ZXtRIEkCkAg5yQRQr/KNpwMdqa8gYnJIqr6GSTuIZQJSmPekYNt3qMsaQMq4zj6ntUkThucYxSbKHx5C/Nz7U6CLLA8jFNZzgYxk0+J9vU9aQO5NECXJ79KmMjiQKOh60sOwg/MMemKjLOJBtGBTWxle7JnJVcDgGpI1UqQccDtTWJMfI596ng8vyxk/U013M3sVZIzsBwRk1LCcXNuq/31/nUkm3JyMgVFbMTexHsJF/nQwTujjrZgx6VdDZAHXFUoQAc96shmHQcCue2p6T1LGM9B3p4QHB/pUKMd1WEOR14qkYyVhjw5FVp7UHnFaKMgO1h2pWUFcr1z0qjNto5q6sQ6njkjpXM6npjxA4HB56V6HLGrLyOay7+2V4yu0k0nBM0hUaZ5rPbqzgMuQKpXFoWyYyN3YYrrNQsMMSFx+FZF1bEjAJVu2KzvbQ67c2qMGSRkjaGUAg8YPem+UV2qMMMcg9q054iRiYAgdx61XmhwgIUbexHWqTJce5nTASoId/IH3WHf61UksnQK0fykVpGFs5IDDPHrTgu5eo2j17VV2ZuNlYqW13NEfnwwA79a001AY3ITuAzg96oOm4kghs9ADVVwysWQkEdjRZEao6mHUBNDtaMkkVUayUxgqpxkn6Vkw381ryrAHHII61dh1fKFTwD1FS09kXGVtizY+dFK0Z71alt584yMEZxVZ72NmjZGC5wDV1LlSm95BuxgY9KJKxMm9ypJaTGMNuYqOcVVEUnmb5WA46LWi86lMZPJ71GEbzTg5HXHtTT0sZXY2KPzV3gZAOBn1pZ7ciULIRyMj608xtHySOTkc0+2kRXkMybgBjBqXoVuZ5lZGETL93oT1qYK6xNuJI6+1R3iv5yyqMgdAOuKntXeRyJMquR1qkyxI1Yxb9wGe2Kj2mOMhmy3XpVmXByFOCRngVTuA2M7vrjvTQXbZXlyznntwK1LMldgYDKjNZB8t/vH5j6VpWpURKV5PQ0upbjZF6UFthI96Yx/eBwMDvUg+dD82DjiogQIwgOWHJNS0JEqqR8+4c9hTgQVBbnHpSx4GQR1H5UrgmPCCpbNo3ZpW0p3DaTjHpWjCE3bhk4GcmsSPcpVBgAcZrSim8tAAN3OKRNSJcYZyuO1ITjg9vSkZxJjH5VFtbzTuB2jvVXM4osLiVz0+XtVlEG5SO9V7b5YxsB3N0qztcbG+6QeadimaMRERRt5VlP8JqczmWTJY59fWqZ2sOvzEU5ccMDyK0RjZGgJjggLjHtTJFZpNwHBpFkXgk9D0qeVsRh8celUtSdmMk6AFc1MhJQjgVGCXxxj0pZVKK2chsUtx+QoA3ZLcUNgAnFMXgDP50/cBk9cUtxtWJ7KQ/NuJAHNTidC5wc47mq0OAjY/i4psCbiVbANCVloZ8qbbNCN/OQnH1p0ce2Qc/uxzimROI8xqDTrh/3e1ePemlpZmT3sOnnDu2w8DjFFuSJ7fJ5Mi/zqqkaJgt25qSKYNcw4HO9f50XuPlSVkc9Eu1uBxUuM9KtLDnPp9PpTXjKq2KSR0c92Vxu3elSo2OSajLEH5utIrBxyCPrU2L3RaVsng59ak2tgsmc1VQEEZxVmGTa3OCD700+5nKPYbvyMNUToA3r6VbfaTnAqs4OSVxinclamZeWokJ+XrWBqGm4OR6V2H31ww56c1SvLbIyQD6VLVzWM3E4Ke3wAApK1Ue3xGzL90dRmusubPk4XjPIqjdWURiccjjjHrUWN+e5yxT/nnkEHPSqzKCTlQAOvFbM1sMnbxj0NUpoWw2BzjpTuOyM6WIN91fxUVV+ePKyRlk9SK1UDbOQVY0ksY2/dJX2p3ZDjcyXkBXkrtHYjrVSRW3kjgDmtSaBcHjjr07VWls2bdtbjqM1aZnKDRThkdGbPJHrVuO8bbiQL078VWe3bHzDkckimqx4DDj1p7kXaNy2lj8nphsVZgkJUMw5x3Fc+JiqAb+PWrsN4wK/OCoHbipsS3Y01kbcGABIOammSVh5gHHUgCqH9oRACPHzY6g9atLeqqkZLPiize4tthGnV3JAwFGNtPG1olyMc9RVeAKboswKjqQT1q7IymNlRfvcg+lSaLYg3Bn2qT6U+cFo8KM4JANMhi2N5jAdccmpySqg8YHQ00xpIyvs584FlBHTp0q/bJ8hwCBjAAoQFipLD3qygAGBwBQmW+w1MtGN3H8NR+XsYD7zZxmhQ5ckY25zmkldhKzL04xQ2XCLZajHmSFDnpnNXoFCjb2xyTVNAXiU4yeQau2wxAu7k1n6FO6VicAM3y7ST+lXIVVSFbPHpUcMar5bP8ALk44qwi75WAxwOKlmb7Ia7bQ24cnpxUobeVBAUVHIm9jk4OeAacm3PzEHAzVJgloXImVRxjAqeULtU54PJqoiqsgYEbT1xVhWDPg+naqTsKxatHwPlCnPHSlUbjtGfl6mmRhcgr8vYVZ/gZYx9aqJOidxLRPMcs+Tg9fWtR48xDIyKbBC8duoZBuPzdalf5VBBB9a0irGM53ZEOoI605yz8nnNJsJXeOFokbavzce1Fg6iBe5xTG5yMdKZ553YWlLhutTc0SZOh4znp7VJZ8SHPHvVVDjcuOc8CrcTAYzgUeRMtCcMFJx1oMikhPXnNQTNnhTwOaRH8uPc3LHpQ2+hChpcnlIHAPJ6VGpCyw9Cd46fWqxcs+WPy0sTgXEWem8Y/OlfoVy2RLCcEgjinSRBh7ZpwTY+xlKn0PapVjbuOBWlrEN9UZ7wZycfjUBjKtkVqyx8ZFVygbgg0mi4zKbKwHymgEjHGKs7dp2n6VHJGegHFLluWpCrJlevWmg/MVPTqKjX5WxjmnAbic9uanUbSHMQT0waXk4/xpjnng0qPxnNK5LiQXForHeBxWfcWQJIIGK21cE4PSmyRB27Zp6CTd7HHXWmbQT264rHnsyqnOc+9d9LCCGVhnmsW9sdzcKOKTjpc2hPocdNakH1NU5EIQjH61089tsYjFZ01twTgZqTTcwGUgnGfcUxwCgIGD6YxWlLAA3A5qvJGykleme9MTM6RQuQoJb2NVpYVkyCQGHHetVlDDIwCecVAy9AFwT05p8xPLcyPJZSVKkqBUQXJwMgenStYxLg7vvH0NQ3NuBECF59fSqTRm6bWxTR/IcttGehBqVJlZ1LHgHPBFV3V0LFjUedpJ6emKe5mrnS2V1AuQ4BZuBmrkDRMy5IC+ua5SKRxksc561bhvACpB4x0zUWZVjpbxAqqyfMp6c1TmlDIFckAY4qjFfucbySo6DNWfNhm6Egg5FDuVFdyeFgjHGDkdqnTMjMSMqOPWqLsYiB8oX+8avaeSIAf4W6k1LRqrJNiBWG/qccgUjrlA3G49farGz95lOB6UeUGjbdgHPAzSuUnoSRsFi2qOR1PrVq3yxG3lccjNVIWMcflsQxq5p65ZinT0qkymaLY/d4JHI4q7AB1XH+NZ+A0inGMdKvWrKTt3fMBRJamL0Vh188cTDuW/SktrYSjLYQ1JcosgG4AEYqORHL+ZG+Fxg1m0OO1kTCKSOJwQC3bHpSxZ8wHHI7mnLMxABweOuKQFlPqO5ovoNX6luJCzDIx3rXZEVVWIdRkmsmA+YF5O2tCKQMQo4x71tFmE0zUiQC3JY5Y/pVeVQicdT2p5kCqBnBPam3EYWQANk4rZbGEU0yFg4VG5Ck9KimkMr/N1FPYsMd8dqhJ3EkA1m7G8Y9Rjthgq9+9OQHeD1OabkEZOBimxN5zjaTge9Zs1toXANpLD7x96RMKoL9c9KFYbScg47elMkbcAPyqtLGe5ZMi4OCDnpTCWPPQLUWwkjdwQKazn7g70XdtQStsK5K/N1HpSQyHz4iwGfMH86iuZtuEx83tVeTzVDzFXEVuPNlfHCKOSx/Cpeo7aanF/BH4np4nt49C8QXGdehXbbXDHH2xAOhJ/5aAf99D3FewxqcYIGRX592lxLazxTQSvFLG4dHRsMjDkMD6ivr/4KfEqLxzpv2HUnRPElsmZFAwLtBj96g/vf3l/EcZA9GdK/vI8ajX05ZHohj4qMwgHOKvCIucj8RThCSCDxxWLijp9pYzHjVjhh+NQyQbep4zxWo9qTmm/Zy6FTkkdDUuNi41UYxjwTnrUMinsOa03hYEq4/GoTCQMMPoaho3jNGSRnPY0q5UEdiO1XZIeSCPxqBottQ4mymmiDgNnOBU8b5I6fhURGM5HFA2qfY1DTG1cmvYlUkgjnms+RDu6ZFW3AYEjioWO3HPA61XM7WYoxsZdzAJO2Oay7i2ZD0wK6N0VwCDg5qjMmSQRn61LLizmZ4cMVPXqKpT267M8g10NxADnb1qg8BBII471LNbJnOywlWJwSvTFViFXHpnpW/PBx6ZqjLbAhcJ9DiqugsZhQBQy7j7elMBD5GDnPTNWZU8vBYEjvVUgbsqdvPYUgVupG9qGLEAKOlVpbZShGCc98VoK3TPY9PWmyqSS27Ax0pqQpQTMeWEoBt+6KagCkAd+c96102OAJEyMVXa2BLNHnOOh4qkzN09TPKkJuGcnvT0ldG56fWrBgZGYDJ4z1qNoCQ3QEd6FZi5Wi7FPvYA9u2K1ISFwYzkDsDXPNHtiBTKyd+9WLa4aAAlmyexPWlYdmdH5h2HPBPQ1PGNqhvvE9axo75iCGx7VbinygCkA44NQyrNIvySA7t3BxxxT7aXYu7PXgY65qmp3Nk+npU0R+YY55z+NCZdjatyrLsYksRmtC1ChQ3HHGayYG2uHdcn2rTgKbCCcKBnGapamUuyLWecsOOlOiQKjAfxetQpKrnHA4PepRIVVdy57Dmm1fchXJ0gUKWd/mA4FRQRZl+dvlbrU4bMmSOMYxSkquTnOe3pS5EWmx8Q2gRqcj1q/ZxoCxccgDFZ0TDdtJ4HStO1yVIPQULRmc9i0pVmXfxinzECU7c+1RRqCc5qR8A47+pra+mph1K0pIyMc1VmmEcfTk1ckXPqPQ1QuY9zYXt6iokb07MiMvmqBjFWLSIg5JOBVeKOTG4cknj2q0JG3hWbA7+9ZWb3NpPohzODnHH0pEViw56UrlcgAcVJG4jy20EEYzmtJGV7IbI2G+c57Cq8jbG4HJ6+1SSPyWOMduKq4klk2xKXkdsYHU1LsUkOVvNkGACTzk8AevPYe9eHfG74nR6qs3hvw1MDo8bD7VdJkG8cdh3CA9B3PJ7VN8ZfiGoin8OeHpgYz8l/dxtkOQeY0P931Pc8DivDnPPBJrroUbe9M8zGYlfw4EdX9I1O60jULa/024ktr23cSRTRnDKw6HNZ9LXWjzD7l+DnxHsfiHop3mO28QWqj7XaKcBx081B/dPcfwk+mK9B8pgMEZFfnh4Z16/8ADmt2mq6RcPb3tq26N1P5qR0KkcEHqOK+5vhX8QNO+IPh1b20Cw38OEvLTOTCx7j1Q44P4HkVLiuhaqNHUOuBnoKj6DO3ir80GRlelVzBx14qOXQ0jNMryKr9QPyqu1spGOMVpiEEcimy2xxkA/SoaLVW2hiS2iqxZenp3qrLCp4PB9625EK/eFVniVhnGPfFQ4HTCs+pz89syn5R0qBojjpit+W2P1BqBoO2OntWTgdUaxguhHQkGkbkdM1rT2+4HjB+lVjbAEkcVEomyqJmTxuCsKjkAc5GcitSW3wM4/GqjxYIwKizNVJMy5IjuzjkVWnt9wbPGe1a7RnPNRNHgnI5qSr9jnngbftI4HfFVbiKRSSoGO2K6OUbgMJk+lVJ4RgEqQfQUr6lcxzcsMbABxhiKzZbFYgdmWBNdPPaoTkA7gOhrOkiKhgwyDzVJlWTMCUA8gHg8UxgTJuJGPStSWJORt6DsM1VkUKw3D2+tAFTH8ORxzTJHGSvXIq06nAwAe/FRNHuwTimNLqVypB+QnBODSSIWAIUlh71OQAD69RTowck5PPt1pDKy23H7w7R147Us9qvAXBFW2CluOw6elGMHpn+VO5DRmPEUIJz1/CpInIfJOcdMVbeEN8pHHrULx/KAo4o0YrWLlrN8oDnqcZq4rfvE2ZHqTWRGSucL71oW7ksBkYPrSaFc3Yp8x89MVbhbegXOCP1rGjkYL0Qn0q5HNsGVbJIycdqL2M7Pc1lIwigFmJ5PpUsZPnFWPyr/DWZBcZAXzOehHWrkN4oLISNxPDYwaFISTRoxO+/bz6g09pAW3McDvVfziEVl+Y5xmonlDZAUn61SloGrLIlCynPT61uafKpjwT71y2f3w9PetzSlkkcbc/QUk7sVRLlN0EAdMmgrxyQM02JSX2t2qVjul25AArp5TkvZlVgWfnGMVE6KWHfFTz7UJCOCf5VX2vs4PPespI2ixjTBSVj4xTIo8qS3PpUtvb7iA3Pqasuqlto6CosynJLREHynAIqKYhX9cjgVL5eHDt8o9Mdar3BJY7OcZ5oYKWpWklGfLUctxxXlXxh+IX9jQT+HtFl/wCJk4KXlwjf8e47xqf7/wDePbpWh8WPHaeFLZtN0yRG8QSr8zryLND/AOzkflnPXFfN9xO0zs0jMzsSSSc5/wAmuihRv70vkcWLxXIuSG41m3Z55xUJpc0ldh5QlFFFADl610fgXxdqfgvxDbaxo0u2eLh0b7kyH7yMO4P/ANeubzSg09AP0W+HPjLS/Hnh2HVdHbGcLcWzN88EmOVb+YPQjmumktwx+XjNfnp8MfH2qeAPEsWqaWxeFsJdWrNhJ48/dPoe4PY/jX3x4L8UaZ4y8O22saJP5ttMOVPDxOOqMOxH/wBemrGUrxNAwNj1IoRSQQw5q0G5ww696XZg80OBPtH1My4h4yBkVVaAdSOK22jz9Kry2+ei4zWbiawrdDElh6kCoSgPBFbDQMv3lz9Ki8gFsDjNRynVGsYcsDD3FVpYd3Tg1vT25jJ4zVSSEP2qJUzphX0MUwsSAcHvVee1DDPQ98VuS23TbVOWMg/d5FZuHc6YVb7GBKrR5OM4NREJMpBBBHfFa8/OVEXPqe9VigyfkK/yrGUDrjLTUy2i8sdefWoZfmU7lDYrXeEMuDjH0qtNaDjYQTisuVlRa6nP3VqrksgZW9DWbNAFI3nPtiuiuLaQSBw+1e4IqlNZvuG58jPApanTBruYE9uCWZUYHsBWfLEDIVYEGuo+xsAT6np7VXkskIBdBSTL0Zx8ltKpOGyD1ppCg9wAOnfNdRNZKFyuACc1nXOmoxyTkelPoFrmP5e4hiOBzSFMfdz+daMlswG1QWXHYVGsQRT8rZ+lCfcOUpBHGcDr61JEhMhHb0qykZDsW/CjyF6k9etO4nEhkibIODt9KiaMFiq5GB2q8ABkHg9hTTFl+n1ouTZmcIjhSeDjNOVSg79c8VfEZG7CE/hThbrgEcE007ktFWN24y2c84q2s5GF+bGPxpPsqDPqKa0OE35wem0UOxNi2ky8ZJz1zU4k8xhgjI596ylc/d2kemKmikYPkcUtAsaouHViCzewBqT7SOfnI9TWaj7myOWqyuO6jB9qQ2i/DcBmUHkDoa2PD9zLDfh1clVP3fUVzSSBCT8qgdK3fDySIZLl1YocgHtQZ1UlFnYyzIzCUMo3c7aWZSYw6DdkZ+XtXMvd7M9+2Kr2urXdu7xoVELEEetdcqvLqcSpNnRyRyEmUD5e9Q+cF3eYevYVky6rI/A6elEl4oi3SH5h3rN1Ys0jBrc2o7kFwu1ufQU2IzzTlUBCDqTVXTrlJoojDln6liOlTalfpbYW3cbujEDrThyzTT0JlJxlaxLOxRiGIIHA5rz34ofECPwjZeRZssmsXC/uUIyIFPHmMPX0B69TUnjzxvB4X0hrqUrcajcAi1tm/i/22/2AfzIx618xavqV1ql9PeX87z3UzF3kc5JJrWlTU3zM5cRW9kuVbkV7eS3dxLcXLtNcSsXeRySzEnJJPeqhOTQTRXZc8vd3EooopAFFFFABS0UUAPj+8PrX0h+xbPMPEPiWASyeSbaJ/L3Hbu3kZx0zjjNFFUtzOp8LPrG7+4PrT4vufhRRVmS2AdqkI6UUVLIK8gGKpycOMUUVnLY6IEM3Q1XkHzL9KKKyOmnsRN3qCYDjgUUU0dFMo3CruAwMfSqMwG7GOKKKxqnfT2KNz/rRVRiRIMEiiiuWe51xJZQDBzVd1Hlg4GcdcUUVjI1W5UYDPQday5P+Pk0UUjogQXnQfjVRf9V/wKiig0RHJwGx6VRcD0oooQDUA3N9Khk7/WiiqYmL1f8AKrCD5noopImWw9eh+tJIP3LfWiirM3uVx90Ux+WOfSiilDcoYOq03+I/WiitGZzHRk+YKtyf6oUUVJDGP/ql+grtrUkaPbgHjB4oopR+Myr/AAoy7s4fioD93PeiitJbsVPYbk7upqXqozzz3ooqOhszctPl0uUrwQvGK56diWkySeR3+lFFN7HHT/iM+f8A4sSPJ471YSOzhJSiBjnaoVcAegHpXEyfeNFFetD4EeLif40hlFFFBiFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gastric carcinoids in the proximal gastric body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Akira Horiuchi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19906=[""].join("\n");
var outline_f19_28_19906=null;
var title_f19_28_19907="LV pressure echo Doppler MV";
var content_f19_28_19907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Doppler-derived mitral flow and left ventricular pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneously recorded left ventricular pressure, with the change in pressure over time (dp/dt) and mitral valve inflow velocity derived from Doppler echocardiography. The peak early filling (PE) corresponds to the early part of diastole while peak atrial filling (PA) is the flow velocity increase due to atrial contraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd ed, Mosby-Year Book, St. Louis, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19907=[""].join("\n");
var outline_f19_28_19907=null;
var title_f19_28_19908="Subcuticular suture";
var content_f19_28_19908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Subcuticular suture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The suture is anchored at one end of the laceration (A). The plane chosen is either the dermis or just deep to the dermis in the superficial subcutaneous fascia. While maintaining this plane, \"mirror image\" bites are taken horizontally the full length of the wound (B). The final bite leaves a trailing loop of suture, as shown, so that the knot can be fashioned for final closure (C). This technique is commonly supplemented with wound tapes, particularly if there remains some degree of gapping of the edges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Trott, AT. Wounds and lacerations: emergency care and closure, 2nd ed, Mosby Year Book, St. Louis 1997. p.160. Copyright &copy;1997 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19908=[""].join("\n");
var outline_f19_28_19908=null;
var title_f19_28_19909="Amiloride and hydrochlorothiazide: Patient drug information";
var content_f19_28_19909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amiloride and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/51/40757?source=see_link\">",
"     see \"Amiloride and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ami-Hydro;",
"     </li>",
"     <li>",
"      Apo-Amilzide&reg;;",
"     </li>",
"     <li>",
"      Gen-Amilazide;",
"     </li>",
"     <li>",
"      Moduret;",
"     </li>",
"     <li>",
"      Novamilor;",
"     </li>",
"     <li>",
"      Nu-Amilzide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is a strong water pill. Sometimes elements (potassium) in the blood may be raised. The chance is greatest in people with high blood sugar (diabetes), kidney disease, very bad illness, and/or in older adults. Your doctor will follow you closely to change the dose to match your body's needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701489",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amiloride, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High potassium levels or kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For men, enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, breast soreness, deeper voice, or more hair growth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11459 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19909=[""].join("\n");
var outline_f19_28_19909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133118\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026214\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026216\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026215\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026220\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026221\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026223\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026218\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026219\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026224\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026225\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/51/40757?source=related_link\">",
"      Amiloride and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_28_19910="Vitamin E: Drug information";
var content_f19_28_19910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin E: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/45/40659?source=see_link\">",
"    see \"Vitamin E: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33988?source=see_link\">",
"    see \"Vitamin E: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alph-E [OTC];",
"     </li>",
"     <li>",
"      Alph-E-Mixed [OTC];",
"     </li>",
"     <li>",
"      Aqua Gem-E&trade; [OTC];",
"     </li>",
"     <li>",
"      Aquasol E&reg; [OTC];",
"     </li>",
"     <li>",
"      d-Alpha Gems&trade; [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; Elite [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; [OTC];",
"     </li>",
"     <li>",
"      E-Gem&reg; Lip Care [OTC];",
"     </li>",
"     <li>",
"      E-Gem&reg; [OTC];",
"     </li>",
"     <li>",
"      Ester-E&trade; [OTC];",
"     </li>",
"     <li>",
"      Gamma E-Gems&reg; [OTC];",
"     </li>",
"     <li>",
"      Gamma-E PLUS [OTC];",
"     </li>",
"     <li>",
"      High Gamma Vitamin E Complete&trade; [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; Kaps [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; Powder [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Fat Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin E may be expressed as alpha-tocopherol equivalents (ATE), which refer to the biologically-active (R) stereoisomer content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA)",
"     </b>",
"     (IOM, 2000): Oral: 15 mg; upper limit of intake should not exceed 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pregnant female:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;18 years: 15 mg; upper level of intake should not exceed 800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 15 mg; upper level of intake should not exceed 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Lactating female:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;18 years: 19 mg; upper level of intake should not exceed 800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 19 mg; upper level of intake should not exceed 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin E deficiency:",
"     </b>",
"     Oral: 60-75 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial dermatologic irritation:",
"     </b>",
"     Topical: Apply a thin layer over affected area.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33988?source=see_link\">",
"      see \"Vitamin E: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin E may be expressed as alpha-tocopherol equivalents (ATE), which refer to the biologically-active (R) stereoisomer content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral (IOM, 2000): Infants (RDA not established):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral (IOM, 2000): Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 6 mg; upper limit of intake should not exceed 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 7 mg; upper limit of intake should not exceed 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 11 mg; upper limit of intake should not exceed 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: 15 mg; upper limit of intake should not exceed 800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vitamin E deficiency:",
"     </b>",
"     Oral: Children (with malabsorption syndrome): 1 unit/kg/day of water miscible vitamin E (to raise plasma tocopherol concentrations to the normal range within 2 months and to maintain normal plasma concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis supplementation (Borowitz, 2002):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-12 months: 40-50 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 80-150 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 100-200 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;8 years: 200-400 units/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg; Kaps: 200 units, 400 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid, oral: 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 100 units, 200 units, 400 units, 600 units, 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 200 units, 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 400 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E-Mixed: 200 units, 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E-Mixed: 1000 units [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aqua Gem-E&trade;: 200 units, 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     d-Alpha Gems&trade;: 400 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gems&reg;: 30 units, 100 units, 200 units, 400 units, 600 units, 800 units, 1000 units, 1200 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gems&reg; Elite: 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gems&reg; Plus: 200 units, 400 units, 800 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ester-E&trade;: 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gamma E-Gems&reg;: 90 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gamma-E PLUS: 200 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High Gamma Vitamin E Complete&trade;: 200 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 1000 units/120 g (120 g); 100 units/g (57 g, 60 g); 30,000 units/57 g (57 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 30 units/g (57 g, 120 g, 600 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lip balm, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gem&reg; Lip Care: 1000 units/tube [contains aloe, vitamin A]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral/topical: 1150 units/1.25 mL (30 mL, 60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral/topical: 100 units/0.25 mL (74 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral/topical [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gem&reg;: 10 units/drop (15 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 28,000 units/30 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 30 units/g (57 g, 113 g, 500 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg; Powder:  (15 g, 75 g, 1000 g) [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]: 15 units/0.3 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquasol E&reg;: 15 units/0.3 mL (12 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal/vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 30 units (12s, 24s) [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 units, 200 units, 400 units, 500 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 200 units, 400 units [derived from or manufactured using soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Swallow capsules whole; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aquasol E&reg; may be confused with Anusol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Contact dermatitis with topical preparation, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Creatinuria, gonadal dysfunction, hypercholesterolemia, hypertriglyceridemia, serum thyroxine decreased, serum triiodothyronine decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, intestinal cramps, nausea, necrotizing enterocolitis (infants)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: CPK increased, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vitamin E or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin K deficiency: May induce vitamin K deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Low birth weight infants: Necrotizing enterocolitis has been associated with oral administration of large dosages (eg, &gt;200 units/day) of a hyperosmolar vitamin E preparation in low birth weight infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Vitamin E may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Vitamin E may enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Vitamin E may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the adverse/toxic effect of Vitamin E. This interaction only applies to tipranavir oral solution. Management: Patients taking tipranavir oral solution are advised to avoid taking additional vitamin E, beyond the amounts contained in a multivitamin product.  This interaction does not apply to tipranavir capsules.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14192601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin E crosses the placenta. Maternal serum concentrations of &alpha; tocopherol increase with lipid concentrations as pregnancy progresses; however, placental transfer remains constant. Additional supplementation is not needed in pregnant women without deficiency (IOM, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14192602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Vitamin E is found in breast milk; concentrations decrease over time and are highest immediately postpartum. Breast milk concentrations may be affected by maternal intake; however, additional supplementation is not needed in nursing women (IOM, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F234553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Formula E 400 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (100): $10.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vitamin E Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 unit (100): $2.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 unit (100): $5.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (100): $7.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 unit (50): $3.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (50): $7.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Vitamin E Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (250): $18.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Vitamin E External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/g (57 g): $3.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Aqua-E Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-2 mg/mL (118 mL): $19.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Nutr-E-Sol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit/15 mL (473 mL): $38.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aquasol E Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 unit/0.3 mL (12 mL): $37.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (E-Pherol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (90): $20.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vitamin E Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 unit (100): $7.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 unit (100): $10.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (100): $16.52",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F234543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma tocopherol concentrations (normal range: 6-14 mcg/mL)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F234546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 0.8-1.5 mg/dL (SI: 19-35 micromole/L), some method variation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aquasol E (CO);",
"     </li>",
"     <li>",
"      Aquavit-E (DO, HN, PA, SV);",
"     </li>",
"     <li>",
"      Dermorelle (FR);",
"     </li>",
"     <li>",
"      Ephynal (AT, BE, CH, ES, GR, IT, PT);",
"     </li>",
"     <li>",
"      Etec 1000 (EC);",
"     </li>",
"     <li>",
"      Eternal (MX);",
"     </li>",
"     <li>",
"      Evion (IN);",
"     </li>",
"     <li>",
"      Ixopolet (MX);",
"     </li>",
"     <li>",
"      Livingpherol (KP);",
"     </li>",
"     <li>",
"      Vita-E 400 (EC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents oxidation of vitamin A and C; protects polyunsaturated fatty acids in membranes from attack by free radicals and protects red blood cells against hemolysis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Depends on presence of bile; reduced in conditions of malabsorption, in low birth weight premature infants, and as dosage increases; water miscible preparations are better absorbed than oil preparations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To all body tissues, especially adipose tissue, where it is stored",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn, &ldquo;Vitamin E and the Prevention of Retinopathy of Prematurity,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1985, 76(2):315-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/3895151/pubmed\" id=\"3895151\" target=\"_blank\">",
"        3895151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bieri JG, Corash L, and Hubbard VS, &ldquo;Medical Uses of Vitamin E,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1983, 308(18):1063-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/6339932/pubmed\" id=\"6339932\" target=\"_blank\">",
"        6339932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borowitz D, Baker RD, and Stallings V,  \"Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2002, 35(3):246-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/12352509/pubmed\" id=\"12352509\" target=\"_blank\">",
"        12352509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown BG, Zhao XQ, Chait A, et al, &ldquo;Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(22):1583-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/11757504/pubmed\" id=\"11757504\" target=\"_blank\">",
"        11757504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2001, 285(19):2486-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/11368702/pubmed\" id=\"11368702\" target=\"_blank\">",
"        11368702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hale TW, Rais-Bahrami K, Montgomery DL, et al, &ldquo;Vitamin E Toxicity in Neonatal Piglets,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(2):123-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/7897750/pubmed\" id=\"7897750\" target=\"_blank\">",
"        7897750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodis HN, Mack WJ, La Bree L, et al, &ldquo;Serial Coronary Angiographic Evidence That Antioxidant Vitamin Intake Reduces Progression of Coronary Artery Atherosclerosis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(23):1849-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/7776501/pubmed\" id=\"7776501\" target=\"_blank\">",
"        7776501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids",
"      </i>",
"      ,  Washington, DC: National Academy Press, 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson L, Bowen FW Jr, Abbasi S, et al, &ldquo;Relationship of Prolonged Pharmacologic Serum Levels of Vitamin E to Incidence of Sepsis and Necrotizing Enterocolitis in Infants With Birth Weight 1500 Grams or Less,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1985, 75(4):619-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/3885152/pubmed\" id=\"3885152\" target=\"_blank\">",
"        3885152",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karp WB and Robertson AF, &ldquo;Vitamin E in Neonatology,&rdquo;",
"      <i>",
"       Adv Pediatr",
"      </i>",
"      , 1986, 33:127-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/3541528/pubmed\" id=\"3541528\" target=\"_blank\">",
"        3541528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee IM, Cook NR, Gaziano JM, et al, &ldquo;Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women's Health Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 294(1):56-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/15998891/pubmed\" id=\"15998891\" target=\"_blank\">",
"        15998891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris CD and Carson S, &ldquo;Routine Vitamin Supplementation to Prevent Cardiovascular Disease: A Summary of the Evidence for the U.S. Preventive Services Task Force,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(1):56-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/12834320/pubmed\" id=\"12834320\" target=\"_blank\">",
"        12834320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saperstein H, Rapaport M, and Rietschel RL, &ldquo;Topical Vitamin E as a Cause of Erythema Multiforme-Like Eruption,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1984, 120(7):906-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/6233943/pubmed\" id=\"6233943\" target=\"_blank\">",
"        6233943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;U.S. Preventive Services Task Force. Routine Vitamin Supplementation to Prevent Cancer and Cardiovascular Disease: Recommendations and Rationale,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(1):51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/12834319/pubmed\" id=\"12834319\" target=\"_blank\">",
"        12834319",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/28/19910/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10049 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19910=[""].join("\n");
var outline_f19_28_19910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234560\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234578\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234563\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234573\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234564\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234545\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234531\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803234\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234547\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234584\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234577\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234550\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234535\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300224\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14192601\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14192602\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234553\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234543\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234546\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539955\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234534\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234549\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/45/40659?source=related_link\">",
"      Vitamin E: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33988?source=related_link\">",
"      Vitamin E: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_28_19911="Head and neck squamous cell carcinoma of unknown primary";
var content_f19_28_19911=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Head and neck squamous cell carcinoma of unknown primary",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     David L Schwartz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Benjamin E Saltman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Marvin P Fried, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19911/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/28/19911/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26830835\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squamous cell carcinoma of unknown primary is a relatively rare entity in the head and neck region. Retrospective studies suggest that it represents between 1 and 3 percent of new cases of head and neck squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Head and neck squamous cell carcinoma of unknown primary is defined as the identification of squamous cell carcinoma in one or more lymph nodes within the head and neck region that are not solely in the supraclavicular region, without an identifiable primary tumor. Many head and neck cancer patients present with a neck mass, but the mucosal primary is found in all but a few percent. Isolated supraclavicular lymphadenopathy, including those of squamous cell origin, almost always originates from the skin or beneath the clavicles (ie, lung, breast, colon, prostate, esophagus, cervix, ureteral, and lymphoma primaries) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of unknown primary true head and neck squamous cancer is directed at cure for most patients who present with cervical lymphadenopathy, as this represents a locoregional but not distantly metastatic condition for most patients. This is in sharp distinction to unknown primaries presenting with distant metastases originating from below the clavicles that are generally incurable and associated with brief longevity unless it is a chemotherapy curable tumor (eg, seminoma).",
"   </p>",
"   <p>",
"    The diagnosis and management of these squamous cell carcinomas are presented here. Neoplasms of unknown primary, and in particular, squamous cell carcinoma of unknown primary not meeting these criteria, are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"       \"Overview of the classification and management of cancers of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=see_link\">",
"       \"Squamous cell carcinoma of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26830842\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of head and neck squamous cell carcinoma of unknown primary (ie, squamous cell carcinoma in a lymph node or in multiple lymph nodes within the head and neck region but not solely in the supraclavicular region) is a diagnosis of exclusion. This diagnosis is given after a thorough evaluation is performed in an effort to identify a primary tumor. This evaluation includes a comprehensive history and physical examination, imaging, and panendoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100461104\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the evaluation of a patient with suspected head and neck squamous cell carcinoma is a comprehensive history and physical examination. The history should include any previous malignancies, including skin cancers. Many patients, especially elderly patients with a long dermatologic history, will fail to mention the small &ldquo;growth&rdquo; that had been removed. Further history should attempt to elicit any symptoms from the head and neck that could indicate a site of origin such as pain, odynophagia, dysphagia, hemoptysis, or hoarseness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination should encompass a thorough examination of the skin for cutaneous malignancy as well as for scars that may represent recent dermatologic surgery of a cutaneous neoplasm. The clinical features and treatment of cutaneous squamous cell carcinoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flexible fiberoptic laryngoscopy is essential in order to evaluate the sinonasal cavity, the nasopharynx, the base of tongue, larynx, and hypopharynx. Oropharyngeal tumors can be difficult to identify since small tumors arising there are often concealed in normal appearing lymphoid tissue. Thus, it is important to palpate the tonsils and base of tongue for areas of irregular firmness or ease of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26830849\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) with contrast is the first line of imaging for patients with head and neck squamous cell carcinoma of unknown primary.",
"   </p>",
"   <p>",
"    If CT and MRI do not identify a primary tumor, positron emission tomography with fluoro-deoxyglucose (FDG-PET) or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is useful prior to panendoscopy. A comprehensive review as well as several subsequent studies confirmed the efficacy of PET in the detection of primary tumors in patients with cervical metastases from unknown primary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In these studies, PET detected approximately 25 percent of tumors that were not detected after a workup that did not include PET. PET also was able to detect new metastases in 27 percent of patients. Integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging appears to be significantly more sensitive than PET alone in identifying the primary site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PET or integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be performed before panendoscopy in order to guide biopsies and to avoid false positive FDG avidity from sites manipulated during endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1714853\">",
"    <span class=\"h2\">",
"     Staging surgical endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A direct laryngoscopy should be performed under anesthesia to evaluate the oral cavity, oropharynx, larynx and hypopharynx. A nasopharyngoscopy and esophagoscopy is also performed concurrently. We recommend directed biopsies to areas of clinical suspicion, ie mucosal irregularities, ease of bleeding, or those suspicious on imaging. We suggest also biopsying the base of tongue because of the high incidence of unknown primaries originating in the oropharynx.",
"   </p>",
"   <p>",
"    Many experts recommend that unilateral or bilateral tonsillectomy should be performed on patients with adequate lymphoid tonsillar tissue (intact palatine tonsils) as part of the initial workup. In two studies that included tonsillectomy in the initial evaluation, 26 to 35 percent of the cases of unknown primary were found to have a cancer in the ipsilateral tonsil [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. When bilateral tonsillectomy was performed in 41 patients presenting with head and neck squamous cell carcinoma, a tonsil primary was found in both tonsils in two patients (one with contralateral carcinoma in situ) and in the contralateral tonsil in two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/11\">",
"     11",
"    </a>",
"    ]. This is in keeping with data suggesting that approximately 10 percent of tonsillar cancers will have bilateral cervical node metastases; thus, a bilateral tonsillectomy is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26830863\">",
"    <span class=\"h2\">",
"     Investigational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even with an extensive evaluation, a primary tumor is often not found. New diagnostic procedures show potential in aiding the identification of the primary tumor.",
"   </p>",
"   <p>",
"    Detection of human papillomavirus (HPV) or Epstein Barr virus (EBV) in the fine needle aspiration (FNA) biopsy from a pathologic lymph node may be useful and provides prognostic information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of primary tumors that are identified among patients with head and neck squamous cell carcinoma of unknown primary are located within the oropharynx (43 percent tonsil and 39 percent base of tongue) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/7\">",
"       7",
"      </a>",
"      ]. Furthermore, more than 50 percent of oropharyngeal squamous cell carcinomas are HPV positive and only a small percentage of tumors from non-oropharynx head and neck sites are HPV positive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link&amp;anchor=H4#H4\">",
"       \"Human papillomavirus associated head and neck cancer\", section on 'Clinicopathologic features'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Immunohistochemical analysis of p16 is a valuable biomarker to identify those tumors associated with HPV infection. The finding of HPV in a lymph node biopsy may help to narrow down the site of origin and may assist in focusing the examination under anesthesia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link&amp;anchor=H11#H11\">",
"       \"Human papillomavirus associated head and neck cancer\", section on 'p16 protein'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Similarly, EBV is a sensitive marker for the presence of nasopharyngeal carcinoma and a positive fine needle aspirate for EBV strongly suggests the nasopharynx as the source. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the relatively high frequency of HPV and EBV negative tumors means that a negative result cannot exclude an oropharyngeal or nasopharyngeal primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/13\">",
"     13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    New technologies under investigation may enhance the diagnosis of malignant lesions in the upper aerodigestive tract. As an example, time-resolved laser-induced fluorescence spectroscopy is a promising noninvasive diagnostic technique, particularly in discriminating between normal and malignant tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evaluate markers such as HPV or EBV staining. While these may help direct diagnostic evaluation, they are not validated for and should not be used to select mucosal sites for irradiation. As examples, EBV positive tumors can arise outside of the nasopharynx, and HPV positive tumors can arise outside of the tonsil and tongue base.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26830878\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Achieving locoregional disease control in patients with head and neck squamous cell carcinoma of unknown primary has two components: controlling the disease in the neck and ensuring that a primary cancer does not develop (primary emergence). Confounding an interpretation of success in the control of mucosal primary emergence is the high rate of second primary development in head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal treatment of these patients is uncertain. The most important factor influencing prognosis appears to be the clinical stage at diagnosis. In a systematic review of the recent literature, encompassing 18 studies and 1726 patients, the five-year survival decreased progressively from 61 percent for those with N1 disease to 26 percent for those with N3 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two broad approaches to treatment include primary surgery (usually followed by radiation therapy or chemoradiotherapy) and definitive radiation therapy (alone or in combination with chemotherapy). There are no prospective studies comparing these approaches, and data on their relative effectiveness in achieving locoregional control and disease-free survival are limited to observational studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26830885\">",
"    <span class=\"h2\">",
"     Primary surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary surgery as a potential single modality for head and neck carcinoma of unknown primary requires curative resection of all gross disease by formal neck dissection. This approach may be sufficient for patients with pathologic stage N1 neck disease without extracapsular extension (",
"    <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, patients with more advanced neck disease (either extracapsular extension or pathologic stage N2 or higher) generally require postoperative adjuvant therapy. Alternatively, it is common practice that if RT is planned, diagnosis can be obtained by fine needle aspiration biopsy, with neck dissection deferred for post-RT residual disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of neck recurrence was illustrated by a single institution series of 24 patients initially treated with surgery alone [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/16\">",
"       16",
"      </a>",
"      ]. In this series, six patients (25 percent) had a neck recurrence; five of these had extracapsular extension in their original specimen and four had stage N2 or higher disease. The two patients with N1 disease who relapsed in the neck both had extracapsular extension.",
"     </li>",
"     <li>",
"      A second series of 70 patients included five cases with pathologic N1 disease; four of these had no extracapsular extension and one had only microscopic extracapsular extension [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/18\">",
"       18",
"      </a>",
"      ]. The remaining 65 patients had pN2 or greater disease, and 26 had extracapsular extension. Postoperative radiation therapy was recommended for all patients with either extracapsular extension or N2 or greater disease. The five-year disease-specific survival rate for the entire series was 62 percent. Ipsilateral disease control was achieved in all patients with pN1 disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both studies showed a relatively low rate of primary emergence (4 and 11 percent) with regional treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Other studies, however, have shown a higher rate of primary emergence, especially with surgery alone. A combined analysis of four studies in which surgery alone was the treatment estimated a primary emergence rate of 25 percent if the mucosa at risk is not irradiated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/19\">",
"     19",
"    </a>",
"    ]. If the mucosa at risk is irradiated, mucosal control is nearly uniform.",
"   </p>",
"   <p>",
"    There are no randomized trials comparing postoperative (adjuvant) radiation therapy alone with postoperative concurrent chemoradiotherapy in this setting. Observational data suggest that concurrent chemoradiotherapy is more effective in this situation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 22 of 25 patients (88 percent) with N2 or N3 nodal disease were treated with neck dissection followed by concurrent chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/20\">",
"       20",
"      </a>",
"      ]. With a median follow-up of four years, the five-year overall survival rate was 75 percent with no emergence of a mucosal primary.",
"     </li>",
"     <li>",
"      In another study, 37 patients with predominantly N2 and N3 nodal disease were treated with neck dissection followed by concurrent chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/21\">",
"       21",
"      </a>",
"      ]. At a median follow-up of 42 months, 33 of 37 patients (89 percent) were alive, and the rate of regional recurrence was 5 percent (2 patients out of 37). There was no emergence of a mucosal primary during this time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are consistent with trials that found that concurrent chemoradiotherapy improves locoregional control in patients with locally advanced squamous carcinoma of the head and neck. Furthermore, the lack of primary emergence in both of these studies is also important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, chemoradiotherapy is associated with significant toxicity, since both studies had high rates of enteral feeding, hospitalization, and esophageal stricture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26830892\">",
"    <span class=\"h2\">",
"     Definitive radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive radiation therapy, often including concurrent chemotherapy, is an established treatment for head and neck carcinoma of unknown primary. With this approach, neck dissection is reserved for patients with persistent disease after treatment.",
"   </p>",
"   <p>",
"    The goal of definitive radiation therapy is to control regional disease in both sides of the neck, to prevent the emergence of a primary tumor by treating the mucosal sites most likely to have been the origin of the cancer, and to minimize toxicity. Two important issues that need to be considered are how much of the mucosal surface should be included within the radiation therapy field and the radiation dose needed to prevent the emergence of a primary tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assuming that an adequate endoscopic examination under anesthesia and appropriate imaging studies have been conducted, current technique is to treat the lymph node bearing regions of the neck, but to limit the extent of mucosal treatment. Sites that are very unlikely to contain the primary tumor, such as the larynx and hypopharynx in non-smokers especially with human papillomavirus positive disease, are thus often excluded. The oral cavity is generally not irradiated, while the larynx and hypopharynx are often omitted from the radiation field as well. The mucosa is thin and easily inspected, and there is a low likelihood of an occult primary and a significant risk of high toxicity associated with RT to this region. The mucosal treatment volume includes both sides of the neck, the retropharyngeal lymph nodes, and oropharynx. Inclusion of the nasopharynx is controversial in patients who have undergone appropriate endoscopic and radiographic evaluation.",
"     </li>",
"     <li>",
"      The dose of radiation is critical. Full therapeutic doses are given to the lymph node containing regions of the neck. However, the use of full doses of radiation to the mucosal surfaces may be associated with significant toxicity, even when contemporary conformal techniques such as intensity modulated radiation therapy are used. As an example, a median dose of 60 Gy to the mucosa was used in a series of 24 patients with squamous cell carcinoma of unknown primary; in this group 11 patients (46 percent) required esophageal dilatation for stricture [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/22\">",
"       22",
"      </a>",
"      ]. We thus recommend that standard radiation doses be used for the index neck, and that the contralateral node negative side of the neck receive standard doses for subclinical disease. This well-established regimen is associated with as good control as higher doses, but is less toxic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest experience with definitive radiation therapy comes from the Danish Society of Head and Neck Oncology, which reviewed their experience of 352 patients with head and neck carcinoma of unknown primary over a 20 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/23\">",
"     23",
"    </a>",
"    ]. Twenty-six patients were treated with RT to the neck alone, 224 were treated with RT to both sides of the neck and to mucosal sites (the entire pharyngeal axis and larynx), and 23 had surgery alone. Treatment of the bilateral neck and mucosa versus ipsilateral neck alone resulted in a non-statistically significant improvement in neck control (52 versus 43 percent), mucosal control (87 versus 77 percent), locoregional control (48 versus 31 percent), cause-specific survival (47 versus 32 percent), and overall survival (34 versus 22 percent). Patients treated with the ipsilateral technique alone had a relative risk of recurrence in the head and neck region of 1.9 compared with patients treated to both neck and mucosa. The emergence of an occult primary occurred in 20 percent of all patients. Both radiotherapy groups were significantly better than surgery to control occult mucosal primaries, and there was no difference between the two radiotherapy groups.",
"   </p>",
"   <p>",
"    Several retrospective, observational studies suggest that intensity modulated radiation therapy may provide effective locoregional disease control while limiting toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/22,24-27\">",
"     22,24-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H1493365078#H1493365078\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'Intensity-modulated RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, 52 patients in one study were treated using intensity modulated radiation therapy to both sides of the neck and to mucosal sites (pharyngeal axis) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/24\">",
"     24",
"    </a>",
"    ]; only one patient recurred at a primary site (base of tongue) and three patients recurred in the neck. Long-term complications included one patient requiring percutaneous endoscopic gastrostomy tube feeding and one patient with an esophageal stricture requiring dilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of chemotherapy to definitive radiation therapy is widely used in patients with locally advanced head and neck cancer and is being widely used in appropriately selected patients with head and neck carcinoma of unknown primary [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19911/abstract/22,24,25\">",
"     22,24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12157510\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head and neck carcinoma of unknown primary is defined by the presence of squamous cell carcinoma in one or more lymph nodes within the head and neck region that are not solely in the supraclavicular region, in the absence of a primary tumor.",
"     </li>",
"     <li>",
"      The initial diagnostic evaluation of these patients includes a comprehensive history and physical, along with a thorough imaging work-up (MRI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CT). PET scanning has been shown to aid in detection of a primary tumor when other noninvasive tests fail to do so. Panendoscopy with directed biopsies and tonsillectomy are indicated to assist in identifying an unknown primary. (See",
"      <a class=\"local\" href=\"#H26830842\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two main goals for treatment: the control of disease in the neck and the prevention of primary emergence:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with N1 and N2a disease without extracapsular extension, we suggest single modality radiation therapy, preferably with IMRT technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For selected patients with N1 disease without extracapsular extension, postoperative radiation therapy may be withheld following formal neck dissection in appropriately selected cases, especially in level Ib. (See",
"      <a class=\"local\" href=\"#H26830885\">",
"       'Primary surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26830892\">",
"       'Definitive radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pathologic stage N2b or higher neck disease and those with extracapsular extension, we recommend definitive concurrent chemoradiation, preferably with IMRT technique (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Single modality mucosal and neck irradiation may be considered for patients with limited reserve who are poor candidates for combined modality treatment. Surgery is reserved for persistent or recurrent disease following radiation-based treatment. Definitive combined modality therapy consisting of formal neck dissection and postoperative radiation therapy (with or without concurrent chemotherapy) is a secondary option. (See",
"      <a class=\"local\" href=\"#H26830885\">",
"       'Primary surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26830892\">",
"       'Definitive radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiation therapy, with or without concurrent chemotherapy, to putative mucosal sites of primary tumor is important for minimizing the rate of primary emergence. For selected patients presenting with limited physical reserve and unilateral adenopathy (particularly stage N1 or N2a), consideration can be made for ipsilateral neck irradiation, followed by close surveillance. In most other cases, we recommend radiation to mucosal sites and both sides of the neck. (See",
"      <a class=\"local\" href=\"#H26830892\">",
"       'Definitive radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/1\">",
"      Syrj&auml;nen S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 2007; 356:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/2\">",
"      Gupta RK, Naran S, Lallu S, Fauck R. The diagnostic value of fine needle aspiration cytology (FNAC) in the assessment of palpable supraclavicular lymph nodes: a study of 218 cases. Cytopathology 2003; 14:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/3\">",
"      Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/4\">",
"      Johansen J, Buus S, Loft A, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 2008; 30:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/5\">",
"      Rudmik L, Lau HY, Matthews TW, et al. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck 2011; 33:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/6\">",
"      Yabuki K, Tsukuda M, Horiuchi C, et al. Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol 2010; 267:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/7\">",
"      Miller FR, Karnad AB, Eng T, et al. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck 2008; 30:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/8\">",
"      Keller F, Psychogios G, Linke R, et al. Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT. Head Neck 2011; 33:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/9\">",
"      Lapeyre M, Malissard L, Peiffert D, et al. Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary? Int J Radiat Oncol Biol Phys 1997; 39:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/10\">",
"      Mendenhall WM, Mancuso AA, Amdur RJ, et al. Squamous cell carcinoma metastatic to the neck from an unknown head and neck primary site. Am J Otolaryngol 2001; 22:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/11\">",
"      Koch WM, Bhatti N, Williams MF, Eisele DW. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 2001; 124:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/12\">",
"      Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972; 29:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/13\">",
"      Jannapureddy S, Cohen C, Lau S, et al. Assessing for primary oropharyngeal or nasopharyngeal squamous cell carcinoma from fine needle aspiration of cervical lymph node metastases. Diagn Cytopathol 2010; 38:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/14\">",
"      Meier JD, Xie H, Sun Y, et al. Time-resolved laser-induced fluorescence spectroscopy as a diagnostic instrument in head and neck carcinoma. Otolaryngol Head Neck Surg 2010; 142:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/15\">",
"      Balaker AE, Abemayor E, Elashoff D, St John MA. Cancer of unknown primary: does treatment modality make a difference? Laryngoscope 2012; 122:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/16\">",
"      Coster JR, Foote RL, Olsen KD, et al. Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys 1992; 23:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/17\">",
"      Iganej S, Kagan R, Anderson P, et al. Metastatic squamous cell carcinoma of the neck from an unknown primary: management options and patterns of relapse. Head Neck 2002; 24:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/18\">",
"      Patel RS, Clark J, Wyten R, et al. Squamous cell carcinoma from an unknown head and neck primary site: a \"selective treatment\" approach. Arch Otolaryngol Head Neck Surg 2007; 133:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/19\">",
"      Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001; 50:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/20\">",
"      Argiris A, Smith SM, Stenson K, et al. Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol 2003; 14:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/21\">",
"      Shehadeh NJ, Ensley JF, Kucuk O, et al. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. Head Neck 2006; 28:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/22\">",
"      Sher DJ, Balboni TA, Haddad RI, et al. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys 2011; 80:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/23\">",
"      Grau C, Johansen LV, Jakobsen J, et al. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/24\">",
"      Frank SJ, Rosenthal DI, Petsuksiri J, et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010; 78:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/25\">",
"      Klem ML, Mechalakos JG, Wolden SL, et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys 2008; 70:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/26\">",
"      Villeneuve H, Despr&eacute;s P, Fortin B, et al. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19911/abstract/27\">",
"      Shoushtari A, Saylor D, Kerr KL, et al. Outcomes of patients with head-and-neck cancer of unknown primary origin treated with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81:e83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14251 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19911=[""].join("\n");
var outline_f19_28_19911=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12157510\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26830835\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26830842\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100461104\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26830849\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1714853\">",
"      Staging surgical endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26830863\">",
"      Investigational studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26830878\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26830885\">",
"      Primary surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26830892\">",
"      Definitive radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12157510\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14251|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/55/36733\" title=\"table 1\">",
"      TNM stage oropharynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15459?source=related_link\">",
"      Squamous cell carcinoma of unknown primary site",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_28_19912="Outpatient and surgical procedures for hemorrhoids";
var content_f19_28_19912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outpatient and surgical procedures for hemorrhoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19912/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19912/contributors\">",
"     David E Rivadeneira, MD, FACS, FASCRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19912/contributors\">",
"     Scott R Steele, MD, FACS, FASCRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19912/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19912/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19912/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/28/19912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H96135853\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemorrhoids are normal vascular structures in the anal canal. Approximately 5 percent of the general population is affected by symptoms related to hemorrhoidal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/1\">",
"     1",
"    </a>",
"    ] The cardinal features of hemorrhoidal disease include bleeding, anal pruritus, prolapse, and pain due to thrombosis. Although these symptoms may strongly suggest the diagnosis, confirmation by flexible sigmoidoscopy, anoscopy, or colonoscopy should be performed in most patients who present with bleeding.",
"   </p>",
"   <p>",
"    This topic will review common surgical techniques for office-based and intraoperative procedures used to treat hemorrhoids. The anatomy and clinical features of hemorrhoids, and the grading, conservative management, minimally invasive, surgical treatment options, outcomes, and postoperative pain management are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=see_link\">",
"     \"Overview of hemorrhoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link\">",
"     \"Treatment of hemorrhoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103488979\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first approach to treating hemorrhoids, excluding acute thrombosis, is conservative management. Patients who fail medical management are candidates for surgical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hemorrhoids\", section on 'Conservative treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hemorrhoids\", section on 'Office based procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of hemorrhoids\", section on 'Surgical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489031\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative assessment includes a detailed history, physical examination, and anoscopy. The physical examination includes external inspection of the anus and a digital rectal examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8184?source=see_link\">",
"     \"Approach to minimal bright red bleeding per rectum\"",
"    </a>",
"    .) Medications, with particular attention to those that increase the risk of bleeding (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , NSAIDS), are reviewed in detail.",
"   </p>",
"   <p>",
"    Anoscopy is performed in the semi-inverted jackknife or left lateral position. The assessment includes an evaluation for the presence of external hemorrhoids, location, volume, redundancy, and grade of internal hemorrhoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hemorrhoids\", section on 'Classification of internal hemorrhoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135860\">",
"    <span class=\"h1\">",
"     OFFICE BASED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubber band ligation, sclerotherapy, and infrared coagulation are the most commonly used office-based procedures for the treatment of symptomatic internal hemorrhoids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, there is no consensus on optimal treatment for internal hemorrhoids and the most appropriate therapy is tailored to the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of all office-based procedures for internal hemorrhoids are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decrease vascularity",
"     </li>",
"     <li>",
"      Reduce redundant tissue",
"     </li>",
"     <li>",
"      Increase hemorrhoidal fixation to the rectal wall to minimize prolapse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    External thrombosed hemorrhoids are optimally treated by an excision of the entire hemorrhoid rather than lancing and evacuation of the clot, an approach which should be avoided (",
"    <a class=\"graphic graphic_picture graphicRef78700 \" href=\"UTD.htm?23/46/24291\">",
"     picture 1",
"    </a>",
"    ). This procedure should be during the initial 72 hours from the onset of symptoms when pain is at its maximum. Reaccumulation of the clot and recurrence of symptoms frequently occur following the lancing and clot evacuation approach [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H96135888\">",
"     'Evacuation of thrombosis and excision of external hemorrhoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The surgical principles for excising a thrombosed external hemorrhoid include (",
"    <a class=\"graphic graphic_figure graphicRef67857 \" href=\"UTD.htm?14/34/14883\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inject a local anesthetic (eg, 1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with epinephrine) at the base of the thrombosed hemorrhoid",
"     </li>",
"     <li>",
"      Excise an ellipse of skin sharply with iris scissors or electrocautery",
"     </li>",
"     <li>",
"      Evacuate the clot",
"     </li>",
"     <li>",
"      Avoid injuring the underlying anal sphincter from an overly aggressive excision of the hemorrhoid",
"     </li>",
"     <li>",
"      Cover the open wound with a gauze dressing or reapproximate the skin edges with absorbable sutures, depending upon surgeon preference [",
"      <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/7\">",
"       7",
"      </a>",
"      ]. A topical antibiotic ointment may be applied to the wound; however, this is not necessary, as infection is rare in this well vascularized site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pain can be controlled after the procedure with nonsteroidal medications while warm Sitz baths will also provide additional comfort. Gauze pads are used until there is no further drainage from the wound. The wound typically heals in one to two weeks.",
"   </p>",
"   <p>",
"    In clinical settings of extensive thrombosis (",
"    <a class=\"graphic graphic_picture graphicRef60155 \" href=\"UTD.htm?42/40/43652\">",
"     picture 2",
"    </a>",
"    ), do not perform an aggressive resection of the perianal skin and anoderm, as this approach may injure the anal sphincter. These patients are candidates for a more extensive operative procedure (See",
"    <a class=\"local\" href=\"#H96135895\">",
"     'Operating room based procedures'",
"    </a>",
"    below.). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135867\">",
"    <span class=\"h2\">",
"     Rubber band ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most common and effective office-based procedures for treating symptomatic hemorrhoids is the rubber band ligation. Patients with grades II or III hemorrhoids are candidates for this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hemorrhoids\", section on 'Classification of internal hemorrhoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    External tags and external hemorrhoids cannot be treated with this technique as it would cause excruciating pain (",
"    <a class=\"graphic graphic_figure graphicRef80650 \" href=\"UTD.htm?37/32/38400\">",
"     figure 2",
"    </a>",
"    ). Banding procedures are typically contraindicated in patients with coagulopathies and those on anticoagulation (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) or antiplatelet (eg, Plavix) medications because of the risk of significant delayed hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/8\">",
"     8",
"    </a>",
"    ]. In the author&rsquo;s experience, patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy can safely undergo rubber band ligation, with a low risk of bleeding.",
"   </p>",
"   <p>",
"    Banding is relatively contraindicated in immunocompromised patients (eg, chemotherapy administration,",
"    <span class=\"nowrap\">",
"     HIV/AIDS),",
"    </span>",
"    because of risks of infection and sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hemorrhoids\", section on 'Rubber band ligation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489077\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure, when performed correctly, does not require a local or systemic anesthetic. Patients are placed in the semi-inverted jack knife or left lateral position. The procedure is performed through the anoscope and the small rubber band rings are placed onto the internal hemorrhoids with either a suction apparatus or a forceps ligator (",
"    <a class=\"graphic graphic_figure graphicRef63288 \" href=\"UTD.htm?26/62/27619\">",
"     figure 3",
"    </a>",
"    ). The key technical element is to place the bands at least 5 mm above the dentate line to avoid placement onto somatically innervated tissue and resultant significant pain.",
"   </p>",
"   <p>",
"    The largest internal hemorrhoid is treated first. If a forceps ligator is used to apply the bands, an assistant is required to stabilize the anoscope. The hemorrhoid complex is grasped with forceps and pulled towards the tip or drum of the hand-held ligator gun apparatus, while the trigger causes the release of the rubber band. Prior to band release, the patient should be questioned as to the presence of pain that may indicate the need to select a point more proximal in the anal canal.",
"   </p>",
"   <p>",
"    Bands are applied in a single column initially. If the patient tolerates the procedure with only minimal discomfort, then several hemorrhoids can be banded at this time. If multiple applications are needed, then repeat banding procedures can be performed in three to four week intervals, to allow any swelling and ulcerations to subside.",
"   </p>",
"   <p>",
"    If a patient experiences intense or excruciating pain as the rubber band is placed then the band should be removed immediately by cutting the rubber band. Severe pain during the procedure indicates that the sensory anal derm from an external hemorrhoid is incorporated with the band.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489144\">",
"    <span class=\"h3\">",
"     Postoperative instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are instructed to avoid constipation by using stool softeners daily and consuming a diet high in fiber and water. If patients experience anal or rectal pain or discomfort, warm sitz baths and oral pain medication is advised. These instructions can be applied to all office-based procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489092\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Banding the hemorrhoids results in tissue necrosis and fixation to the rectal mucosa. As the hemorrhoidal tissues become ischemic, necrosis develops in the next three to five days, and an ulcerated tissue bed is formed. Complete healing occurs several weeks later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354307\">",
"    <span class=\"h3\">",
"     Complications and outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications include pain, urinary retention, and delayed bleeding, which can be extensive in patients with coagulation disorders. A rare but devastating complication is perineal sepsis that is usually heralded by a triad of severe pain, urinary retention, and fever. These symptoms require immediate evaluation of the patient. The outcomes of this procedure are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hemorrhoids\", section on 'Rubber band ligation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135874\">",
"    <span class=\"h2\">",
"     Sclerotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injectable sclerosant solutions can be used to treat symptomatic hemorrhoids. The most common solution used is phenol (5 percent) in vegetable oil, although other sclerosants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=see_link\">",
"     sodium morrhuate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , urea hydrochloride, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"     sodium tetradecyl",
"    </a>",
"    sulfate (Sotradecol) are also used. This approach appears to be especially beneficial in patients with grade I and II bleeding hemorrhoids, and those patients treated with anticoagulants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of hemorrhoids\", section on 'Sclerotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489188\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure does not require a local or systemic anesthetic. Patients are placed in the semi-inverted jack knife or left lateral position and the procedure is performed through the anoscope. The intended internal hemorrhoids for treatment are located, and injected with 1 to 3 cc of the sclerosant material into the submucosa plane with a spinal needle or a long intravenous 21-gauge needle. A wheal should be raised with the solution. If the injection is too superficial, the area will become tense and blanched and the injection should stop immediately to help minimize risk of mucosal necrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489220\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sclerosant causes fibrosis and eventual obliteration of the redundant hemorrhoidal tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489195\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are uncommon, with the most frequent one being minor discomfort or bleeding with the injection. Recto-urethral fistulas, rectal perforations, and necrosing fasciitis are rare complications but can occur with misplaced injections into nonhemorrhoidal tissues or with systemic injections into the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103489181\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 18 prospective trials, rubber band ligation was superior to injection sclerotherapy and infrared coagulation in the treatment of grades I, II, and III hemorrhoids. However, the risk of complications and pain tended to be greater for rubber band ligation when compared with the other modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135881\">",
"    <span class=\"h2\">",
"     Infrared coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrared coagulation involves the direct application of infrared light waves to the hemorrhoidal tissues. Patients with grades I or II bleeding hemorrhoids are optimal candidates for this procedure. Infrared coagulation is sometimes erroneously referred to as laser therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354134\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is positioned in the semi-inverted jackknife or left lateral position, and anoscopy is performed. The tip of the IRC applicator or probe is applied to the base of the internal hemorrhoid for two seconds, with three to five applications per hemorrhoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354127\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrared light waves are converted into heat, which results in protein necrosis within the hemorrhoid. This is visualized as a white, blanching effect to the mucosa approximately 3 mm wide by 3 mm deep. Over a period of one to two weeks, the white discolored mucosa changes into a dark scab, and eventually leads to a puckered or ablated area, causing retraction of the redundant hemorrhoid mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9356816\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure is safe, and minor pain and bleeding are the most frequent complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354239\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although previous reports demonstrated high rates of recurrence especially with grades III and IV, recent randomized studies have demonstrated outcomes similar to rubber band ligation. In a meta-analysis of 18 randomized trials, rubber band ligation was superior to injection sclerotherapy and infrared coagulation for the treatment of grades I, II, and III hemorrhoids. The risk of complications and pain was less for infrared coagulation and tended to be greater for rubber band ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/12\">",
"     12",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135888\">",
"    <span class=\"h2\">",
"     Evacuation of thrombosis and excision of external hemorrhoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;External hemorrhoids arise from the modified squamous epithelium. Unless thrombosed, external hemorrhoids generally do not require surgical management. An exception is for large external hemorrhoids that cause discomfort, burning, itching, and the inability to provide complete hygiene in the area. These hemorrhoids often amount to large, redundant skin tags, and are amenable to a surgical excision. &nbsp;",
"   </p>",
"   <p>",
"    Patients with a thrombosed external hemorrhoid present with an acutely painful mass with a purplish or blue color in the perianal area (",
"    <a class=\"graphic graphic_picture graphicRef72916 \" href=\"UTD.htm?14/30/14831\">",
"     picture 3",
"    </a>",
"    ). Most patients who present with significant pain within 72 hours will benefit from complete excision of the thrombosed external hemorrhoid [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/14\">",
"     14",
"    </a>",
"    ]. Conservative management with sitz baths and pain medications is typically recommended when the patient presents after 72 hours of the onset of symptoms. However, therapy should be based upon the individual patient symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hemorrhoids\", section on 'Thrombosed hemorrhoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hemorrhoids\", section on 'External hemorrhoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not advisable to lance or incise the hemorrhoid to remove the clot, as this will often lead to reaccumulation of blood and reformation of the thrombosis. Therefore, complete excision of the thrombosed hemorrhoid is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354413\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;This procedure is performed under a local anesthetic. The patient is positioned in the semi-inverted jackknife or left lateral position. An anal block is performed by injecting a mixture of 10 cc of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    solution with 1:200,000 epinephrine into the ischiorectal fat immediately peripheral to the external sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    (1 cc per 30 cc lidocaine) can be added per provider discretion to help minimize local irritation with injection.",
"   </p>",
"   <p>",
"    The skin overlying the thrombosed hemorrhoid is prepped with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    solution. The external hemorrhoid is excised in an elliptical fashion and dissected from the superficial fibers of the external and internal sphincters. The thrombosis and the resultant edematous tissue create a readily identifiable plane for dissection. The excision can be performed with either a scalpel, scissors, or with an electrocautery pen, depending on the preference of the surgeon. The skin edges are left open and allowed to drain to prevent a reaccumulation of blood. The anal area is covered by a protective dressing to protect clothes from soilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354450\">",
"    <span class=\"h3\">",
"     Postoperative instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are instructed to use sitz baths and pain medication, including narcotics if needed. Patients are instructed to avoid constipation by using stool softeners daily and consuming a diet high in fiber and water. The entire area will heal within two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354429\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complication rates are low with a proper excision of a thrombosed hemorrhoid, including mild pain, minor bleeding, and local swelling. The most common serious complications include recurrent hemorrhoids that require another procedure (6 percent), perianal",
"    <span class=\"nowrap\">",
"     abscess/fistula",
"    </span>",
"    (2 percent), postoperative bleeding (&lt;1 percent), and damage to underlying sphincter (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/16\">",
"     16",
"    </a>",
"    ]. These wounds typically take a few weeks to completely heal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9354437\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence rate for a completely excised thrombosed hemorrhoid is 5 to 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In comparison, simple excision and drainage of the clot is associated with a 30 percent risk of reaccumulation, which may disseminate to adjacent columns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135895\">",
"    <span class=\"h1\">",
"     OPERATING ROOM BASED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision of hemorrhoids remains a very effective approach for treatment of symptomatic hemorrhoids and should be reserved for patients who failed or cannot tolerate an office-based procedure, or have extensive or multiple grade III (prolapsed hemorrhoids that can be manually reduced) or grade IV hemorrhoids (prolapsed and incarcerated), or patients with substantial external skin tags (",
"    <a class=\"graphic graphic_picture graphicRef75759 \" href=\"UTD.htm?35/27/36272\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with combined internal and external hemorrhoidal disease, those with extensive thrombosis and significant perianal edema, and patients whose body habitus limits appropriate visualization are all good candidates for operating room based procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of hemorrhoids\", section on 'American Society of Colon and Rectal Surgeons Guidelines'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In general, those patients undergoing evaluation in the operating room will undergo a surgical hemorrhoidectomy, using a combination of intravenous sedation and local anesthetics. These procedures are rarely performed as an office-based procedure. A formal hemorrhoidectomy in appropriately selected patients allows both the resolution of the patient&rsquo;s symptoms and minimizes recurrent disease when performed properly. The technical components of the operative procedures are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of hemorrhoids\", section on 'Surgical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A surgical procedure is reserved for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Refractory to conservative measures",
"     </li>",
"     <li>",
"      Refractory to office-based procedures",
"     </li>",
"     <li>",
"      Unable to tolerate office procedures because of pain",
"     </li>",
"     <li>",
"      Grade III hemorrhoids if more than one column is involved",
"     </li>",
"     <li>",
"      Grade IV hemorrhoids &nbsp;",
"     </li>",
"     <li>",
"      Large external hemorrhoids",
"     </li>",
"     <li>",
"      Combined internal and external hemorrhoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135910\">",
"    <span class=\"h2\">",
"     Hemorrhoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major types of hemorrhoidectomy operations are the closed (Ferguson) hemorrhoidectomy and the open (Milligan-Morgan) hemorrhoidectomy. Both techniques are performed using a variety of surgical devices, including surgical scalpel, monopolar cauterization, bipolar energy, and ultrasonic devices. The open hemorrhoidectomy is the preferred approach to surgically treat severe acute gangrenous hemorrhoids where tissue edema and necrosis precludes closure of the mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9356871\">",
"    <span class=\"h3\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is instructed to undergo a cleansing enema before the procedure. A full mechanical bowel preparation is not indicated and may be counterproductive. There is a paucity of data regarding preoperative antibiotics, and a retrospective study reported that there was no benefit to preoperative use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    compared with no antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/19\">",
"     19",
"    </a>",
"    ]. The authors agree that antibiotics are not necessary in most clinical settings. Patients with underlying immunosuppression or extensive cellulitis may benefit from perioperative antibiotics, such as metronidazole or a second generation cephalosporin. This preoperative preparation is used for all of the following described procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9356809\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is administered intravenous sedatives and is positioned in the jack-knife position. An anal block is placed using 10 to 20 cc of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    solution with 1:200,000 epinephrine. A regional (spinal) anesthetic or general anesthetic may be used in select cases, such as those with severe respiratory conditions. A Hill-Ferguson retractor is placed into the anal canal and rectum to facilitate visualization of the individual hemorrhoid columns.",
"   </p>",
"   <p>",
"    The junction of the internal and external component of the hemorrhoid is grasped with a small clamp, which serves as a handle to retract the hemorrhoid away from the sphincter muscles. Using a scalpel or electrocautery pen, an elliptical or diamond shaped incision is made to delineate the plane for excision of the hemorrhoid.",
"   </p>",
"   <p>",
"    The hemorrhoid tissue is carefully dissected away from the superficial internal and external sphincter muscles to the main vascular pedicle in the anal canal. The base of the pedicle is suture ligated and the hemorrhoid is excised. Various advanced bipolar energy devices have been described to perform this procedure with similar efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The difference between the open (Milligan-Morgan technique) and closed hemorrhoidectomy (Ferguson technique) is the intraoperative management of the incised rectal mucosa. The mucosal edges are reapproximated with dissolvable suture when the closed hemorrhoidectomy is performed. Care must be taken not to narrow the anal canal with multiple hemorrhoidal excisions and closures, therefore the Hill-Ferguson retractor should be left in place in the anal canal until all suturing is complete, while preserving a minimum of 1 cm of anoderm between columns. In the open technique, the mucosal edges are not reapproximated and the wound heals by secondary intention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9356846\">",
"    <span class=\"h3\">",
"     Postoperative instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative instructions include warm sitz baths, stool softeners, and pain medication including oral narcotics and anti-inflammatory medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H20439434#H20439434\">",
"     \"Treatment of hemorrhoids\", section on 'Postoperative pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9356966\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of hemorrhoidectomy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of hemorrhoids\", section on 'Complications of hemorrhoidectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9356973\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, there appears to be no definitive advantage between the open or closed hemorrhoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Either open or closed hemorrhoidectomy can be performed with a variety of surgical devices including surgical scalpel, scissors, monopolar cauterization, bipolar energy and ultrasonic devices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individual patient factors and preferences need to be carefully weighed and considered prior to a decision for operative therapy. Factors include the extent and grade of the hemorrhoids, those with grade III or IV appear to benefit the most. Patients that are unable to tolerate office-based procedures due to significant comorbidities or taking anticoagulation medication would also benefit from an excisional hemorrhoidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135917\">",
"    <span class=\"h2\">",
"     Stapled hemorrhoidopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intraluminal circular stapling device resects and fixes the internal hemorrhoid tissues to the rectal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/26\">",
"     26",
"    </a>",
"    ]. This procedure is best utilized when offered to patients with significant prolapse, such as those with grade II, grade III, or IV internal hemorrhoids. This procedure does not effectively treat most external hemorrhoids, and often requires separate excision of the external component when performed on patients with combined disease. Similar to all these techniques, appropriate patient selection will maximize the likelihood of achieving optimal results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9357092\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are placed in the semi-inverted jackknife, left lateral, or lithotomy position. An anal dilator or obturator is provided with the surgical stapler and is inserted into the anal canal. This provides gentle dilatation of the anal canal.",
"   </p>",
"   <p>",
"    The most critical component of the procedure is the placement of a circumferential purse string nonabsorbable suture in the",
"    <span class=\"nowrap\">",
"     mucosa/submucosa",
"    </span>",
"    approximately 4 cm from the dentate line. It is of paramount importance that the purse string suture be placed far enough proximal as to avoid any sphincter muscle being involved with the stapling device to avoid changes in continence or increased complications (eg, stricture, fistula).",
"   </p>",
"   <p>",
"    The circular stapling device is introduced into the anus, and the",
"    <span class=\"nowrap\">",
"     mucosa/submucosa",
"    </span>",
"    contents are brought into the stapler. Before the stapler is engaged or fired, a thorough assessment of the posterior wall of the vagina should be made. When the stapler is fired, it creates a circular fixation of all tissues within the purse string to the rectal wall. In effect, it will draw up and suspend the prolapsed internal hemorrhoid tissue. The staple line should be fully evaluated as this is a potential source for early bleeding, and may require a suture ligation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9357140\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complications include pain, bleeding, and urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/26\">",
"     26",
"    </a>",
"    ]. Less common complications include rectal perforation and sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/27\">",
"     27",
"    </a>",
"    ], rectovaginal fistulas, retroperitoneal and pelvic abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=see_link\">",
"     \"Rectovaginal, anovaginal, and colovesical fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9357100\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes for a stapled hemorrhoidectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of hemorrhoids\", section on 'Stapled hemorrhoidectomy (stapled hemorrhoidopexy)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96135924\">",
"    <span class=\"h2\">",
"     Doppler guided hemorrhoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler guided ligation (transanal hemorrhoidal dearterialization) of the terminal branches of the superior hemorrhoidal artery is an alternative to a hemorrhoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. The technique includes an anoscope fashioned with a Doppler probe for identification of each hemorrhoidal arterial blood supply, which is subsequently ligated.",
"   </p>",
"   <p>",
"    Prospective trials with longer-term observation are required to determine the utility of this approach. A retrospective review of 17 reports including 1996 patients found that the overall recurrence rate at one year after the procedure based on surgical indications was 11 percent for prolapsed hemorrhoids, 10 percent for bleeding hemorrhoids, and 9 percent for hemorrhoids associated with painful defecation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19912/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=see_link\">",
"       \"Patient information: Hemorrhoids (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=see_link\">",
"       \"Patient information: Hemorrhoids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9357001\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with thrombosed external hemorrhoids who require surgical intervention, we suggest an excision of the entire hemorrhoid rather than evacuation of the clot (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H96135860\">",
"       'Office based procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with medically refractory grades I and II hemorrhoids, we perform an office-based procedure for initial surgical treatment. We recommend rubber band ligation as the initial office-based procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H96135867\">",
"       'Rubber band ligation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of hemorrhoids\", section on 'Classification of internal hemorrhoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infrared coagulation or sclerotherapy may be used for patients with grade I and II bleeding hemorrhoids, as well as those patients treated with anticoagulants. (See",
"      <a class=\"local\" href=\"#H96135881\">",
"       'Infrared coagulation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H96135874\">",
"       'Sclerotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical excision remains a very effective approach for treatment of symptomatic hemorrhoids and should be reserved for patients who failed or cannot tolerate an office-based procedure. (See",
"      <a class=\"local\" href=\"#H96135910\">",
"       'Hemorrhoidectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a single symptomatic grade III hemorrhoid, the authors perform a rubber band ligation. If two or three hemorrhoidal columns are symptomatic, multiple banding procedures are performed. Depending on patient",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgeon preference, a surgical excision can be performed in this clinical setting involving multiple hemorrhoidal columns. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H25#H25\">",
"       \"Treatment of hemorrhoids\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with grade IV internal hemorrhoids or those who have combined grade III internal and significant external hemorrhoids, we recommend surgical excision (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H96135910\">",
"       'Hemorrhoidectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=see_link&amp;anchor=H24#H24\">",
"       \"Treatment of hemorrhoids\", section on 'American Society of Colon and Rectal Surgeons Guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with isolated grade III and IV internal hemorrhoids (no external hemorrhoids), we suggest a stapled hemorrhoidopexy as an acceptable option to an excisional hemorrhoidectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H96135917\">",
"       'Stapled hemorrhoidopexy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/1\">",
"      Sneider EB, Maykel JA. Diagnosis and management of symptomatic hemorrhoids. Surg Clin North Am 2010; 90:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/2\">",
"      Linares Santiago E, G&oacute;mez Parra M, Mendoza Olivares FJ, et al. Effectiveness of hemorrhoidal treatment by rubber band ligation and infrared photocoagulation. Rev Esp Enferm Dig 2001; 93:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/3\">",
"      Poen AC, Felt-Bersma RJ, Cuesta MA, et al. A randomized controlled trial of rubber band ligation versus infra-red coagulation in the treatment of internal haemorrhoids. Eur J Gastroenterol Hepatol 2000; 12:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/4\">",
"      Marques CF, Nahas SC, Nahas CS, et al. Early results of the treatment of internal hemorrhoid disease by infrared coagulation and elastic banding: a prospective randomized cross-over trial. Tech Coloproctol 2006; 10:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/5\">",
"      Chand M, Nash GF, Dabbas N. The management of haemorrhoids. Br J Hosp Med (Lond) 2008; 69:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/6\">",
"      Rivadeneira DE, Steele SR, Ternent C, et al. Practice parameters for the management of hemorrhoids (revised 2010). Dis Colon Rectum 2011; 54:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/7\">",
"      Grosz CR. A surgical treatment of thrombosed external hemorrhoids. Dis Colon Rectum 1990; 33:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/8\">",
"      Nelson RS, Ewing BM, Ternent C, et al. Risk of late bleeding following hemorrhoidal banding in patients on antithrombotic prophylaxis. Am J Surg 2008; 196:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/9\">",
"      Kaman L, Aggarwal S, Kumar R, et al. Necrotizing fascitis after injection sclerotherapy for hemorrhoids: report of a case. Dis Colon Rectum 1999; 42:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/10\">",
"      Barwell J, Watkins RM, Lloyd-Davies E, Wilkins DC. Life-threatening retroperitoneal sepsis after hemorrhoid injection sclerotherapy: report of a case. Dis Colon Rectum 1999; 42:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/11\">",
"      Schulte T, F&auml;ndrich F, Kahlke V. Life-threatening rectal necrosis after injection sclerotherapy for haemorrhoids. Int J Colorectal Dis 2008; 23:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/12\">",
"      MacRae HM, McLeod RS. Comparison of hemorrhoidal treatment modalities. A meta-analysis. Dis Colon Rectum 1995; 38:687.",
"     </a>",
"    </li>",
"    <li>",
"     Chapter 8. Hemorrhoids. In: Colon &amp; Rectal Surgery, Fifth, Corman ML.  (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/14\">",
"      Aigner F, Gruber H, Conrad F, et al. Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the course of hemorrhoidal disease. Int J Colorectal Dis 2009; 24:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/15\">",
"      Greenspon J, Williams SB, Young HA, Orkin BA. Thrombosed external hemorrhoids: outcome after conservative or surgical management. Dis Colon Rectum 2004; 47:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/16\">",
"      Jongen J, Bach S, St&uuml;binger SH, Bock JU. Excision of thrombosed external hemorrhoid under local anesthesia: a retrospective evaluation of 340 patients. Dis Colon Rectum 2003; 46:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/17\">",
"      Nystr&ouml;m PO, Derwinger K, Gerjy R. Local perianal block for anal surgery. Tech Coloproctol 2004; 8:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/18\">",
"      Pattana-arun J, Wesarachawit W, Tantiphlachiva K, et al. A comparison of early postoperative results between urgent closed hemorrhoidectomy for prolapsed thrombosed hemorrhoids and elective closed hemorrhoidectomy. J Med Assoc Thai 2009; 92:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/19\">",
"      Wesarachawit W, Pattana-arun J. Antibiotics and early post operative complications of closed hemorrhoidectomy: a retrospective matched pair study. J Med Assoc Thai 2007; 90:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/20\">",
"      Nienhuijs S, de Hingh. Conventional versus LigaSure hemorrhoidectomy for patients with symptomatic Hemorrhoids. Cochrane Database Syst Rev 2009; :CD006761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/21\">",
"      Ferguson JA, Mazier WP, Ganchrow MI, Friend WG. The closed technique of hemorrhoidectomy. Surgery 1971; 70:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/22\">",
"      Reis Neto JA, Quilici FA, Cordeiro F, Reis J&uacute;nior JA. Open versus semi-open hemorrhoidectomy: a random trial. Int Surg 1992; 77:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/23\">",
"      Hodgson WJ, Morgan J. Ambulatory hemorrhoidectomy with CO2 laser. Dis Colon Rectum 1995; 38:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/24\">",
"      Senagore A, Mazier WP, Luchtefeld MA, et al. Treatment of advanced hemorrhoidal disease: a prospective, randomized comparison of cold scalpel vs. contact Nd:YAG laser. Dis Colon Rectum 1993; 36:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/25\">",
"      Leff EI. Hemorrhoidectomy--laser vs. nonlaser: outpatient surgical experience. Dis Colon Rectum 1992; 35:743.",
"     </a>",
"    </li>",
"    <li>",
"     Chapter 8. Hemorrhoids. Operative approaches to the treatment of hemorrhoids. In: Colon &amp; Rectal Surgery, Fifth, Corman ML.  (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.210.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/27\">",
"      Faucheron JL, Voirin D, Abba J. Rectal perforation with life-threatening peritonitis following stapled haemorrhoidopexy. Br J Surg 2012; 99:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/28\">",
"      Felice G, Privitera A, Ellul E, Klaumann M. Doppler-guided hemorrhoidal artery ligation: an alternative to hemorrhoidectomy. Dis Colon Rectum 2005; 48:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/29\">",
"      Scheyer M, Antonietti E, Rollinger G, et al. Doppler-guided hemorrhoidal artery ligation. Am J Surg 2006; 191:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/30\">",
"      Ratto C, Donisi L, Parello A, et al. Evaluation of transanal hemorrhoidal dearterialization as a minimally invasive therapeutic approach to hemorrhoids. Dis Colon Rectum 2010; 53:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/31\">",
"      Faucheron JL, Gangner Y. Doppler-guided hemorrhoidal artery ligation for the treatment of symptomatic hemorrhoids: early and three-year follow-up results in 100 consecutive patients. Dis Colon Rectum 2008; 51:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19912/abstract/32\">",
"      Giordano P, Overton J, Madeddu F, et al. Transanal hemorrhoidal dearterialization: a systematic review. Dis Colon Rectum 2009; 52:1665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14997 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-125.39.66.146-9893370942-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19912=[""].join("\n");
var outline_f19_28_19912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9357001\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96135853\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103488979\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103489031\">",
"      PREOPERATIVE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96135860\">",
"      OFFICE BASED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135867\">",
"      Rubber band ligation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489077\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489144\">",
"      - Postoperative instructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489092\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354307\">",
"      - Complications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135874\">",
"      Sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489188\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489220\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489195\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H103489181\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135881\">",
"      Infrared coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354134\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354127\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9356816\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354239\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135888\">",
"      Evacuation of thrombosis and excision of external hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354413\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354450\">",
"      - Postoperative instructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354429\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9354437\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96135895\">",
"      OPERATING ROOM BASED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135910\">",
"      Hemorrhoidectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9356871\">",
"      - Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9356809\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9356846\">",
"      - Postoperative instructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9356966\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9356973\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135917\">",
"      Stapled hemorrhoidopexy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9357092\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9357140\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9357100\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96135924\">",
"      Doppler guided hemorrhoidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9357001\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14997\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14997|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/34/14883\" title=\"figure 1\">",
"      Excision and clot evacuation of a thrombosed hemorrhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/32/38400\" title=\"figure 2\">",
"      Int and ext hemorrhoids PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/62/27619\" title=\"figure 3\">",
"      Rubber band ligation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14997|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/46/24291\" title=\"picture 1\">",
"      External hemorrhoid thrombosed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/40/43652\" title=\"picture 2\">",
"      Circumferential thrombosed hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/30/14831\" title=\"picture 3\">",
"      Thrombosed external hemorrhoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/27/36272\" title=\"picture 4\">",
"      Prolapsed internal hemorrhoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8184?source=related_link\">",
"      Approach to minimal bright red bleeding per rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5348?source=related_link\">",
"      Overview of hemorrhoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/47/40689?source=related_link\">",
"      Patient information: Hemorrhoids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=related_link\">",
"      Patient information: Hemorrhoids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32951?source=related_link\">",
"      Rectovaginal, anovaginal, and colovesical fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/61/6105?source=related_link\">",
"      Treatment of hemorrhoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_28_19913="Salicylate (aspirin) poisoning in adults";
var content_f19_28_19913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Salicylate (aspirin) poisoning in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Edward W Boyer, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Kathryn W Weibrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/28/19913/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/28/19913/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and other salicylates are among the oldest medications remaining in clinical practice. The use of aspirin has declined due to its association with Reye's syndrome in children, and the development of other nonsteroidal antiinflammatory drugs (NSAIDs). However, aspirin remains a common analgesic and a widely prescribed antiplatelet therapy for patients with cardiovascular and cerebrovascular disease, and thus aspirin toxicity remains an important clinical problem [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/1\">",
"     1",
"    </a>",
"    ]. Salicylates are found in a number of medications other than aspirin, including salicylic acid (a topical keratolytic agent and wart remover) and methyl salicylate (Oil of Wintergreen). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2807?source=see_link\">",
"     \"Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations and management of all salicylate intoxications are similar. Throughout this section, the terms \"",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    \" and \"salicylates\" will be used interchangeably.",
"   </p>",
"   <p>",
"    The management of salicylate intoxication will be reviewed here. A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef74079 \" href=\"UTD.htm?3/32/3597\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    poisoning in children and general issues relating to the clinical management of drug intoxication are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has multiple cellular and systemic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibition of cyclooxygenase results in decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. This contributes to platelet dysfunction and gastric mucosal injury.",
"     </li>",
"     <li>",
"      Stimulation of the chemoreceptor trigger zone in the medulla causes nausea and vomiting.",
"     </li>",
"     <li>",
"      Activation of the respiratory center of the medulla results in hyperventilation and respiratory alkalosis.",
"     </li>",
"     <li>",
"      Interference with cellular metabolism (eg, Krebs cycle, oxidative phosphorylation) leads to metabolic acidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ABSORPTION AND METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;When therapeutic doses of standard formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    are ingested, the drug is rapidly absorbed in the stomach, and peak blood concentrations are usually reached within one hour. Absorption and peak concentrations are delayed when enteric-coated or delayed release formulations are ingested.",
"   </p>",
"   <p>",
"    At therapeutic levels, 90 percent of salicylate is protein bound and therefore limited to the vascular space.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is metabolized via several different routes in the liver with a half-life of two to four hours. The drug is partially glycinated in the liver to salicyluric acid, which is both less toxic and more rapidly excreted by the kidney than salicylate. Only a small amount of drug is excreted unchanged in the urine.",
"   </p>",
"   <p>",
"    However, absorption and elimination are drastically altered following overdose. Peak levels are frequently delayed, and may not be reached for six hours or longer after absorption as a result of pylorospasm, bezoar formation, or the use of extended-release, enteric-coated formulations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In one extreme case, peak levels did not occur until 35 hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    concentrations rise, normal mechanisms that protect against toxicity become overwhelmed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/5\">",
"     5",
"    </a>",
"    ]. The degree of protein binding falls and hepatic detoxification becomes saturated. Thus, more drug reaches the tissues. As the normal hepatic detoxification is saturated, elimination becomes dependent upon (slow) renal excretion and drug half-life increases from 2 to 4 hours to as long as 30 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2029003\">",
"    <span class=\"h1\">",
"     FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    (acetylsalicylic acid) is rapidly converted to salicylic acid in the body. Other salicylates, such as salicylic acid (a topical keratolytic agent and wart remover) and methyl salicylate (Oil of Wintergreen), can also cause intoxication when ingested or when excessive amounts are applied. Methyl salicylate is a common ingredient in liniments and ointments used in management of musculoskeletal pain. One teaspoon (5 mL) of Oil of Wintergreen contains approximately 7 g of salicylate, the equivalent of 21.7 adult aspirin tablets, and ingestion of just 4 mL can be fatal in a child [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/10\">",
"     10",
"    </a>",
"    ]. Bismuth subsalicylate (eg, found in Pepto-Bismol&reg;) contains 8.7 mg of salicylic acid per mL and can cause acute or chronic toxicity, particularly in infants, if large quantities are used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Herbal medications may also contain high levels of salicylates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF ACUTE OVERDOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early symptoms of acute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    toxicity include tinnitus, vertigo, nausea, vomiting, and diarrhea; subsequent symptoms portending a more severe intoxication include altered mental status (ranging from agitation to lethargy), hyperpyrexia, noncardiac pulmonary edema, and coma. Early symptoms are typically present within one to two hours after a single acute ingestion, but various factors can affect symptom onset, such as multiple aspirin ingestions separated in time, ingestion of enteric coated preparations, and coingestants. Therefore, neither the diagnosis of aspirin toxicity nor an estimation of overdose severity should be based upon the timing of symptoms and signs. &nbsp;",
"   </p>",
"   <p>",
"    Fatal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    intoxication can occur after the ingestion of 10 to 30 g by adults and as little as 3 g by children. Although toxicity does not correlate completely with serum salicylate concentration and symptoms, most patients exhibit signs of intoxication when the serum level exceeds 40 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.9 to 3.6",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    the usual therapeutic range is 10 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.7 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperpnea is often observed in salicylate overdose and is an early clinical finding that helps establish the diagnosis. Clinicians should, therefore, pay particular attention not only to the rate, but also to the depth of respiratory effort. Salicylates stimulate the medullary respiratory center, causing tachypnea and hyperventilation. In addition, salicylates uncouple oxidative phosphorylation in the mitochondria; this generates heat and may increase body temperature. However, a lack of hyperthermia should",
"    <strong>",
"     not",
"    </strong>",
"    be used to exclude the diagnosis of salicylate toxicity. Patients may also develop tachycardia due to hypovolemia, agitation, or general distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tinnitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylates commonly cause tinnitus, even at concentrations within the therapeutic range (20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.5",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    This symptom should be specifically sought in all patients with potential",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    toxicity. Tinnitus generally resolves along with acute salicylate toxicity and no further work-up is required. Other hearing abnormalities associated with acute aspirin toxicity, including alterations in the perception of sound and transient hearing loss, have been described but are rarely permanent. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    can cause nausea and vomiting through multiple mechanisms. These include direct irritation of the gastric mucosa, decreased production of prostaglandins, leading to deterioration of the protective mucosal barrier, and direct stimulation of the chemoreceptor trigger zone in the medulla. Vomiting can be severe and contribute to volume losses. Hemorrhagic gastritis, blood-tinged vomitus, and hematemesis have been described but are far less common.",
"   </p>",
"   <p>",
"    The authors of a case series of 177 patients treated in intensive care for salicylate intoxication reported that hematemesis was uncommon but noted that nearly half of the 26 patients who died had gastric ulcers noted at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acid-base abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of acid-base disturbances can occur with salicylate intoxication. Salicylates stimulate the respiratory center directly, resulting in an early fall in the PCO2 and respiratory alkalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]. An anion-gap metabolic acidosis then follows, due primarily to the accumulation of organic acids, including lactic acid and ketoacids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Salicylic acid itself (molecular weight 180) has only a minor effect on serum pH, since a serum level of 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    represents a concentration that is less than 3",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The onset of metabolic derangements depends upon the amount and type (eg, standard or enteric coated) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ingested, whether the ingestion is acute or chronic, the presence of coingestants, and whether pylorospasm or bezoar formation has occurred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect of these changes is that most adults have either a primary respiratory alkalosis or, more commonly, a mixed primary respiratory alkalosis-primary metabolic acidosis. A pure primary metabolic acidosis is unusual in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/16\">",
"     16",
"    </a>",
"    ], but may be seen in children who are brought to medical care soon after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/15\">",
"     15",
"    </a>",
"    ]. Acute respiratory acidosis is rare in the early stages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    toxicity, but it may occur in later stages of profound poisoning. Respiratory acidosis that occurs early in the course of aspirin poisoning suggests coingestion with a respiratory depressant. Approximately one-third of adults who intentionally overdose on aspirin also ingest one or more other medications, many of which are respiratory depressants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salicylic acid is a weak acid that exists in charged (deprotonated) and uncharged (protonated) forms. The uncharged molecule can easily move across cellular barriers, including the blood-brain barrier and the epithelium of the renal tubule. This causes an increase in the salicylate concentration in the central nervous system (which correlates with lethality) and an increase in the amount of salicylate reabsorbed from the renal collecting system. Metabolic acidosis increases the fraction of uncharged (protonated) molecules, which exacerbates toxicity.",
"   </p>",
"   <p>",
"    Treatment of salicylate intoxication is directed toward decreasing the fraction of uncharged (protonated) molecules, which is accomplished by increasing the systemic pH (ie, lowering the H+ ion concentration). This is referred to as &ldquo;alkalinization&rdquo; and is most easily accomplished by administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . Increasing the systemic pH reduces the diffusion of salicylate anions into the central nervous system, as charged molecules do not easily diffuse across the blood-brain barrier. Alkalinization also \"traps\" salicylate anions within the renal tubule, preventing back-diffusion across the renal epithelium into the systemic circulation. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Alkalinization of serum and urine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Alterations in mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate poisoning produces alterations in mental status via three major mechanisms: direct toxicity of salicylate species in the central nervous system (CNS), neuroglycopenia, and cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. As noted above, progressive acidosis promotes the influx of salicylic acid (HS) into the CNS. Acidemia increases the likelihood of changes in mental status, with the most common findings being agitation, confusion, and restlessness; coma is rare. Lethargy develops as the patient&rsquo;s metabolic derangements worsen and they start to fatigue.",
"   </p>",
"   <p>",
"    Seizures may occur and it remains unclear whether they are most often due to direct salicylate toxicity or neuroglycopenia. Salicylates lower the CNS glucose concentration; therefore, neuroglycopenia may occur despite",
"    <strong>",
"     normal",
"    </strong>",
"    serum glucose levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/19\">",
"     19",
"    </a>",
"    ]. Mortality from salicylate poisoning correlates closely with CNS salicylate concentration, and altered mental status due to salicylate toxicity is an absolute indication for hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate-induced noncardiogenic pulmonary edema and acute lung injury (ALI) generally occur in older patients with chronic salicylate intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/21-24\">",
"     21-24",
"    </a>",
"    ], but they should be considered in all patients presenting with salicylate toxicity. Salicylate-induced ALI and pulmonary edema can complicate volume resuscitation and the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , two mainstays of treatment in this setting. Thus, the presence of salicylate-induced pulmonary edema is considered an absolute indication for hemodialysis. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11398926\">",
"    <span class=\"h2\">",
"     Arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylate poisoning most commonly causes sinus tachycardia, but ventricular arrhythmias have been described as a preterminal event. Fluid and electrolyte shifts are the most common cause, although salicylates can directly alter the membrane permeability of cardiac myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11398933\">",
"    <span class=\"h2\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid losses associated with salicylate overdose can be significant (up to 4 to 6",
"    <span class=\"nowrap\">",
"     L/m2),",
"    </span>",
"    and are caused by hyperthermia, hyperpnea, lack of food and drink, osmotic diuresis, and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/26\">",
"     26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11398940\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylates can cause thrombocytopenia, capillary fragility, and decreased platelet adhesion. These abnormalities are usually not of clinical significance; frank hemorrhage of any type is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11398947\">",
"    <span class=\"h2\">",
"     Hepatic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver injury from salicylate poisoning can lead to decreased glycogen production and increased lactate production, although hepatitis has been described in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum salicylate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic serum salicylate concentrations fall between 10 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.7 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    values above 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are associated with toxicity. Although toxicity does not correlate exactly with serum salicylate concentrations and symptoms, most patients exhibit signs of intoxication when the serum concentration exceeds 40 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.9 to 3.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/2\">",
"     2",
"    </a>",
"    ]. Fatal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    intoxication can occur after the ingestion of 10 to 30 g by adults and as little as 3 g by children.",
"   </p>",
"   <p>",
"    In patients with salicylate poisoning, serum levels should be measured every two hours until two consecutive levels show a decrease from the peak measurement. Levels might not begin to rise until five or six hours after ingestion because of pylorospasm, bezoar formation, or the use of enteric-coated tablets, and may rarely peak as late as 35 hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring serum salicylate concentrations may help assess the response to therapy and determine the need for more aggressive measures, including hemodialysis. Levels above 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are associated with increased morbidity and mortality, and are considered an absolute indication for hemodialysis. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Hemodialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some laboratories report salicylate concentrations as",
"    <span class=\"nowrap\">",
"     mg/L;",
"    </span>",
"    such values are therefore 10-fold higher than those discussed in this topic review. Thus, a laboratory report of \"an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    level of 110\" in an asymptomatic individual should prompt the clinician to check the units of the result in order to avoid confusion.",
"   </p>",
"   <p>",
"    The Done nomogram is no longer in clinical use. Developed to correlate serum salicylate levels with toxicity, the Done nomogram fails to predict toxicity based upon the serum concentration alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In animal studies, mortality from salicylate poisoning correlates closely with salicylate concentration in the central nervous system, but these measurements are not routinely available in clinical practice. Ultimately, serum salicylate concentrations must be interpreted in the context of the patient&rsquo;s clinical status and blood pH. As an example, if a patient has a decreasing salicylate concentration but worsening acidosis and lethargy, this may reflect increased tissue distribution and more severe disease, rather than increased excretion. A small decrease in serum pH will increase the fraction of un-ionized salicylate (HSal), despite a slowly declining total salicylate concentration. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Alkalinization of serum and urine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Elevated concentrations of serum lipids can interfere with the spectrophotometric determination of the salicylate level [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/29\">",
"     29",
"    </a>",
"    ]. Treatment with a lipemia clearing agent or ultracentrifugation must be performed prior to measuring the salicylate concentration to prevent such interference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is eliminated almost exclusively via the kidneys, so the serum creatinine concentration should be checked in all patients who present with known or suspected salicylate toxicity. Renal failure is an absolute indication for hemodialysis in the salicylate-poisoned patient; mild renal impairment is a relative indication for hemodialysis, and must be interpreted in light of the patient's overall clinical condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypokalemia, if present, must be treated aggressively. Hypokalemia promotes the absorption of potassium in the distal tubule; this absorption occurs via a",
"    <span class=\"nowrap\">",
"     K+/H+",
"    </span>",
"    exchange pump. The secretion of protons involved in this pump interferes with efforts at urinary alkalinization, which are a mainstay of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link&amp;anchor=H10#H10\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\", section on 'Plasma potassium concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Coagulation studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, large salicylate overdoses may cause hepatotoxicity and interfere with vitamin K metabolism leading to a coagulopathy, which manifests as elevations in the prothrombin time (PT) and international normalized ratio (INR). Clinically significant bleeding seldom occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11398966\">",
"    <span class=\"h2\">",
"     Lactate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylates uncouple oxidative phosphorylation, which results in abnormal cellular energy production and utilization; the cell becomes dependent upon anaerobic metabolism, resulting in accumulation of lactate. Thus, a significant salicylate poisoning will lead to an elevated serum lactate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link&amp;anchor=H5#H5\">",
"     \"Energy metabolism in muscle\", section on 'Anaerobic glycolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link&amp;anchor=H7#H7\">",
"     \"Energy metabolism in muscle\", section on 'Oxidative phosphorylation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11398973\">",
"    <span class=\"h2\">",
"     Anion gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anion gap is generally elevated in the setting of salicylate toxicity (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?1/17/1298?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). However, there are case reports of patients with a normal anion gap despite severe intoxication, and clinicians should not be dissuaded from making the diagnosis because the anion gap is not elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66723912\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with clinical signs of severe salicylate poisoning, important treatment interventions (eg, hemodialysis) should not be delayed in order to obtain imaging studies. The need for imaging with a head CT depends upon the clinical picture, but imaging should be performed in any patient with altered mental status or focal neurological deficits that are not clearly attributable to a noncerebral cause (eg, hypoglycemia). A plain chest radiograph should be obtained if there are clinical signs of pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of salicylate intoxication is usually suspected from the history, physical examination, and acid-base findings. Confirmation of the diagnosis requires measurement of the serum salicylate concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2029376\">",
"    <span class=\"h1\">",
"     CHRONIC SALICYLATE POISONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic salicylate poisoning is generally seen in young children or the elderly as a result of excessive therapeutic administration of products containing salicylates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The diagnosis and management of salicylate poisoning in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic salicylate poisoning can be difficult to diagnose in part because there is no clear history of ingestion. Clinical findings in chronic and acute salicylate poisoning overlap, but classic symptoms and signs may be milder or absent with chronic toxicity and are often attributed to other disease processes. As an example, difficulty breathing and pulmonary edema in an elderly patient is often attributed to cardiac or pulmonary illness. Another problem is that many of the signs and symptoms of chronic poisoning may be attributed to the ailment that was being treated with salicylates. The delays in diagnosis caused by these difficulties result in higher overall morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of chronic salicylate poisoning does not differ significantly from acute overdose. However, a lower salicylate concentration is generally used as a threshold for treatment with hemodialysis. In fact, some patients with signs of severe chronic toxicity may have a salicylate concentration within the therapeutic range. Hemodialysis is often needed, and should be discussed with a medical toxicologist and nephrologist, for any patient who has a therapeutic or elevated salicylate concentration and any of the following symptoms: CNS dysfunction (eg, delirium, lethargy, seizures), renal failure, pulmonary edema, or severe acid-base (eg, pH &lt;7.3 despite aggressive resuscitation) or electrolyte abnormalities with no alternative explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all poisoned patients, treatment consists of rapid assessment and stabilization of the airway, breathing, and circulation. This should be followed by gastrointestinal decontamination if indicated and the initiation of specific therapies designed to mitigate the effects of the toxin, which in the case of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    consists of alkalinization of the plasma and urine, and in some cases hemodialysis. A summary table to facilitate emergent management of aspirin intoxication is provided (",
"    <a class=\"graphic graphic_table graphicRef74079 \" href=\"UTD.htm?3/32/3597\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Airway and breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheal intubation of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -poisoned patient is dangerous [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/36\">",
"     36",
"    </a>",
"    ], and should be reserved for cases of clear respiratory failure. Intubation of tachypneic patients to prevent physical exhaustion following an aspirin overdose has resulted in death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    acts on the respiratory center of the medulla to increase the respiratory rate (RR) and tidal volume (V",
"    <sub>",
"     t",
"    </sub>",
"    ). Minute ventilation (MV) is determined by RR and V",
"    <sub>",
"     t",
"    </sub>",
"    (RR x V",
"    <sub>",
"     t",
"    </sub>",
"    = MV), so an increase in either can produce a dramatic increase in minute ventilation. As noted above, the resulting respiratory alkalosis \"traps\" salicylate anions in the blood, preventing them from continuing to cross into the CNS. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Acid-base abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinicians should be aware of how airway management can exacerbate the condition of patients with salicylate poisoning. The brief period of apnea that occurs with the sedation and paralysis performed in preparation for intubation can cause an acute and substantial worsening of the patient&rsquo;s respiratory acidosis. During this period, salicylate anions become protonated to uncharged salicylic acid, diffuse across the blood-brain barrier, and increase toxicity. The high respiratory rate and minute ventilation observed in unintubated patients with salicylate poisoning is difficult to replicate with a ventilator. Therefore, orotracheal intubation often causes relative hypoventilation, resulting in a higher PaCO2 than is maintained by spontaneous ventilation, and possibly respiratory acidosis, leading to increased toxicity. In addition, ventilator asynchrony may decrease a patient's ability to maintain appropriate acid-base homeostasis.",
"   </p>",
"   <p>",
"    In general, intubation should be reserved for those patients with",
"    <strong>",
"     hypoventilation",
"    </strong>",
"    , as determined by clinical evaluation or blood gas analysis. When intubation becomes necessary due to primary respiratory failure, maintaining high tidal volume and a rapid respiratory rate becomes critically important. Ventilator settings should mimic the respiratory rate of the patient prior to intubation and tidal volumes will likely need to exceed the 6 to 8",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    commonly used. Unless there is ventilator-patient asynchrony or a comparable problem making ventilation extremely difficult, long acting neuromuscular blockade and deep sedation, which blunt the patient&rsquo;s ability to breath over the ventilator, should be avoided as much as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, clinicians must remain vigilant for auto-PEEP, which can prevent adequate ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6554?source=see_link\">",
"     \"Mechanical ventilation of adults in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supplemental oxygen should be administered as needed whether the patient is intubated or not. The presence of acute lung injury may lead to high oxygen requirements. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pulmonary edema'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    -poisoned patients may be hypotensive due to sensible and insensible fluid losses and inappropriate systemic vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/24\">",
"     24",
"    </a>",
"    ]. Aggressive volume resuscitation is warranted in such patients, unless cerebral edema or pulmonary edema is present. Hypotensive patients who do not respond to fluid resuscitation can be treated with a vasopressor (such as neosynephrine or norepinephrine) as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     Activated charcoal",
"    </a>",
"    (AC) effectively absorbs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and at least one initial dose (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    up to 50 g PO) should be given to all alert and cooperative patients and all intubated patients via orogastric tube who present within two hours of ingestion. AC should be avoided in any patient with altered mental status or increasing somnolence and an unsecured airway. Maintaining high minute ventilation will probably have a greater impact on clinical improvement than AC. Patients who present after two hours may benefit from AC because of delayed absorption due to enteric coated tablets, pylorospasm, or bezoar formation.",
"   </p>",
"   <p>",
"    Treatment with multiple-dose AC results in lower salicylate levels in volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and we suggest such treatment, if it is tolerated (eg, does not provoke vomiting), to prevent continued absorption. Dosing is 25 g by mouth every two hours for three doses or 50 g by mouth every four hours for two doses",
"    <strong>",
"     after",
"    </strong>",
"    the initial dose is given [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/40\">",
"     40",
"    </a>",
"    ]. Multiple-dose AC should not be used in patients with poor gastric motility or in those rare patients with salicylate-induced gastrointestinal hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, whole bowel irrigation (WBI) is not routinely used for salicylate toxicity but can be considered for massive ingestions (eg, entire bottle of tablets) of sustained preparation or enteric-coated drugs in an alert and cooperative patient. Animal and human studies have not demonstrated a clinical benefit in patients treated with WBI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Supplemental glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    intoxication may decrease cerebral glucose concentrations despite a normal serum glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/19,42\">",
"     19,42",
"    </a>",
"    ]. Thus, supplemental glucose should be given to patients with an altered mental status regardless of the serum glucose concentration.",
"   </p>",
"   <p>",
"    There are no clinical studies in humans upon which to base treatment recommendations for supplemental glucose in salicylate poisoning. One reasonable approach is to maintain the patient&rsquo;s serum glucose in the high normal range (approximately 80 to 120",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    or 4.4 to 6.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    In patients who are not able to eat, this can be accomplished using IV boluses of dextrose (50 to 100 mL of 50 percent dextrose) or by adding 50 to 100 g of dextrose to each liter of maintenance fluid. In patients with any neurologic deficit, including altered mental status, a serum or fingerstick glucose concentration should be obtained every one to two hours, until the signs of severe toxicity resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alkalinization of serum and urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkalinization with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is an essential component of management of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -poisoned patient [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The usual initial dose of sodium bicarbonate is 1 to 2 mEq (or mmol) per kg given as an intravenous bolus. This is followed by a sodium bicarbonate infusion of 100 to 150 mEq (or mmol) in one liter of sterile water with 5 percent dextrose. The rate of the infusion is titrated to a urine pH of 7.5 to 8, but is usually 1.5 to 2 times the maintenance dose for intravenous fluids. Hypokalemia must be corrected or prevented for alkalinization to be effective. Enteral or parenteral potassium supplementation should be initiated even in patients with serum potassium concentrations in the low normal range, as alkalinization will further lower the serum potassium. Close monitoring of the serum potassium (hourly measurements) is required during alkalinization therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H169061747#H169061747\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Recommended approach'",
"    </a>",
"    .) Evidence supporting treatment with alkalinization is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link&amp;anchor=H30#H30\">",
"     \"Salicylate poisoning in children and adolescents\", section on 'Urine alkalinization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To appreciate how alkalinization acts, it is important to note that salicylic acid (HSal) is a weak acid. In the equilibrium reaction",
"   </p>",
"   <p>",
"    &nbsp;H+ &nbsp; + &nbsp; Sal- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp; HSal,",
"   </p>",
"   <p>",
"    if the systemic pH is increased, the equation will move to the left. The ensuing fall in the plasma HSal concentration will allow HSal in the CNS and other tissues to diffuse into the extracellular fluid down a favorable concentration gradient where it will be trapped as Sal-. The decrease in the CNS salicylic acid concentration then causes the first equation to move to the right in the brain cell. This increase in the cellular salicylic acid concentration promotes further drug movement out of the CNS.",
"   </p>",
"   <p>",
"    Alkalemia from a respiratory alkalosis is",
"    <strong>",
"     NOT",
"    </strong>",
"    a contraindication to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    -poisoned patients commonly present with an arterial pH between 7.50 and 7.55; these patients should be treated with sodium bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/43\">",
"     43",
"    </a>",
"    ]. Blood gas analysis every two hours is indicated for monitoring to prevent severe alkalemia (arterial pH &gt;7.60). A urine pH of 7.5 to 8 is desirable, although this may be difficult to obtain in salicylate-poisoned patients, particularly in the setting of intravascular volume deficits and whole body potassium depletion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=see_link&amp;anchor=H8#H8\">",
"     \"Enhanced elimination of poisons\", section on 'Urinary alkalinization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concurrent alkalinization of the urine is also beneficial by increasing salicylate excretion. Since the salicylate anion is highly protein bound, it enters the urine primarily via secretion by the organic anion secretory pathway in the proximal tubule, rather than by glomerular filtration. Alkalinization of the urine converts urinary HSal to Sal-, thereby minimizing the back diffusion of secreted HSal from the tubular lumen back into the renal epithelium and ultimately the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/46\">",
"     46",
"    </a>",
"    ]. As an example, raising the urine pH from 6.5 to 8.1 by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    can increase total salicylate excretion more than fivefold [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IV fluids are needed to treat dehydration and maintain urine output. Initial fluid resuscitation is performed with isotonic saline, usually at a rate of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for the first two to three hours, and is then titrated to maintain a urine output between 1 to 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?19/28/19913/abstract/26\">",
"     26",
"    </a>",
"    ]. We do not suggest the administration of excessive IV fluids beyond the restoration of normal fluid balance (ie, &ldquo;forced diuresis&rdquo;) nor do we use diuretics because the excretion of salicylate depends upon pH not on the urinary flow rate. In addition, patients with salicylate poisoning are at risk of pulmonary edema and may not tolerate excessive IV fluids.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in the standard management of salicylate poisoning.",
"    <strong>",
"    </strong>",
"    Acetazolamide is a carbonic anhydrase inhibitor that alkalinizes the urine by reducing bicarbonate reabsorption. While this does enhance salicylate excretion, the bicarbonate loss from plasma lowers the arterial pH, which promotes salicylate movement into the brain, potentially worsening salicylate neurotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Repeat laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    -poisoned patients require frequent laboratory testing to assess both clinical status and response to therapy. A salicylate concentration and blood gas should be drawn every one to two hours until both the serum salicylate concentration is falling and the acid-base status is stable or improving for two consecutive measurements. Urine pH and serum potassium should be checked hourly. Ideally, blood gas measurements are taken from an arterial source; venous samples can substitute until an arterial line is placed to ensure close monitoring and avoid multiple painful arterial punctures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficiency of salicylate removal can be enhanced by hemodialysis. Indications for hemodialysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mental status",
"     </li>",
"     <li>",
"      Pulmonary or cerebral edema",
"     </li>",
"     <li>",
"      Renal insufficiency that interferes with salicylate excretion",
"     </li>",
"     <li>",
"      Fluid overload that prevents the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"     </li>",
"     <li>",
"      A serum salicylate concentration &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in acute overdose",
"     </li>",
"     <li>",
"      Clinical deterioration despite aggressive and appropriate supportive care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consultation with the nephrology service should occur early in a patient's course, even in the absence of the immediate need for acute hemodialysis. Alerting the nephrologist early in the patient's course will facilitate hemodialysis in the event that the patient deteriorates despite aggressive and appropriate supportive care.",
"   </p>",
"   <p>",
"    Treatment and continued diagnostic testing is no longer necessary when the patient has clinically improved, their acid-base status has normalized, and the blood salicylate level is no longer in the toxic range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salicylate poisoning remains a significant clinical problem. Fatal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      intoxication can occur after the ingestion of 10 to 30 g by adults and as little as 3 g by children. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early recognition is the key to successful management. The diagnosis must be considered in any patient with a suspected drug overdose and in those with an unexplained increase in the anion gap. The diagnosis is made on the basis of the history, physical examination, and acid-base findings. Confirmation of the diagnosis requires measurement of serum salicylate concentration. A summary table to facilitate emergent management is provided (",
"      <a class=\"graphic graphic_table graphicRef74079 \" href=\"UTD.htm?3/32/3597\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prominent early clinical features of acute salicylate poisoning include: tinnitus, vertigo, vomiting and diarrhea; more severe intoxication can cause altered mental status, hyperpyrexia, coma, noncardiac pulmonary edema, and death. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features of acute overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of acid-base disturbances can occur with salicylate poisoning. Most adults have either a primary respiratory alkalosis or a mixed primary respiratory alkalosis-primary metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acid-base abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapeutic serum salicylate concentrations are 10 to 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.7 to 2.2",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      values above 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      may be associated with toxicity. In poisoned patients, serum concentrations should be measured every two hours until two consecutive levels show a decrease from the peak measurement. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic salicylate intoxication is often misdiagnosed and a high index of suspicion is needed, especially in high risk patients such as the elderly. Treatment is the same as for acute toxicity, with the important exception that a lower salicylate concentration is used as the threshold for hemodialysis. (See",
"      <a class=\"local\" href=\"#H2029376\">",
"       'Chronic salicylate poisoning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intubation of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -poisoned patient is dangerous and should be",
"      <strong>",
"       AVOIDED",
"      </strong>",
"      if at all possible. When intubation is necessary due to primary respiratory failure, care must be taken to ensure appropriately high minute ventilation and maintain alkalemia with serum pH 7.50 to 7.59. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Airway and breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that adults with salicylate poisoning and clinical signs of toxicity be treated with alkalinization of the serum and urine (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Alkalinization is the mainstay of therapy. We use intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      for this treatment; details are provided in the text. Early nephrology consultation should be obtained and hemodialysis considered for all patients with clinical evidence of severe intoxication. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Alkalinization of serum and urine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      -poisoned patients may be hypotensive. Aggressive volume resuscitation is warranted, unless cerebral edema or pulmonary edema is present. Hypotensive patients who do not respond to fluid resuscitation can be treated with a vasopressor (eg, norepinephrine). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      intoxication may decrease cerebral glucose concentrations despite a normal serum glucose. Therefore, we suggest that adults with salicylate poisoning who are hypoglycemic or manifest alterations in mental status, regardless of their serum glucose concentration, be treated with supplemental glucose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Supplemental glucose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/1\">",
"      Herres J, Ryan D, Salzman M. Delayed salicylate toxicity with undetectable initial levels after large-dose aspirin ingestion. Am J Emerg Med 2009; 27:1173.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/2\">",
"      Hill JB. Salicylate intoxication. N Engl J Med 1973; 288:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/3\">",
"      Temple AR. Pathophysiology of aspirin overdosage toxicity, with implications for management. Pediatrics 1978; 62:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/4\">",
"      O'Malley GF. Emergency department management of the salicylate-poisoned patient. Emerg Med Clin North Am 2007; 25:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/5\">",
"      Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/6\">",
"      Wortzman DJ, Grunfeld A. Delayed absorption following enteric-coated aspirin overdose. Ann Emerg Med 1987; 16:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/7\">",
"      Shkrum MJ, Gay RM, Hudson P. Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin. Arch Pathol Lab Med 1989; 113:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/8\">",
"      Pierce RP, Gazewood J, Blake RL Jr. Salicylate poisoning from enteric-coated aspirin. Delayed absorption may complicate management. Postgrad Med 1991; 89:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/9\">",
"      Rivera W, Kleinschmidt KC, Velez LI, et al. Delayed salicylate toxicity at 35 hours without early manifestations following a single salicylate ingestion. Ann Pharmacother 2004; 38:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/10\">",
"      Botma M, Colquhoun-Flannery W, Leighton S. Laryngeal oedema caused by accidental ingestion of Oil of Wintergreen. Int J Pediatr Otorhinolaryngol 2001; 58:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/11\">",
"      Feldman S, Chen SL, Pickering LK, et al. Salicylate absorption from a bismuth subsalicylate preparation. Clin Pharmacol Ther 1981; 29:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/12\">",
"      Lewis TV, Badillo R, Schaeffer S, et al. Salicylate toxicity associated with administration of Percy medicine in an infant. Pharmacotherapy 2006; 26:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/13\">",
"      Baxter AJ, Mrvos R, Krenzelok EP. Salicylism and herbal medicine. Am J Emerg Med 2003; 21:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/14\">",
"      Thisted B, Krantz T, Str&oslash;om J, S&oslash;rensen MB. Acute salicylate self-poisoning in 177 consecutive patients treated in ICU. Acta Anaesthesiol Scand 1987; 31:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/15\">",
"      WINTERS RW, WHITE JS, HUGHES MC, ORDWAY NK. Disturbances of acid-base equilibrium in salicylate intoxication. Pediatrics 1959; 23:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/16\">",
"      Gabow PA, Anderson RJ, Potts DE, Schrier RW. Acid-base disturbances in the salicylate-intoxicated adult. Arch Intern Med 1978; 138:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/17\">",
"      Eichenholz, A, Mulhausen, RO, Redleaf, PS. Nature of acid-base disturbance in salicylate intoxication. Metabolism 1963; 12:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/18\">",
"      Rauschka H, Aboul-Enein F, Bauer J, et al. Acute cerebral white matter damage in lethal salicylate intoxication. Neurotoxicology 2007; 28:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/19\">",
"      Thurston JH, Pollock PG, Warren SK, Jones EM. Reduced brain glucose with normal plasma glucose in salicylate poisoning. J Clin Invest 1970; 49:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/20\">",
"      Hill JB. Experimental salicylate poisoning: observations on the effects of altering blood pH on tissue and plasma salicylate concentrations. Pediatrics 1971; 47:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/21\">",
"      Walters JS, Woodring JH, Stelling CB, Rosenbaum HD. Salicylate-induced pulmonary edema. Radiology 1983; 146:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/22\">",
"      Chalasani N, Roman J, Jurado RL. Systemic inflammatory response syndrome caused by chronic salicylate intoxication. South Med J 1996; 89:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/23\">",
"      Niehoff JM, Baltatzis PA. Adult respiratory distress syndrome induced by salicylate toxicity. Postgrad Med 1985; 78:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/24\">",
"      Leatherman JW, Schmitz PG. Fever, hyperdynamic shock, and multiple-system organ failure. A pseudo-sepsis syndrome associated with chronic salicylate intoxication. Chest 1991; 100:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/25\">",
"      Kent K, Ganetsky M, Cohen J, Bird S. Non-fatal ventricular dysrhythmias associated with severe salicylate toxicity. Clin Toxicol (Phila) 2008; 46:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/26\">",
"      Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981; 141:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/27\">",
"      Garber E, Craig RM, Bahu RM. Letter: Aspirin hepatotoxicity. Ann Intern Med 1975; 82:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/28\">",
"      Dugandzic RM, Tierney MG, Dickinson GE, et al. Evaluation of the validity of the Done nomogram in the management of acute salicylate intoxication. Ann Emerg Med 1989; 18:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/29\">",
"      Charlton NP, Lawrence DT, Wallace KL. Falsely elevated salicylate levels. J Med Toxicol 2008; 4:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/30\">",
"      Jacob J, Lavonas EJ. Falsely normal anion gap in severe salicylate poisoning caused by laboratory interference. Ann Emerg Med 2011; 58:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/31\">",
"      Gaudreault P, Temple AR, Lovejoy FH Jr. The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics 1982; 70:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/32\">",
"      Karsh J. Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient. Drug Saf 1990; 5:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/33\">",
"      Anderson RJ, Potts DE, Gabow PA, et al. Unrecognized adult salicylate intoxication. Ann Intern Med 1976; 85:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/34\">",
"      Proudfoot AT. Toxicity of salicylates. Am J Med 1983; 75:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/35\">",
"      Fertel BS, Nelson LS, Goldfarb DS. The underutilization of hemodialysis in patients with salicylate poisoning. Kidney Int 2009; 75:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/36\">",
"      Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med 2008; 15:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/37\">",
"      Greenberg MI, Hendrickson RG, Hofman M. Deleterious effects of endotracheal intubation in salicylate poisoning. Ann Emerg Med 2003; 41:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/38\">",
"      Barone JA, Raia JJ, Huang YC. Evaluation of the effects of multiple-dose activated charcoal on the absorption of orally administered salicylate in a simulated toxic ingestion model. Ann Emerg Med 1988; 17:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/39\">",
"      Kirshenbaum LA, Mathews SC, Sitar DS, Tenenbein M. Does multiple-dose charcoal therapy enhance salicylate excretion? Arch Intern Med 1990; 150:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/40\">",
"      Olson KR. Activated charcoal for acute poisoning: one toxicologist's journey. J Med Toxicol 2010; 6:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/41\">",
"      Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/42\">",
"      Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose. Clin Toxicol (Phila) 2007; 45:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/43\">",
"      Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. J Toxicol Clin Toxicol 2004; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/44\">",
"      Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or urinary alkalinisation for salicylate poisoning? Br Med J (Clin Res Ed) 1982; 285:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/45\">",
"      Vree TB, Van Ewijk-Beneken Kolmer EW, Verwey-Van Wissen CP, Hekster YA. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. Int J Clin Pharmacol Ther 1994; 32:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/28/19913/abstract/46\">",
"      Chatton JY, Besseghir K, Roch-Ramel F. Salicylic acid permeability properties of the rabbit cortical collecting duct. Am J Physiol 1990; 259:F613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 329 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-9C20EB8C63-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19913=[""].join("\n");
var outline_f19_28_19913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ABSORPTION AND METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2029003\">",
"      FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF ACUTE OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vital signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tinnitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acid-base abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Alterations in mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11398926\">",
"      Arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11398933\">",
"      Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11398940\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11398947\">",
"      Hepatic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum salicylate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Creatinine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Coagulation studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11398966\">",
"      Lactate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11398973\">",
"      Anion gap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66723912\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2029376\">",
"      CHRONIC SALICYLATE POISONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Airway and breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Supplemental glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alkalinization of serum and urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Repeat laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/329|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/32/3597\" title=\"table 1\">",
"      Salicylate poisoning in adults - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?1/17/1298?source=related_link\" title=\"calculator 1\">",
"      Calculator: Serum anion gap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2807?source=related_link\">",
"      Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=related_link\">",
"      Chapter 11B: Regulation of renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=related_link\">",
"      Energy metabolism in muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6554?source=related_link\">",
"      Mechanical ventilation of adults in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_28_19914="IASLC lymph node map";
var content_f19_28_19914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    The International Association for the Study of Lung Cancer (IASLC) lymph node map",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 786px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAMSAjgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKCcUAFIzBRliAKxNf8T6Zols8t5cIu3tmuJ+1eJvFtxughm0nRMbhcS8SS+gVOoHuaVzSNNvV6I9K+2227Hnx5+tTq6sMqQR7V5snga3dW8zUNTiuCeJEmY4P06Vj/254j8D30sOtQzX+kLjbfxjOB/tjtRcpUlLSL1PYqK5nw94y0rW4la1uEYnsDzXSowZQQcimZSi4uzFooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWT4nuJbbR7iWAfvFQkfXFa1VtQhW4s5Y2GQRQNbnmXhV9EuYY9Wa3FzqhwpmuCX2P/sg8A13dpcyXKtvIIHGa8I8P3D+HfHeqaJcBntJWM0Wf4c9CPpmvUvDzTQyOskm6JlLLk5/P3pR1R014crOvhPlW++Q8LnJzXnnjPxq9m0tvZxxOwOGLcjFdB4n1R7XQ8qoAOMtnHFeK3119ovSHJbe2Rx3rSmk9WRThfUt+Kp4La0s9Y0iK3tLoyIknkrt3MT2A49a978J3El1olvLL95lB/SvmNFfX/HllpVsW+xWLBpF7GTvmvqbRoBb6fDGowFXFZJpt2NcTHkjFPcvUUUVRxhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUyX7hp9Mm/wBWaAPn/wCK8H9n+M9N1OMAFpBE5PAIJ9a7U38Wk3sYuZERZFLKW4XPpmsP42ae15o7vGDvj+YEe1XNDv8AT/E3g7Tru/8AId1ASYyD7jAYNTF2bR2P3oRfyNLxRK17oaSQkglR8owQPfmvLZrhdJa5vpY/PWBGZTjjdjjkds16zeW+jSaXGJ7u3NsMbQJPy4ry/wCKLacljb2unuv2q7lEflouBsByW/MAfjTbsh0dfdL/AMCdAbdNql2u64uGLkn3Oa+gbcbUArz74cWYs9HtkA5Kgn8q9ChztGfSpgrIxxE+ebZJRRRVmAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBleLNX/AOEf8K6zrPkfaP7Osprzyd+zzPLQvt3YOM4xnBx6V5rpPxG+Iur6VZ6lp/wo86yvIUuIJP8AhI7Zd8bqGU4KgjII4IzXa/Fj/klnjL/sC3v/AKIej4T/APJLPBv/AGBbL/0QlAHKf8Jt8T/+iR/+XLa//E0f8Jt8T/8Aokf/AJctr/8AE16rRQB5V/wm3xP/AOiR/wDly2v/AMTR/wAJt8T/APokf/ly2v8A8TXqtFAHlX/CbfE//okf/ly2v/xNH/CbfE//AKJH/wCXLa//ABNeq0UAeVf8Jt8T/wDokf8A5ctr/wDE0f8ACbfE/wD6JH/5ctr/APE16rRQB5V/wm3xP/6JH/5ctr/8TR/wm3xP/wCiR/8Aly2v/wATXqtFAHlX/CbfE/8A6JH/AOXLa/8AxNH/AAm3xP8A+iR/+XLa/wDxNeq0UAeVf8Jt8T/+iR/+XLa//E0f8Jt8T/8Aokf/AJctr/8AE16rRQB5V/wm3xP/AOiR/wDly2v/AMTR/wAJt8T/APokf/ly2v8A8TXo+s6vp2h2D32s31rYWacNNcyrGgPYZJ6+1Q+HvEWjeI7V7nQNUstSgRtjvazLIEb0ODwfrQB59/wm3xP/AOiR/wDly2v/AMTR/wAJt8T/APokf/ly2v8A8TXqtFAHlX/CbfE//okf/ly2v/xNH/CbfE//AKJH/wCXLa//ABNeq0UAeVf8Jt8T/wDokf8A5ctr/wDE0f8ACbfE/wD6JH/5ctr/APE16LoOtad4g01NQ0a7ivLJ2ZFmiOVJUkHH0IIrQoA8q/4Tb4n/APRI/wDy5bX/AOJo/wCE2+J//RI//Lltf/ia9Hi1fT5tYn0qK9gfUoI1mltlcGREPRiOwNXqAPKv+E2+J/8A0SP/AMuW1/8AiaP+E2+J/wD0SP8A8uW1/wDia9F1XWtO0mewh1G7it5b+cW1sj9ZZD0Ue9aFAHlX/CbfE/8A6JH/AOXLa/8AxNH/AAm3xP8A+iR/+XLa/wDxNeq0UAeVf8Jt8T/+iR/+XLa//E0f8Jt8T/8Aokf/AJctr/8AE16rRQB5V/wm3xP/AOiR/wDly2v/AMTRo/xJ8T/8J34e8N+K/Af9g/219o8i4/tiK6/1MRkb5UT/AHRyR97vivVa8q+In/JdvhH/ANxf/wBJVoA9VooooAKKKKACiiigAooooAKK858T/FzQfD2v3OkXVpqs9zb4EjQQKVBIzgbmBPB7Vf8AC/xQ8LeI7lLW1v2trxzhbe8QxOx9ATwT7AmldbF+zla9jt6KaWC9aUMDTIFooooAKK5n4jeJJ/CfhK91i2sHvngH3BnameN74BOwcEkDgc8DJHjOo/HnWk0q1Fpp2n/2igkN23kyyo21wo8uNXDDOc8scfrTUW9jalh6lX4Ffp+F/wBD6Mpkv3DXl/w3+LFv4lSS11WKC11SGYwuIWJjk4UhlzyB82CDnBBGTXc+LtUl0jwvqOpWsQmmt4TJGp5BPv7d/wAKLO9ifZSU/Zve9vmcv45tvOspVYcYNeFoy2sV4tvM0M8bmKSMn5WPZsfTFJqXirWL27Fw2q3ckjctlsJ+C9AK0vC3h298Zx3uoWce4x7Y5QhALsc8gHrxXNjcLUsnB6n0+Hoxyx2xVpQlp31+Zf8AEfhe88P22myNrVxdfaj5U+VCpnbuBQdcYBHNY1rZRXXiC2ii+eO3GSx5JY//AKq6PXfB2tHSUeQXxSyiKqJVCk8Af3j6dq5WWa40O4gt40a1l8lHZmIZjnJzUewnVr3T09TPCzhUw6w1O3tJN3drab7n0N4Zj2RRKOgArrovuCvBPhz8Q7r+3bfTNU2XEM7BI58bWVvQ+or3sYCZ7V2ODhozw8bhp4ar7OpuOoBrxvxn8Xb7w78QG0ZtKjTTYGgSWSYMJJhMcCSM8LsByM/Nkqw4IwZvhh8Xf+Eltpl12C1tbsMjxiAsFZHXcBhiTkdCe/XA6UWe5i6E4x52tP8Ah1+jPXqKZDIssSuhypGRT6RkFFMdwo5NUbnUFjB5H50BY0CwFAYHvXN3OtQ28Uk9xPHDBGMvI7gKo9ya427+NPhe1lZIDf6gw6tawZX82IzU8yRoqcpbI9Xorjfh58QtI8dLfDSY7yGWyKCaO6jCkbs7SCCQR8p712VUnchpxdmFFFFAgooooA5X4sf8ks8Zf9gW9/8ARD0fCf8A5JZ4N/7Atl/6ISj4sf8AJLPGX/YFvf8A0Q9Hwn/5JZ4N/wCwLZf+iEoA6qio7meG1t5Z7mWOGCJS8kkjBVRRySSeAB61wjfGHwKtyYf7cyAcectnO0P180Jsx77sUFRi5bI7+ioLG7tr+zhu7G4iubWZQ8c0Lh0dT0II4IqZ2VFZnYKqjJJOABQSLRSKwZQykFSMgjoRQ7KiszsFVRkknAAoAWikRldVZGDKwyCDkEUtABRRRQAUUUUAFFQWt5bXZmFrcQzmCQwy+W4by3GMq2OjDI4PPNT0AeT/AB4hsr4aFb3Y8RWtzazm+tNR03SzfwQSqNoWWPBBzuOBjseR34mx1bxhbXHgW41jQ9WsYJ9Ru7nUn0fTpIZLxI4wLf7RDHyC56q3GAPTj6Htby2uzMLW4hnMEhhl8tw3luMZVsdGGRweeanoA+XjrviKK08E2HibUfFFhdaxqd9repw25uTdW1shKxQbEBdY24woG0Zycda0/COg+ONTv/C2ialf+LtK0g/b9SnuBPIk0cDsFt7eWU5BkGCxU5ID9ARx9AtpOntrKas1nAdTSA2y3RQeYsRO4oG64zzirtAHzNpB8Y658SPDU8Fp4j0u3TVXS88579wlvAOFmd2EBEgHRE5J+9k1atLzXJ7XxHqOsW/jlvHNs149vaW0dwLFUCskMaKo8t0OVPGWJGenNfR9FAHyLrGm+MLHw1aeGdA0fXbG+0eysobeW2+34lllPmzSr5RWFNruyln3n5egwSvo3iiy8dn4k3/hzSLnXBpGtWllv1je4h09IgwnMbfdSVwo4XBJbJ7GvbbW8trszC1uIZzBIYZfLcN5bjGVbHRhkcHnmp6APm3VP+EwhGsX8yeKoNEvfEaWM/2dZ3u4tMgj2rJEDl1WQ8s68nHU55u3Gp6r4e8WaDLoNn47uvD0WlXt9Bbzx3M7T3LlkSGVTztAQOofkbweCa9+gvLa4mnhguIZZbdgsyI4ZoyRkBgOhxzzU9AHzFLaeMLK18FXmpaVr+tXmgaFdaxM04lLy3dw2xIS5BPmRqwbaOQF6VBo58dWFl471Gwg8SNF/Y0NvY28ceoN5t1OwzNELhmkLxjdll2gdcCvp2K8tprqe2iuIZLm3CmaJXBePcCV3DqMgHGeuKnoA47w5pU/gjwbcS3+oeINfvI4BNN5sjXc7OsYBSFcdyOB3JyT3rw3SB42Twn4t1vTn8ewawI0is9M1H7XKttA8qh5F83/AF04QMflGF7ZOK+o6KAPmrUYPFq6d4nTwQ3i5dH1OawsNOmvGumuFlLA3F0PM/eRpgEFjtGW44Ap+p2njzSNA+IU2hS+J3t21i3s7Y3RmnuUtYwRNPAGIZgxYcoRwOCMZH0lUEN5bT3Nxbw3EMlxblRNEjgtEWGV3DqMjkZ6igDzf4E2Oo2+maxcXmp6ld2c9yv2WG9tbmAQAIN3li5d5SpJHJOMg4qH4if8l2+Ef/cX/wDSVa9Vryr4if8AJdvhH/3F/wD0lWgD1WiiigAooooAKKKKACiiigDg/iV4Ci8URpe2Trb6vApCPjiUdlb+h7V47aeFbPWFubK9D2ur2rlJEYcbh3zX05IcKa8/8a+HF1G6OoaeRDqiqMkcCUDsff3qJLqjopVdOWRwvh/xjr/g+f8As/X1m1LTU4EjHM0Q9Qf4h7HmvVtH8RafqdlHeWV5DJbScK+7Bz6EHkH2rgLKaHU4/I1WHZcw/KS3BB96828d6Imj660xQpYzDIZCQN3ocdKumud2OqhhYYiqqcpct+p9Swzq4BBBHqDVgMCOK+WPh94rv9D1yC3inklsLiQJ5DNnGT1X0r6Jt9SB2kknIzzVTjyOzMsbgpYSp7Nu4z4geHG8V+Fb3SFvpbHzwMyIu4EA52suRuU9CMjI718r+K/hj4gstXmt7Wc3CyYDzRQGLowbKjcdpyOuTX15DeK+PWsuLxL4butYbTk1Czk1BSVMWecjqM9Cfakm+hjSnWjFqne27t9x8l6H4b1fwl4hHiDWk8uDeoZYIyvmP7LnG49T09a+o/BHjLSPF9jLaQCWO4iTbLbzqAxB7jqCKx/jfoc1/wCF4bnT4g72UvnMijO5cYPHtXifg/V77Sdbl1Swj82a3idnGPlAIxz7ZwfwrWMFKN+p6VHCUsThpVXL95f+vvPS/Fvws0YXUtxA00KMcmJW+X8qZ8M7O70/WNRTRihhiWNGgLbdx55z9K8/uvF2uSXIuW1e5nlY7nR2ymfTb0A+leh/CKC51iXU9VtL0W0jBE8jAZXIByT+dZ1KcoSTbDHYGrhYL2slK/qdt4w1nVLbQpQ2keYJBtYibGP0/rXjut6Sde1dUukNnKtvEEKNuIHNe16xaa7c6XJbeZCGI4ZIw36GvCvFVxquk6vNFd3LfayVVpAACqgcAY6dalXnpHRnLgKcqlVQg7N9bnZeAPhnFZazb6heXr3LQtujTbgA+tdf4i+Kmg6JqhsGS5ujG/lzSwKCkZ6EZJ5I9q8k0Hx/rGkTtAl095byoUAuOWRmGAVbrwe3SuRe0v7i8SwFvK1477RHtOSSep/xroVLV87PW/syEas5Y6peyutd/v10PSPit8ObjxLPeeJ9H1ozw6hFE0cMlsZGjVVG0RvvG0ZywG04ZmPOa8l03wb4ptLuym+yoDbFVV44mV2VRgAncQffivqK6lfwP8LA5jWe4srZUVX5BckKM+wJzXz/AG2tX6eJbbUluJpb95l8wljh8n7uOmPapjFyTaehxYXC1sTQnNTtCOmv3/rufSngS6u59Dh+3RlJFXBBrcmuFQEZ5rMN+iWkRVQhKgkCsa61EtJgNzXO5WPKjBsx/HXxGttBn+xWsLXl91aMPtWMY/iPr7VwVv8AFmSWZk1HTwGfiFbdidzehJ7e9c34106+uvFV2NEh+3tO5eQgnEZ9Ca1fCHw+khuVvvEEymReFjTgLn0rVunyabnsSjgoYdKCbm+uuhHcW+r+M7hpNTnMOnxnPkqSI1/+KPuazjo73uqf2R4ZjM0gGJJmG1R7k9hXf3ol1H/iWaVGIbVDiSY9F/xPtXTeGNIttKtRBaR4ydzufvOfUmuZ66I5OdQV+pofCrwnB4Q0OS2SQT3lxJ5tzPjG44wFHsB0+p9a7odKz9Ojwg7VoDpWqVkcMpOTuwooopkhRRRQByvxY/5JZ4y/7At7/wCiHo+E/wDySzwb/wBgWy/9EJR8WP8AklnjL/sC3v8A6Iej4T/8ks8G/wDYFsv/AEQlAHK/tIRXb/D+FoA7WEV/FJqIXkfZwr8t/siTyifYZPANeAq6mMOrKUIyGB4xX2iyhlKsAVIwQehFcg3wx8Etdm5PhfSfMLbyv2ddhPrs+7+la06nIrWPWy7NPqUHDkvfXscb+zPHdDwvq8uHGkS3xay3fdb5FEjJ/sF89OCwY966D492S6j8LtZtBZanfXUsTLaw6fHNI5m2tt3LFyU9d3y9M9q9AhjSGJIoUWOJFCqijAUDoAOwp1Zt3dzzatT2k3O1ru5zPw0mabwDoCyWt5aywWUVvJDd27wSK6IFbKuAcZBwcc9aX4m20958NvFlrZwyz3M+k3ccUUSFnkdoXAVQOSSSAAK6Ws/xDrFl4e0S91bVZTFY2cRmmcKWIUegHJpGZ4vaazr03wv8I6XpuleLNMXShp9prZj06WG5MAhKv5GV3OA6LuKAsAR61BeXXxLtPCnh67tE1ie5upr7TWikiJnjil3C0uZ1A+Ux4BYnHBGea6vU/jLZW+n6LeWOgazdQajqUdgCYsEB0Lbk27hI2AMICCeeRitiL4reGpPFieH1kuhcvdmwE5hxCLkDJhJznd26YzxmgDK+D0vjC71XWn8Yfb4odNSLS7dbhCi3bxlvMuhkDdv+TDDg84rn7+48ZDW/FHPikeIVuboaJFbwZ0trcQt5BdiPL3Z67iG37R0zXU2vxi8N3emWV/a2uuy299KsFoV0yX/SJGEh2x8YcjyzkrkDIyR2kuPi5oEHhW31/wCy6q1lLLLBIv2cI9vJEcOsgZgA2egBJPbODQB5fpt18RF8M6kILvxS15I9iNk+nzebbv5yrMUaRMMCpJIUMgAzkCuq8a2PjrSPEmmaL4f1LXdQ0zWYYreXU5Arvp8iXCvJKzKgVQ0LMo4GSBiuw8LeO18SeNZdO09In0d9GttVt7jayyP5rMMEHoMAcYzmmXvxV8P2fiB9Klh1TdHqCaXLdLZsbeK4fGxWk6c5H9cDmgDgrp/GEVzqQnh8QW+gt4rvPtcmmWrC7a08hPJaIBdzRmTOXUE8dayPG+peOI7y3fwzB42RbW3tHtnuLeWU3YMvz+aiLsRlU/MJMsQBwOTXqdt8VNBu7mWC0h1GXdHdPZy/ZiI79rcHzUgb+IjaewzjjNUPD3xe0/VfDWh6hLo2rJqWreZ9n0y3gM0sgRQzujEKGjAYfMcZOQORQBT+HeoP4b17xFp2pabqK3OveLb1rIeRtDRCCNjOSxH7v5SNwzkkAZqt8d7jxXBf6UfDDa1LAsMjSWmnwTATSZAX9/ErFGHOA4Cep9JD8XdPtPF2sx65pF7FYae1lHb3yWDl7ZLqGNyLhj/q/nZF2jngZBIru/F/jDT/AAq+nR38N9cXGoSNDbQWVu00kjqpYgKPYUAeS3Gu+Pba6u9Lk03xP9qfXLGWGdbfzoY7JhH5qGZBtODv3YHcngdKfhPXPF2r+Jo30688Q3bwaxqUF6ZIj9gSzQuEUNtAMgbbtAJb1wK9DHxh8NPpVnfW0Wq3P2i3mu3t4bQtNbQwvsleVc/KFbjvntmsbxx8UdF8H+HNUfwXpiXl1Faxao5trTbaILhgVeZl24aQEsOpPU0Ac9KvjW3+F/hu5vLnxfdavqc0ZvyqsJNPCpIMGKGMSlSSuQT1CksBwami33jifR/DjeMT40hsf7NuQ7aTaOLxrxbqRU85QpYDyRGV3DaSck16fd/FbwxaeLP7AlmufPF2tg1wIswJckZERbOd3IGQCMnGc1c8C/ELSPG8s39hw37WyJ5i3UsO2KQbscHJIPswBwDxxQB5NNB4n0zRfEUdnpviK3N/4yuZmubWKVZFgNugWQpGu+RCw/gIG5eWxwYYrz4pr4R8LSQjW5dR1e2n0m6E1sytYSi7xFdyAjK/ud2WPHAPfNfR9FAHhmuL4ztLjxSlgmtCwGuWKS3Frb/6TJYeQBM8B25dt2MlckfNiqmqa34q0qbUf7GtPHN9pV14cuotOe5sneeK/Esu1pBgMvy7NpYZIA4Jr36igD53VPFljF421JdJ16S/vrHQF863jkimZljPnspClmKk4dUG4ZI4PITwd/wsHVLrQ9L1HUPFNlYvrGowzX32RopRaC1jeFmMyNgGQuFZ8nOQDkcfRNFAGL4Z1631v+0ktI7oJpt4+nvNOqgTSR4DlCDyASVJIHIPHFeBaXqnxFbUNamjtvFVus+j6mfslzBNMLe6RSYAkjKEZycbfLAU9BmvpO3ghto/Lt4o4o9zNtRQoyxLMcDuSST6k1JQB89Xq/EfSbLVU0m78R6hPd+GLS+3XUIcw3pmCzRw/IAsgi3ER9c4PpXVfBSwubfxf48u3t9fWxu5LE21zrUEkc9wFt9rEl1BODx7cV63RQAV5V8RP+S7fCP/ALi//pKteq15V8RP+S7fCP8A7i//AKSrQB6rRRRQAUUUUAFFFFABRRRQA1xkYrG1CE5yK26r3EQZTQNOxwOt6Ol0xuLZhDeActj5ZPZv8a5yUx3oNhqSxrOuR5cg4I9vX616DqUOwnFcL4kSG5AEy/Mv3XHDKfY1k3Y6afvGXB8P9EN39otle2u4zlHjb7p9q2UudW007b3ybqMcCRDsY/UHg1iWetS6eNtwPNRfuygc/wDAh/Wur0/WrW9twJQjow9M0JqRck1uMtfEttLFLGs4gn2kBZflIP414NcNLbu8ZGy4ilLGQE7gQeuf617/AHGjafeQ7oZEXPBG0HH51yGu/D+xkuPtKhmPcL0P1GMYralU9nfzO/AY1YRy926keheAtffVvCdjPeHfI0YVyf4iOM/jWzFY6Uscyx2kKiYEPhB8wNcBpmoTadbJax28QjiAAXBjIH6ir3/CTyRuqNaN83cPkD9KjmPKlTu20cx4o+F2nfaZJ7K6mggY5MKnj6D0rb+GWg2kMF5JZ3DxXFvMIQqtj5doIyO+cmofE3iqyt7TdNIVlb5fJHLg+mKyvhTcadqniLV1nuJbe7uBGYEP8SqDk+meRR78nd3sdcqdedB1JXaXV3Z6ddR6xCrSfaswj1IzXjHiiC01LX7iO4BPmhXZt2Tu5Gf0r1DxVo95FYyldZnWED7kahSfbdzXimq3NrZ61utriS6URqJHwflcE5Hv25pTTkvdTbJwdKdR+4r+iOp8LeANMXUILue6nmWNw6xs3GR0zXbeJvG+h+G51jFmLvUlUEpGANg/2m7fSuN0HW1eItbkyBF3MQeB9feuL8S6fq8uqXNzbWUk8d0/mK2/uexq6MlJ/vGdNCnRqVr4yTsvX7j0y1+IVl42trrQtTsjaLdJhMPvDY5644IwDXPaX4Q03QNVW+1HUFmSI7olbAAPrjua53wj4d1CC/8Atd2kn2hflVY1OE+hr0ax8L72E9zKyyHu/J/WlOetobEVp0k5RoNqD6X3Fn8ULdlhaxyOF7n5R+tRR2OpakSbi6W3tj/DDncf+BEVupYabYnLhZJOpBA6/SqGueKbKwQqWTJ4CAZ4rO3c5tPsoW3srfT7YpbMkaL99m6moY1bUj5cRP2QcFu7+uPauWk1NtWuVM5aO3B+WJT1/wB71ruNDZHjVUAAAAAFJST0Q5RcdWXLSySKNY4kCoOABW9p1mRg4pbC2D444rct4RGoxVxRyykPgQKuBUlFFWZhRRRQAUUUUAcr8WP+SWeMv+wLe/8Aoh6PhP8A8ks8G/8AYFsv/RCVq+LNI/4SDwrrOjef9n/tGyms/O2b/L8xCm7bkZxnOMjPrXmuk/Dn4i6RpVnpun/FfybKzhS3gj/4Ry2bZGihVGSxJwAOSc0Aev0V5V/whPxP/wCiuf8AltWv/wAVR/whPxP/AOiuf+W1a/8AxVAHqtFeVf8ACE/E/wD6K5/5bVr/APFUf8IT8T/+iuf+W1a//FUAeq1R1zTU1jSLvT5Z7i3juYzG0tuwV1B9CQR+YI9a84/4Qn4n/wDRXP8Ay2rX/wCKo/4Qn4n/APRXP/Latf8A4qgCe1+C/h600xra0vdVgujqUWqi+haGOVJ41ZUKosYiAwzZGznOTk1pWfwv0ex8USa3Y3upW8k139umtlaJopJurOS0ZcbiMkKwBPasb/hCfif/ANFc/wDLatf/AIqj/hCfif8A9Fc/8tq1/wDiqAN7S/hpo+m6J4U0uC51Brfw3dG7tGeRCzud/EhCYI/eHoB2rKvvg1oF0sO3UNYgljuby4EscsRY/ajmVMNGQBxwQAw/vVW/4Qn4n/8ARXP/AC2rX/4qj/hCfif/ANFc/wDLatf/AIqgDpvB/wAP9K8KahDeadcX0kkWmQaUondCPKiJKscKPm+Y5PT2FV7v4aaPdf2j5lzqA+3axDrcm2ROJ49u1R8n3PkGQcnryKwf+EJ+J/8A0Vz/AMtq1/8AiqP+EJ+J/wD0Vz/y2rX/AOKoA2tE+F+haRrFvfQz6jNBaG5NjYzTA29kbgnzTEAob5ssPmZsZOMVUsfhLpmn6bpNtY63r9vcaSZRYXqTxedBFIFDQj93tZPlBwykg5Oaof8ACE/E/wD6K5/5bVr/APFUf8IT8T/+iuf+W1a//FUAat58K9HvNP1+0utQ1eX+2/sP2uZ50aQm0CCNgxTq3lgsTnJJxiuk13w1Z61rOhandSXCT6NO9xbrGyhWZkKEPkEkYJ6Ec1w3/CE/E/8A6K5/5bVr/wDFUf8ACE/E/wD6K5/5bVr/APFUAWm+DegraJDa6jrVpJ5d1BLcW88ayTwXEhkkhclCNm48YAYevel8RfBzw/rEV1BDe6vpVld2VvYXNrYTIsc0cHEO4OjHKjgEEcdc1U/4Qn4n/wDRXP8Ay2rX/wCKo/4Qn4n/APRXP/Latf8A4qgDYl+F2j/8JTca5aXupWctzdLez28DxeVJMMfNlkLrnAztZc1L4J+Gej+EdfvNatLm+u9SuoPszzXJiHybtxyI0QMxIGWbc3HWsL/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Vryr4if8l2+Ef8A3F//AElWj/hCfif/ANFc/wDLatf/AIqjR/ht4n/4Tvw94k8V+PP7e/sX7R5Fv/Y8Vr/rojG3zI/+6eQfu9s0Aeq0UUUAFFFFABRRRQAUUUUAFQ3EgVDmnyuFGT2rD1K8wGw2BSbGlcq6pcBicV534rv7LTxm+nVGYErGOWb8Kz/GXjiSR3tNDYEAlWuexPon+NcHJbzKrXeovy558w7nY/1rOdkryOqmrPlW5rS655ys1miDH98549eKpT3l+kkkkN28MgGQLcYU+5/+vWa2p2kbwtYW7/aIzlmk6N9Mdvaq9xPd3Ey3EI2qCT5WBgH6VySrpaRR1xw85fEzstF8aC0VI9UdBJtwZYjn/voDvXd6T4rhlUNlJIDjEgcEH8q8UubHMEjCNZQeS69BUuk/abG1klgx5QYKUYjB9/YD1ohiv5xywyt7p9FW01hqStiJdx+ViByap64sMMAt4IA0zLhSBg/WuH8Ka/FHLbABVOwYAfIOOv61xGt6/ry+JZ31C8khuQ2YjGcIF7YHcfWvRw1L6w7RaOKa5N0TeKrKez1yMWcct7c3XyqI13FjngYr0T4bfDi6sr+PWNcuPKvosmK1iYELkYJdvX2HH1rnNO8dQWehXmpNCBqYHkqD/fI5I9u9cj4a8Vaoniqy1G61a6zNcJHOgc4MbHBwOnGa6MNSrV+eEX8C1/yOnE5jVhQjQb916H01rGkm/sJIpLl1jZSMrjIrwrxV4H1Lw7zpZbU7RhliifvE+q9/qK7PxF8TtDgvrjSYJ9TlMTeW10Aoi3DqM9fxxXHaz4l1ITxahpMqyWUMZR4pCW805ySD1H/1qIUcRryRd7X+RxUc5hlbU5TSUnbur/p6h4K017RoblWy7HfLC3XPqfw4xXrlmLK8gjlEYQL/AAgda8b8N+KraadVIlhZs+WWHyv7HuK72y8SW1lYyi4UhV6bemTXD7Tn946q/NOo5S3Z0d7qllYswVFVh1wO/vXK6740trIstxII2xkKvzE/hXHeK9duGuIttqYVkG5WkPzc9Mjt+NcHdQE6k5uhIZVYhwQQ2feueeJitI6mlPDc2sjstY8U6lflfsg+y2rHJlRgz/ie1Ygt5H82ZZ2nIOWkdsn9aohDaRyXNvCXQYQMf4DU+m6o1vtbUIxMBnYOhJA65PHHuKzWJv8AEipYaSV6bNOGf7GVMkmc9cA4rt/C+tRsBskVsHkA8ivOojpk0JZrnbcscsknJI9c9BSSQy2bpPGrIAeHQ9fp6/jW1Nwn8JlNyirVD6U0XUY3C/NXTwyB0ypr558LeK5I54oL07XY4VyMBvb2NeuaBrCzKo3DmuhO2jOWpT+0jrqKZE4dQQc8U+rMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKRiQOKWoriQIhOcUAUdSuNiY715F8S/ELeS2l2j4llIEpU8hf7v4113jPXE06xkmY/OfkjX+8x6CvGNQVbNbm+uZPOmd2MUrdWY9Cf8PpWU6ignN9DenH3lFbsh1K6js44GtYgb1lIdJjlIT7e5Fc5dXEl2/2wh8qcMGOf8ira3FxcspuIVaTblSMgmhrdlmaWaFjGzbvLj4IHpz3rzZyk3eR7FKkqatEPD2mRajqCQyOVdlYqobG7AJwCe/FOt1EV1OZ45DhSMJ2J4ANQzG3SczWG9FxkEn5kbPQVbs4r0xGdCzMwyjDHzA8c/nWb1NLXNCwMmm6LOXhWWC5IRhkHGMnisO4YCMeUNoweop9zJccLMxV0kCygg5U1Ztok8ku4yjjHXGckgfyqVGwaLUbpcgtSVmldIZwquQoJXPoPy5rzzUJbiUpJNdX93E88UNtc+bN+8Qvh2bLEKpBGMAcnjjmvXNavoL7SrOC/tI7ae23RefEcmQp8w3jt1x1rhdZ8Dy3oeLT2DSZGER27YJOM8YOPpXbhK8aMm5dTjxEHUV+pzU2orpt3byyyyy2z3klvKRNJKgReArbydsn04Iz1ru/hvpI8S+KbaG4kiW0B89irckZyF9ucV5cvha4+zyO8ztli7DcSGI7+9d14K1hvCV9Z31pAtzNASGjf7kqkYw3+e1fQ0KVX95OD5brXzPKrSvyxkuunkXNahk0m8v8ATbxSssc7oUPfnqD6Ypml+JPKsX05g7TKNsIUcMT6ntj1qrq2qXviLxC9zeyRLdXcmGKptjgXsAOwFdBBpllB4cuDkHarlZNvJwTznt0r1FVr1NIWUlH1X9X+48DOVhKVKCxKck5LZ2a/pfec7cs8F/Obt5I7aBdzTQSsn2YCPjKbdrMW6Akk7vu8ZK6b4un0vyLy/LXJ1CyV/wB4cpE7MQSg6DgAD8+vWxdxWx09JbRbwXsuDMUupo1PygBsIwG7AAyfQVykPhzW73FpDeXv2ZjxA07FAuc8gnGBXysa+HlQ9nNe9bey3v8A15nvzweMjinVjL3L7XdrWa26ei00Xq+4t9RubiZJ3d3kkUbec8dq2LLyZb23uLuZ3bLGQMM7iOcEelVLDw9FZ2GnxJepcXjsFn2PxGT0BP4frTjKIhcSbFJiAkUdcZODz+f515Lik9D3oy543LmpMsuto0LCOydwU3Hjbn+Lis427z6gbcuGcsUDH7qknA/DNa0l5b39vGX3PDDFhgFC5wQDnj3qjFeDTtRS5Fqu5WBEfYY6f0pJNXKS7GXeWctncss+BhuoFXdK1We3JErr9kBP7ts4H096Qw3WsahNIZFLyt5js5xtyemaryQjzIrebYEVyCw5H6datPzBrm0fU6GyitdSSa4tmCQxqHmjnXDpjupB6ehrp/BuvSRSeVKSdpwGP8Q7fjXCW1xDYziSSUFCOgzlhnv298VqMzrAL+zfZDKNyp3znBB/GuyjVc/dlucFan7H3l8LPo/QNQE8Q5zwK3lORXkXgfWGKKkuUdTtZT2PcV6pZTCWIEGuuLujgqR5XoWqKKKozCiiigAoorFvfFfh2w1Mabfa9pNtqJxi1mvI0lOenyE5/SgDaooooAKKKKACiqWk6rYaxbNcaVeQXcCSNE0kLhlDqcMuR3Bq7QAUUUUAFFFFABRWLpvivQdTbTl0/WLG5OorI9mIpg3niMkOU9dpBBx0raoAKKbNIkMTyzOscSKWZ2OAoHUk9hVG61rTLWTT0uL+2jfUG2WgaQf6Q2M4T+9xzxQBoUUUUAFFUtO1Ww1OW8j0+8guZLOY29wsThjFIOqN6HkcVdoAKKKr6je22m2M97fzx29pAhklmkbaqKOSSewoAsUVFa3EN3aw3NrIktvMgkjkQ5V1IyCD6EVLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAAaw9bu/KRhWxO4RCc15v491lbCxubiQ5WMFsDv6Cpk7F043Z534v1WTUvEqxgt9jsB5jle57/pxXH6/enVb8CEOtkPliQkHb9ff3p0V47W1w0zkS3bnePReuM/X+VUoIpbR2VebefHUfl16GvNxM+aXL0R6+GpK3P1f5D7d0sEmiuEcuDhCTwp7GrItrpI7XVQszQSSYd85246/5NV4FiS9V5FAU/u3yN2O2fY1bs/tdtJJFa3CFJCIpI2YgSAk8keo9feuZM6ncTWZ9Muoi8EQtp95IWEnDZPfPQ49KkjjjtdL+0pePMuMSQFCCCew6+n6VWt5Yo2EqW8TFTu3EZ2sP89K0LqCO/ikvFeVFjKCUIoxk8BsZ9adrkvRqz0KOoSSSx/aXlbMgQKCAd+04GT6471e1jyk07SYIoW3MGkkK9ZArkAAfi1dBbeF2ew3TuIN0gtHWZCAsp5jkQ9NpbAz71heL7gxarpse9VWCziR9pBxIdzH9SKu1oszjOMpJROivdIbUreA2FpIt3KIpmRjgR+ZkNnj0SuS8RkaPqEkW/NzEhMhDcb2PQevaunsNcvTo9rqV5LIunKWSeRONwVFVF+paQn6Zrl/HeivptpY3ct0tzHfu7xvnnA9fzFddCj7SrGDW5j7TlTbfoczEgMRBwECkmrXhTwze+KtTlsdO8wRQxtIzKoJ46AcjviqhH+jSHtgCvWPgjBNbavZvYzxxu9k0jxyfdlJk9ex4r6LEVHTj7vU4JR0uzidD8H6jbXyLqOm3MMMJLSs4ALkemetafijw/dbLm4iR7XRj5biJlBOSeQT6cZ/Gur8WXl7q0d7LeBhOJWXZu4TBxgflXJz32palGlpMxlWFBjngA8cj1rwsfnOIq600lpZ2/l6np4fh6jLldZ81nf0fQr2uyCykkFvCzkFUO4/Lx168/jWcJZrpWRnZZRwFU8sa3buyMSRQqC2VzzWj4YhsbXVPsms6ZJKkq4LbPmhGM7sHsfWvIpy59T1sVhadKm5xu2uhl21hJNbwTqyqHzH/ALW4YwfU81WlshKZm34aOYlwD1UAuM/+PflW/qeiaZd6ZfXOnXd011aktHAH2ttyMk+o6nI/GsiBTq2n3mqQldjxqs20Y2TKSjA47MJNw/H0rppq+55c5q91oReH5bb7FrLXKMxitmkjRjxkkBif0NRa8bq2szd3ejS21jNJlbhmBIyMKCvUAmqmmC4uJEREa4uJVKqgOfM2ru2cdyVAwa2PGGv3PiS1bS49OubG2jmRbqS6ULhhhhGozyehJ7CuihRpTpylUeq2PMx2JxVLEU6eHheL3fZfeUtM0C71Bd3yWdvkJvlbG8eg/vc/rxVTfHDcyQRWxkiRirMG5A+taGmLfCCfzZg0e5UiXqGwdxxnoBgEn/Gm3w0yxsp4I98+pTczSbvkhGeg/vN39K49FqevzOO+xQvYQlqJ1iDRuTsXPQe/fNTeFtRFrOYLpGMMhAVl/gPY89aoSW8sckEcreasuHCq/Kj3HalvfKQfafl8wthIhzj1OaFJ3Vnr0CcFNOLWh3Gn3j6R4nNrPuVpsHJORv8AY+9e2eGb7zYl54OK+bFmNzpC3E7SC5tpA4JPO32/GvYvAOrrdWkMob7ygn616dKpzpSPKq0nFcr6HrCnIzS1Xs5N8YOc8VYroOIKKKKACvkC7vLfw3qupHw7f+G/GVrqOrs0ug6jYH+0/Nd8MqnbuJXHDk44yB6/X9RiCITGYRIJSMF9o3EfWgD5p+IvxM1LQrD4p6Y2vXFpr1tf2x0iIgh0gLxFinGNpUt19fcVN8SPF9xa+MPihZ3njXU9Hl0uGyk0OxtZlXz52ttxQLtLMC+3IBA+ck9sfSXlp5vmbF8zG3djnHpn0rE03wrpen+Jtb16CJjqGrmBrlnbcuYUKIVH8PBNAHzp408Y+M3182eta0fDU6aNZ3FmZdQ/s+JrhoVaZ2Hkv522UlTHlcBcDqSO28J6l4i8W/EZLWbxRd2tlDoem6nJFYooiuJHAZ8b03KjHPACnB7dK9vlhimCiaNJApyNyg4PrT6APmK08X6zLoXh2PWPEF7pOgXmv6lb6lq1uVjeFY+YIvM2kIGbIz7daltPFfie90bQrWw8Sah9hufGLaVY6wUQy3dlsOGO5dr4OfmIwce1fS0iLIhSRVdDwVYZBpVUKoVQAoGAB0AoA4fx41/4Y+D+uyW2qXc+o2Omyul/KV85nCkhzgAZ/CvGmm8UNql1YHxz4i8u48EL4mZxJEGW4U7QikJ8sfchcMe7V9PUUAfL/ifxv4nuLHwEt/q8um6XqOgJdS3y6h/ZwnvDwQ0/lSYIUBtmACWPPAFWLDxjqmo3vgyx8YeNpdN0eXSp521bSn8tdQvI7l4hH5jJzhFVsbcMTxnINfSs0UcyFJo0kQ9VYZH5UNFGwQNGhCEFQR90joR6UAfMHwR1y803TPhLaxyzGwmsdamnt41DGUxzSFcDqT6Cq3w98e6vP488Nmy8R3k2marb3/2i21DUft8kLQwNIrSRrCgibcAdqFsgY44z9V01ERM7FVckscDGSepoA+SND8Razr+jeL9H1DXdV1e8k8PXtw11p+pJdWkpC5A8nyg0BbG3b1IYjAOCOl8E64LXRPhLbaH4nu9TjubyK3v4pZEcWzC1XNuuFBVVPQHJ9zX0jFDFEWMUaJuOW2qBk+poiijhBEUaRhjuIVQMn1oA+Zk8QeJ1hh8Rf8JTqzNF44OjCwZk+zNbGTBUrt3E44BLcDoAeaq6/wCPtUT4jLLouualbiHxMmm3Gn3upBzJGZNrbbURAJH2DGTd+PT6mpqoiuzqqhmxuIHJx60AeW/BD/kO/Ez/ALGa4/8AQUrzfx/4g8T29n8S9fs/FOrWzeGtXt47KziZBAyu0asrjbuYfN0zj2NfTlFAHzZ8R/F2pWniTxz9v8W6poeraWYf+Ef0u2KrHeBkBBKFT525uDz8vNZXxI8SahqjeOLLxlr99od1a6NAdO0WBxHFdtJb7pSwKnzcPkYz8oz6ZH1K8UbyI7xozpnaxAJXPXHpSmNDIrlFLqCAxHI/GgD5P17xV4kt7q00s69/wj9lb6BYSaTJJqX2GKVjApeRv3L+fh/lKbl4HHUkTeL/AIga9D4hsrm68Rz3kL2WnFLHQ78Ws8cssMbu32eSLNwHZ9wAxhTg7SDj6plhimCiaNJApyNyg4PrSNDE0yytGhlUYVyoyB7GgCSiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopG4FAGdq8wjhNeEfEi+a91GDT0I2MS8mTwAOmf89q9f8T3flxPzwBXhOrOrSapqcoIdz5UTHoBnHA79DWNSfInLsdFKN7Lucw6JBdRB8PEhztUgnHpz3rWsdOe7imlRdrQKT5fI7Z3HjH+TWJp8y27S3EnzRuSAD6HvWi96tn50yXkkZdVjaLDOXHQAADk5OPfivH3dj22+VXWhXuhtCrsMbMoZgo4wfUHmpra1iuLSS6ZlSWMfxceZzwB7+v4VWjv2t1mjlWW1lVliaOVMyuz4KAJ94lgy4AGe3YirNuzyxNDDpmoPf2zbJ0RB8hPzLuz3PXAzwRW6w9RtqMX9xzSxtCMVKdRK+u6/qxFqkQ095mtsGJWBxvDAbgDg46dcc1vaFcRnScwXcEN9GQscdxGTBID/Cxx09D271b1RdDn8J22oWDxW8+FWWGQeWXYPsdWDYbcjDBB/pWBY3L2l/JDpk4L/ejPHzLzgn0OO1LlcW7otVI1Y3izV8R6leX93ptnqFxLp7SuscsYfMLRZHzRP0ODg47UnxI8M2Gn+Ve6deYZ8I6yy/K7BSRtz/Fx071yusSyHT9od2RXMzRsBtU9cr6Guy8VaIU8VwaXGWa1vmtYPKlbeg8xVJIU/dx1BrtpTpexatq/zPKxGGrrEwqU52S3XRr+u4txZSXej+FvDpJi0zT7FdW1SUDkySkiKP3cjOB757VyfjW9utX8RW+ny20tlaWSqghZgsu1uAFzjAAG4kc9h3x33jrxGr+OorSwcw6Xos6LKkaj/SJUGGLZByFGFHf0riPjFqdn4luNLubPz43iSQK8jfvVy+4YcdhnA5yKm06tX2VKVpWevyO6jNUrTqw5o7nGwIz2SvdSz+YPtXmeXN8wELbRsjAIc9M9K2fh94wmltbZra4eC8gjCbozxwc/iM1wMmh6grQy29/dIYmYxETNmMt94rzxnvjrXXeA9MXw7DNe6lZLexvAWUMMtu3feFGKw9enTtWqtcz01e+uh2UMRCdROnRuorVabaa7ep6hfa7Ay3dzeSOPPHmuqjoxA/UnoPesVby8sAfPsLVLiS2e58tLwkrHHnerkJgSKQRtGRkY3Csi11O31e8V4Jnsp/MWSIlVyrr90jcCpweeR1qjq+q67ZapZRy6dbalDb29xabAogMyTHnPlqMHGB8ox1PBNeVWjWk3dK33f8Dc9CrV9nGLoPS3r/VjqrPWJ7qG91DSYZtQvbW1ea3gji8xnk4WP5B1AdlZv9lWNVPDZ8Q6VokmnyW+oOYby2Q3pCalJ9lkKC78oASI7JJGx27WZVlJ28ZrjvA880Hj2CyXSPsdrLOkbWxmeZYxtGfmbJJPXHbNdnP8LrDWdS1DUhdw26+bL5EQbBbyz85B7Aetd+HlGnHla0fp/wAMeRjJ+3/ec1mlYztV8Y3XhzWNN82Ef2irTusdza/ZneETMkMjxgL5bOi8qAOMHGDXY+Fksb3VWk0eOQaP4iRrG+tm5fTrsqWiJA/gY52t05xxivPtK8BafBrNptMd0HUybbFxMZAMn5McEnHr1+legw6yvhDxLpeqw2senrDGkGpW0cnnB1J+ZdwGCyDaf94HFWqkObRaM5+WfLZu7t+B0XhgaVdaf4Zmunis9YtrgRNbxqF81w20549R/wDXrnPEljOniW6tr5nu7kSzSQWVrIM7XcsXkc8JkYHPOBVzWbe20n4y2ltuTyLjU4LuIlucSEHj23EmuO8eXE0Os+J52uBFbDUplkwpf92shDSMAQW2rkhcjpxRCHKmpd7Anyvmj2uad9eGGyYGa0S4UbI7WzXKRjvhu7e/P51jLKCgijs1TJ3O7fM2enOajsLS4h8VXuh2c07f2fPEJrtYC+1HVSuVAI3FnI9AFLHgGs/UNRudPsr2W8fy0h1qXSGDRhd6LGZFmPoW44HHORTlgq1m7bXM6eb4RyjCMruVnt32uat27XNyzAo0shJRAcHA6c1FqlukV5DDIrl0VfMUMGUk89Rx3qWwAvzHdiUNBKSAIvvAY4GB61oW+nS2Nu9wbY3MsgwsW1jt5x1//XXC7xbPUTWjM2S9MN6/lJ+5ddhGMnYfb6V1fw9u302/urGR2YbxLGT/AHT/AJFcvMZ9R826uhEjW4ERTIBbtirGluYbixv4ywR5DA35V0Yadm49/wAzCvC65j6c0C6EsI+bORW6K858E3/mRIN1ehxNuQGvTi7o8epHllYfRRRVGZyvxY/5JZ4y/wCwLe/+iHrzT4e/A34dav4B8NalqHh7zr280y2uJ5Pttyu+R4lZjgSADJJ4AAr0v4sf8ks8Zf8AYFvf/RD0fCf/AJJZ4N/7Atl/6ISgDlP+GfPhh/0LP/k/df8Axyj/AIZ8+GH/AELP/k/df/HK9VooA8q/4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcr1WigDyr/hnz4Yf9Cz/5P3X/AMco/wCGfPhh/wBCz/5P3X/xyvVaKAPKv+GfPhh/0LP/AJP3X/xyj/hnz4Yf9Cz/AOT91/8AHK9VooA8q/4Z8+GH/Qs/+T91/wDHKP8Ahnz4Yf8AQs/+T91/8cr1WigDyr/hnz4Yf9Cz/wCT91/8co/4Z8+GH/Qs/wDk/df/AByvVaKAPKv+GfPhh/0LP/k/df8Axyj/AIZ8+GH/AELP/k/df/HK9VooA8q/4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcr1WigDyr/hnz4Yf9Cz/5P3X/AMco/wCGfPhh/wBCz/5P3X/xyvVaKAPKv+GfPhh/0LP/AJP3X/xyj/hnz4Yf9Cz/AOT91/8AHK9VooA8q/4Z8+GH/Qs/+T91/wDHKP8Ahnz4Yf8AQs/+T91/8cr1WqWt6jDo+i6hqd1xb2VvJcyc4+VFLH9BQB5v/wAM+fDD/oWf/J+6/wDjlH/DPnww/wChZ/8AJ+6/+OVVsfiN4il8LfDaae00xdd8U3i+dGsUgijtMM7ug353CPYckkZJ4rR8PfGXRNc1PRIIdM1i2stYa4Sz1C5ijWCVoM78EOTj5Tzj+uACD/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8Axyl0f43+H9Qm0pp9O1nTdO1O2urq1vr2FFikW2UtLja7HhVJ6enrUWifHfwxqp1IrBeRR2emyaqG8yCUyQocEYjkYxyHIwj7TyM4oAk/4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcrs/BXiqLxZpP9o2+lavp1uQrRjUbcRNKrKGDKATkc4z69M1x9t8a9DaTWxf6N4g0yLRYvMvpruCLZExICxEpK37xiwAXr9KAGf8ADPnww/6Fn/yfuv8A45R/wz58MP8AoWf/ACfuv/jlWLn4xaTptlr8uvaPrOlXOjQQXM1nOkTSyRzMFjKbZCuckAqSCPwOEHxn0GCy8S3GrWGq6WdClghnhu441kkeYExqgDkZODnJGBySBnABB/wz58MP+hZ/8n7r/wCOVyt18PvDHgT47fDD/hFNM+wfbf7U8/8A0iWXfstfl++zYxvbpjrXpnw3+IWmePI9T/s6GWCbTpVinRpYplywypSSJ2RhgHoeCK534if8l2+Ef/cX/wDSVaAPVaKKKACiiigAqK4fahPtUtZ2qy7IWoGjz3x/qQtrGeRm4Arx3Xnz4ft/4pJpi5BPIwDzj69PpXZ/E68MvlW6tw8mW+g/yK4vX4WimspUUCSOMZUDIAP+f1rjr/D6noYWKdRX6Ir6bcGGylma3WVJBsPbuCR9MgVRvNPuP7Eur23XKK4jCjDOFJG4gEgEgcjJHIHNSLfyWMwNumI+hQjg+tW9PvozNcm6hJimQ5CjjJBwfwrgu4u56EqfMml1OQ8QeJo7fxXJqNtp11c+faeSYrxxE6PsWPzEeJ25Khhngjceat6n8Q7GDW7y7/sC6lSfUra7CXMSnCJFsLDDnbJnlcZHHPWukt/D1je3EYit4md1zH5j4x71Wm8PW1rdfZ4reO6lkBKlY3cbvTg/rXpwzKd9tzwKmQ4d2Tb0Vt+n9I4DQdRe68TTPvubnT1u2u1+1RL5h3Eks6qSOp5x19B0r2/UbS2vfHPh690y2E9vJsguzEvHzH5GOP8AgX4da5Kw025k8SaSmswaLNYkuslpKijamBlmHAyDjCtn7xO3IyMzwal1d+IJv7ftLB9NsN0FxPOtpJ5TIiBdzu25YgNrZT+Lv1rrpx9rTaf2mZTwvs8RCqpfArW7lvXklS1lWGCRwm6KSQ8BG3YO78eK9U1DS5YPEmkeIb67R/IkhmmhUcMETapH04rxvTP7Jv8Awjbl00u61+80u8mVZbeITXE3msA/2jhw6rkhcDI7jHE/w98Y6xq+jBbyW1awslUTiXd9oliDKp2fw8A8k98DHOamhh6VCL9prfY751p12lBamrJqck+qasWkkW3vL+eZlXB5Zz/XFYniu3e2ntojKrIEyqDqg64NO1K7+yDXtQtJ4Zls5wZLJ4nRoRLIVj/eH5WPIOAMYzgnGKZ43t7rTII7m9nt5YoLj7E5SKSIhypcY3jDjA6g8e/bkwsXDFcz21O2cb4fTsn/AF9zKcYxbA+/9K7n4e6bd+Ib2ztrWa1iS1MbM8j4JUHJUDHXj9a8/tLiOSw3qwZQ2TzXbfCLSbrVPHaXgWfT9LgXc85BAYjHyqSMEk/pmvSzKjGtCmmr2dzPDYiVGE3CVm01/X5HY/FT4badc6i0vhq7sbXVGBkn04S8Meu5R/Afbp9K5Lwddf2Nd6nb+JUulvoI40gEapITknPJOBxjmtjxdpV5L4qura0jmnkluC6XfIUoTnJboMDIrd146XD4YvpUjijeJdobaAdwOB714FXFQjyrFUnZz5bfr/W51+xcVy0Kt/dTfl5P+rnDaBc2Vl8QhqklrLBZxyGXaT5jsxHUnj68VoSeMtQ0+W7tbVolsLuWQkGMZIc+/Tj0riJfGCw3b/Y7FZI8/elPJrVgubPW7P7V9nuvO+0QWa29vs3tLM+1MFyFxn1I+o6j3p0MI7xtp/Wx5znKKTk7mlcQxQQxtMsTOFzB5UoBHPJ46cdqs/aLR/Dbw3TXiG6EiR7I96KQASzkj5eBjOe54rOtWtoLe5uJtM1CN4LHUrmBbxojFJLaKRJE3lSbiA+35vl3DOPWtPS/Ft1Z+C9W1K8061j0uHT4bpHhtLm3inlljdPIZZmJkUSPDl0IGGB7jHjSwk07XNZYyDR2Hh2Sw1HQbfVdSgimvvs0cayuuTEiDC4J6Y65ryi9eDUE1O4uJ1SBr2SaOaRVbcQ+QdrAhuR3BFaWoahpeqaNFrV9Jbo0Ec2ky2elyMbSS7hlADqWbDRtG8J3FsYZjnjIxtZaOPxag0IaXEzpHNDDay2YQLthSXYJCUWQbSFyM4zjjNetiI+3hGMNLNHFRqKDfMrpq1g8QeHfFs2t2uq2tzqD3b21tcrOqxxmU/eUFUVVfbnncDwQOmKpXmkeM9Ltplu9Rtm+33TXbwz2sE/mTMACVDIecDHGAO1aV1Lbrq3iuXw1caS2oW91ZPZGOeCHYuwmVUYsFHJbdtOCxb1IqTSPFuparbO8t1ZxzREo7SxLJ0OCFIUg8jscGsqzqUtVIzpYTD1Hy8i+4reBrTWdEsFaC2cv92KbGVx93j3rrLzT5orDGozFJlw0iOTuZSc54/lT7bV5r2JIZmtMKhzKNynrk4AGAfwqH7NaX9ysSRXUsmfv+ccHPUtlePavHqO7bPapvlVmZN1Cro88S4jGSApwNtWo9w8Ph3OGiuEdR6A5H49Ks6pOkM6afpqxMuSmZEBIOOTuxVGaYDTLtfNDDhckY5Gemamk3GSZpP3oM9R+Ht/uZAD1r2jT33wKfavmj4cagRcRDNfRuhy77ZfTFepRldHlYuHLI1KKKK3OM5X4sf8AJLPGX/YFvf8A0Q9Hwn/5JZ4N/wCwLZf+iEo+LH/JLPGX/YFvf/RD0fCf/klng3/sC2X/AKISgDqqKwfG3imw8H6BLquqeY0asI4oYgDJNI33UUHAyeepAABJ4FeNH47a6bjzF8OacLbP+pa9fzMf7+zGf+A4qowlLZDUW9j6DormvAHjCw8a6F/aOnpLC8chguLabG+CUAEqccEYIII4II+lX/E+uJoGnC7fT9S1AtII1g0+2M8pJBOdo7cHk1IjWorztvi/4ZOl6De2yandjW1uDaQW1m0k2YMearIOQV/oT0rsfDWuaf4l0Ky1jR5vPsLtPMik2lSRnByDyCCCPwoA06KZPKsMMkr52IpY49AM1yGnfEjw9qFv4Ynt5bjy/ERmWxLxFc+UCX3f3ehoA7Kise18U+H7s3Atdd0qY20Xnz+XeRt5Uf8AfbB+Vfc8U628SaFdWt5c22taZNb2XF1LHdRskHGfnIOF/HFAGtRWRD4m0GaxhvYdb0uSzmLLFOl3GY5CoywVs4OBycdKtX2q6dp9rHdX9/aW1tKQI5ZplRHJBIAJODwCfoKALtFYdz4v8NWunWuoXPiHR4bC6JFvcyXsSxTEdQjFsNj2NW/7d0nz0h/tSw851VlT7Qm5gwJUgZ5BAJHrigDRorlr34g+E7XQ9R1ceINNurHTwDcvaXKTmPJwAQhJyT0HetO08SaJdi3+z6vp8huArQqtyhLhiQuBnnJBH1BHagDWorH0vxR4f1YXJ0rXNKvhbKXn+zXccvlAd22k7R9aw774m+E7TUtItV1iyuYdReeMXlvdRPb25ij8xvNff8vHA68+lAHaUVj3fijw/ZWFpfXmu6Vb2V3/AMe9xLdxpHN/uMThvwp03iXQodXi0qbWtMj1SXaY7NruMTPu6YTO457cUAa1Z/iDSLXX9Cv9I1FWazvYHt5QrbTtYYOD2PNU/CPiWz8U2N3d6fFcRx215NZOJ1AJeJirEYJ4yOO/sKraB400jWdLbU0lNnpzXT2ltc3jpEl2VJBaL5uVJVsZwTtJxjmgDjW+FDaZpc1xp+s6nq+t2Wlzadoh1SZBHYh49gK7EHOMAsckgYrNtPg9d6V4GihttUn1DxDZ6NLp2nJcukdrYyTptmePYgJJJb5m3HGAa9Kt/FmlSPqzS3MFvZacsMkl9LcwiB0lQOrBg5IXBHLhc9sjms/VfiL4a06XSA2pW1xa6lcSW6XlvPE9vCyR+Y3mPuwo249eooA5vw18HNMtNItrXxBf32rtFpTaVFHKyJFaxOuJfKCIvLH+NstgDmpIfg/ZHwpfeHb7xHr91p1zBHaqGeBXhiR1YKCIuSdgBLZ44GK6lvHfhkazpOlrrVlJdarEZrMxyq6TKG28ODjluBzyQQM4NW/C/iS18QrqC28Nza3Wn3T2d1a3IUSROMEZ2sQVZSGBBIIP1FAFzUtMS70OfTILi50+OSAwLNZsElhXGMoSCAQOhxxXntj8FtFtPB2o+GTrOvXGmXhSQCaaLdBIrh/MQrGMsWAyW3ZxXqNFAHm9x8I9Iv47l9Z1PVdQv7u8try8vJXiV7jyP9XCVVAqxeqqASe9Sap8JNB1LTdetZ7rUvO1bVBq7XYlUSwTr9wRkLgKoyAGBOCeehHolFAGH4R8Pt4esJYJdTvdTmlk8x57oRq3QAKBGqqAMemck81w3xE/5Lt8I/8AuL/+kq16rXlXxE/5Lt8I/wDuL/8ApKtAHqtFFFABRRRQAHpXOeJJ9kL89q6GQ4WuE8aXYitpWJwACTUydkXTV5HjXii5F54g2nJSM7W9h1Nc79otzNdJcGaMsS0TR9CpPQ/h/KuhSFxbXV9OoEdyD5cuecHqPbiuWjjD+ZBIx81WKq45GOuK4MRLmaiuh6mEgrSn3ZcdmljFuD5sStuVSecY7/hUouLadHhNqqTeWPLmVtpBB6fiKo3Fm9tcBW+SM4JkOSqkjuRVuFJBbI8igxuOGC5G4H9a40dhrw6jPp6RH+zlhYAAzltp6+oXmpdKWXxJfXlhBH9puPL3GWS6JhjJP9wAcn8Kq2+qQor2xglkklO9iqLGp9zuyBUN3qUWh38l94PBa8KBblgmY8ehOB37iuyhGHN+82ODGKs6bVDSfQguPDesz+IYtAuIoGnlG5HSAyx4GRzkgAiqfin4Pabol/Yw6rrMYu76XYFijWNE/MnFaOja5rMuuDWtUvV8+G3la1tIUIUsRgZ9eSOa5DVLq4uLq4udfZJ5zd+RcCVGMgOCwYMTtCkDgAHgjkHiupyoUXeK0OBVKypwWKaUm7aLq9tl9/S5p618MNF8NSQTXEcl5byyrEQGYncQSMDv0rQsdM08Nd2ukXdlbPPAYTaX1tKzMMg7YyskYGSM55OQPQVyDX0ssukusyn7duS2DmST7IyyohBLMN+Nx6BPu9xzWyNbltZraC/kto55TI8TvAbZ1ZGA3FWduG5IPGcVFbFxlNKEdCcNi8O5Rgp2nK9tH0un+TMfVrDxC2hNpJ0jT5YreTzRIscyyyS8AyuRJtZ8DGSOnAwOKxNb1HxB4otdRg1iC04n+1KZEcPaNgBljJbKqwHKnIzzwea9Wt/iLLFvj1KyWVW4NzGNoJ6c8EV6mPCnhn4heEYjNCv9ptD+6liby5E9sjqPY5rSKc/eid1SrBRSjO/R+R47oHw3Np4asrm/kug09zDFJFCF8wKxx8gYEM3TggjGa7Lw/q2rh38PW76l9m0/WzpAis1jWSCNpJ2W8m3RtuGxI8AgIcknOQB19l4e1nVtOks9evbaO2s5GhiW3iIkkKDCyO5PB74XHXrjivEfFXhSRP7U1qbUGgsSWilaGd/36g7Qp5JYHoAeK+fwdbF46VWjUrWnHor6a99Oz/Ixn0aWh6FeeK9T0zwdY+ILjWpbljbafeXMAWFk23EmHDRiHKR7Q+x9+dwAPfOtp1vofxB0O9vHtUMzo2yTJBTA4I7Z968G8EeF45fEOizapPLdWt7Klo+nyTSRKbUnLDzAQCqAbyucHbjvXaeC7Oys7XWrHUHit7e11W7gum/tBkexshbF4ZIwsg5Z/l3YbcBtPenjKlfCwdONR86aleyenazfdeW9kTHRnK6z4N1jSNOi1WSzkfRpyPIuuMsG5Usucrn3o0K7udJillijjZi8ciLIuQro25HHoynkGu/sPEl/o2jeHjdot7oOpWdjLO09wkwa5aHdImxnLICRnAXaMds12k3gPS9X8Kxajojx2pnHmraOuVLHqu7qvpXq4DFzrRdSaTd3ou3z6/15GynCS5ZaeZ4Hd+KPEc7sBFpzQ4lXYbYAbZTmdeD0kPLevQYHFX/Bun61f+JoZDc20kl/JDmJ4gY4EhGUZB/D5Y4X+RrV8T+GZdBmQXKiGd+TA3XBOM/0rv8Awzptr4K0BrnxBElvdXKmR5G5KL2U/hgkV2TqwnZ0/maU8JFvlk0jzz4h/b7G/iheQXMscgupmhhLPIQuxZZ26AbRtBOAfesm2j0y7F5qviixmsYEfatxFZMYD/CQXRMZ3cfXjOa1rvW7TVb/AMQkXF7FBf25hgWOB5Fk+7iQjIAIC7RxnB61yD3lhF4N1e3S+uI9avUEdxGbRjGqqxYRI2QBlurnPU4AyaIV2pXSI+rU+X4r79V0N3w/4W8I614kvbXV2utPfeqRfaEaFwcA/MrDjIII9jXaaz8H08K6PdX1udYu7ZIy4eyijmAHuu5WH1ANeZeLdd0vUfFE+p6VqUtzFeTIZbOW0aMRgRqm7eTg5KDt39q9N0XxRqVpoKW2n61dWzWbCS1O7cGRuDG2eoBwRn3HvUyqRm/fWrE6LhJ+zldIv6npXhyfwjBqen28S+TCsscittLnH3W9yeCDzUfl3s2n2FqbeFGulyoEifJ3wxA6/iTUFrc6fc6j5vi7w1b3olO6Wa2YqSf7xQHGa625k8M2VsJ9CtruO2lXCXUcazJbt0wwP7xG9/1qcZy1rOCStucmWYerglKNSbkm9PL8Thrm1e3W4hnjERBHU/y7msa6tJJ7O6jt1G+P58DI3Dvx69DitrUJIknaRVSdnyJGZm8z2J3VShnnsr4TlkkBPG05A5715kZezlc95x542IPAt2Yr2NTwQcEV9R+ErjzbSPnqK+XruD7HqsN7FGI4Z2yAPrXvnw61AS2sfOeK9Gjozz8UuaN+x6VRSIcqDS11HmnK/Fj/AJJZ4y/7At7/AOiHo+E//JLPBv8A2BbL/wBEJR8WP+SWeMv+wLe/+iHo+E//ACSzwb/2BbL/ANEJQBmfGfwle+L/AAlFBpJQ6jY3S3sETttWYhHQoW7ErI2D0zjPGa+dW8PeI1uDbN4X8QC5B27Rp8hXP/XQDy8e+7HvX1/qF9a6bYz3uoXEVtaQIZJZpnCoijqSTwBXAf8AC5fCfnYVtUa2zj7SunTeXj1xt3Ee4Wt6M6iuoK4niI0fiklfuJ8D/B2oeFNBvZtaVItR1KcTPbowYQIqhVQsOC3BJI45wM4yeg+I9h4m1TwzLZeDNQs9N1GZwkl1chspFg7tmAcPnABIOBnvg1uaRqdlrGmwX+l3UN3ZzrujmibcrD/PBHY0/Ub+z022NzqN3b2lupAMtxIsaAnpyTisW23djbvqeK6j8GNQ1nTPBmn3dzp+lWuhw6hA40qWZWxPGFjdGbktvBZ9xAbJHOSK9O+G+j6h4e8FaVo+rfYDdWMIg32IKxOq8K2CBgkdffJ71txajZTC1MV5bv8AalLW+2VT5wAySnPzDHPFWqQEdxEs9vLC5IWRShI64IxXi3h/4Ua5pg8MW2oalp8+l+FkvTZG2jcT3RmVgokB+VcZ7E5/WvbCQoJJAA5JNVo9QspBbmO8t3FxkQlZVPm467eece1AHzfpXw08SP8AC8Xl/ZQW93Z+GbrTrXTrWBxdTSS8nzs9xjhRnk5z2rov+FP6vruh6hPqV5p+mahdWlhDb21pFIsQFsd48/kMWY8HGNuBjOK94ooA8X0n4Q3C3mjS6pFo7W9vq02pXltvmuVn3wCPJMuctuAPQDgdTzW98adF1LUrHwZFoGnx3Ulp4htZzG8ZMMUaxyjc4UcICVBPbNelUUAeF3vwg8QvoUFpBq+nA3F1fXl/ap51vAHuSCFiaM79iY+4SA3f0rX8DfCi50K4mub+fTJrxdEtNNtLkQec1tNEjqZFDjpllOO+MGvXaKAPn6y+COuy2eux6tqenPPqGhLpglEk02Z1lDiUiThRwPlTAXsOpPZ+Hvh3dweK213VY9ES5XSIrG3FtBvFrOju3mxh1GOGU9iSDXpkjrGheRlRByWY4ApwORkdKAPn3Tvgfrsw1ZNY1q0Vr3Qn0kz28k0jF/OjkVyj4VUwm0om0YPA5Jrq4/h5qup+KvDGqeILXwslrpMk/m21jbNtmRrcxpkMMEhuQDwoHBJr1eq1xf2dteWtpcXdvFd3ZYW8Mkiq8xUbm2KTlsDk46DmgDwkfA7VIdE0GBL7T7iWxtLywntZJZ4oJIprh5QVaPDAgMFIIIIHsDVnUfg/4iu9W0qT+1dOawsJdOlhj8ydPJFuqK6KgJV87CQ8hZgOM9692ooA4/4feFbnw3oWq6fe3EUj3mo3d2rwZ+VJnLAcjqAa4fRvA9/rvw/8GeH9VsoraXwvrETXkV3CTFdxQCRN0fBDhw6tzxnIPSvX7DULPUYpJNPu7e6jjkaF2gkDhXU4ZSQeCDwR1FVf+Eg0bzPL/tfT9/2r7Dt+0pn7RjPk4z/rMAnZ19qAPI/H/wAOryA+JtWsI4poZ9S0q+stOtrVpVK2saxmKSNQPkPoucAdKpeAfh7rOry2mseIdPtbGMeJrzWXsbiIjfFLbpGoEZzt+ZScNg4APXive2YKpZiAoGST0AqhpGuaTrMBm0jU7G/hDFTJa3CSqCMZGVJ5GRn60AeUeGfhNqWgat4UvoJNGm/sqe9E0UkbY8iefzF8sgcOgzgHABPWuu+H1leSeJvGXiC7tJrKDVLyKO1hnQpI0UEQj81lPI3ndgEA7QtdhpuoWWqWaXemXdveWjkhJreVZEbBIOGUkHBBH1FWaACiiigAooooAK8q+In/ACXb4R/9xf8A9JVr1WvKviJ/yXb4R/8AcX/9JVoA9VooooAKKKDQBDdPtiNeSfEm6xYyqDy3yj8TivUdXkCQGvA/i7qMkVlIID+9Lqqj15rOb2RtSW7Oc8UxSx+HtO8veqDchKscBuMfpn8qraX4ki02CSC0t4gssJicsgLb/wC8Sen4VgtrOttYNYSG0njdgxRmIII7g44+tZyavdW4aGXQEmZmysglJz7H2rz5xU5Nxe56NFuNNRqRZ0djct9reFmEccyEOZ14T8an066l2CNGV9jnG4ZUCsxdQvnt5J7q3sbO0hUvI0UZmKAc5JPH86sC/a0u/s+tT6vpqyxCZC8qxsyHIBCp05GNpAPtWSpys2le34G0q1OLSk7N7J7u25b1Q3F3LbuLVmkjG3ManaffirWmXc9tb3Vt5D7p8Kc2zMCB0/Wse/F3BdTW7Wess8MSzyLd6lGm2NiQHJMoXBIIwTkdxVUQI95Lb3NvPb3MDeXNBJO26NiAeoYgkgg5BPBrWdKpCN5ppehnRxdDEPkpyTfqjeu7BoI3u3uI4Xk4G+RVkZ+PlC5z64AGenFch4n0m9TTJY4J7e7guALppI4xOUBGQ7SKTs46FsYBrodKSDwxrel6hLG1rbNvaS4SOWZtgwDGVRWPzHByQB8p5zjPM+CNZ03QNdlmuddMNrFLITAiXgMmUULOibdhY5K7XXjb3GCOnD4eNS05S/I5ca4ztTnFNJ3W+5gY1ZtN05kjtUj06YNbyrAAu4HBy+cEFuvPLe9S3nhTxXqNhCs9oJYbd2lRyFDru5Kg5+7nnFbmi+NdHt/BNnoX26S3uzpV1bNNIs7wQyPISFkiUYbKk4cbtp7HpWF4V1jU7jT5V+0XXmFSqgScY9K0q0Y0knF3OKjhaLlpBJrb+vmdZoXiiC20KDR9Rs5UmiJUhY92/tjNe1/s9WtzF4fvbm8V1Tz/ACrYydo+px64ORn2ryK7udJn8KRWlokH25go80OPNV++fQ9zmvcrvxRpvh/4f2h02e1kt/sg8oxzKyuwHO1geT61z4SN3KUE0ebliozdSpTi4tu2vl8v8/Up/Fe8ukkgsbWOa3vNRlS2SVZCschY4GcfXn2rlPH3ga40KLQ9S1LVTf8Ah6yu4Pt9s0ITapYAycfeUccHoDXRQeBrrxXo2naxfeJL6PUtqXdoIHVoIW4ZBgj5u2eeamlv9T8feDI9OutOax+3XH2O7uC6+XtjYmR4h1OdhC5HBPfFenClGN0kk326nVUxGq5Xp/mdLq0XhrxVBDpNw2m6jEALmK3R1f5VIwwA/h5A9OcV4V8R/hjY6n8RNG0PS/s0F3exySyhVCiGNRkHA9cNgV6tcfDzQ/DVsb7ww8+k6ukfkw3AnLeczYAR1bIIJx0HuKry+BvsWpSatpMkl94zVRM99e3DLGSRt2bVGNpGQABxxzWri5LVHLGcafvRZ4d42+FN18OvsV6Jre/sJ5RF5hixLE+CcDB5yAcfSvXPhn4r0a//ALM0OyvJYnjXfMl0uxyF5Kjsc+3at7wx4tudT8YTaD4v0m20y/to0mtIncSCZuQXRzweOmOetc98XfDNnq/ii3ms7YR3MdsWuZ4cJsO75CW/vYz74xXJVUaV6qPQws3WkqM1q+p6cbbTdZns9QvLeK4ks5i9q7j7p/r0/PBrzz9obXRa2ltZyWTyi4cO7RgkCMEZNY/hnxHfabqdlpeuTxyx4CWlxHKNrEdBKOzEdDXV/GazGpeBIbkuIjZyrKrhclQThgfbBP5CpunFygb1qfs7xq3tZ7foeR6s0finULfT9Dkt4hDGHDA5wOmMD8sViX3httM1iK21XymjnJBli9QOmD0p76EItQE3g2SY3UKbpZy/ysTzgjoRVvTINb1uWNr+1Ei28v7xYUJw2Op615MXy6Qen4ng5NKr7dU8PNOG7Tsn92vl19S7Z+DLNtJBxECjhnIGXHp14otdNtx54VcjcFDA9c/0rnr/AMQXOl24unvXczrcW7M+DGHUrjYMccbuue+c4FN/tCaBp9OtJ7tTJZ/b0d8edkR525A6bsEgDHGOnFV7zW/9I+g/tjDUk5OL+10X2XZ9TsHD6VNDGXSVcYTaf3i/8C/xzWpHrKtEBewRSSopC3cB8idB7qPlavPNH1qPWbuGHcEwwMmeq12AjsEuF2SPKm/5lC7dyjrjPSrlKcNGz1VGnJcy1G3cjTXCSmSaRnwCZEUZHrt9aoKsapICCJwcKqjK+xNTWs6+bLeNKqRxH93Gw6+1aNhayatFc3lvc29o8ShiJW2B/YD61hdt6mvMkrMz+L3SpLQhhNG/mQhhyOCWA/IflXd/C7VGCxxucMOCK83Z7211uEXI2XAlDtz94E/4V2NnKNN8RYQMis3QjFdlCT5bdv1OOvFc1v5v0Po/T5fNgB71arnfC9559qhznIroQciu9ao8mSszlvix/wAks8Zf9gW9/wDRD0fCf/klng3/ALAtl/6ISj4sf8ks8Zf9gW9/9EPR8J/+SWeDf+wLZf8AohKYjnf2gLO7ufBdpNbxSTWlnqEd1fRxgsTCqONxUdQrmNz6BCe1eLreWzWv2lbiE2+N3mhxtx656V9aVycvh3wM2ub5dH8NHWS+7c1rB9oLeucbs16OCzB4WLjy3ueHmuSRzGcajnytK21/8jk/2eLW5j0HWL0xvFpd9e+dZqwwJB5ah5VHZWYceu0t3yej+Lt21n4RaSDwofFV2ZlW3sTbiZEkKtiVxg4VRnkDPIHGcjtQMDA6UVw1JupNzfU9ehSVGnGkndJJfcfNei6Pe+Fn+El5aeHvE97Z6GdVF6g08idXmjUAiPOFQsx289FPevozT7n7bYW115E9v58Sy+TOmySPcAdrr2YZwR61YoqDUhvomnsriFCA0kbICemSMV84+D/D3iOKH4caZcaHqNjN4UGoyahczoFhG5WCeW+cSEkj7tfSlIyhlKsAVIwQehFAHyxoWteMJvAM/iC0v/EqwJ4YuZb68v52ML3Of3LW+TwwAOWUAevNbka/EG88Pa9deGX8SfY5rawK/wBoyk3Ekmc3LWu5gVUoR0K5OduDivoFdNsV03+zlsrYafsMf2YRL5W0/wAOzGMe2KsxokUaxxqqIoCqqjAAHQAUAeA6HpvjW7XQLB9U8WRafLrE/wBouHieCaG2NvlULSNIxQPwGfnJOOgNdh8bdQvNF0bwdFZXmqok+vW1pcGykb7RPCYpdygrySdoPHcV6hUF1Z212YTdW8M5gkE0XmIG8txnDLnowyeRzzQB87atB8QT4R061WDxSqS3d/JbXAuJ3u4IMj7MlwsUqMzkZ+Z3Kr3B6V0Xgaz8b31+95r8/iFDZ6HZSxWhm8iO6vPLcSI5ZT82duenJyc17dRQB8rx6J4+13w14s069h8StbXmgpNHa3Zn4vFmBMStNI5Y7Qc42Buyjgn0Twrp3iG48VwyCfxXBollo9vNb2t3MYvtF0skm6OUsD1G0EZHykZr2SigD5l8NR/FLbrwsV1+GafQJGhi1EzMsV6JkG1JJpGBfyy+CoRSei8ZrYfwzea/4w8GC0j8e2mnwTXf2u81K4cT25a1IykhLMgZsKTnGSduK+gqKAPmi7tfiZN4V8LRX1z4lihS0vIria2SV7tLgXDiF5VjdHYeUFwTlSfvA5zVrV2+Ikni3RZ4YfEkRgl0wTOolMN1GUT7QzosvkxYO7cm12zk7gK+jaKAPPfhBpmo6X4Y1yG7tZLW6l1m/mhWdCu5XlJRvoeDmuC8P6bNqXwz+Fg0u1nuLmx8SQz6sFXdJDMvni4eXuCJG5J9R7V7/UFrZWto872ttBA87mWVo4wpkc/xNjqfc0AfOMWk/EK+vNZt9dufEgnnt9Singhika0nUxyGDy38wxoMiMAIgY5IYck1o+EPBWoaD4o+Gd7NbeIvs6aElvdGJ2It7kmNjHKP4Y+WBB4+UDtX0JQRkYPSgDzz4VlG8QeP5NP/AOQM2tn7Pj7pmEMYuCvt5u7p3z716HUFjZ22n2qW1hbQ21smdkUKBEXJycAcDkk/jU9ABRRRQAUUUUAFeVfET/ku3wj/AO4v/wCkq16rXlXxE/5Lt8I/+4v/AOkq0Aeq0UUUAFFFI3AoAwPEs4SBznoteB+KpReai8TcljhR7npXsXjW6EdrJ9D3rxC3b7TrlyXBKZIXae4B5rCet/JHXSVorzZyNxH9mklG1vMEu3caZdebcXG5lYueRjgflV7yo1adJ8kKxcPnIPHGaIrtfLCFNzoMjK8Hj0rzXfoey9yui3SpIkKRszRsu1gWBGCOR3FY/iPUTptz4futJ0qU3Olw+Qi3pWSFgA21gEKkMC5I5GMA4yK7ayjsrkRKFlFyxIKhgvBHHXtV+z8M6XdusN3NbQBmy/nyRtx3wAwYflW+GrTp35ep5+OwtLEtOd9L/jo/wPOrvxdM9sRbeHYfObTLXT1hkQSxFopNxDI5OUxkD+L1OcEZS32oa58Rp7rTLfUIJblvOaOdtzxSYAxu7oMADPQcY4r24eAtHe2uZrHXtIOjqf8AWXakhW9A42/oay72LQfD96t94d1y8vZ/LEckL2xmjb02MxBHtya9BVZ1fdqLQ8j6hTwzdTDfF8/L/Iz7uW7Nx/Z3iVPPuZE8xJVCglenBHGePSs7QPBWkeIdae3WaSJYUDSeYAHIzgYwcV0s/iq00ZxfT6U+qa/JEP3UyqI7JM5+bg4P8R6msXxJ4+vr+6gsLfTtJ07UTMsIv4HYAh1DAcDJ6gehOOmeM0qNKtd/D+JssXOFFQxGk7N+VlvYj1P4f6PaeI49NtbXUrgSxF3ltITMIecfMPQ/UVdT4fPo+m3c8N5bFUQlkEbKxXvg5OD+Fchpd/q7XF40OoSRSpJ5M0mHcysZHTgLk4yh5Pr2q5Y6nLO8dlqWsSpaLLJHPai43ZZH2kbiAdpxnH6VliK1KUm4I0oZlhqUKnO+ZxV7K/8AT3XoVb+awSDQfs1xocF+kLwEpc26JbSbyyvMPmAwBkkqRuyOpGZ7nXdMtvEup3d3qNi8cOj+Sl3bS20slzMJF3SLHuKhyOArZJVRk+naXnhuzn8HahqN3ePHpwcmzikbJKKOWXPY9K8lk8L2LXx+23VujSPwTKu056AHPPYVV1ypvqdWFxk8RD2sY2vZ6+ljq7Tx3rNr4uvdC8IPBNZ6kwntjpuJ3IMY3sFUDY52MzLtBByf9o+36H4p0PTfCVrpeti40+8srRM2t5C8MknUK0eQNxLKeRyD1xkV4yPhtpS2QjDRS3LsiNAjx+dsZgGZFc4LBSSAepArO8avqVx4xRoLY2NrGiW1tZjB+zW0WRFHkEjOMseThnYZIxXRTqckbo4cTR9tVaa3d3Y9H8JLd391Bc6ldXF3cwt5kbTyGTZg5GMn6VuxfEq5Tx5HaT6dENOa2AlaJi0gbJ2t2yPb369qyvAilLfMhywj3Guc01PM+Id4vURoif8Ajo/xrloVpxTaZ7OLwVCcfejstOh6B8R9N07xXNY3EavmGNkM20q2CQcc4PGD+deYa3ZW+j6hNp81iZVJBVpJ3YSIeR/FXvMGnLJp2MD7tcL4p0qO4xDcp86AiCX+4T2PtSxCc/f6nLg+SkvZ9Dy6aK0u4mihhjgyCQOcjHoa9e8Aa6mveDZbHUm+2XjAwSRkdSOMk+4wa8wiX7HdXFpdLi4U7WXHT3rb8CXZ03xTcW9p/q7uEYUc5dPT8D+lZYeq4txO6pSpza5tEYtgL7wTrd9osenTXck7GW3SBS5K9M+wHHJ4FZmgEX8GoagqatK0z5cWZIFucBsY3As20jhQTg9K7Txot/B4j07xHNZXj2VsCsnk7BIfTh3UBDlsnJ+6OOcjyHRtS0nSNSvruVNYXVEDw2FwltCfIjZdpcr5o3SYLgclRwcHoK9klJt7s8+GAwlLESr095aPXTpt6v8ApFrVtIjvLaOHR59XitwizQia4YoYwSFdFzjAKnHTGPpWdNoeuGSKX+2L9pkUgSPPIWUHGQDu4zgdPQU6fxHZ/wBm6Qlr/asOo2Folo0bW6eTKA5PLCTcBgnsa76DVLLUtCgmtrcxXJbDxHjb1HHPfg8VNRunsVDCYacuXkXyt13OK0fRtTg1NLm4mS8lkIGbiSQO2OPvHNd/Mtytsn2mwe3O3ClLxHDfgQP50t6Zm0yyCiACIeSgyN3JLbj+dZOpyXUpWGabzUhGxNrZVs+9czqOerO2lQVJcsNuxYkeKSKOxkultyrbgtzF5TZ+vQ/nU0thqBZhaFpoyodmWRWzj6dvaqkogTT44bphPcOCQhbKqOnKkc//AFq5mfSrRrnbC9xbg5LLE/yn8O1OCi9xy518KR2GhwT6nrNuLyTylTJd2G0Ig5xk/kK19evoZNVW5gk3Eyc89v8AIriG0qK1CBJp5mxu4nJ4x3AqOKHyZVmtjI8IGZMnO09q3pyik0upy1IVJTjN7H018PdS821UFq9LhYMgIrwH4ZajkIhPWvc9Ml3wLXbSldHDiYcsjD+LH/JLPGX/AGBb3/0Q9Hwn/wCSWeDf+wLZf+iEo+LH/JLPGX/YFvf/AEQ9Hwn/AOSWeDf+wLZf+iErU5zl/wBozXNT0TwDD/ZE8ts17ex2k9xESrxRMjscMPuklFTPX5+OcV8p/YbXaR9niIJySVBJPrn196+8Nb0mw1zSrnTdWtY7uxuF2SwyDIYf0IPII5BGRXljfs++FjdGRdS19bfdn7MLmMpj03GPzMf8Cz71Eot7HJiKE6jTiw/Zn1zU9V8J6laalPNdQ6bdi3tp5WLNsMat5ZY9dueM84YDtXX/ABVkhXw0Fl12bRpjJuhMOox2DXLBG/dea6sAP4uBn5PTNdB4d0PTfDmkQaXotpHaWMIOyNMnknJJJ5JJ5JJJNT6nplhqtuINUsrW9gDbhHcRLIufXDAjNUjpimkkz560/wCLmt6Z8LvCk9rf22p63PZXlxdNqFtzKIZNvD+dGuByu7LM2AQpJIr3nwfqza/4S0TWJIhC+oWMF20anIQyRq+Ae+M1Nd6FpF5BbQXelWE8NsMQRy26MsQxjCgjC8AdKu28EVtbxQW0SQwRKEjjjUKqKBgAAcAAdqZRJXzB8LvF3j1/CQ8WSXGqahpttouo3d++p+WbaWeIyeQINuH/AIMP24PtX0/VODS9Pt9MOnQWNrFp5VkNqkKrEVbO4bAMYOTkY5yaAPHPEHxP8XaVpfhYPp+iJqHiCKS7gcFnhjjWKN1jO948yFnbPzYAAwGOaNS+LfiGzk0ezbR9P/tLXbK2fTEWQyxG6M6xTxu6MQVUNvBB6dTXsV5pGm3tglleafZ3FmgAS3lhV41x0wpGBjtR/ZWnZsz9gtM2Wfsp8lf3GRg7OPl49MUAeOX3xf1O2+In9lW8el3ej/2jNpjsU8iSOWNCTl2lJIBHJ8oL6Me+VYfG/XP7J1STUbXSo9ShW2McHlOkNuJphGJZJ1ldJIhnO4bSeOByR7m+gaPJftfPpOnteswdrg2yGQsBgEtjOccZpbPQtIsbe4t7LS7C3guP9dHFboiy/wC8AMH8aAPNpPiXdaN4h0zTdf1TwvPb3UV6739pI0UQeFI2VPndgrHecjceMHjOK4/RvilqTy6r4n1G6S1i/wCEYs7tbVvNltYppLl48iIMDk/KM5HbJA5Huy+HdEW1gtl0fTRbwOZIohapsjc9WUYwD7inR6DpEcLxR6VYJE8P2d0W3QBouTsIxyvJ46c0AeMaX8XvE91ZJbnTdIbVj4it9FBYlISk0LyBiI5JdrAqAcO30B6e46d9q+wW39o+R9u8pfP8jPl+Zgbtmeduc4zziqlt4e0a2VFttI06FUlWZBHbIoWRRhXGBwwBIB6gVp0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlXxE/5Lt8I/8AuL/+kq16rXlXxE/5Lt8I/wDuL/8ApKtAHqtFFFABUVwdsTH2qWquoNtgP0oBHmHxDuStswzyc15Cs8tul3cROyvEvVR2JA5/M16L8S5yIpAp5wQK891OJbPQIbjh5JphwDxgDpXLUlaMjvpw5pQiVpEPkxTrNbOuCSB94nPIP40SrBb3kVzcQqqyjO1c4TsTjuc9s1Po+lWC2skl9O6TPE0tvFFyPxP9KpWc5jIsZBFJFO2I2Y58s9M47V5zdmel5I1F0yV2jjtZAltInmb064yc7j2/lTPtX9kXZtpY3lV1z5gkAyPTdg8fQVWgW4UvZsGJicZdSenPGew6077NK6iN4flQkxs52sQOvB5PHoPyq4z5UJ7a6m0dSg1TTzE1jGxgclCVLtn03OW/QVTOmXV7GZLm4s7KzB+9LLszjnvz+QFQRahbWRCyW808cnMoWTygw9gvP5k1yOvWdofBsupWmm2SuNXkVZjIgna2dGjG9mbOBK+3HAAUNgcmt8PGda/K7W1Oeu1RtodHq0fh19Iu7e11W8ub1iAXgty6A55BbIJB6HBHB4IrgNSh1ltZt75bG3AiZWEksTxRMU+6SvmEkjA6HsMg12djp9nHqPhCHXrPSra4nup0vLSSK1VZI/ILJhYSUaJWHBcbskY9+S8SavZafZ+G7zSYbSWzu7Z/Puba3jtfMmEn3XgThHQcZ53bupArrlgvZxcr3/pHnVfZYmadVd1e/R79jJkvNds7u+kgEdubidJy0EbgBlJOBlvusWJIOc5PQVc8B6JdXnjJLu40+FLcv5zQQqRGoHXAJOBk9OnPHHFd/J4f1O48FtrjLE1ukZmNsSd7IBnr0BwK6XR4h4V+FK6hcxibxD4okSOzgjX5o4/4EX8yxPv7U6dCcVeSs3sEKGFoTU6S10v/AF8iv8TdRtUvvC8Vy1nHB9rDNHdsogWNR8xbcQowCxGf4guOcV59od8lv411yZdb0mDTUuXlKG7tmF5GZJHSKMvwBhsNgjGfUDHb+JoIYfEunQzQzRFbNxvmPLNlQTmuZi8I2934mkMjEFtpyeDyorGT5J+znueq66m/aU1bW/6DdG8QaTHpOnW11e6Wl/KNRLQPLC1uzq58pZZTlkXH3GBGQByRiq/grxDHq0apdHfdRJ5e9iCXIGM5HB6dq77UPhLpq6FfX2N8kcDSfkM1laL4S0/SfDUN3EAZJIfOx6fL1rXkXK2cf1iVSpTi1s0vyR2PhaHyrK7kP8MWB9cVw2n3Usfjy/W3TfPLMFUE8DCjk16LpUflaBcP13KT/wCO15pZajDpnxL1CS4fy0aSSNXPRW4xn0rHCq6sz08fJxpyaPfPCWpS3Sy2V8sa3MYyChyGFUfFNmH3cVU+HSPealc6go/0ZU2K5/jOeSPb3rZ8ROBnNdFRJaI8SjJ3ueAeIt0+uku5MZRA5Uc5CjkmtfwZNDaeL/DU4AK/bBEfo6laragWa6nMMSkMEY5xg8DpVjwXp1xr3iS3lidLZNMkSdzjO5uy/wBc152GpyqV0o9z1sRJKk2z0WTVE1rVvEuhTQRvfaS7SRw4/wCPm3P3kx6//WryfVtH02wuoryx2T2NyfMgk2Btvqh/2geMVFrWs6n4R+NJ1WaUzvIRI/l/8tIz1XH4H8q9A0/w5o2qaDe6haeZFDqkxu1QNxGzHI2joOtetUwk614rRo82nWjSd2rpnmd5Z6VBIRJ5YuJAX9wvdsdhnHPSptO/sy0tybzz0jLlfNWIiJcD/nocKTx0BJ9qmdZNPs9d/tO6e30+902bT/tKW808ck+4qm7y0YJsG8ckE7+hxXGNrdknw81uzvdYlubm9giWG1RbndA4ZG8ohx5QRSGOV5OWwe1csMEmvflrr23Np4tpvkR2tqhuEKQsdwzgCM7s9dpU8g+1MvSLa1Lbf32cAtxt9sdqxta8V2k/jie/0DXIbm01G5jPkCGeJ4yIlXeWZAuMoBgHPI963pbJLhZpYG80BtjBjli3r9PeuPEUfYz5b3R1UMT7bcp3sEcNtAzuTcMCZBtwFz2HrTbzTTayRLMVSQqWKK2dpBxg46GrMEE01wgc/d4bf/APWrWqXEd/cuwjYhMIpZiSwA71hudF2mkYdurCSR+UXYVGRnP0rX8PWouBfW4jB823JHYD3pscSmIrM3lDIIPB2+xFaHh97f8A4SDbFO7wCN4y5G3c2OP61rDWSuZ1W+SVi18OLsxXCqTyrYr6N8Oz+ZCue4r5m0HNj4iuIexfcPoea+h/CE2+CI+1d1HRtHnYr3kpLqT/ABY/5JX4y/7At5/6Iej4T/8AJLPBv/YFsv8A0QlJ8V/+SVeMf+wLef8Aoh6X4T/8ks8G/wDYFsv/AEQldJwFP4ueMLjwZ4Wju7CGOXUby5WztfNBMaOVZyzAYJAVGOMjJAGRnNfPx8b+M2uPtLeK9R8/O75UiEY9vL2bcfh+NfSfxA8JWnjTw6+l3cr28iyLPb3CAFoJVzhgD1GCQR3DEcda8TPwU8Yi5Ma3vh9oM4+0GWYNj18ryyM+2/8AGuTERrNr2ex14eVFJ+03PUPg141u/GGg3Q1aOJNU0+YQTvCCEmBUMsgH8JIJBHYg9iK3fH2o6vpPh6S90Iab5sLbpn1DzTGkeDkhYlZ2bdtGAOhJ7YNb4b+CrXwRoT2UNw13d3Evn3V067TLJgDhedqgAADJxjqSSTo+KvDyeIrOGBtT1bTWik8xZtNujBIeCMEjqOehHUA9q6Y3subc5pW5ny7HC+Hvi7FdeFfDl7qOi302r6vZz3i2WlhJwFhbDcs6gHGDtJyOQeRivQ/DetWfiLQbDWNLdnsr2FZomZdpwR0I7EdDXnF38HLRL/w3Bot/d6Zoul2d3bSG3uGW6kadlYtvIPUhs9OvGO3pehaTZ6Fo1npelwiCxs4lhhjBJ2qBgcnkn3qiS9Xhnwt+N134s1GzTUrHTI7OWxub26ks53d9OWFiMzqVwAwGRg55Fe515zoPwe8MaEdJOnfbUbT7aezJMqn7VBM7O0c3y4dcu2OhH4CgDCvfj1ocvh/Wr3RdPvrm8sLJdQjgm8tRPCXCb8o7FQCwyGAYZHy109p8TdOl1S20yfStagvpLWO8mVrXK20Tsy75WBIVRtJJPYj3xFZfCfQbXR7/AEn7XrE2l3Vm1iLWa7LJDESDhOM5G0YLFsAY6E1r6F4H03SdTlv/ALRfXt1NYJpsr3kok8yJWZhngZPzkfTFAHJ6h8adMXw7qeoWGk6qZ4NNbVLKK6iWJb6AOEMiEMSFBIJ3ANt52mtjT/ibZXF3othLo2tpqmp2S3wtktfMMUZlEZZyD8q5O7ceNpHc4pth8JfDVna3tsTqFzBcae+lxpcXTOLW1c5McX90Zxycngc4rV8PeBtO0TV7HU4rvULq9s9NbSo5LqYOTAZRJ82FGSCAAfQYoA56L40eFxq+p6dfreWEthbTXUjTeS4KRn5hiORmVvRXCk+lVfEPxUvrP/hHZbPwzrEEWoahHbyQ3toDNNE8UjgwBJCN2UGQx4zyBnNWtP8Agt4Vs9sZOpXNklvcWsdnPc7oo4pzl1XgEc8g5z7nArVtPhvpsM+mTXOqa5fvpt1HdWv2y783yyiMir0+7hznuTjJOKAMO6+OPhe20izvXt9UE9wZw1i0ccc8Pkttk3h5AoIPGAxJ7A81Z1z4y+GtH/siS5jvWstUgguILpPJC7JThco0gkOO+1Gx3qxL8JfDzGOW3n1O0vI7m4uUu4LgLKDO26RPulShIGAQcY61Dq/wd8PapJM895rKm4gtre5CXeftIgYNG0m4HJBA9B3xnmgDa+HviW88STeKlvo7eMaVrlxpkHkqRuijSMgtknLfOckYHTiuurG8NeHLLw8+rtYGYnVL+TUp/MYNiVwobbwMLhBxWzQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V8RP8Aku3wj/7i/wD6SrXqteVfET/ku3wj/wC4v/6SrQB6rRRRQAVQ1c4hP0q/WdrP+oP0oY1ueI/EGYLOGY8Bx/OuVvUk1XR5beNkaWHMqouOQeoH6ce1dF4/ge7meCMHc+QCO3vXmd/pWpaQBuvraNj1VGJfB7kY4H1riqNNNM9BRlzRlDcbb/adQuY7aFw7Yyg6beKtJdabpNwkSr/a2tspZYoXxFAw67274Hpx7msJdJnvoSZ9SuniX5m2IEUD3NLpEVrYySJZq29vleSRslh6ew+lc1oJN7nYnOTtaxtXN/cpP9pknV7nPCwriOI9cj+8fcipoLsSQrvAZt2/zQPmB9M1BcPDfQoSohmiOAI12gjH/wCv86msLaEqWflyMLFtPX2xWD1WpvGKSsWb9bTFnPDvG5Csy8cMDxj2PFHiXQdHm0yP5IJb27BdZEADbQBnoMZ56HmrFxpmrXtnDDBp8gThDJIm1VyeuTg1b8ReEH8OaN/ad7rDyLCgaaNYhyMgYXJ688ZrpoYarNc0Fojz8Zj8NQlGjWlq+m/XTbbU8zXwHDcXcVtZo9wzkYiiXczH0wO9bvin4TReGNOtrjUB/wATS7IFppcXzSufVsdMe1eq/DLxA8tlcahpukjSdBhPlIzMGutRnPRd/QKOpxwPpmt7UtJt9G0678TazfwyarcoTLqMxJt7VD0SIdWHYY5Y+ma7KUJR1k7mVSUW7JWOD0nxAuq6GdE0uC5+3LBi5R4yEtFxhndumAM49as/EPWYNG+I/gmN5MadYWgjVm+6hddisad8VZrbRPC9h4P8Nq8Fxqi/bdVuJRiZkADfvD2+nQAYqn8Z7CO61vS79F+06ddwWckToM7l2vwPrgGu6eIk2ptbHNGld27i/EzXba8vdKgglinvpJTIvlEPtjAwckev9KyZ7n7Aba8RhKFhcEMdvzLyASenBFSS6NBb+EtB1fRINt3b3k1vOM/NnJK/pVGSI3uj30d5iRtwmKn+JSCrj8iD+BrzMXWVWsqlraHpYWm405ROmh8b3mmQvLqVx9p0yfyYZo2iRViE0ZYcD95GQMAiXruGMZrLsLm9h024tAsVzpao3kXQfDKmRhWHf0zXK+JfD2parok72+ozPBKEe5LRRB5PLHyb3VAz7R03E10vhnRbyx8K+ZeztsMZIi7EYyK6ZO8G4djjw6ca8FU7o9GtV2+HrpT2DHHoNteaadBbz/ErVVuo0eNZWfDdK9MsnEukajxx5JP/AI5XmNjYJqHxG1Te0qbNsi+W205Kr3rnwy5lZHrYyXLCTZZtvGOp6LpMOqLqtw00EFncXcHmny9kr4ceSVCrHtPysvz5xv6Gu2tPFsPiPTftMRABFcHr3gZ9UguNFiuLxEjAdYmupDHs7DYW2jGOwwMcY5q3o+kt4c0kWZbL429a6KzSR42Hi3IJvL8hsKGYBWOT9B/XFN8O6jd+HLzWLiW0kktFgFxMYyNyHdtAGeud2Khl8yEvPaxO8Kvhsnhm7VPqRFn4MmkKTltSvU+0yBCQkEY3AD/eY8fSuDBSnTqupHojvxXJyqE5L3nZevkc1fy3PiPxrb6j9nZT5sEcMB5IXLcH8ia9EsbDUota1/QPDF5ZjyYlv9NS5XgwyDdhD0IBJHPSjwHFBbaTreu4BkgjmMIflgIrfr/31KorF8Kz3KeHPCvigIzT+HrmTSr0DnzIG5BPsAxH4ivTp4idudvV7nHOkm+RdC94a0WXRdJu7i9gub3Q7w41qxlXMltJnmZR7Hk47cisfxl8JI7RhdaTIuo6TKhnEkf34lPILD+If7Qr1nwbfLp2q3GiTOZWaM3Gi3G8ZvbY8iLc3DPHnHPbFcfrU8WpltFS6m0W+t5DcaPd7jEiz877ZgeUzzhD0PQkYzlUjzDpytLbQ890jwdos9uVuUuUnCfuPIQN82M5b2x1NXfsIsmDRojJG4Y8cDB5HvXVaUviC3tYtb13TInuGU7rixAE4XkEtGBtc+uOfrVmy8OnWbBbrw5q2n3thHJunRZfLkXJ43o3Q4GOTXFVw9WHxK6N8NjsPVb9nJab/wBfkcPczPd3Us7NzJJ90dcVLNDdSI0scMiIuSXYY2r/AI1oa5p91pmqR2c1tNHM8m3zWUfvBk8g9P1qjsvL6UW0e92VWURnouM5OfT1rkaaO/mXLdbFKC2kuoTKmcZA+bOD9at6Su3V4kgIeCJvMJ25606zWVLaW1kkCxKvmuoGeR/jUNrMsaCSNGDFuCTw2O2KtaJ9wemjNO7JTxMkoztc7ckY5Fe6eCZM28PPavD7zUJNSi0md1UCMmP5RjkHB/kK9l8CP/o0X4V6FJ3d+55lVWp2fS6N/wCK3/JKfGP/AGBbz/0Q9L8J/wDklng3/sC2X/ohKT4rf8kp8Yf9gW8/9EPS/Cf/AJJZ4N/7Atl/6ISuo88u+M/E9j4S0KTU9REjqGWKKGEAyTSN91FBIGTz1IAAJOAK8mPxl8RGbzV8PaWtvn/UNev5mP8AfCYB/wCAke9d78X/AAte+KfDNumk7G1DT7pb2CGRtqzEI6Mm7sSsjYPTOM8Zrwo6brizm3bwz4hFyDt8sadKVz/10A8vHvux715ePrYqnJKhG69Lnv5PhsvrQk8XO0uivbTv5s+i/Afi6y8ZaKb6yjlglikMFzbTAb4JQASpxwRgggjggg+1aHiXXdP8NaFeaxrM4t7C0TfI5GT1wAB3JJAA7kiuP+DPhPUPDWj39zrSJDqOpTiZrZGDeQiqFVCw4LcEkjjnAzjJ1fiT4Ki8baVb20mo31jLaSNPAbdkCtLsKqXDowIG4ngAjqOcV6NNycE5qz6ni14wjUkqbvG7s/Iz7z4reHrbTvDt4kep3S6/FNNYxW1o0sjrEAzkqORgHP4Gur8Na5p/iXQrLWNHm8+wu08yKTaVJGcHIPIIII/CvGpvgdqN7oPgXSr7XmCaHbX8NxNDIySBp4gqeSVVflVlBIbqMg5zXqfw30fUPD3grStH1b7AbqxhEG+xBWJ1XhWwQMEjr75PerMjpa5/wv4u0fxJ4Rg8TWFz5WjzLI4muf3QVUdkYtnoAVPWugrwzQfhZ4tg+Fp8CanqGgjTYF822ngWZ3eYXInCyq2FMZ+YHHPTrQB7BZeINGv4LWex1fT7mG6cxwSQ3KOszjkqhBwx9hT4ta0qYQGHU7GQTq7RFbhD5gQ4crzyF746d68q1D4Va1daBq08Go6dZeJrnWYdatTbq62trJGqx4HG47k3ZOBkkelUtL+Bclouv2J1ZU0qfSm03SwilntTKEM7sDgHc6Z4PIYg4zQB61Z+KfD97aPdWeu6VcWqSCFporyN0Eh6IWBxuPp1q3Jq2nR6et/JqFoli2Nty0yiM5OBhs45PFeK23wZ1N9OlgvW0bzZbvT5Z2Wa4mFxHbOSQwkyBlTgKBjk5OK6/wCNegT3nw1Gl+HdMSRkvLQx2sEPyKqzoT8qj7oAJOO2aAOtk8XeG49KGqSeINIXTDL5H2tr2MQ+Z/c37tu7g8ZzxU//AAkOi+Xbyf2vp3l3CeZC32lMSpkDcpzyMkDI7mvKbn4W+JJbW8nj1PS4L3UNY/tG7s7bzYLfyxCYgiSJiRWxyWXbuyRx3m8A/CGfQ7vws+uNpeow6PY3duyGMyDzJbozI6bx/Cpxk85oA9Gfxl4aDagia9pcs2nxvLdQxXcbyQqn3iyg5GPcVHpHjbw3q2kWmpWmtWH2W6TzIzJOqNjjOVJBBG5cg8jIzXmGmfCHXj4sh1LW9VsLuJE1GGSUNKWlS4UhP3J/dJtzyExnuW4xf8JfCi7s7vwc3iCLQbq10GzuLRoooSwmLiMJKQ643/Icn6YoA9MtPEmh3mqz6XZ61pk+pQFhLaRXUbzRlfvbkByMd8jisTWfiT4X0yK1lTVbXUEm1CDTXNjcRS/Z5JSQrS/N8ijByevHQ153J8HPEF/4u/tHVdbtXt92pKbiJ5RN5d1DJGu2L/VIymQE7cE9STxWgPhhrd3o3h3StSXwwtro17p8m+2t3V7qC3Zt4kyCMsCMLyMlsnmgD0t/Fnh1NHXVn1/SV0pn8sXhvIxCW/u787c+2aW+8VeHtPe0S/17SbZ7xBJbLNeRoZ1PRkyfmB9RXkuo/BbUGuZrvT72wiaPXL3UrezDSwwmC4iiTYWjwUdfLPQEfMR3NU/E3wX8Qal4etNHsdR0uCwi037GLUS3KJDIJWcMCCWlGGAxISARkL2oA9j0LxLZ61rOu6Zax3CT6NOlvcNIqhWZkDgpgkkYI6gc1Dp/jDS7271uNWeCz0i4W0nv7hkjt2mOMxqxbJKllU5AGTgEms/wL4Uu/D2u+KL66uIZU1a4gmiEecoEhWM7sjrlSeK4qbwVqms+BvGngiSAW00usG9t7y4jYwXMEl0lzncAcsAGQj1A7GgD0qPxTpkmqy2iTxNBFZm9e9FxCYAgkZGBO/cCCpySu0YxuyCKzdY+I3hnTrGwvItTttQtbu/g08S2M8UqRPMSFaQ7sKnBJPoOhrh/il8MH1H+3rzSVhtNPk0CLT4bOytiz+bHefaTiNcAo3QgHJyeD3wPDngPX/F2oarqusaXaaTbz6/pd/8AZZoGjSWG1j2SKsZyQDnA3AZ56UAeu6j8QfCmnxaXNPr2ntb6nO1vbTxTrJE7qMtlwSAB3JOASB3FXtJ8SWmo+INX0Xybm21DTfLZ451UebE4OyWMhjuQkMOxBBBArzG6+EV/GJJdObRDLF4om1y2t7iJvI8iSJU8pgBwcrnABHArsNHsry++Lms649pNa6faabFpMMkqFDdP5jSu6g8lFyqg9CS2M0AdzRRRQAUUUUAFeVfET/ku3wj/AO4v/wCkq16rXlXxE/5Lt8I/+4v/AOkq0Aeq0UUUAFZ2tf6g/StGszXP9QfpSY47nh/jl5Euv3RYMzbSV64715JqD3El4Rc/M8mSJQM7hnufavYfFGX8QWce3Ku5BPp/nNeQSDdclGZgyuUGfXNedX3Pawv+RIW2sBA2yN0wwz1I7H1qe2s/NlAij3+ZnhVJ59qeVG9op12qvJBHX2q3MgingcOHtwzKBgkEEd/rmuds6X5Fe1jDLKhRi/3VAGOfp1rU0yHU52NnayLbAHLSLgCJR1JbrU2m2El4l9NLFPI4w/lR42he+W7fhzTL4alFajQICTNdMJZYYFC7B/DHn1PUknuK0px1MpzvobEuka54jurTT7LWrXToI/mt4nuWe4lx/wAtZAuTn64ArS1TwZaSanbWXjXxRcaiLeJ76a3jjEaRwxjJkdV+6OwZuSTgCs22RvAelyx2UaL4p1FTucKGFpEOSTnOT3+pHpWHZoNP8KpLf3lws/i7VUsJZeGuJbcZG5S3ZpGXcf7o4Br0aTd+RdTyMTCml7eaT5dnbX5HR2sd34gS01a6ji07w1aZFhb4Cw28WCQWT/lrKVUsQflAHOc4pfCiXPjXXpdd8UXM0ug+H1N2ljcNuc4DFDIBgBiRnBHQYAArKs9QvPFB0/SRLPHYaHLNYPNbhFkLiWRVwuNoIjSMs5HfCj5mIyNAl1SHwXNZ3WpX1tb341CXVFilh3J5LbSRGY2eUk4DEMMevIFbxw1R6s4aub4eHuq99PxTf32X6HT/ABC097rTZtcKmW98QzW9tCFOdkTKGKj64b9KXUbZ5vhjYTnJe0iQRo3O0RXjIefpKorktL8fW929o17GDp1vLZlDE5PlbI2RlQ+oLDB74rpNX1YN4a+ytaXVmHsLgp5643M11HIB/vbVzWM7yk7LoehGpGLim1q9B3h0o2g63C8XmJbTwXqxZwQejEH6Ac1iSkW+qyuoEcbyF4xnJQHseORXR+Hruzjj1y4I/wBHFqiMp5JLE1yupwGyuZIr1Xwj4DZ6c8H8q8yTvFXPTp25211N3R7driw1TS4CAZY2EPPGDyP8KV/EFvNpw0yZZkvlgZGhaMjYVTkk+hxxVfQbpLaSCc5CpuQ+6gBh/M/lWn4it9Tu449RLRLbsrBogmDtKnnPrXZRk3TaRz1YxjXhJ91+Z0Wi5/s+/JyUMAwPqprzODVY9J+Id3NMshhljjUsi5KHYuDj0yK9K8Kkvp6k5+eCPI/CvObjSYb7x+6Ts6xNbpNhGwScYxn8KMK9dDux6/dyudtpt4097daoyvHG0Yhj3jBYAk5x+Nc7ql4Z71mdjsQE5x37Vavp5dMkfT5pWkXyxLC7n5tp7H6Vh3Eqx2wZzmWQ71UjgDoDUYmTTdziwkVypxKYhmVVlE5SxFxGsxY4zubBwPpk12/j/WrQ29tpFkse67wFEeDsiXHzHH4AVi+H5Y0mitLho5LaZ3muDImWXC4/AUDQLO007w2LeHyHuTNazSk8lmVWT6dxVYWsqdKUIrV9Thx+A+t4qnVnK0YPbv1/Mu6A7zeHRo6SbZrzT7lI8joz3agsfwT9K6Hwfpv/AAg2pnStQdNQ0PV3EcqzKP3cpGBkd1bGPY4rDuLSZtEB0PfFqGhtFBMsi5EpLtIwz6NuA+q1X1C+1nxFrun6A2mPYXLXW5pZpd2TFvPyj0yh5rrw7pSp3lucWPeMWKgqK/d9dtNdb9drWsa1pqHh2W6uvCt5JqVkun35hsp/IkZ9PmLfux5oBUKxYBQxBOceho8V6l4X1y0vLfxDehNYKfZTcw2srxzXKjARXRCGdvlZUBLggjHJFYXxdubg2XifUxBd6dHcfZfs8kMLSxNcwHcZGIOEd32xngY8tSc5rz4+M9KutA0YHTL2yi0/W7W7EazGZIYkA3vu2Akn5yVPzFmLZPStI0oNK8jOpjcRGT5Kd7O3ystfPXtpod34e8ZalpfhGybU7Se7sRM9o00fySRuhxiRGAOcfjwR1rSubOx0K7ttenkubJ9WVmjngUXVlKn8UU6AZww9M9SeCK8uTW4LrV77TdN1ie9tdRmmvoY5rVofs0vmGRVGSdwO5ueP1r0PwDf/AGwXPhLXS0dldN5lqxH/AB7TjltvtnnHufWorVJXVN69jbA4OjG+Kgmm91rt5J+Y/UtNvNHt4r7RdTF14Wuh/oyyuZo4j/FGwbIUjnByOB61jwF7SKQRfaItQfGyW3lEkZXHPPUfmav2Fm1nrWo+Fo9RwfOJhZd0YW4XoSh7MMqeoOQeaS0t5ZUuJbSDyZ1O1ngnBjUA87lP3eeCp9eK86vq72PdouysZEUMjF5riTZuXHzch8dge9VSLidlRXwv989vrWlPA91HPJdFYIIlIRdu35sY4HvWRl5WRUYRLjjd9OprmOlG9FKraXZrGu1Y5dv6cnHua9k8Ayf6PGM9MV4lZsBpYhjIeOOXdu9Tjqa9i+Hr5gj/AAruovb+up59dW5vX9Ds/ipz8J/F/wD2BLz/ANEPT/hP/wAks8G/9gWy/wDRCUz4pf8AJJvF3/YEvP8A0Q9P+E//ACSzwb/2BbL/ANEJXYeYdFqF9a6bYz3uoXEVtaQIZJZpnCoijqSTwBXFj4paCx8xLfW3s8/8fS6ZNsx/eA27yPcLimfGaCV/D+mXRikm06x1KO6v40Ut+5VJAHKjqEkaKQ+gQntXNpqVi9h9uS8tms9u7zxKvl49d2cYrxc0zOpgpxjCF79f0PRwWChiItylax6vpGp2WsadBf6XdRXdnOu6OaJtysP8exHYjFWpHSKNpJGVEUFmZjgADqSa85+C8TPba/qNtG0Wj396JrPI2iXEarJMo/usw4P8W0t/Fk2fjVoXiDxH4RbTfD32RoJGLX8M00kT3ESqSIkZEY/M23I4yBjIya9ajN1KcZtWutuxw1IqEnFO9jto7+zkNsI7u3Y3IJgCyKfNAGTt5+bHtVmvmvQ9O8R+H7f4M6jqfhrVJ10ODUkuoNPgaaWJZIlSPepC7WJJ49jya+jNPuftthbXXkT2/nxLL5M6bJI9wB2uvZhnBHrWhBYqK1uYLuBZ7SaKeFs7ZImDKcHBwRx1qWvnLwG/i3T/AIDR+FNM0DxHpviKyjeWSdrbyQ0TXe50gkY/60xSHHGeDjkCgD6NorwZx470/wAM3mraPF4huLfT9ciuLDTr6R5Ly6sigSWOQElmG9iyhjuAU+1VtGsPisqaxp815qEl3pGkTfY7uV8Jf3c+1xyflYxjzFGeFO2gD6Cor5w0q18ff2FPFDe+Llee/wBO3CeGVZLZd5E5SSSSQsMYLfwDAxwcV6B8Y5r7wv8ACtBpmqaobmG7tIftfnZuXVp0DfMMZJBIoA9Por56vY/G3/CP3cdrbeK/7JuNczZyT3E7X1tbeSQS6xyLK0ZkJwpdcYGeKu+ANO8darP4Ot/Et/4lsYI9Ou2vpAxjZ5UuyIVlLA8mMDvkjvycgHu5IUEkgAckmkR1kRXRgysMgg5BFfOWm2Xj3VPGFzDdweJLPT9Qg1S3uraWWZ4YjtPkFZXkKcnGDGiADjLZ4ufD7w/4la38C6OZ/F2kabBYXCanucx7J1EWxQWBATIbbjH8WO9AH0HVa+v7PTxAb+7t7YTzLbwmaQJ5krHCouTyx7Acmvn2E/El/iHPPp1vrlmkz6pGYLp5prRG8mQ2rb3kMW0ybMbEQAcEnNNu9B1nWdC8N2rW3jr+0o9Y0qXU5tRlZ1idWfzZYCS20L1yuEA296APo2ivnHVNO+IlrYyWEN14lm0W11++iabfLJePa+XEbdgyOkrxhzLyremcgYqr40X4jvoOkxaePFT39vpQZL6FJke4nErfLJDHKFRtgUlpPMyP4Qc0AfR9rf2d3c3Vva3dvNPasEuI45AzQsRkBwDlSQQcHtVW78QaNZPeJeavp9u9n5ZuRLcohg8wgJvyfl3EgDOM54rjvhlp2o2vi3x3d6laTQJfXttLDJIm0SgWyBivqAwIrgdU0261b4VfEPTrO1mu/EreJS13BGu6VgLyJ4yB12eQEI7YB9DQB9BVnafruk6lcXFvp+qWF3PbSeVNHBcJI0T8/KwByDweD6GvF0s/HknxVuW1G88QQWZ1VhCLWJ5LSSwYYUEiURoQDksU3hhkE9K5jQfAGraX4Z+Ht7cWfiYS22rXsl/Dau3nQK7SrG4XqAQFJPo7H+KgD6WsdRstQNwLC8tro28pgm8mVX8qQYyjYPDDIyDzzVqvPPDZV/jX4wbTf+PMafZJfY+6bzMmP+BeSY8/8B9q9DoAKKKKACiiigAryr4if8l2+Ef/AHF//SVa9Vryr4if8l2+Ef8A3F//AElWgD1WiiigArM1v/U/hWnWZrf+p/Ckxx3PEvGAlTWbeaAMTHvJCjJxxz+FeWbfMuSyqPNDA5PrnnPpXqPj9xDdxPudW+baVrzCZUkv3CMwmJO7I4BHWvOxG6PYwj3Om1nVLK90lrSO0EZiJEUu/cxGec4FYcTySWLod28MAEPT65/CltbYARzSsFi3hWUDnn271dtM2uqR2he2d5TgMRlMHoTn8K5k+x0xUYx0NSxsbW8itL65Yx/ZkwtuWx5siDjnoo4yc1a02z0xJE8Q+IL22KrKJfkdmTzQeApHDYOOBnpWJe6fcXUywXUj20MLfMBhVm9NvYhvXt1rZ8NzjVNUtbQwWyaLprCWZp3/AHIIPUnsAM49W5PpW1N6XZz1I8q91lrwXbS+KfGWoX93bs0IBXZIw4Q8KGH1yTVfU4LfX/HtzKktxDovh2B4Y5LeVotqop8wgqR95mAruPGR02TTYtM0Ndj6/cKHmhOG8kZZ2z1wQpA7c1y7afZ6V4T1HSLiSeC4vEXUtSljHMNsSSIlJ/jO38z3xXVSbjq93qzlko1FZrS1rHj+h+DdZ8U+PUu7K6u0uZJC/wBrDszwqq4BLnngAKMnmr0fgXUk1YR6frV1FHpeoC1t3WZh5LTff2+m7v616b4QvJYdJ1DWpBBptnGDa6ZZRtiOMsPnllJ5kcLgbj/tYFXNVgtNP+FD3elrN9sDW2pzSzgCSRjLkOw7ZHOOwIFdFOcmrt+ZzVMNSvy8qstP6+R4zofhdvDvjSW0vFM0dheqZlJ4HIw2PQE5P0r1TxnfJ4mvdJ0HTJIZrq5y5kjIZURVOWJHrVDxdPJp/wAQPFs8Co10buEqrJkNG6ruB+oIroNLSx0GSFLCzhi1CTTJJJMnHkRfw/ix2/gCan61yqVO2/UxqZYqtaniOb4Vt3OdsrMReH9cigYP/pcVojkY3lWXcf8Ax6jUrwXuoajHekyeVM2wgAFRn6fTFS6XqENr4e0+2umCR3PnXDOE3bySRjPUHIHPtVZUgOqXfDslwI3CJjLBgM/iDXnVmtUj2oJ3uzMm+eK4EIMe5N8YJyCy8HH4E12On+IbDVNGgtzcwLcsvlNC7gOHxjbiuXnuYjqjwFUCLiNn27eq7SR+fWqWlW8Da5pszxJ9oE8YL45B3AVrhqqgmlsya9H2jjLsel+DW3WW0gHEaEZrhNZuoNJ8cWM93IIoXtShYg4GJHFdp4JlxBbxsRuO+NvwbiuM+Ikap4isC4DYkuIsEf7QYf8AoVXh5crud2LhzqUe5U17VU1bVnvIARbpEIYyRjfjkn6c1BI0wK+XGsjAhBkZ29v/AK9QTODPEmMjcOB3xWzp8N0vlkICC4DLx9459euKxryc5XOSjBUoWGxWrWdrcSygmSZBEuDglSQTj8B+tWb3UZbrQkUE7oNWi8sgdMggCqd2kt/qEMSguQ20BO7E81a+wzRW5tF/11xqEbICc8rk5yPw/OpoytIc43SXU76LxPHaX3i1ZbaJpoRCzonAkiK5UkdupBrkPCuo3Gq/FPw3qepSq04t5rqfA2hNqSED8sfnVzUooLP4jXDn501DSnEpHfajdvqlc/4bEkMHiHVVy8y6f9lhUnkNMdmQPoK1i+Wppsc7iuR2Wp6ppelW3i7wZqiyr5Vnqtut6iOM+U7A7vwBANeXfDnw/bi41rQ7+xs1vJrV1ghmJVZD821D3yGBGeuGJ7Cu+OuP4cu9FspCWtopILaUL91kaIqwP/Aj+lcr4/Evh/x6t4gU2kMsTRSJ/EoCsFY9m4z75B710yla0umxhGN+aNtd0Yi+HLK60zQNf0axkWXTbr7PewOPniCnOxz3+Ukbu+Aa3/GWmi+0jR/Feg2s1sXbDrjLRSq21cj2IK+/FdDY3UMHi/UrMIy2er2cmQg+9Kg3xsPcxsP++atMmq+HrfWrOxhEgvXkv9MWZSyyNtV3iwO5Utgf7JpVE3ouv5/0hwai7tf8MYdzPp/iTSrjxFqOhz2etaW4ivWtpAWIUZWRV/iwOecHHc4rmPENvbXoGpaW6jz9rTkqUV/WRQfXoQf1zT7nVLrRJYvEmis66fdL5F3a/wCsAI7c9cZypPPY8Utzbx3M7alpsoFioCzQA4EWRk7R/cPUA9Olc9RqS5vvOmmnCS7dP8jJvMXrw2NnDudskBDwT0GB0FVtd0650oR29yq/aBw6jnb9KmRJbG8luY3Alj5yvAwehX0qDUtQlukT7S8sjRbgm5txwa5up1pNNLoTWSBNBLM371rjG3oQMcV658OifKTmvJbSGM6PFK7M0zFmCKPugd2P+eterfDbJjj57Cuyjsjhru/Md98Uf+SSeLv+wHd/+k71zvwy8feDrP4beE7W88WeH4LmDSbSOWKXUYUeN1hQFWBbIIIIINejyW0F5pzWt5DFPbTRGOWKVAySIwwVZTwQQSCDXPf8K48D/wDQm+G//BXB/wDE13HlB/wsfwP/ANDl4b/8GkH/AMVXPvqPwefUDfvefD9r4tv+0GWzMm713Zzn3roP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaAEHxG8DgYHjLw1/4NIP/iqX/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAD/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAD/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAD/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAD/hY/gf/AKHLw3/4NIP/AIqoLzx38P76Hyb3xV4VuItwfZLqNu65ByDgt1BGan/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoAP8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Ko/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoAP8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Ko/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoAP8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Ko/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoAP8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+Ko/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoAP8AhY/gf/ocvDf/AINIP/iqrx+Ovh9FeTXcXinwol1MFWWZdQtw8gXoGbdkgds1Y/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JoAP+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKo/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JoAr2njr4fWQm+x+KfClv50hmk8rULdN7nqzYbljgZJ5qx/wsfwP/0OXhv/AMGkH/xVH/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTQAf8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUf8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAB/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VR/wrjwP/wBCb4b/APBXB/8AE0f8K48D/wDQm+G//BXB/wDE0AH/AAsfwP8A9Dl4b/8ABpB/8VXn/ifxHofiD47fCn+wdZ03U/I/tXzfsV0k3l7rUbd20nGcHGeuDXoH/CuPA/8A0Jvhv/wVwf8AxNWtL8FeFdIv4r7SvDWiWN7Fny7i2sIopEyCDhlUEZBI+hNAHQUUUUAFZutf6k/StKs/WBmH8KTHHc8K+KBWIwu38TOv44rzuW1334khkUOz5YZ6c9a9H+LMPmQWpwcefgke4NeakxvqLMM4ZcjI9B/9avPxOlmethXq15FgPNPfgTbmIbhyOoH9at65bNaSKJdrscBnAydpHGc9+RV/RZNPfTpFmTfffdhLNgLjPJ9e3FYt65vXAvZcbSAzY5IH/wBauOOjOuMk36DmkluFtYpp5JISDEmeTnp/gK6fTJIrKBLFF+z21uwmvpyAwdtv3fcgHj3A965m0hEt9K1tl9gDQqeAv1PsO5q3poutQYWemy70V/MmlIxGu08AH0HX3NbxtuZzjdWO/wBFu4JIdY1Ro5YfstqSjn/l1XYQkY9WwWY+hbFc3rN1f6lpt2GCm41y5jtyG6qsaoEUe2d2abJfmTRtR0+KYtYwolssQHNxLJICzt74U4HpWhq9/a2S2up2wS6FkHS37brpmxkgdlAY/lW/937zm5bakN/Yw3PjXSvDl0N2jaTaAXCA7RLNjJfP1GeaWz1GXxFc+N5rpxHa31obaxhbplMsoA+gJ/Gqs6yTT+Ir0Mftcp+yxgNgk4G4/rWPb3gi1Wxt7Zx5dghQkcea235m/AcUpVGnpsNUk15k+uSxap4oFzPIw/tC0tGYr/eCqrf+g1ZWYy634qvJXy0im1gxzgDgD8lzVfSQt1dx6hEBJbWPzrxj92eQMex4/Gjw9eoFvTOCryXBRAAMbjkbj6j5ulZObbbOhQUVbsU70IbfSrViQy2KmIY/iyOKzhFdWF8lxcE7GIxnI2kdq6bxDp/9iyW6XMkd2tsTCzxfwJLloye4NQajLBd6FFHKvmXUTZ3A5LjPX3x0rKcrejHBprQveMr6y1C4hu4PkuDDudVTgcLgcdec81zXiG7n0XR/Eepac6R3VtBDPbSsqts33MCkjcCM7XYZI71ak0uc2H2qMH7O7GLd2DDsfTrVsSSWsllLHObd3tVUsDt6EjHp2/lVYedpXZM6X7twgT6v4sHhrRtMvVvNI1RZLi4+0Xa6hBdiEKEIVRELbzjlgTtBKbuQ25RVTxXq9lq/iK6t5IrK2eHU57eOFpXW9jVLYS/anRiB5BCYPyDAwdxORWfLaeJLzUru5t/EN/HG0gVdkx2qMZBX0I3HkYNY/jLQPEVnpFzaTa9qMtqVTcjTsS6MxBUnOSuTnaTjJ6V6EZU29DmlQxMerE0K+i1WcyRcqiM/6Y/rXb+G7S7Fhqt+5j8iGM7ecup+6SAeo5xXD+G/D1zoGnvcSRMsLr5as/GeQcgV1MmtXR0e4sI8mJyHAAAxznB9v8a82q05abHXyVFFKSs+pUGri3upbmBEaYgqEYfKQVxir91ctbtZy8i4t1CqEwoVsDkD2HFRW2lLBplreTqfNdiyLxy/p16VBdySANBNIv2rzSRt78D9OlK6S0Ktroi1rt//AMVBY3LDkWwiYdyGDDn/AL66VvaFHZaFpv8AxMkgm8yZN8ZjId5hgxgeoUZJP4VhxpJunluTEbxGXaZFwUc85x6Dr+VVJ76d77ThPh2RxIWb17sfrVxndkzp30Rv+F5ZtYtPEttfQyXnlJJcLCpw0qGUMQp7MpXI/CotY1O01XSLfWbdpL6wm/4lt/E0fDBAdsnPKsFJw3bp0qppt8NC8SwahCW2PcAsMkhomJ3D6AmtXTNNJ1fxhoCW4MUoa5tEXAG/1A6cg/zrojLmi0c01yz5lsOvYf7S0m1t7WaX7XpkKQmbBUujqwikUj64NbOuanHruiRXlteT2eqaXaQXVwqgseFLRzRKfvFTlSOMhiD2rK2XFhb6TfSzReVPCloxhkEi4jlGDkcH0pRdC31qxexTEsAeB4mwCV5OM+hXkfT61SqkuCkrorx3Nk9sLy28uG31YMl1Ap4gmXG4hfxzj+6fasFTHbxXEMW5rhfluMjCiHPAUdwCc1e8QWsVleanFpETTWlz5c1xZONsgHIDxMeoGcfoRWReakTHp7W4E9vEojEoXaxHcN79iOlZ1N+Y6Ka6IsXHlQ2UdvKsZKPu3heZVycKT2rGvzCkReNsyP2C/c+hrpI7ePVraKysIwLgKWZc4+hye4ArEu4ltkeARKzRnd83QHFcibvc2Vk9WOs5Jf7MbcxBZfmHrzivWfhqv7lD9K8hMsrJCxGBKOcDjr0/SvafhnF/o8fFehRWkThrvST8z1uHiFP90U+kjGEUe1LXaeWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVR1QZhP0q9Va/XdEfpQNHi3xPXZpxl/wCecynn64/rXj2tb4b9Am0M21yVOAcivb/ilbeZ4dvzjlF3j8CDXi+pf62zd1EisNpI9j/9euDEHq4S17+QyzznfhgI8NhR83P1qxcEPIVDEHIwSOCR6mpJQsLGK3bMZOVLjBA9DWeswjlO0FlOAuRxmuJavQ7VrY1DCqW5Qg7ZBvdUOA3YL9Aa09HWeN7OAjbLf5jto92xdmcbiB688+1I+hXVjZ2F9dEtY3jeUCj5OSMkHsB+NTXF1FcR237uQXdq2ITnG0DoPbHX8aalYlL2nwkmoA6XprxparvRzOrJzuZtyoeOuFHH1pdStRBYaPZ2pyoj8yQ99z4yR79fzrb8SW12NQtLq4iBjkSPGxNgA2gDgdOn61yNxMwuVuJjlgrxspOeCSP61Slo0KEeZKRsXDz6dqd3NMXRZVIhVukmWBZs+v8AhWM1tFFc3MtqA26IOpHRQwy3454rs9N8LWd/b2l618EuZLB7a2jkb55ljO4cHuMt74PtXnhmlWOSWZSYlwiqewNEpO6XUzpWqN90aOi3C2iafBIzLHO5imQcEKwx+fce4q3f6e2j2/2VpDeB/wB5FcgD5mUn5sjg9Rn6VW1p4llX92VRkV1deS+Rnn9a0NKuoI08iWK3awdzJI+07mbu3XCk459aSlZGrVpXQtxrLXmn3ljciGR54Il3sBuiZOdue4649M1gaLqosdRMTp5kJfaOeg+tb3ifS7OK3t7/AEib7ZZyyk70ySvYqQfSsG4s0tWS4jiPlv8AKfNxlD9KhyTCKgl7vU7HVtajGjXEVtFE0kkSpOgAKKwIw6jv3561ztlrt/JBDa2kNn5Uc0dmzSWj3G52DP0Vl2IAQN53c5445oXiSCCSQuQJF2qM9cVQGnasiHUdFCzSpF5eDEZXjxyGjXcFJ+c/eVugrSjG+jJadJc1Lc6XSPEVpqMrxRosMsmGaJekbqdrL+YrY+IwDaMJcD95ZsAfUoyv/IGvKfA/hTWdGuor7Uopo1lkZcS/eG7kZ9zg1654uha48JruOSiSBeexiYV1cqhOyOmlUlWpqc99Sv4jvI7rQbEvGsKqEb52+9kd8dKkl0G1m0aCW3uEXbCJZ5s8MWwAg7Lj3rn9RvWuPCOlT+RMjSRKFaRMBsDkj1HHaobXUp/IhiTKRGMEqOQx9SO5rjqRd9UYPmqWlck1a6aJ4rGGVZTGCsZxgJzz+PvXRp/Z2gaSuZbS5ury1TJClpFbOSdx+7xgbRz1PpXDWNrKNT86BkYRnfl+g/CtrRdFvdeuVljH7tGbcOixgdzUqy0CUIvVuyMtWnjvYy6zzsJApWNNxXJ6k9hgHk0/XCDc+bFhE2bCAOOO2fpit24lGmx/ZdMKPNl/tBeHJ6YGwngDkknr29ax4LRHtXR5cmMeYqkg49WzTe3Mi03JvsCiS9aV3cfZYkEgyOxAG0fiOPoa2pNVEV/e3EMdw8UlgsBfcFcgMu7n0I445waxLe4a5umsoEKi4kUKq/dJ7YH1NdW2j6ho9hexavbwLG8ysHIO/wArADHJ4JLdMdhVxk7uxhNRi1GW7M7V7s3Giw21kiQ28GJLeGMbUSLcpwB7HHP1qlaidruSR28+aJxvXoXUE8fXBNKyBrW1MmQIndSQduVYcD+Va5uU03w7PKsbxXVwxtkm2jYox/FnnPHGO5pylZl8nLHRGXZyPqMd3aTyeZe2S+ZaYPzTQYxIgPcjAYd+tZBVoJpIWIkaX5k2nhj/AHvYn09a2Z4Yra80W6gmieeAEyyKcbiAfl/Ks/U1ubhfNuYjA20lDs2+YoPXn/PSk5c6XcElF26EFrc3FgkptwVkZvvHGRWXe3pzJk585uGz2z/9arNvNkrI4zz9dvYmq+o2awwJK7BVZiFXOWIHr+dZpK+paWpehjTybYFmZ3fI9AOele9fDaDFnGccHFeG2qtNqFlDtIWKMDH+fevojwLbeVZw8dq9Kh09DzMRpF+bO1HQUUV5r4i+LemaH8VdL8FTWkkj3flJLeiQBLeWXd5cZXHJbC9xw3fBrrPPPSqK5XxH8QvCfhrVF07XNds7O9ZQ5icklFJwC5AIQH1bFSar488LaTqQ0/UtdsLe9YRlYXlwzCT7m0d8+1AHTUV5Jp/xt0PWvCGsaro89hFf6e/zW2oXJiTy/OSMSM6q2FbeMcHkge9dnrfxA8K6Hrcej6rrdrBqTlB5GSzKXIC7sAhM5GN2OooA6iisvxF4g0nw3Ype69qFvYWjyrCJp22rvOcDPbofyrI0/wCInhHUfD97rlpr9i+lWTbLi4L7VjbsDkA85GPXtmgDq6K5bTPiF4T1PRL/AFez12ybTrDH2qV2KeRnpuVgCM9uOe2awPDPxZ0bxD4p1yzs57b+w9MsI75tTeQouGJ3BlYDaBjOTQB6RRXI6V8SfB2q2OoXlj4gsmt9PQSXTuxj8pD0YhgCQeACOCTitDwp4v0HxbFcSeHtRjvVtyqzBUZChYEjIYA84NAG9RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUVwMxmpabKMrQB594vsvtdhd2+P9bE8f5givBLuzf8A4R1GkiUPDIoLA9OMYI96+ktbj+b8a8IvbMr4g1uxCtiRmAHtnI/pXLWjdOx2UZ8rTbOTjUPtLM5cLtVRzkZ6GpYYJYpDLGAdx2FDz17VRQT2kkjHI8tgMDuc/wD1qvWs09lLHP5LyxuQwBU4PuD9a8vXoexqmaem62TbHS7mWX7I7b41JysbDo2O2OQapWjPEt2RIzOoK+xHY0y4zqEl3dww+WqAsFQYA55H9aLmUvpsDREtIwwcAf56U9LiS5dVpc7vWfFqjUNAuI2M9pFDtngZccljkH6DGOah8TaCskkd5ZPDsni8wRo3yAjk7PbHY9ORXBSNLGu53/dAhG5zitzTtRkD2sTlfIWQDAbOc9WGfatJK3vEqlyJcnQ2PDfiS70jTrm3aCO8eJjJAko+eBsYLL6cVS8S3Eb6X5iwIhuEG8RD5WYdG9vcVXubU6b4hvkAdwVcRl2BypyM575zWJLcSGdYpVfylUAKPT1rPd6Gns4/Gt2akkiz2FuZQruVPPIEfHp0NVbdgloXfdsZ/LcEZJBHJp9tDM9uIYYXnO/O2NSePetSe0sLMtBq17FaoxDmFD5sgGOnHQ/Wkk29BtpJIBqVs+nHTbcx+XGMRdQ2QBz+lZUjPcBmnkwwz8o53EVd1LVPDccca6NpV1PcR/8ALxNIVyfoKoQajdyy7v7OsiCckGI5P1Oafsn0IUodjOaVzlH3NGq/KPQ1buNQ1PRotITTpHS4kRpdkYyXy2ACO/3a37Z5p1C3OnW5jzkBMqR+NY+ux+d4q0o3MKxWkzxWwSSUqm0clWYdc4OB/ESFPBNdWGpy9ouZaGGKq8tJ8m51I8axeJdFOm39sLbXYMsqBSBLtG7PsflIx71NNMtz4XbYc4ZevoeP61454p1GLwr4h8N6hYWi2kpQvLavClvKMStjzIk+RcqQAR97BJ7V6Fp+rwW1nNbOxMCzxuvvCxDA/gD+lb14ckk0dGVVfrEHTe6dzPstXn1XwXY2fkuselW+Fcr98lyGwfYEVWhvmjg8nCN5gBDf3ataFex+Hnv9E1g+VAjO8blTiSJujL6gjBFNjn0lYyy2dxMpPyuWC8fSsMVBqV0rpkQmtYz3JbeT7PbhZYVeFjvB4Jcn1x0rejuPK8NjT7S6ks5pWEm6M7ATg/KxzyOawn1PRkYYt749MkuByPpWlpWmaDrAklfXfs1yT8scwwo/WuT2cnuVLktdmbdzP5CbW/dk7Mk/fPfn86dsS20W4wS+flcjgj29+fStafw5cxRrDABdxKWbzLchiwx19awrgl7ZYwCMOQ4bg4HrRZ3RSaaujoPDh06xFrq1wryCz8shUOQxBySfTHpVzxprcepx2thYPc3Fv5hnM9w2ZXdj0HoADgCuQtL99rWiZaDgjAxyD3rZ0yCe78QXE8RkRIkaZht6YBIHtmmnyu7JlSS/ePobGi6WkOlXl/rvmC0VMlF67geM56DOB9T9afqOrw33w9iEsNukgvcLGPvYGMEdxxkVzWp6zczaebaV2EG4yY3fKeec+prHM9yLc/LgHDAADofb8K0S0uS6blrJ7P8Ar7y/afvLxkuXRLTAeRh/Cuen1/xq74n8RS69cpIVQ28S+XDFFlVX3+vrWQ6l4beCLBmm5AAycg4/lmlgnt9PhuIHtvMmcgK2SNoBPb61krJaFNcz53qV0ilQskzbJehY+nvToUe8vrSCX5k3KCQOT6n3qOaWaNfnJLT8/MuOh61f8L28qG5vG4MKlQeuCR1qoJuSRM3yxcn0Nvw1ZtP4jlOxwFwoDc96+ivDFv5VonGMCvGvhdZNOrTsGYmTqevFe76bH5cCjpxXrUlbU8evK6SLlfPevfAvXdej8U6ve+IBB4n1HU1vrKOCbNoixnEAkJi8zcql1BXgZHXmvdPEOqwaDoGp6veJK9tp9rLdyrEAXKRoWIUEgZwDjJFea2nxtgvLWG6s/h/8RJ7aZFkili0UMkiMMhlYSYIIIIIrY5jN1/wB4ze98Ytpg8P3EfjCyggvnuppVaykWHynKYQ+YvJK52kHHHHPQ+CfhzP4d8by6ncTWl3YR6LZ6XAzgmbfAoBdgRgZwDwxNVf+Fyf9U4+JP/gj/wDs6P8Ahcn/AFTj4k/+CP8A+zoA5m6+F/jCf4a+LfBAbQxa39415ZXzXEoLFrmOXbIgjO3Cq3IzzgdOa6iDwp4r8P8AjrxLqPh+DQr/AE3xDPDNK9/LIktsVXaykKpEi4yVGRjp703/AIXJ/wBU4+JP/gj/APs6P+Fyf9U4+JP/AII//s6AOg+KvhO98XaZoltp8lrG1lrFrfy/aGYBo4ySwGAcsc8A4HuK4rxL8J9Z1K/8Y3tpd6bHLqGq2Oq6fHIXKM1upDJOAvAYk/d3Vq/8Lk/6px8Sf/BH/wDZ0f8AC5P+qcfEn/wR/wD2dAHOeIvhV4o8WJ4o1fVpdHsdZ1L7F9msYZHltiLdt2JmKgtu6cDgY61Nrnwu8T+L5fGFzr8+kabLrmmW1pEllNJL5MkMokG4si5U7QDj1PHru/8AC5P+qcfEn/wR/wD2dH/C5P8AqnHxJ/8ABH/9nQBykfwo8Q3tprB1jSdGubq50xbDdd67fXRn2zxSYDOMxIAjlepDbe24Hufg34U8S+GYtXPibUnuYbl4vsVrJevePaooYMDM6qSCTkLjAx6k1R/4XJ/1Tj4k/wDgj/8As6P+Fyf9U4+JP/gj/wDs6APVaK8q/wCFyf8AVOPiT/4I/wD7Oj/hcn/VOPiT/wCCP/7OgD1WivKv+Fyf9U4+JP8A4I//ALOj/hcn/VOPiT/4I/8A7OgD1WivKv8Ahcn/AFTj4k/+CP8A+zo/4XJ/1Tj4k/8Agj/+zoA9Voryr/hcn/VOPiT/AOCP/wCzo/4XJ/1Tj4k/+CP/AOzoA9Voryr/AIXJ/wBU4+JP/gj/APs6P+Fyf9U4+JP/AII//s6APVaK8q/4XJ/1Tj4k/wDgj/8As6P+Fyf9U4+JP/gj/wDs6APVaK8q/wCFyf8AVOPiT/4I/wD7Oj/hcn/VOPiT/wCCP/7OgD1WivKv+Fyf9U4+JP8A4I//ALOj/hcn/VOPiT/4I/8A7OgD1WivKv8Ahcn/AFTj4k/+CP8A+zo/4XJ/1Tj4k/8Agj/+zoA9Voryr/hcn/VOPiT/AOCP/wCzo/4XJ/1Tj4k/+CP/AOzoA9Voryr/AIXJ/wBU4+JP/gj/APs6t+H/AIu2Or+LNK8PXPhfxdo17qfm/Zn1bT1t438uMu+CXJOAOwPJGcZoA9KooooAKRulLQaAOf1uLjNePeJ44rTxeWYLuuI1kBbjJHBH6V7jqMJdOma8V+LtrJa6npV4uAjRvEWPQEEEfzNRJdjRNWszzzxnZpbX9wEdVWQ71UHP1GfrVSx1J7W1EMbBdyZXHOexx3HNXtYiS80OJmPzxOfuDJCnufbP86z/AAytkuqedftvhh+ZoicFxnoDXlTXJJo9qjPmgm9bafcX9E1WS2ju7GVYw16pCyyJlVJHB9uah0p3snurK+UYkRsqw5B7H86seLpEm1me40+IRJHhvLUcKvGP51RumlkFnqMgVxJ8uevI4IxWS97Q0bU/e72Ld8lt9k8pJNzyJ0UcE8cEetZVq5hWOJFUsCFJJ4IzU84PyNBHvDSEtuxgKcck9qnsy67kt7YXBY5Mkw+UH2Xv9TVxbtypFXaNO4h+0uommWKMjY0sr4Vcds9TSPf6VZSgWcEupyKNvz/u4sf+hH9Kfa6DeajKHuN0jH26f4V12jeBydpdMfhWkMPfc551lHqcZcahq+pRLDEsdlbjpFarsH4nqadp/hOeY5ZSSTkkjrXsul+DoowD5efwrpLPw9HEBhAPwrqjhzmliktjx3TvA7cFk/SulsfBipjK/pXqUOlxoPu4qylpGo4A/KtlRSOaWKkzzZfCyohwv6VzfivwnHd2MkMijBHGVDDPuD1Fe3NaoVPA/KsHW7FWjOFz+FN010FGs3ufIGo/C+eXV0ci3jhVuEgi2An6VvTQQR3slvBKs0UMKQF15DlRzg+nb8K674lXc9vqEel2bGF5FzJKvBC9MD685rlbGxaJYY0XGVGB/vAn+ormrTbVmfTZVho0V7XuVHk8y0FnqMZv7KMZibpNAv8AsN3H+yeKdpbJbzx2lw4ktJj/AKPcgYDex9G9RW3p+kyb8oAclsKTjKnqoPqDUJ0GS2jlU20ps5OJBnOD2YejCnGT2lsb4qjSqaw0ZcufC0jDcg3KenFZ0vheYE/Ic/SvU/hfL9stW02+w9xABtcj/WIehrvJPDULf8s1/KrdA+dniHTk4yPmtNHvrVt0Ek0bDoUYitOHUdShh8m9tINQi9J1IYf8CHNe6T+FIW/5Zj8qzbjwhGc/IPyqHhwWKi9zx0vptwziWK406Rxjp5kY/wCBD5hSQF4Yp1huEcMm3cj/ACvgHr3/ADr0658HKTlUP5VlXPgmMtuWLY/95Rgn/GsJYV9DVYlPc8klU3JhjkXblgSR0IHpW/KdPMq+WxZVdRtYcsB16dB2roNW8DajGPtOnMJ5IwcQsuOPbtXFyxXFlGwu4WjuUBDAqflJrKakrKSsdEaiqbMs2szza62qhU+y2zbiuz5SP7oHvwP1qGbVLme+m1AJ5aSHkBRgVWnV7bTbdUn2/aySR0AHbP61taJqtpZaFd2c0cU8c0gXeRuK4Byyms720Q78vS99DnL+5F1dQzyPjdk5HOOeOO30rsLb7Pp/hzcxjLyHe69+egx6YrjNPhiudRjiiQupkAUMcHrxmunvYX1PXLXTkMsbXc0cSqQOASB/KurDxvO66HJjppQUej1PZvhrpH2bRLNiMNIgkPHduf616TEu1ABVPTrFLWJI1ACoAo+gFXwMCvSSsjypO7OV+LH/ACSzxl/2Bb3/ANEPR8J/+SWeDf8AsC2X/ohKPix/ySzxl/2Bb3/0Q9Hwn/5JZ4N/7Atl/wCiEpknVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV4v8ctbuNb1G28D6Tp+qalbsFu9dGloryx2+f3cXzMoBdhzyDtHfNeY2d1deLvAXwi8K22mR6vKjXN5eafNceQrpau8Sq74baDlu3p0zQB9bUV5r8NdBf4Z+BtauPEV1a2dqbmfUjbQO8tvp0JAxEhb5mAxngDJOAO58m0b4n+KH8KeLPE1l4uGr21giRWlhcWVussYklVPtM/lINgA3EICenPSgD6jor5s1Xx/wCJ9MsvFMXh3xM+v2zTWGn6Tq0sEDK19Mw81YyiBHUKGOMNtOBn1dqPj7xnoWhfEG6h1dtVg07WbfSba/ntY0FoQCLiRgiEYBKAZDYJBwehAPpGvKviJ/yXb4R/9xf/ANJVqx8DtV1vV9P1mfV9cstZsUuVjs5be4W4aP5AXR5UiiVz8ykYXjODVf4if8l2+Ef/AHF//SVaAPVaKKKACiiigBki7hXnHxo0xZfBzXJAza3Eb59FJ2n+Yr0qsnxZpf8AbXhnVNNXbvubd403dAxHyn8DikwPmGOeSTTLiyxvPlgIABgkHdnI69OlcqQsREiMcPnjHT/JrYtbubTdSSw1G2ng1CB/KlhK/OG9h3z7UuseHtWtb8iPTriO3m+aP7QhiIB5x82MkV5uJg7qSR62AmrOm35mPme8mSKPe0n3V5xkeldFZadJd2ltbQQpMImzI5HyL7bh1+grtfhh8Mpr9H1TXIpIrZW2xQMCpn77j3Cfz+nX1WHwxbx7VSCNEXhVVcAfQClTwrn70i6+KjB8i6Hi9h4WuLhgJCzIDwgGFH4D+tdpovgxRtMifhXpFpokUX/LNR+FasNpHEBhRmu2FCMTiqYqUtjmtK8ORQqPkUfhXQW9hHEBgDiroAHQUVskkcrk3uMWNVHAp4FFFMkKKKKACq1zAJRirNMnbbDI3opP6UAfNGuldT8W6vctGZQkv2eBM44Gc89v/r1q6Z4Ylur+JTgkEGRl+6D6D2AFL4P0Y65qN7tyIGuZG3DqQWJ6/lXpMeoWOiXkunLaRxvAEzJdTrAsmVz+73feA7npniudU+d3Z9JisY6CVOnukRaV4LtxEquoIzlvc+tb8Phi0SFo2jQhhgnHUVgap8QrW3sZY7GBf7QyY4zI6vAG/wCuiEhiByUHzYB4A5rMPxVWGeKxhsJNQudpaS58xIIECqd5LEnOCOdoI5wCSOduVI8dyr1NbnU23hO3sruC5tMJJH8ufVfSupA+Uetc/D4u0mTSbO/a4AS7AMaL8zHIyM+nTqcCsjVviTolmIfs06ThpAs0hJVIEAJZjwS2AD90HkckdaZg1UqPVanbbQe1NManrXL3vjGAaO2q6X9nvLDaPLYO/mSuWKqixhCclsAE4zmsGfxtHPayC88T6fo8yopkSO0d5E3f3DJ98D+9sx36UCVKT6HoMlpG/OKrPp0ZPAqvo3iPSNStLZrPVLW5MmEBWVSzNgcYHfvjFY3inxsumajDp2mWVzfXbE+ZJFEXiiC43AsCPnGV+Uc5ZR3FAlGTdkbTaavasnWfCmnaxGy31sruRgSp8si/RhUN/wCOF0WznOuWqm6gjjLpZyCRRI5OImJwFYYJ5OMDOaq3HxJ02OzsZVtwbi4J8y2aeNXjXcyqc52nLDjnpz0FJxT0ZcY1FqjzD4gfDe70izWS1M97pkSkmVV3SQDrh1HVf9odO4ryv5g5Xcpxwp7Y9a+oYfiGbi70qG00eSZL67SzcrL81uxBLbxt4xtYgdwpJ28Zs+Kfhd4W8RyNNc2JtbonJms28pifUgcH6kVxTwa3p6HdTxbp+7WR81+H1xeecmFECF2I7t0AruPgzp39rfEGGRlDQ6fG1yxxwD91B9ctn/gNdtqPwWtINGa18O6ncW9wzbna6xIsnscAEfhXQfCbwE/gqyvnvruO71K9dTJJGpCIi52qM89yc+/tWtCjKkrM5cVXVad1sd8KKKK6jlOV+LH/ACSzxl/2Bb3/ANEPR8J/+SWeDf8AsC2X/ohKPix/ySzxl/2Bb3/0Q9Hwn/5JZ4N/7Atl/wCiEoA6qivNfj/4w1Hwb4FS50VhFf312llHOVDeRuR3LgHgnEZAzxkjr0r5JbX9ca8+2NrusG8zu8830u/P13fpQFj9AKK8n/Z08aap4u8KXseuyfaL3TbgQfaiADMhQMpbH8Q5BPfg9Sa6D4uX/iyw0PTm8DW7T30l+iXOyBJmS22OXdUd0BIIXA3DJ4yM5oA7iiuS+FPiD/hKPAmnaq1+2oSymRZJ2tBasWWRhtMQZgpXG3hiDjPetXxhdapY+F9TufD9tDdavHAzWsEzbVkkx8oJyO/bIz0yKANiivBfDnxY1DS7e+PiaXU7jVIFtRNpWoaYthLEZZliMkbqWDxZbjPPA55ONnxz8SNVi1q303w9b+Vc2fiiz0mdXdNt5HLbvKUyynywSFGRkjHHpQB7DRXj998ZpbfQ1uI9AjfVo7y8srnTvtrsyvbEBzEY4XaReR821VHcilvfjUi6cNR0/wAPzXVjbaXbatqLPdLE9vFOcBY1KnzWGCTyo4654oA9foryPxL8UtXXRvGtx4e8PeYvh8SIb6e5URl1RHB8vhz8rE49sZ54hl+KVzo1xNeeJLW5hFv4Xj1eWxt5I5Ii7XDRqVbYH3N8vVtoB6ZBJAPYqKxPC+o6zqEMx1/RYdKmXaY0ivRdB1I7kKpBB4Ixj0JrboAKKKKACiiigAooooAKKKKACiiigAooooAKQgMCCAQeCDS0UANjRY0CRqqIOAqjAFKyhlKsAVIwQehFLRQA2ONIkCRIqIOiqMAV5Z8RP+S7fCP/ALi//pKteq15V8RP+S7fCP8A7i//AKSrQB6rRRRQAUUUUAFFFFAETW0LTCZoYzKOjlRuH41IyhuoBxzyKWigAxSYpaKACiiigAooooAKKKKACiiigAqG8RpbSaNOGZGUfUipqx/E3iPTvDdmlxqkxQSNtjRRudz6AVMpKKvJ6F04SnJRgrsyvh94b/sHSUjmUeeSSa6qWNJUKSKroRghhkGvNT8YNHSYCWxvVh/vjaT+Wa9A0jUrTV9OgvtOmWa1mXcjj+R9D7VnSrU6mkHc6sXhsTSftK8Wrjn06ydIFe0gZICTEpjGEJUqcDtwSPoTUxtoSqqYYyq9AVGB9KlorY4rsqyafaSQyQvbQmKT767AA319aZ/Zlj5sb/Y4N0cLQJ8gwI2ILIB6HaOPartFA7syLrRIrnWLG7coLe03OlusYAaY8CQnuVXcAMfxE+lWrjSdOubhZ7mwtJp1G1ZJIVZgPQEj2FXaKAuzD1rRZru2ittKvBpMef3sltEu9kxjaDj5fqOeKrWfg6wh8v7VPe3pjBVVml2xgEgkeXGFQ8gHJXJPU10tFA+dpWRTg0yxgs/skVnbpbZyYhGNpPqR61MbW3Kopgi2pgqNgwuOmPSpqKCbkH2S3MiSeRF5iOXVtoyrEYLD3I4zU9FFABRRRQAUUUUAcr8WP+SWeMv+wLe/+iHo+E//ACSzwb/2BbL/ANEJR8WP+SWeMv8AsC3v/oh6PhP/AMks8G/9gWy/9EJQBoeMPDWm+LtAudH1qJpLSbByjbXjYHKup7MD/wDXyMivD2/ZoH2wlPF0gs933G08GXb6b/MC599n4V7R458S/wDCMaRHPFbfa766nW1tLffsEkrBm+ZsHaoVWYnB4U4BPFcCNf8AGxPntrOkrLnP2ddOJhH+zkybz9cj6dq5MTjqGFaVWVmyJVIw3Z3/AIF8I6V4J0CPSdEjcQhjJJLK26SaQ4y7njJOAOgAAAAAFT+KvC2i+LLGK08Q2CXtvFJ5qKzMpVsEZBUg9CR171R8A+KH8S6fdLe2os9VsJvs93Ar703bQyuh7oykEZ5HIPIqP4leOLDwFoUOoaghmkubhLW3hEix75GyfmdiFRQASWPAArpjJTipRd0y076m/o2lWOiaXbabpNrFaWNuuyKCJcKo6/zJJPcnNO1bTrPV9NuLDU7eO5s7hCksMgyrr6GqHg3XB4j8N2eqhLZBcbiFtrpbmPAcqMSKAD0z7dOoqx4n1ZNA8N6trE0TTRafaS3bRocFxGhcgH1OKoDDh+G3hCLStQ04aHbPa36qt0JWeRpQpyoLsS2FPIweD0qEfC7wYunvZJocMds1yl4UjlkX98iFFkyGyCFZu/fPXmsnwr8W9P1f7Quq6XfaS8enQasgYC5822mICMoi3NuywG3Gea2B8TvB40xdQk1pIbY3TWRM8EsTrOF3GNkZQytjnkDNAD7j4a+D7jTbCwk0K2+y2IkFuqFkKiT7+WBBbd3yTnvTrj4ceEbhNOSfQrWRLCFLeBW3ECJDlUbn51B5AbIzTm+IXhlNXtNNe/lS5u3ijgL2k6xO8qB40EpTZuKsp27s84xmtXWPEWl6RYNeXlyzQq6xkW0T3D7jnACRhmPQ9u1ADF8MaMLfWYP7PiMOsO0l+jEsJ2ZQjEgnuoA4xVGy8A+GLKMxw6RAYzYnTWWVmlDWxdpDGQxORuZjzzz6VUm+JvhGLR7LU21cNa3jypAEtpnlYx/6zMQQuNn8WVG3vipbj4jeEre6traTW4GnubeO6gSNHkMsT52uu0HIODQBqeGfDGj+GIJodDshaxzMGceYzk4GByxJwBwB0FbNed+EvirpXipfDcmmRiKPWHuIzHdu0csRijLkKAhWTgZJ3gAHqTxXQ+GfG3h/xPdyW+h3zXTohkDfZ5UjkQNtLRuyhZACQMqT1oA6OiuSsvGkVzqviZTamPRdBIhn1DcztJOFDvGkSqSQisuTnJJwAetQr8T/AAi1jLdf2pIoiuFtHgeznW481lLKggKeYSVBIwvQGgDs6K4+++JXhSxhtJLnUpF+1QtcJGtnO0ixKxUyOgQtGoYEFnAGRUr/ABE8KprcuktqyC9ieSNh5Mnl+ZGpZ4xJt2F1AOVDbh6UAdXRXGaR8UPBuryXSWOuwMba0N/I0kckSiAdZAzqAwHfBOO9c/H8YtOvL7VU0y2R7GyWyZLu8ea2E32iQoMI0JYYxkHBDZHIHNAHqdFcfF8SvCMviJNCj1hDqb3UlkIvJkC+ehIaPft2hsg8Z57ZqXRviF4X1nWY9K0zVBcXkrypEFglEcxi/wBZ5chXY4XuVJFAHV0VzXifxz4f8L3iW2u3stq7Ishk+yzPEisxVS8ioUTJUj5iOlInjvw1J4lOgJqiHVBKbfZ5b7PNC7jF5u3ZvA52bt3tQB01Feb6x8Z/B1hp0V5a376jG11FauLWFyYy7suWyB02McdeOAcjO9J8QPDUWs2ulzX00V3dPFFD5lnOsbvIodE80ps3FWB27s84xmgDqqK5/wAV+MdB8KfZxr199necO0aJDJM5VBl22orEKoIyxGB3NQv478Mrq9lpf9sW7X99HFNbRIGbzY5f9WykDBBx1zQB01FFFABXlXxE/wCS7fCP/uL/APpKteq15V8RP+S7fCP/ALi//pKtAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeGfHdi3i3S1JyqWhIHoS5/wr3OvBvjg2/wAb2aj+GyXP4u1cWYfwX8j2chX+2L0f5HmOqSlFOO1e7/s8yM3gecE5C3smPbKrXgusj5WxXt37Ntxv8KajCesd3u/NB/hXBgNKqPdz27wjXmj1yiio55Y4IZJZ5FjijUs7ucBQOpJ7CvcPiSSivE/HfxVku3k0/wAJsVhHyyX2MFv+uft/tH8PWvKptY1CwuluYNQu1uw27zBM27PvzXn1cxhCVoq59BheHq1aHPUly32T3+fY+waK5v4daxc6/wCDNM1G9XbcyoQ5xjcQxXd+OM10ld0ZKUVJdTwqtN0punLdOwUUUVRAUUUUAFFFFABRRRQAUUUUAcr8WP8AklnjL/sC3v8A6Iej4T/8ks8G/wDYFsv/AEQlHxY/5JZ4y/7At7/6Iej4T/8AJLPBv/YFsv8A0QlAEnxA8NzeJNHgSxuEt9Ssbhby0kkBMfmBWQq4HO1kd1JHI3ZHSvP/ALD4uVjC3hC4afOPNS/tvs5PruLiTH/bPPtXs1FcWKy+himpVVqiJU4z3OS+Hnhm58P2V7Pqs8U+rahMJ7jyc+VGAoVI0zyQoHUgEkk4GcCXx94RTxZaaZsvZLC/0y+j1CzuUjEmyVMgbkPDKQTkZHauoorrhCMIqMVZIpK2iOa+HnhK28FeGYtItbiW6IkknlnkUKZJHYsxCjhRk8AdB+daPinSF1/wxrGjPMYF1GzmtDKF3FBIhTdjvjOcVqVzPxN1a70H4e+ItV02QR3tnYyzwuVDBXVSQcHg1QznI/hHo9p8PpfDekSHTbue3t4bnU7eICW4MW3lxnlW2nKZxhiO9UfDnwct9FnspU1VT9m1oayI4LJII93k+V5aopwq98j/AOvXm3ibxH4g8T+FtYtxqUur6akukSxXrWAiEF006mSFdqqHVeG7kdCa6R/FHju28Qv4bGuCaZfEUenjUpdNjyYJLYycouF+VsYIx756UAdPrnwgj1Xx5H4kl1pyY9TttTSKa0SWSMwlT5SSk7ljO37o/XFbHi34YaLq+itYaJBZaAz3cV1O1nYxhLvy92I50G0Sp87fKT15+vA6j4z8b2XxNGkXOpQW1rbXtrbpBPa7V1GBgoklTbEzF2Ytja4VMYI4Jqna+LvGssWkX1/qYurDVLnVLGbTn0+MKiRJKY33AbifkHB4IPT1AOs0z4NLpFhYDSPEEtpqNnLeFLlLKPYYrnG+Pys7RjaNpGMemOK6LwT8OrLwhrSXmnXczwx6VBpSQyKM4jZm3lu5JY8YArzLTvF2tWmkeFbW81eTwppDeHYLqK4tNJWdbi6JIMO3YQoVQD5a7WOeCK9C0NE0743eILLTMLZ3ukwahexIPlS6814w/oGdF57nYCaAKHh74RR6VH4ZtrnW5b2w0Br1baFrZULQ3ETRlGYHkjcx3Y56YFdJ4B8JX/hK2h09vEE2oaPaQfZ7O1ktY42iXOQXdeXIAwOB3yCa6+igDzRfBWpTR+PPD0k89npGuztf2mp2soEsUkqqJYmXIPDJn0KuRkVhR/Aq3Sw1S3GrWZF/cW9wyf2REsKGKNk+VAw2k7t25SGznJOTn2iigDy7S/hTcaEbGbw74r1G0v4dPGm3FzcQpctNEJGkBAf7rKXIHJAUAYOM1AvwYsoNfv7601CJLe7uZrvyptPilliklDbgkx5C5Y4GMjpmvWKKAPLJ/g7YXWl6bYXmpzvb2egSaEdkQVnDFSJc5OCCgOORUEvwgnvf7Rk1bxNJd3N6LBWlFksYVbWTeoChv4uh/P2r1qigDzpPhhCvk/8AE0k/d+Kn8Uf6kcs279z16fP9726VyHw7+HniXSPG3h43aG38M+HFvksUnlieRluDwoKcn13NjsMda90ooA8q+KHwgi8e6rdXc+tPbpcWqW3lS2iXAgKsW3wliPLJzg45PrV6L4XQJ4lW+Or3LaSusv4gTTTEvF6ykFvM+9syxO3HU9a9HooA83X4XRp8NNP8Jw6vKklhe/b4L3yASJBcNOMoTggFsde34Vnaj8Hf7R8ZWviG98QPcTw6ha6j+9skaTfDtzGkmcpGxXOwcDPfFes0UAcV458DN4k1S21Ow1abStRitJrB5VhWZZIJcbl2t0IIBDDp3BpfCPgCz8L6+l/p91K0EekW+kRwSKCQkJJDlu5OeeBXaUUAFFFFABXlXxE/5Lt8I/8AuL/+kq16rXlXxE/5Lt8I/wDuL/8ApKtAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEF7dQWVrLc3cqxW8Sl3djgKB3rxXxX8W725nkh8ORrb2q5AuJFy7+4B4A/M1p/tDX9xDpmlWUbFba4lZpQDjdtxgH25zXj8CBgAK8fHYucZ+yhofXZDlVGpTWJrLmvsuh0Vr8TPFGnXkdxJqDXcanLQTKNrDuOACK+jNA1WDW9Gs9StD+5uYxIoPUeoPuDkfhXyJqELKSMV6F8NPiPF4V8LahZ3sUtzJHJ5lnGDwS33lJ/hGRn8TUYLFOEmqj0OjO8rjVgp4eCUk+itdf8A+gNRvrXTrSS6v7iK3t4xlpJGwBXzX408QQ+J/Gl5f2RZ7NFWGJiMZVe+Pc5rn/ABZ4m1TxVfC51WfeFz5cKcRxD2H9TzVSyik+yTRxNskkRgrf3SRwaMVivbe6tEGV5T9TvVm7yt8kR6jdwywGZEuWti4j+0/ZpPJ3FtoAk27TzxwcZ464q54d8Sat4dglXRr+S2Wb74TBDY6Hkda53x1q+lP4ad5RDFdw2lrFp1ukM0dzbyJgOkgPyeWOcY4PbJANVfA0sl9p4afJPvXPGMlD2mq1M8szGWPlKliIJPtbp8z0OD4peL7eQFNUMuD92WJGB/Sk8Q+NfEPiu2S31S4VLUY3QQLsRz6t61jfYkA4HNXYtNu1gMiW0hTGchTUSxErWlLR+Z631bC0JKpKMU+myKhIgiKx8H1rV+HPg+bxpr7RuWj022w11KOuD0Rfc4P05NYV1LuJXBB716l8FvHukaNY/wBg6sFs5HmLxXR+5KWPRj/CegyeMenfTDQhOolPYnMqtalh5SoK8vy8z3GytYLK0htbSNYreFBHGijhVAwBU1ICCAQcg9CKWvoj85bb1YUUUUAFFFFABRRRQAUUUUAFFFFAHNfE22nvPht4stbOGWe5n0m7jiiiQs8jtC4CqBySSQABXmvgj4nz6D4L0DSLv4d/ER7nT9Pt7SVotEJRnjjVSVJcHGQcZAr2+igDyr/hcn/VOPiT/wCCP/7Oj/hcn/VOPiT/AOCP/wCzr1WigDyr/hcn/VOPiT/4I/8A7Oj/AIXJ/wBU4+JP/gj/APs69VooA8q/4XJ/1Tj4k/8Agj/+zqpq/wAUrTWNLutO1L4ZfEeeyuo2imiOiEB0IwRkSZr2CigDya1+LsVrbRW9v8NviQkMSCNFGh/dUDAH+s9Kk/4XJ/1Tj4k/+CP/AOzr1WigDyr/AIXJ/wBU4+JP/gj/APs6P+Fyf9U4+JP/AII//s69VooA8q/4XJ/1Tj4k/wDgj/8As6z9N+JWn6be6heWfww+JEd3qEglupjorM8rAbVyTIeAOAo4HYCvZaKAPKv+Fyf9U4+JP/gj/wDs6P8Ahcn/AFTj4k/+CP8A+zr1WigDyr/hcn/VOPiT/wCCP/7Oj/hcn/VOPiT/AOCP/wCzr1WigDyr/hcn/VOPiT/4I/8A7Oj/AIXJ/wBU4+JP/gj/APs69VooA8q/4XJ/1Tj4k/8Agj/+zo/4XJ/1Tj4k/wDgj/8As69VooA8q/4XJ/1Tj4k/+CP/AOzo/wCFyf8AVOPiT/4I/wD7OvVaKAPKv+Fyf9U4+JP/AII//s6P+Fyf9U4+JP8A4I//ALOvVaKAPKv+Fyf9U4+JP/gj/wDs6P8Ahcn/AFTj4k/+CP8A+zr1WigDyr/hcn/VOPiT/wCCP/7Oj/hcn/VOPiT/AOCP/wCzr1WigDyr/hcn/VOPiT/4I/8A7Oj/AIXJ/wBU4+JP/gj/APs69VooA8q/4XJ/1Tj4k/8Agj/+zrnz4gvvG/xn+Hl9beD/ABdpNlpP9o/abjVtMaCMebbYTDAkdVxzjkjGc17rRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAef8Axu0M6t4JnuIQTc6e32lMd1HDj/vnn8K8A02UMAc9a+u7iFLiCSGZQ0cilGU9CCMEV8gT2403WNQslbettcyQhvUKxH9K8bM6dpKoj7HhrEOVOdB9NV8yzqMe5cj0rEMTKWHVT1FdE+JIh7iqgt8nkV52x9K/MpWUHmZxzg81u6Vpst1cxwwgZb17VFZWojkyByfSuj02Q6fcJOyOFAOeP5VFSUuVuO/Q48VUnToy9lrKzt6kmtfDCzvbRXvZSzY59qwpvC8WgQqLfBiY4B6EGu8/4S3S762BOo2y46h3CkfUGuA8aeKba9ngsdKfzysoaSVR8o9ga48PWxNSqoa8vW58Vl+Y4x42N7tPe6/4Ghv+BdMgvNSaW5UMkOMKfWu71doY4tkSBcdMCvHdL8SzaLM8iRGaNvvoDg/UVPq3xOSaFksLC5NwRjMwwB+VLE4SvVqPljdPr2Lz3D4qtiXaN07W7f1czvFrRrr9zHGAG2hyB6mudmXfw1PheaWWa6vG3XExyfamysB0r1adJ04qDeqPp8FGdLDQhUd2lY9y+AXjaWcN4a1efdJGubGRzyyjrHn26j2z6Cvba+HrLUbjTr+2vrNylxbSrLGw7EHNfZ3hvVY9c0Gw1OEYS6hWTb/dJHI/A5H4V7ODquUeSW6PmM4wyp1Paw2l+f8AwTTooorsPHCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiikYhQSTgDkk0AcJ8XfFjeG9AENk+3Ur0mOIjrGv8T/hnA9z7V82RZ898kks2SSeSa6Px9r7eI/Fl9e7ibdX8m3HYRrwD+PJ/GsG3TMhJ7189iqzrVG+i2P0HKMF9VoJP4nq/8vkbFou6EZqRFUgj9aitjhMVNGMsaw6HptHdeBtBhuIvtNyM5+77CtHxBbQRxTJGAVCE89jWJ4f1+GztY4ZZ44JMYG84DVkeM/F1utrNbWUq3F3MCg2chc968acKlWrypPmvv5H5tmDxNbGyjZ86lp5K+lvI5O5hsr+Jbh4IyzjOcYNUfLhtgRBGqZ9KsQRm2sIo26qvNZ9zLivfTb0vofetKKUmtRkshzS/ZbkxCURkoec1nXNyseMn5uwr0LwyI9R8KOzf6xRVSvFXMfaJuxwZfk+tRSscVn+IGuLTVGt2JReoI/irNnuprVwUkLjurHNdkMM5RUkzy62awpVHTknoa7v81fS/7Nurte+D7qwkbLWM/wAoPZHGR+oNfMaOJoklTowzXsX7M2pm38V3+nMRtu7beB6sh/wJp0fdqL7iMwj7XDSa6a/18j6Wooor0z5QKKKKACiiigAooooAKKKKACiivGtI8R+KYPjB4r0rUteF1omh2f8AaH2ZbGJGmV0LLHvHI25HPfbz1oA9lorybw38YZda1LQrY+E9RtYtetLi40qWS5hP2p4ULumA3ydMBmx1HAHNcf4G+LGr6d4PvfFnjR7q4Gpaj9h020aW2htw++QEK/BjVQuGeQ44BGepAPomivHrT46adNoE19/ZE8t3b6rDpUtrZ3UVyGaUEo8cqnY4O0jqOeKuJ8Qza+NLg6/bavpEdt4Zm1e406ZoXjjSO5ZN3y5YylVGAG24IGM80Aeq0V5do/xYea80+HXPDN7pCatYTahpcklxHKLpIo/MZSFOUbYQ2D61v/DbxtN4401dRTQL/TNPlhSWC4unjInJJBChSTgY6kDOaAOyoryLxJ8aV0TUdYjHhfUrvTtHv47C9vYp4gqM+NpVCdzEk9OB0yeasr8Y7Sy03xfceI9EvtIuvDb26z2jyxyvJ54/c4ZTtye/JAHOaAPVKK8asPj1o7adr02p2HlXOlwRXAhsb6G+W4EjhFVJIzt3b2UEHpnPNYesfETxND4j8VDXbbUNAtbLw2l8tjBPBNLHIZwvmK+0rkg4w3AweO9AH0DRXkvjb4uDwVZ6fJc6Wl5bSWMN0ZZdVt4LiQMOdkJO5yMZJAAycCm+IPjZY2OvW+l6ZpRvJZbOC9zc38FkWSVQyLGJCPMfB5APXigD1yivGbL4heJLjxX8RdNvNInXSdFEgjvbeWBXtEEDurEEkuXKgrgHbkbh1qaz+K1xb6b4estN0LVfEGpX2hrq4Zp4InKA4YyE7Vz3+UdSABQB7BRXleqfF+GDwToHiWw0qGW01WKSTbe6pBZeUUIBTMh+dic42j+HJxxWfZ/EefxP4r+Et3octxaaN4hXVDd2kiqS5giwoJ5+66sQQRn9KAPZKK43x943bwrqWg6dbaNdavf6zJNFbQ28scZ3RoG5LkAA5654wevSuatPjHDe6Dp0tp4fvZdfvtSm0qPSPORWE8QzJmU/KFUY59+lAHq9FeUv8Y4F07yv+Efvz4o/tT+x/wCxRLGW+0bd2fNzt8vH8f6Y5rmtJ+L17oR8X3Xi6GQTx61Fp1hpr3EKrAzx7tjTcIEGCS7Hj9KAPe6K8WPx+0lPDdzfyaYft0Gox6a0Ed9DJb73Usr/AGlTs8varc9iMY716T4G8Qv4o0CPUntI7Uu7IEiu47pGA/iWWMlWB/8A14oA6CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4z4u60dE8D3rxPtubnFtF65bqf++d1dnXhn7ROoGTU9G01G4jje4ce5IUfyNc+KnyUpNHdltFVsTCL23+7U8jUY47CrduORmqwxVqDGRXzp+j09jQt+Ksxjk1FbombVZrm2ge7m+z2yTShWuJPl+RB3PzL7fMPUVoWdlc3Fs1xb21xJCh+aRIyVH1OMVpySsnYxlXp3ceZXW5Vu4IriExzoGU9jWWmnWts26GMBvU81ryEYqlMeDSu1oLlTd7GZfue1c/qNwIInkY9Olbd8etcf4mZvJTH3Q2TXVh4KUkjzswrOlTlJdCpJNKYzNkDPOD3r0/4YXyXehSRj/WF9hQetePTT5hA9K9P+CyPBfWzY63ETYJwPvDv2r0MTQhyKx87l+Mqyqvmd1Y1vGPhC7u7PzbnT7qHYeJWiZQPxIrgP+ESuFfJDuufUV3OoxxeGPDeoiz2vbxWUzzalNo7WVxBKSCkBd8+YXZghA5C8g4Bqt4Ivm1PSlll5c1DpyoK0XoaRr0sZK9SPvGUmiRraKgbZKB26VqfC+eTRfiVock3yBrjyWPYhwV/rWvd2YJyvBqGTRNVjEV9Hp13thYTJN5LbQQcg5x7Vze8ndHqc0JQ5HpdWPrKiuV8BeLV8T6Sk01rNaXSgB1dCI3PqjHhhx9RXVAg9K9eMlJXR8fUhKnJxlugoooqiAooooAKKKKACiiigArzy1+FVhb+L9V8RHX/EM13qcTwXUUk8JieNkZQmBEDhA3y88FRnPfqfG+qz6D4L1/V7NInudP0+4u4llBKF442YBgCDjIGcEV5p4e1X40a9oGmavZp8O0ttQtYruJZReh1SRAwDAEjOCM4JoA67Sfhpo+mT+DJbe51Bm8KRXEVlvkQiQTJsbzcIMkDpt28+tUm+EmgnwRaeGVudSWCzvW1C1vBKguIJyzNuVgu3jcRgr0/Os7/i9/8A1Tb/AMnqP+L3/wDVNv8AyeoA0f8AhVlpc2UUGsa/reovHf2+oq8jQoFeDdsUKsYUKdx3cZOByK2NY8BaPrPii91zUftMs15oz6FNblwIWt2kLk4xuD5OM7unbPNct/xe/wD6pt/5PUf8Xv8A+qbf+T1AF3RfhLp1hd2s99rWt6t9hspbDTkvJYyLKKRNjbNqDLbfly2eK7Dwh4ftfCvhnTtD0+SeS0sYhFG87AuRnuQAM89gK4L/AIvf/wBU2/8AJ6j/AIvf/wBU2/8AJ6gDW1X4VaHqdp4jt7i61JU12+i1C5KSICkkZUqEyhwvyjIOT71NrHww0DWLnxfNqDXkv/CTi1F2nmKBEbddsbRYXKnoTknkenFYf/F7/wDqm3/k9R/xe/8A6pt/5PUAWpPhHZX2j6jpuu+Idd1S3u4FgUTPCnk7XV1ddkYzIGUfM2eMjuaST4P6bef2tJrGva9qV3qmmjS7i4nli3eUHDgqBGAGyMc5+mearf8AF7/+qbf+T1H/ABe//qm3/k9QBZ1z4O6Rqt/eXA1fWrNL7Tk027it5IsTxImxclo2IOOu3APp1zF4k+DWleIYrW0v9Z1htKgggt/sTGFl2xKqjazRloydoLbCMnPTNR/8Xv8A+qbf+T1H/F7/APqm3/k9QBrTfDGxPiTW9TtdX1a0t9agMF/YRPGYZf3DQhvmQsCA2Rz1A7cVY0X4aaPpGoaTeW1zqDS6bo50SESSIQ0JOdzYQZf3GB7Vg/8AF7/+qbf+T1H/ABe//qm3/k9QBZg+DukWcHhhNM1fWrKbQIpYLe4jkiMjxyMWZWzGVzk8EAH9CLvhv4VaH4f/AOEO+xXWpP8A8It9s+xebIh8z7VnzPMwgzjJxt2475rJ/wCL3/8AVNv/ACeo/wCL3/8AVNv/ACeoA7XX/CljrfiHw9rN3LcpdaJLLLbrEyhHMibDvBBJGOmCK5ib4R6N9hEVnqOrWl7Hqs2sW99FKnnW88v3wvybShHG0g/WqP8Axe//AKpt/wCT1H/F7/8Aqm3/AJPUAWH+DujtpSxLqmrrrA1L+1v7Z81DdG5xtJ+7t24427cUSfBrQ5rDUIbnU9anvLy/j1P7fJNH58Vyi7Q6EIAOCcggjn6VX/4vf/1Tb/yeo/4vf/1Tb/yeoAvy/DBptKuLSfxd4gklmlSR5G+z7CFDDYYvK8sqd2TkZyAc8V0Pw/8AB2neBvD/APZOkvPJE0z3EkkxXc8j/eOFAUDgYAAAxXH/APF7/wDqm3/k9R/xe/8A6pt/5PUAeq0V5V/xe/8A6pt/5PUf8Xv/AOqbf+T1AHqtFeVf8Xv/AOqbf+T1H/F7/wDqm3/k9QB6rRXlX/F7/wDqm3/k9R/xe/8A6pt/5PUAeq0V5V/xe/8A6pt/5PUf8Xv/AOqbf+T1AHqtFeVf8Xv/AOqbf+T1VdP8V/EXSPiV4T8PeNIvCTWWu/a9r6StyZE8iEvyZCAMkr2PGenFAHr9FFFABRRRQAUUUUAFFFFABRRRQAUUVHPKkEMk0zBI41LMx6ADkmgDM8QeJNJ8PRxPrF6lsJSQgIJJx1OBzj3r5n+I2uxeIvHGoX1pL5tn8sUDjoyqoGR7E5NXvGetvr2t6jqkjbrdQywKf4Yxwo/qfrXB6cf3SfSvFxGJdZNLZM+wyvL44aSm37zWvkaA61ZhqstTxZ4rzz6aGxF4y0x7wCSTUtOs7aCwSDT2mxK32p2E7zAq4aBlaOOLewPA6EEmjxLfx6pqGp6iNQ0a31KZNPayvU1SPGiSRhTcqibtzgtv/wBUrht3NWLiwjvowkwBWmr4W06UDfCv5V6dLHKMUmtj5nGZJKdSU4y311MzRfFI17xDqslrGyWD3UrW4IxiMuSo/LFdBOTzTbHRLTTgfsyBfpTpxzXFWnGUrxVkevgqc6dJRqO7My6XOaxL62jmdY5RlJAVNdFcJ8ucViagGwNgywbgetVSnZ3M8VBSTTMeHwwROCp3oDwWPSu60CFLOJYkOTnLH1NZFnIfuuCr9CD2rWtGCsP0rtlUdRas8enQhQl7qsN8T+HF8QtF9qkdxHwgZiQo9B6VfstNudD8L6udDjeTUobN2tVSISt5gx91CDk4z2NW7eYcZrYtEEgDEke4NEZu6Ir0ocsmtGzMvbXxNa6r4gjiu9RvYdPudN+yRtptvi7SVgtyp2QgsqeiFdhPPIBrmL3T428XxajfLYWC3uvQzWN6ySi7ugIocpEwXy/KYuAXZto3McNxW3qvgC21K7E3muCN20BiNueuPrVWL4YWi7FYllQYUNzgeg/Ou1VY2ueFOlLa5l2Fprj+Njqthp2oWpv5pNNSRcCWCzKpHZyyQA+ZEqywb2ZlAOfcZ9Y/Z9+LK+KYBpOvypHrC8RsSAtxj07bvbv2ry7xR4MsYQ00srI+CrHcdzdiK4qG3stKkBt5jEytuVgcFSOhGOlL2yteJpTwrm7S2PvmivCvgx8YP7Xurbw94kmWS9kPl2t6OPNOOFf/AGvQ9+/PJ91reE1NXRy1qMqUuWQUUUVRkFFFFABRRRQByvxY/wCSWeMv+wLe/wDoh6PhP/ySzwb/ANgWy/8ARCUfFj/klnjL/sC3v/oh6PhP/wAks8G/9gWy/wDRCUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHLeK/Hmg+F7+Gw1Ke5k1CWIzra2lrLcyiMHG8rGp2rnjJxW1oGr2Wv6Pa6ppUrTWVyu+J2jaMkZx91gCOQeorx74q6Fr+q+K7y+8O+Gdfs9ehgW20/XNM1WCKK4TAbbcRs3CK5bjBJAHsBh+LPDHxEn1vxXMND/tXUtQ8OWujW+owXMMMXzBTdHazKRly5AwOnuKAPbrzxXpdp4ttvDk8rjU57Vr0Db8ixBtu5m7ZbgeprbkljjZFkdVLnChiBuPoK+Z/FHwu1u71LW7D/hFGv4TpdloehXslxCIbVI0HmzyfPvXDZYAKSefXneTwLqsXjTUo/EvhOTxZEY7W30nVJ7uMRWsUUYBypYOjbhuJUEsc/WgD3lZommaJZEMqjLIGGQPcVX1nUYNI0y4v7pZ3hgXcywQtK55xwigkn2Ar528I+BvGreO9L8Wan4eSzvbO1vrudIo7O3E95IHCRgxuZHBLA7pWI+gJzat/g3fW/w88L6UulF9Y1C/t38SXD3QbZbCUzSLgvtOG2DCA5K5560AfQsFzHNbQTZKLOqsiyDY3IyBg8g+1P8AOi84xeYnm4zs3Ddj1xXzqvwt1/U/EthrWqaMItQuvFzatdXP2mMva2MQ/dRcOc7v9nJ4GcYqLQfAvjPVviP4e8SeIPD0eny219dXuoPbJaRAsAfJVJFYzShjgEucDPTHJAPd/DvifTvEN7rNtpjSu+k3ZsrlmTC+aBkqp74yM1t15n8KtD1zwj8MLyTUNLNx4ovJ7rUrmxjuI1MtxI52r5m7aMqE+bPFeUaR8LfEtv4S8W3dp4SOieK72NI4Ps15AsS25lUyQQbXbaSinLucnOBjmgD6gjkSUExurgEqdpzg+lKrqxYKysVOGAPQ+9fN+q/DTX9Q0/xMnhzw4fD+la9Jp9gumCaFHit4mDTXMgVyu7jGAWYgknk07Vfhd4ltfD3xATw3ph09NT1i3EOnwXMam5sIQQShJKqX3EkPgnBBHOCAfRsMscyB4ZEkQ9GU5H515b8RP+S7fCP/ALi//pKtWfgf4Sfwzp+s3EtlqOntqFyr/Zbz7MmAqAb1jtgI4wckYHJ25NVviJ/yXb4R/wDcX/8ASVaAPVaKKKACiiigAooooAKKKKACiiigArzj486+2i+B3ggJFxqEotlx12kEt+gx+Nej14J+0XMb/XtG05WG21iadhnuzAfyWufEz5KbZ25dS9piIrtr9x5rrU6W/h9Yx/rZhn6Af/XrE004gjDdcVJ4reSS38+AhrYEQj2AqK2I8tcHoK8Zx5YH2NGd6hpqRip4W5qlE2QKsxHkVznrQZpQt0FX7djxWVETWlbnGKVwmWZh8tUZVHTvWkx3R89TVSRM5wKe5gpWM25HyHNUrKzmutShENu8yI437VyAPrXRWOmSajOIIxjI+Zv7orvbPSbfTdOSG1RlZR8xHf61nUqckbnJiKsYtLqeY3misLl0HDjkN61nh3hlMU42uPXvXpV1aslwXAwcYYsOgrA1bR5b1ZI5I41P/LObpiqoYq1kznmlU1MS3mBxzW7p9yR8pNcfKLnTb1rS+TZMvIOeGHqDWzp9wWAORmvTUk1dHBUTeh2trPzj14q/eX9vpGmSXl2wwo+UHua5/TZVeZEY8niuI+N2uMJbbS7dyF2lnwe2aqLcpKCOB01G8pHIeMvFt1rOoTGNyELHp0A9BXLiN3bdIxOe5qW1iBPI4qy4GcAcV2WUFZGMb1XdiWby2Fxb3ds7JPBIsiMDyGBBBr9BtKuhfaZZ3ajAnhSUD/eUH+tfAdpaSX13aWVuu6a4mSJF9SxAA/Wvv+wtks7G3tYv9XBGsS/RRgfyqqDbuZ4+KiopE9FFFdB5oUUUUAFFFFAHK/Fj/klnjL/sC3v/AKIej4T/APJLPBv/AGBbL/0QlHxY/wCSWeMv+wLe/wDoh6PhP/ySzwb/ANgWy/8ARCUAdSzBVLMQFAySegFcqfiN4PEpT/hI9N2hthlEwMQb0Mn3Afxqj8WvLbSdHh1BtuhzanFFqhJwhgKSbVf/AGGm8lWzwQSDwTWvHDClusMccawBdgjVQFC+mOmK0hT5jCrX9m0rHQQyJNEksLrJE6hldTkMD0IPcU6uB+FSwwy+JbbST/xIINQ22YXmNH8tTMkX+wJCeBwGLgdMCH48Ppdv8P7q71S0ur24ibbYW9tcTRNLcsCqD90ykjkkj0BqGrOxtF3Vz0SiuT+FPhy68K+ANH0nUrmW61CKLfcyyyFz5rkswBPUAnaPYVZ+IodvA2trFqFzpjtauovLaJpZIMjG8KvzHHtzjpSGdHRXyt4W8Qaz4Z0LXbnRNPtZPsCWXna1pS3UsFxGZlEgeKYHMoQszMo45z2xqeOPGF14ku4rk38sGjad4xsDZXhsypghNpKzSbWXLAMScsCOnUUAfStFfP1t458WSaZoh1bWLrTNDub2/jPiMaYpkngjI+zM0ZjKR+ZluSnO3jB5qtcfEjxOvj7Q7Sw1S6n0+XUNOs54buxSD7RFNHHvnSPyS6gli2WlGCdu04oA+iqK+fpta8Uap4KsNY1m7tr1JPEkNpFZSaan7lUvCnmbjnJ2gYOBjr15q1H4u8aR69DqEmqNLpn/AAmc+gNpgsI8NbDeVk8zG7ICgDoD3zQB7vRXypceO/E/iPSPFmnX11cXemXXh29nWC4t0Wa3lRgoVgkKBTgn5N0h6HdX0v4UBHhfRwQQRZwgg/7goA1KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryr4if8l2+Ef8A3F//AElWvVa8q+In/JdvhH/3F/8A0lWgD1WiiigAooooAKKKKACiiigAooooAhvLiO0tZriY7YokMjH0AGTXyZrOpz634ma/unJaacn6LnAH0A4r6E+MN+1h4CvyjbWmKw59mPP6V812SZnALYPQH3rx8xq+8odtT6bIqHuSq99PuIfE0CW9pdwICYyQwJ7EVi2r/IhzwQK1Nd85rNXckrIck+/cVhQNiCMdxkVhC7hqeo3y1LmzA+TVuM461l278A1fgbzJYo/77AVzyjZnp06itc1beN5EDDhfU1p2luzglZckdttMYBFVVwVA6CrUERERZZPm9O1c7ld6Dc20TQW00sbkso2+gzVaSG4QkjYR2yCM1pwyyQW+E2l5ByRzgVHL5jIrN64Gaj2rRldtkuhlreYLcsCjHJZOMV2kc1rjEUpdu/PNZml6fAbZYZ2Bz8zOeKubLP7TFHatH5SjG5WBBrOpzWu+p51aUZy06FyeOCRmdoy6lcE5xisxNPhu2lRWIUjirWuRCC3WLfgsv+TXM2Oq3enAxy4MJYknHWs4qztIilCUo3gyv4m0K2vI/s07OJohhJc8rXD3EF9olz5N+hCZ+WUD5WFeiM51WSWRDh+oNR3hiKW9tfbJgw2srDgiu2hWcF72xUodOpz2h3oe8TB6DNeU+Prt7zxdqDuc7H8sfQV6ldafHpOoxXFizPZmTYQxyYye2fSvJfGcTQeLNURxg+ezDPoeR/OvVwk1Obt2PLxkOWCfmVbTkVaCjOar2eMAe1WwsksiQwRtLNIwRI0GWZjwAB3Ndc5X0MsPTtqejfs+eHW1/wCItvdvGWstKH2mRu2//lmPru5/4Ca+v64P4NeDB4M8GwW9wgXVLrFxeHrhyOEz6KOPrn1rvK6aUeWJ5eMre1qNrZBRRRWhyhRRRQAUUUUAcr8WP+SWeMv+wLe/+iHo+E//ACSzwb/2BbL/ANEJR8WP+SWeMv8AsC3v/oh680+HvwN+HWr+AfDWpah4e869vNMtrieT7bcrvkeJWY4EgAySeAAKAPcbmCG6t5YLmKOaCVSkkcihldTwQQeCD6VyX/CtvDG0xra3q2x/5dE1O6W2x6eSJPL2+23Fc3/wz58MP+hZ/wDJ+6/+OUf8M+fDD/oWf/J+6/8AjlAmrnp1jaW1hZw2ljbxW1rCoSOGFAiIo6AAcAVPXlX/AAz58MP+hZ/8n7r/AOOUf8M+fDD/AKFn/wAn7r/45QM9Voryr/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygD1WivKv8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKAPVaK8q/4Z8+GH/Qs/wDk/df/AByj/hnz4Yf9Cz/5P3X/AMcoA9Voryr/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xygD1WivKv+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAPVaK8q/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA9Voryr/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygD1WivKv8Ahnz4Yf8AQs/+T91/8co/4Z8+GH/Qs/8Ak/df/HKAPVaK8q/4Z8+GH/Qs/wDk/df/AByj/hnz4Yf9Cz/5P3X/AMcoA9Voryr/AIZ8+GH/AELP/k/df/HKP+GfPhh/0LP/AJP3X/xygD1WivKv+GfPhh/0LP8A5P3X/wAco/4Z8+GH/Qs/+T91/wDHKAPVaK8q/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA9Voryr/hnz4Yf9Cz/AOT91/8AHKP+GfPhh/0LP/k/df8AxygD1WvKviJ/yXb4R/8AcX/9JVo/4Z8+GH/Qs/8Ak/df/HK5W6+H3hjwJ8dvhh/wimmfYPtv9qef/pEsu/Za/L99mxje3THWgD3+iiigAooooAKKKKACiiigAooooA87+OwB8CNzz9pjwPXrXz7p/E0YxyZBz6V7d+0Jd+VomlW2eJrhmI9lX/Fq8Rs8BVI6q2TXz+YSvWfoj7LJY2wiv1b/AMiPW45Es72FuCrB1B+vOK46GX5ZQf4XNd14iUPCJCcBlJye/FebRTFbmZP7wyK0wvv02aYqXJOL7mzBOAMk11/h3Spyq3kqfKR8o9PeuL8OxNfazbwYG3O5gfQV61YI6q/ncJ0UDpXLjJKD5e5vh5uUeYrLDzyufTFSQxFp1RzjcegqzI0aklMNiq4ujK2RDjB6iuFHWrs0LVfL81tuWQ4Ioup1nXbs2LnoO1UdQvH2howQ0g+Ye4qvDcs3yshzjk1DWlhqm37zOojVXtg0x3xKMgE8H61SOqxfbUeeP5V7INvFVorm4jseHUoTjBqlK/ysWAqWRGlq7m1dawskoYuXXbtAJyQPSomtDcs4DfKeRn0rk7FpJL4oodx1wvauzsGP7jeCDwHDcGtFC2hNan7Je6WLC2ays3CkMzEY45xWbdpFMwS4fa4JwfT61pXrTyvNJGSIlbAI9BWU0lrLA2R+/GdxwTWiVtzkTbdytdPBbK9vIuUnGCff1rz74maLLObfVLZS8scYhuVA5OPuuPXI6/SvQ5Gt72NbeddzMPlf0NZupwTaf5S7g69VUjcDW+HrOElKJnWoqqnCR4vYmQuqRxs8jHCqBkk+wr6e+Bfwmk0eWHxH4oiH9o4DWlo3PkZ/jb/b9B2+vTrfhJaeG9R0uPU7HR7O31aA+XO4TLh8feBPIyK9Ir6ClBTSqM+cxOIlTvQjpbcKKKK6jzQooooAKKKKACiiigDlfix/ySzxl/2Bb3/0Q9Hwn/5JZ4N/7Atl/wCiEo+LH/JLPGX/AGBb3/0Q9Hwn/wCSWeDf+wLZf+iEoA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/iR4k/wCEQ8Ca5ryrG0tlbNJEsmdrSH5UDYIOCxUHBrpK5r4heD7Lx14al0PVLq9trOWRJHa0ZFdtjbgDuVhjIB6dhQBSvfGZ8P8Ag/Qb7xHbvLrWpiCBLCwj+aa6kUExxh24AOeWbAA5NZen/FzRrh7eG7sNSsbp9Vk0eeKdYsWs6JvO9g5XZtB+ZSelS3/wyjvbOxW48UeIp9R0+9F9Z6hcSwySwOF27QPK2FCOSCp579qraj8G/Deo+GrfRrufU2RdSbVbi6E6ie8ndWWQyttwQwbBCheAMYoAbpnxp8L6hZ2dzDHqSRXMl0pMkCqYYrdBJJO/zcR7WXB5J3AYzxVLRPjv4Y1U6kVgvIo7PTZNVDeZBKZIUOCMRyMY5DkYR9p5GcVuQfCnwzFqvii+aK5lbxDAba5iaQBIY2UKyxAAFN21SeT91cYxis2H4P2R8KX3h2+8R6/dadcwR2qhngV4YkdWCgiLknYAS2eOBigDrfBXiqLxZpP9o2+lavp1uQrRjUbcRNKrKGDKATkc4z69M1x9t8a9DaTWxf6N4g0yLRYvMvpruCLZExICxEpK37xiwAXr9K9D1LTEu9Dn0yC4udPjkgMCzWbBJYVxjKEggEDoccV57Y/BbRbTwdqPhk6zr1xpl4UkAmmi3QSK4fzEKxjLFgMlt2cUASXPxi0nTbLX5de0fWdKudGgguZrOdImlkjmYLGU2yFc5IBUkEfgcIPjPoMFl4luNWsNV0s6FLBDPDdxxrJI8wJjVAHIycHOSMDkkDOJrj4R6Rfx3L6zqeq6hf3d5bXl5eSvEr3Hkf6uEqqBVi9VUAk96k1T4SaDqWm69az3Wpedq2qDV2uxKolgnX7gjIXAVRkAMCcE89CADR+G/wAQtM8eR6n/AGdDLBNp0qxTo0sUy5YZUpJE7IwwD0PBFc78RP8Aku3wj/7i/wD6SrXc+EfD7eHrCWCXU73U5pZPMee6Eat0ACgRqqgDHpnJPNcN8RP+S7fCP/uL/wDpKtAHqtFFFABRRRQAUUUUAFFFFABRRRQB8/8A7Qepef4nsNOA4trfzCfdz/gorzm1P7pwOtdp8eECfEdXbo1nGf1YVxqKFtyqk7m7181jH++l6n3mXRSwlO3YXUGSbT1iYgMpJyTwRXDazo11bX63IjJgyCxHZa7Wewa4jC52jPzc84qS6tTLbRW2/JXIGTnI96eHreyehWIoKtG0jOsLKOLU4LvSLeRgikSKDnK468+9dxp94b+BFiUqxO1xjoa5zSYjoWoIsG4wXKZXdzgjhl/rXU+GlihMhcjcSWUVy4hc8hU/di9Ca/sILdlXJLlcnnmqsckSZ2LkKMnPUmpdXadrSa8tggfIBD9l9vesC1/tWSIiKJGJG4+aQA30K8/pSjC2uxsp+7rdl/bLcOGVeOuKuhN21CgQgckdzWJaJ4nt7eS5tIYxJJy3nkYAxwqrnqP5jv1rVsW1eK3cX9mJ5CMxuCqBj3yBkgfnVToWV7olYnmduVov/ZxEilsfMM49R71n3KRNG6rnHpTLy91q4ttsOmxxOxWFZC5OCe5UgED3P5Vn3cmoRWm67tmtZwQkaLIjecx4HOOpPp0HNZ+w6pr7wjiF1v8AcaPh6JoZZpBE0hYYUdMc9a1Li6aOUglCxGDtJIFckZNXtojFdWtxdgpgmC62ITnuABgY9M9qt2t61vbpJdW32VFAH72ZSFH1ySaVSnK1lqHtYzk3JW+//hjrre7cWEO6MhlzvPUNVDULZkSS7sSWtpRllHVfrXO3mt6jfTRRaZKEtsbiyB2l9PuqMgd8Yzx2zSzXuu6WpaygllglKrmZF8wDncxTOOeMZro9g3GzaOSNVKT5V/wS/bXTCALGihlycleTUN7HJNATG/PUc/dNVZp9YneJ7a1jTKYlIZSC2eTj+H071BbjVJrtjdGOKHbvKqoyCei8e/6UewtHVmvtVz3Udzd+Hvii88G63NPcWslxYXahbhE+8CM4Zc9+Tx719CeGvEel+JLM3Gk3IlC4EiEbXjPoynkfyr5tsr/yWaLUlzg4RlHBqSy1y68N6kup6O4M6tl06CZO6MK6sPjnQtGS938jhxuVxxN5x0l+DPqaisnwtrlp4j0K01OwbMM65Knqjd1PuDWtXvppq6Pk5RcW4vdBRRRTEFFFFABRRRQByvxY/wCSWeMv+wLe/wDoh6PhP/ySzwb/ANgWy/8ARCUfFj/klnjL/sC3v/oh6PhP/wAks8G/9gWy/wDRCUAaHi7xHaeF9GbUL1JZSXWGGCEAyTyt91FBIGTzySAACSQAa8+HxD8Vs3nDQtGWLOfszX0hfHp5gjwD/wABI9+9dV8UPD99r2iWb6QI5NR027W+hgkbas5Ebxsm49CUlbBPG7GeM15j9rvg5hfw54jF0Dt8kaXMwz6eaB5X478e9Ukuonc9f8FeKLXxXpT3VvDNbXEEpgurWcDfBKACVOOCCCCGHBBBpPGfi7TfCNpZTamtzLJe3KWdrb20e+SaVs4VRkDsepArI+Ffh3UNHs9Sv9ajS3v9TnWU2qsG+zxqgVEZhwzcEkjI5wCcZMfxe8FXfjbSdMtbSazaK0vVuZrK9DeRdqARsYp8y4zkEVIzovB3iXTvF3h621nR2laznLACVCjqysVZWB6EEEVd1vU7fRdF1DVb4sLSxt5LmYquSERSzYHc4BrnvhV4Wu/Bngmy0S/vxezQM5DIGCRqzFhGm4liq5wCTmtXxrpMuveDte0e2kSOfULCe0jeTO1WkjZQTjnGTQBheG/if4Y11Lllu5dOFvax3z/2nEbUG3k+5MGfAKHIGc9x61v2/ifQLmxjvrfXNLlspHMaXEd3G0bMBkqGBwSAM49K84tvhFJpngF7LR9SKeKprC0s5dQupXmQJCUJijzzHGSpxtGRkHqBjL0P4M38DWq6rNpdzar4h/tia3d5bhWj8jyyhMoJdt3OWPP6UAetL4p8PtqsWmLrulNqUqq0doLyMzOGG5SEzkgggjjkHNSReItEm1G60+LWNNe/tVL3Fst0hlhUdS65yoHvXlniD4Va7qXj601ZNR0/+y7TV7PULeLdLEYYYdgMIiT92ThcByCcADIFZth8Eb+zup4pZtK1C0UXwt5ruW68wrco4KPGrher/MwOSBkAHkAHrsPi/wANT6dc38HiLR5LC2YLPcpexGOInoGYNhSfepLrxR4ftLOG8u9c0qC0nQyxTy3capIgIBZWJwRyOR615JpXwh8RWmmwmbWbG4uLLU7a/srK53z26rFG6GN5SA5B35GQdm3jOSazp/ht4i0nXfDVppkGnX0v2XVXuJ7mB/sNu9w6tsUDJAAJ2jvg9M0Aer3PxD8OWfiaXRb/AFCCzkW0hvFurmeOO3lWVmVFRy3zMdpOMdOhNa8/iTQ7fWI9Jn1rTItVkxssnuo1mbPTCE7jntxXkrfBKVdK1GxN1YXfmeGotFtZrmIlo50ZmMnQ7VywxgkjHtSa78JfEmp+IbC6fV7GSztbmwuIlZ5ozF5AQOoRfkcttJDuCw6cUAeuJ4j0STVm0pNZ01tURtrWYukMwOM4KZ3Zxz0qOLxV4emF8Yte0mQWAJuyt5Gfs4BwfM5+T8cV4RongzXj8QNP0mPTbhNHsNX1G9l1Z7VoJGWZJFBMhOHOWAUrnIwTtxitLSPgrr+k6Vd2tjqelw3yac2n2mpBp3kZPNRwrRMSkYIQ5K7iCcrgigD1S/8AH2gW9vo1xZ3sWqW2q6nHpUM2nSxzoszqzDcwbAACnOMnkcVf8SeJLTQZ9Ktpobm6vNTuRa21tbKrSMcFmY7iAEVQSxzwPcgV5XoXwh1mxubeee9sBt8SWmtsizzzYSKF0ZN8mWZiWByTj6cCu18dWV5D418F+ILaznvLWwlubS6jgQu8SXCKBMFHJCtGAccgMTQBoeH/AB7oOt6tqOlxXkdtqVnfzaf9lupY0lneNVZmiTcSyYYc4B4PAqTW/HPh/StP1q4/tK1vZtHge4u7OznjkuI1Uc5TcCD9cVwEPws1h/Fctxc3WkJpTeJz4kEsaO13kABIckBQpxzyeprBtfgVqlppt5p63unXCizvLW0vpprjzcThvvR5KDkjJGc46Z5oA9qi8T6K0mmwzanZ215qMSTW1pcXCJPIrDI2oTk+nGatx6xpssiRx6jZvJJK0CKs6ktIv3kAzyw7jqK8l1n4RanfX14sWoaeLLU1037XNJExubVrMKMW7dMPt74xk9c1B4o+Dmr33iTXdU0fWLa0Elx/aOkRvu/0a8kMPnyPgchlhIGM48w0AeyQalYz6cdQgvbaSwCs/wBpSVWjwucncDjAwc/SslvG/hRdPW/bxPoYsWkMIuDfxeWXAyV3bsbsc461gar8Okuvg0ngW0uxa7LKG3FwEyrPGysSwyMh2U5Hoxrn/EvgDxZr9rZiSbw5YBJpPtNrYLPbpcRtEqKzSpiTKlT8owCCATxQB6edd0kS28R1SwElwqPChuEzIrnahUZ5DHgEdT0rKsvHOgS6NaajqGpWWlJcxmVYr68gRgu4pklXZSMjGQxHbrxXFfD/AOFMug69oWoa0dMvxpegxaYn7suyTpcPKJU3LwMMADwcisfw/wDBa8s9NtLXVJtKvPs/hi60VdyM4W4lnaRZRuXgANjPWgD1y78T6BZ39tY3euaXBe3IVoLeW7jWSUN90qpOWB7Y61HpPiS01HxBq+i+Tc22oab5bPHOqjzYnB2SxkMdyEhh2IIIIFeO+Ivg14m1TTNPsBrOnvb22madaIHkmjEMlvt3kKnEobaSDIDtzwBwR6Jo9leX3xc1nXHtJrXT7TTYtJhklQobp/MaV3UHkouVUHoSWxmgDuaKKKACvKviJ/yXb4R/9xf/ANJVr1WvKviJ/wAl2+Ef/cX/APSVaAPVaKKKACiiigAooooAKKKKACiiigD59/aNiW38TaXdNgCS0KZPfa//ANkK8vsroAuSRtA4Br7B1XRNL1doW1XT7S8MOTH58Svtz1xkewqFPDOgoPk0XTF+lqn+FeZXwDqzc07XPocJncKFCNKUG7eZ8lrdLEgO/BJz1pi3O+5QFuB3Br65PhzRDjOj6acf9Oyf4U5fD+jKcrpGnA+otk/wrJZbNfaN3xBTf/Lt/efKzXUbi3UshIlBB7jIINb2mI8UW5ioy3B9a+ixoGjhgw0nTwQcg/ZkyD+VWBplgBgWVsB6eUv+FL+ym2m5GTz2Oyh+J8zahfwlrmFXBxgHB4zS6BL5zFNwIQZ4POK+kv7D0nn/AIlljz1/0dP8KdFo2mREmLTrNCf7sKj+lEsqcvtfgUs+go2UH954uhb7SsB2mFVDcdSCKW3jWObymwrnld/Tb617WNOsgci0t8+vlilOn2Z/5dYP+/Yo/suX834GLzpfyfieNi2QJIuVPmvuU+oH9KyGSBr2NZPLeRGJQvg7T049OK98+wWmR/osHAwPkHSqMcekTX8lqtrbNcRDJHlDj9Pesp5ZyuK50m9F59e/ZMIZwtfcbPBb1oZJBG20MM9Kyb+KJiC6xuoPG7Bwa+mTo+mlsmwtSfXyl/wpf7K0/G37Da49PJX/AAqllVS9+ct53C1uT8T5vsL+OBSrOoRuOD0q8s6zQFkZQyd/WvoH+x9N/wCgdZ/9+F/wpw0uwHSxtR/2yX/Cq/sudmub8DN5xFu6h+P/AAD5082B/lMkcUx+7lsZPp/9aoLgoseJIuR12tgn8K+kJNI02UASafZuM5+aFTz+VObStPb71jan6xL/AIVX9mT/AJ/wKWdRX2PxPlbUXhZTjIU8e4rJmXy49/mN5R6F+BX1zNoOkTDEul2Lj/agU/0plx4c0W5thb3GkafLAOkb26FR+BFS8rm95L7jRZ7BbQf3nhXwE8UHT/E0uhzSIbXUMvHz92VR/UDH1Ar6KrDs/CPh2yu47qz0PTYLiI5SSO3VWU+oIFblelhqUqUOSTuePjsRDEVfaQVr7hRRRXQcYUUUUAFFFFAHK/Fj/klnjL/sC3v/AKIej4T/APJLPBv/AGBbL/0QlHxY/wCSWeMv+wLe/wDoh6PhP/ySzwb/ANgWy/8ARCUAdFqF9a6bYz3uoXEVtaQIZJZpnCoijqSTwBXDj4teGy+5I9Ye1zj7UumzeXj1xt3Ee4XFR/HG2nm8L6fcJFJNYWWox3V9Gilj5KpIAxUdQkjRufQIT2rgEv7N7L7Yt3bm0xu84SDZj13dK561Z02kkdFGiqibbPd9I1Oy1jToL/S7qK7s513RzRNuVh/j2I7HipL++tNOtWudQuoLW3X70s8gRB9SeK85+BcEv9na5fxRvFpN/eiazBG0S4jVXmUdlZhwe+0t3yX/ABy0SbU9M0G9tIrq5udM1JbmO0i0430cx2PxJEHTj0bcME44zkbxd1cwkrOx6RBLHPDHNBIksTqGR0YMrA9CCOopZpEhieWZ1jiRSzOxwFA6knsK4X4G+H9T8MfDHSNM1xBFfp5sjwBtwgDyM6xg5PQMOnQ5FbHxKtLi/wDhz4qs7KF57q40q7iiijGWkdoWCqB3JJApiNuxv7O/Rnsbq3uUU4ZoZA4B9Dg0X1/Z6eIDf3dvbCeZbeEzSBPMlY4VFyeWPYDk188aV8O/Fnh34c3uu6T/AKL4jn0fTbaLTtKhNvKBE8bytLk/POVDqeB3HOa0NYTxV4o8TveS6Pr0OlJ4p0O7s7a9iwYIEQ+c4UEhVDctg8Z5weKAPoCivnm30Lxxfa9ZNd6n4vt7a91DV4LsRXLokVsqs1sV4+TLAAMOSDgHFRajH8Q5/DWgter4pNx/wjzJANPkaOVdWDkK11gglNgT7+V+9nk0AfRdFfP3ibTPiDNJ4q1Fb3xEmo6fJpD6db2MrLbTsUhF1iMDDoD5hI6Dmi/bx43xWNxaW3iG209dUlgeLfPNbSWpjbZKCZPKAJxhVjBU9Wz1APoGoL27trCzmu764htrWFS8s0zhERR1LMeAPc14Dqcvi3wb8HNG8Y3mr63PrlnNbzahp+o3BCyozGIw7MDkl0POT8uetdvrOha4P2fdQ0i/lvNV8QzaPIJt5Mksk7qWKD1wW2j2AoA9CstU0++uZ7eyvrW4ngWN5Y4Zldo1cEoWAOQGAJBPUDirlfPPiH/hMNLt9eYPqtlpAGgxM8L+VL9nEbLdLbscYkztB2nNZel6t4l17wteLo0nia708+J7qCO8S6nlntbZYI/LVhHKjyDcWH+sADZ3UAfTVFfOBsfiJqvhPR0vbnxTa3sPhi+ll+zyPDJJfJIfIRyOSxAHHVh9TVm4sfiVbaT4hj0651+4lubLTLotcOTIsjZN2lvkqEYD+BSuO2DigD6GppkQSKhdQ7AkKTyfwrwHRNM8Z3i6Bp8+peLV02bWJ/tM7pLbTQ2xt8qhd3eQoH4DOc5Jwehqp4a8P+J18WeANU8RJ4oufsb31jLPvZnRRc5gabvsZfvMfvKoz0oA+i6KKKACiiigAooooAKKKKACiiigAryr4if8l2+Ef/cX/wDSVa9Vryr4if8AJdvhH/3F/wD0lWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAoPHWivHfjBrd0ni3TNOtpnSCCEXDqrEBnZiBnHXAX9axr1lRhzs68FhJYur7KLsewO6oMuyqMZ5OK4Gb4v+CYtVNi2sKWD+WZlicxBs4+/jGPfp715xe67eeKfDWp2VxdpAbcyRxyM5DMrDG335rwdLdrdpbSdQHQ4+tduDhTxC5mzOvh5UKjpy3R93a9evY6TPdQbS8a7hnoR3/SuJ+Ivji50f4c6vqWmlE1SAJGmRkIXZVD474DZHvXmHhL4gT6t4Sj0CUMdWghMKuzYE0YGFIJI5A4P51T+I1zcf8ACFpPcA5u7NbKYA5AlinjYfpvrgq89DG0YyfuzvF+q1T+aTX3DjBSpy7rX5FL4VfE3xRB400my1bVbjUbDULlYJUuMMVL8BlPUYJHHSvoXw38/iLUZD1+b/0PH9K+SvAxVPGnhdnxgalBnP8A10FfWvhc513UyPU/+htTzuioY3CW/vP/AMlYU3enP5fmdVRRRW5zhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvxY/5JZ4y/wCwLe/+iHrmfhl4+8HWfw28J2t54s8PwXMGk2kcsUuowo8brCgKsC2QQQQQa9Lu7aC8tJrW8hintpkaOWKVAySIRgqwPBBBIINc1/wrjwP/ANCb4b/8FcH/AMTQAf8ACx/A/wD0OXhv/wAGkH/xVc++o/B59QN+958P2vi2/wC0GWzMm713Zzn3roP+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaAEHxG8DgYHjLw1/4NIP/AIql/wCFj+B/+hy8N/8Ag0g/+Ko/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgA/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Ko/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgA/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Ko/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgA/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Ko/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgA/4WP4H/AOhy8N/+DSD/AOKo/wCFj+B/+hy8N/8Ag0g/+Ko/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgCve+Ovh9fRLHe+KfClxGriQJNqFu4DA5BALdR2NWP+Fj+B/+hy8N/wDg0g/+Ko/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoArah45+Huo2r22oeKPCd1bPjdFPqFvIjYORkFsdadZePPh/Y20dtZeKvCttbxjCRQ6jboij0ADYFT/8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0AH/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVR/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQAf8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVH/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNAB/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFUf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0AH/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVR/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQAf8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVH/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNAB/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFUf8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0AH/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVR/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQAf8LH8D/8AQ5eG/wDwaQf/ABVef+J/Eeh+IPjt8Kf7B1nTdT8j+1fN+xXSTeXutRt3bScZwcZ64Negf8K48D/9Cb4b/wDBXB/8TVrS/BXhXSL+K+0rw1oljexZ8u4trCKKRMgg4ZVBGQSPoTQB0FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXy94s1eTVvGGr6gx+T7QYYsdBGnyr+eM/jX0N421P+x/Cmp3qnEiQlY8f32+Vf1Ir5i2CG3Kk5IBb615GaVPhpr1PquGsPf2lZryX5v8AQy2ukFjdwuuW80FWzgg4Oa57UrYTW32iEsZozznuKvTOPKuzIPlMvHPcCpNDs5LiKQKx2nmvcwK5aETw8xk3iqj8znra5lilhubZzHPEwZGHYiux1/xhaaz8P/7Mm3x6qL9Zymz5CuDnae3PY1zGr6XJYTNLF8yHlh6VXiMc6ZGM+ldNbD08U4SnvBqS9V/w5zwno7dRySSwNFNAxWWB1kQjsQcj+VfX/wANdTj1u3XVoVKJe26zbG6qSxyPzzXyGEwhxXa3HiTVvDfg/wADa1oVy0NzbNd2kg6o67wwRx3GBXPm9L2lXCy680l98JP9AhpGa8l+Z9gUVx3ww8d2Hj3w+L6zHk3cJEd1bMcmJ8dvVT2P9Qa7GsmnF2ZiFFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK4v4va7rnhrwVc6r4ct4Jprdg1wZRu8uHDbmVdy7mztGM9yecYKbtqNK7sdpRXzd4c/aB1C0aW18S6fHdzLClwjwKIHWPkP5mWK7gdnQj73Tjn1XwD8TdI8X2pKD7JeJtL27SB/lbO1lYcMpwcH2NTGpGWzKlTlHdGV8cb8iy0zTEb/AFshuJADztQcZ+pP/jteJahLgsNwAxtGa7r4i6gdS8ZavLuDwWqrbR4P90fN/wCPFvyrzuOS1uLO6kucGck7cn7vPYV4GKvWrt9F+n9M+4wc1l+CgrXctfv1/JowyokDRuMh5HIz+Fd14P8ADglsiwU/MOMGuGjnU3ph271QZOPevXfBVlY3CxbZMOFzsOQa+ow+tCLPj8RK9acu7MXVvClpb2zS3M7k9dhbg1zUnhGDVNA1K/0ONlvbGQMYlORKhxkAevcV6J43s9Mh0uViQZVB43E/oKzvg7ciSDVWjjZEieHkrjJ3f/WrizPETw9FVabtaUF8nJJr53Jw65pu/Zni9tPvzu4I4INdPp6jVfh5r+msSZdNlj1S3AHO37kg+mDn8KvfHTw+nh34lXX2VBHa6ggvI1HRSxIYf99A/nVL4ayxp4zsILjm2vVks5l7MsiEYP44r08x97AyrR3p2mv+3dWvmrr5kU3edn10+/8A4JT+Efi9/BXjizvC5GnXLC2vF7eWx+99VOD+Y719uIyuishBVhkEdxX58ahZtbX1xZyA74ZmhIPqrEf0rpbrXNdia0aTVb4PDGqxkTsNgAwAOeOKnHThzRlHqr/I8/E4pUGotXbPuSivLPhn4u1rWvh/qNzDCNR1qzgLW8UjhPPfaSqlj0yR14+ory3Rf2g/EOmX83/CUWlpcWvmSRlIoxEyMoONrB2UpuwMnJ5znArkbsbe0jZPufUtFeVfDz40aR4tu2s7izl027EZlQPIskcihgp2twcgkZBA6969ShlSaMPGQVPQinuWpKSuh9FFFAwooooAKKKKACiiigAooooAKKK8i0r44aXeeJvFmh3GnS2t5on2vyC8wK3xtt3mKpx8rYUHHPBPpQB67RXlfiv4xW3h34baL4tk0HUrpNUgSZYYBmODdt4lmxhPvYGR8xGAOuPUpHWONnchUUFiT2AoAdRXIaD8SvBuv6xBpWjeIbC81CdDJHDE5JYAEnHGMgAnHXAzin6b8RfCOp+IP7EsNfsp9T3tGsKsfnZfvKrY2sR6AmgDrKK8y8UfGDQdO13R9H0S6tdV1G71q30m5ijkYfZxISGcNtKsVIAKg9+cV0UvxD8JReJR4fk16zGrGUW/kbjjzT/yz3Y2h+23Oc8YzQB1dFcta/EHwrd+Jf7AtdbtpdW8xofITcQZFBLIGxtLDByM54NdTQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXGfFXwhP4y8Ox2VrqkunSwzCcMqM6SYUjayqyk9cg54IBrs6KTV9Bp21PiDxJ4B13RtRkihsDqEK2cloohj8uNclSMgvnHByQc1T8Baf4kg8SSXskf2a1tYgHWNSqKiA4A6njnv3r7imsbaYMJIUOevFcL8S7LTtD8E6k8ECJLdbYFwMEljz+maylGNKLmuiOiip4ipGjfdpfeeL6YJZbR5Lh90kj+Y7HqSfmJP4sa4vWLa9tZJmtkV4i3ytnpk+ld/wDJBpocnAYE8/nXJ6hN5sQUo6K5BVmHDV4EG+dH32KhSlT5Ju1tjntLjeG5kZ2DykjcfWvfPAG6Q2o+ztGpj5c4INeDWjKdQkznO7Ax9a92s9ZvvDvhH+19O0hdYa1j8ya2F0lsUhVHZ5NzA7sbQNoGTu9q+v2prQ/PW7SkWvHCfZbK7WG0eRiD8xUAfma5r4RebJYasXVF8y7giUKc87hn+dVvEHjz+2tDgutQhg0Se8jE8dqbtLp2geNHjkO0DZuD/dYZ4z3rpfhTaC31PQNJgXcDbSavduR1LELGP1b/AL5rx81ftY0sOt5Ti/lB8z/JL5mlDTmn2X5nP/tWQhfEfhqbHL28yE/RlP8A7NXlmiym01bTLlfvRXMbj8GFevftYIPtnhWTuRcr/wCi68fiAQ2rHoJEP6ivpqEVPCyi+qa/Mwi7STE+JEX2P4ha/gdL15Mf73zf1rR8P+F9f8aRC70jTZJrJJfKllVhw2ATwTnoRSfGSLb8RNaIHDmGQfjCn9c17L+yTID4N1mLul/k/jGv+FePhoRrZfh60t+SH5IwxWEp1ajlLdNna+HfAKWXw8u9Ca4ls7u/hKzT27fNEcYAU+368184+NvhFrmjXapbXi6jIJhMsgtmQFhxlsuxPHGARj8q+za+OviJ4o17VfEl9dSX91BHFcyRRwxSFEiCnAAA7+p71E5KNrmOJqwoqKktzmrTwL4ws9VsJIofLEZYZjV8kMQSCSTnkCvsrwNHcReHbVLzPnBRnP0rx74IfEOfU7waN4iKXL8CC4YDd6YJ719AKoUYUAD2qltobUZRlBOGwtFFFM1CiiigAooooAKKKKACiiigArwjXfghda14W8WW091ZQ63d+IbzWtJu4nf9ykwQeXIdoI3BSGAyB8p5xivZ/EOqwaDoGp6vdpK9tp9rLdyrEAXZI0LEKCQM4BxkivNbT42wXlrDdWfw/wDiJPbTIskUsWihkkRhkMrCTBBBBBFAGd41+G3ivVvgtoXgbS5dDEkNtDFfXFxPKoDRFCvlbYzuBIbO4DtXq9lHqlz4e8vWUsotUkidZVtJGeEMcgbWZQxGMdR6159/wuT/AKpx8Sf/AAR//Z0f8Lk/6px8Sf8AwR//AGdAGb4c+FOr6dp/wyt7i507f4aa8N68Mj5cTBgvlEoMnkZzt/GqXh74X+KrW18HeHdQk0VNA8MaqNTiv7d5PtN1tZ2RDGVAXJc7vmP4453/APhcn/VOPiT/AOCP/wCzo/4XJ/1Tj4k/+CP/AOzoA5fR/hX4vstJ8LeHWfQTo/h/xHFrC3vnSi4uolkdyGXy8b8ORycHAGQBkwp8Hdfs9XurZFstT0iXVjqcMtzrF3CISX3Ze2QbHcdmBGeM+3Xf8Lk/6px8Sf8AwR//AGdH/C5P+qcfEn/wR/8A2dAGL4T+GvirR/iJDqVvcWuk6Gt3Lc3VraajNPBd7s4K28iYjbJyTuOO1e315V/wuT/qnHxJ/wDBH/8AZ0f8Lk/6px8Sf/BH/wDZ0Aeq0V5V/wALk/6px8Sf/BH/APZ0f8Lk/wCqcfEn/wAEf/2dAHqtFeVf8Lk/6px8Sf8AwR//AGdH/C5P+qcfEn/wR/8A2dAHqtFeVf8AC5P+qcfEn/wR/wD2dH/C5P8AqnHxJ/8ABH/9nQB6rRXlX/C5P+qcfEn/AMEf/wBnR/wuT/qnHxJ/8Ef/ANnQB6rRXlX/AAuT/qnHxJ/8Ef8A9nR/wuT/AKpx8Sf/AAR//Z0Aeq0V5V/wuT/qnHxJ/wDBH/8AZ0f8Lk/6px8Sf/BH/wDZ0Aeq0V5V/wALk/6px8Sf/BH/APZ0f8Lk/wCqcfEn/wAEf/2dAHqtFeVf8Lk/6px8Sf8AwR//AGdH/C5P+qcfEn/wR/8A2dAHqtFeVf8AC5P+qcfEn/wR/wD2dH/C5P8AqnHxJ/8ABH/9nQB6rRXlX/C5P+qcfEn/AMEf/wBnR/wuT/qnHxJ/8Ef/ANnQB6rRXlX/AAuT/qnHxJ/8Ef8A9nR/wuT/AKpx8Sf/AAR//Z0Aeq0V5V/wuT/qnHxJ/wDBH/8AZ1b8P/F2x1fxZpXh658L+LtGvdT837M+raetvG/lxl3wS5JwB2B5IzjNAHpVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeR/Hu8J/sWwQ/eaSZl/JVP8A481euV4B8TL86n8RbmIj91p8aQL7kjcT+bY/CuLHz5aLXfQ9rIKXPjFJ7RTf6fmzmNZ+TTREeMpgVzWqX4u7G1i+UPEMEY7iuk1vBjjBzzXLaxp80W+6tV3ocsynsfUV41PWo4H0+Y0HOkqq6XuZ+nx7b6RgDtO0nFe56Tax6v4fmsGWSOO6s5bV5QMFVkQoSO2Rk14T4cFzObm5l2qAygL+de/+AmmFlG0mQpxtC19bThJUYqe58JOUZTlKOzPHPEXgpX8faXZKs8ttHBa2IcjG5YYUjye2SI8nHrXqnwmuri4+KOsSsoWyWJ7GDnnERX9OGP410niyY2clxfmAbrKyluF3fxPt+UVy3wE0+eHVVmu1DP5L/NuOQzYJryqa9tjqkulOKXzlq/wUfvG/dpJdyn+1Vhr3wqvcC5OP+/deM3LEW4I7YNew/tRNnX/Di9hbzH/x5a8dm5iUe4r6zA6UEYnZfFaz06LxbZ3GqMxm1aNI4Ua7js4U8qBGdpJ3Vgud6gLt5PcZGey+D+s6f4BnvNPvbW5t7e/099YNxLcxzKvk/fiUoAGIiZZdwPKnopBFc/8AFzxBHaat/Zk0k0NuLSGWRY7O3uknyvAeOZSMjbwQeNx4NcH4Kth4000aIunajHoukELZtBOv2hN3mmZGfaBtlEnzYHGxQARkH5fKp1XltDm25UaV/wCLL1Pf5PjPey2+lpp/hVJb+502PVbqO41WO3gtYpWIhUzMvzOwAO3auNw54OPKPiNpdxqev3V94btzcxXu24ubOAiZ7eZlBdcrkNgkjKkjIPtWjb6TrWqaje399b3NhdlXicwWsF3DNCZ2mRGhmXaGQttVwchQBjHB5e78c6poXim4OjWCWbxFFlecCR3YKBlsBV3NjccADLHAAreai17xwYuFOULz6HR/Brwbr0viy3uLnTLqzghdXd54mTABz3719X14/wDCL4sy+KbptN1yCCG9AHlyQghX9iCeDXsFUti8MoKn7mwUUUUzcKKKKACiiigAooooAKKKKAOV+LH/ACSzxl/2Bb3/ANEPR8J/+SWeDf8AsC2X/ohKPix/ySzxl/2Bb3/0Q9Hwn/5JZ4N/7Atl/wCiEoA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigApjyxxsiu6KznCgnBb6etfOPiHWfEMXjn4neOPD9xpEVpoNqujhr+GSRm2KHdIyjKA3mkdcjkcVz9veS+FND0yy2wCPwx4Rl1aVpIEZ49QvGwihyCynMg6EZxQB9WWlzBeQLPaTxTwtnEkThlODg4IqWvkK68Ya34U8N6Z4Y8I6hd6fqmkR2Vi1s8tuqS3c58yRhC0TySLlyM7kUYyM559j8O654i8QfELxbcf8JHHY+E/Dt1FavB9jiIndI91xmQ8oA3Xk8dMY5APVXuIUnjgeWNZpASkZYBmA64HfGadDLHMgeGRJEPRlOR+deLXGszQ+EvF3xWvQ0U0ti9voMcqj9xa5xE+D/FLIVc57bB2rgdT8TeJ/DXhrVtP0bWBo9t4a0KxNzBZ2FuBJqV04cgDZ8o+c5C46E4zmgD6qor501nU9Yb4zO9zrM51Xw74aF1DpsaRj7ddmPfLFGpUlldVOSvzDPBFY3hj4o+Kv7B1fxFd+JtNvIYtEluZbJZo5XgumIWHEawJ5QDuqlWZ88nJ60AfT91cwWkYkup4oYyQu6Rwoyegye9S186+J4vE13N8OdD8U6s+uX99crrlzbJaRweUtrB5jRHZ97c7YyccjgDpVfwv8TteuLnQtabxANTjlsr/UNf0yOGIQaZDEjGJchd6OSMfMxLemKAPo22uYLoObaeKYI5jcxuG2sOoOOhHpUtfI3w68X6j4P0vSr6y12XVtPbT73V/ENlawRSCzkkP7k7wMiVnK5Vm4CnjFa2k/FDxPZ2njzUG1p7zT9L0eF4DLLb3ZjvbhgIWDxRIuBk5TDDjqaAPqOiuO8OSat4Z8G3Gp+PvES3skVutzPM1okC2wEY3LtT73OT79AB0rw3Rvif4ofwp4s8TWXi4avbWCJFaWFxZW6yxiSVU+0z+Ug2ADcQgJ6c9KAPqOivmzVfH/AIn0yy8UxeHfEz6/bNNYafpOrSwQMrX0zDzVjKIEdQoY4w204GfV2o+PvGehaF8QbqHV21WDTtZt9Jtr+e1jQWhAIuJGCIRgEoBkNgkHB6EA+ka8q+In/JdvhH/3F/8A0lWrHwO1XW9X0/WZ9X1yy1mxS5WOzlt7hbho/kBdHlSKJXPzKRheM4NV/iJ/yXb4R/8AcX/9JVoA9VooooAKKKKACiiigAooooAKKKKACiiigAPA56V8tyXn9o65reor924u3kT/AHdxI/pX0f4rumsvDGr3SHDw2krqfQhCRXzVpUHk6cFPXaCfqa8vMZfDE+q4bp6VKnov1/yI9SZ3niiRS7YGFH51k6lqTRQXVtPAYnVGAIbPOKteIbuSyvo5oyRt+XPpxXI67eNJbzMDmWTge2TXDhafNUTW9zuzLF1aalTWiS+/Qn0AubO5dHAUOoII619F/DiSU6HbkGMnFfN/hmKZrW6dG/dqVDD3r6G+GjyRaAsoWMhRnJOK+tnsfEx2Dx7NeT2l/Cwia4u5orOIA4AXO45/AGuQvrrXvCN9a6nZ3Fukcb7XhTkOG7N6jitfxbcXV5q+m2tvtEkW68nZugZuEH4AN+YrkvF6XssCtc3odFcfuVXjoec18/gG5YWrif8An5KUl6L3Y/gkz0aMU8VTpNaKyf6kfxr8UWfiy48O3lmGjljglSeFhzG25eM9x6GuDiTzJ7WPrvlRfzYUa5lZbU+zD+VXPD8Ym1/SIyMhruIf+PCvp8DXcsvdR7pS/C5njcPGhi3Sjtp+Je+NL+Z4/v4+MQQQRf8AkMN/7NXpH7JVtA2j+I2aNS4uoxk+mw15N8TJWn8feIXc8i6KfgqhR+gFdX8BvHum+BrfV49YhumS9miZGhUNtChgSckeorgwcVSyrDwf8kfyRwYitGEpSm7XZ9UrZ24ziJOevFfLP7QHhyfRPF1xfeSRp+oESRSKONwUBlPoe/0NfT2h6zYa7p8d7pdwk9vIMhl7fUdqm1PTrPVLR7XUbaG6tn+9HKgZT+BrKUVJHNiKKxEEk/M+Pfg/Bc3fjSyFopJ81BkdvmBJ/IGvsysTQvCuiaDK8uj6bb2sjjBZF5x6D0rbppWVi6FL2UOUKKKKZsFFFFABRRRQAUUUUAFFFFAHK/Fj/klnjL/sC3v/AKIej4T/APJLPBv/AGBbL/0QlHxY/wCSWeMv+wLe/wDoh6PhP/ySzwb/ANgWy/8ARCUAdVXPyeNfCseoGwk8S6It8G2fZ2v4hJu9Nu7Oayfiq5Om6NZTzPBpd/qcdrqDoxX9yY5CELDoHlWKM+ocjvVqPSdOj03+zksLRbDbs+zCFRHj024xivBzbPI5bUjTcHJtX3t+jNadLnV7nWA5GR0org/hYUt5vEemafIZdF0++ENmM7lgJjVpIUP91GPA/h3Ff4cCv8fr5dO+FmtXA1u40e4WJvIlt5VjaaTY22LJBPzf7OG44Ir2aFZV6UaqVlJJ/eZtWdj0Sivmfxj4ht9S0jwHcalrNz/wjT6Bc77m3unRX1FIFCq7ocmQMDtBP3s9TmvbfhTNqlx8NvDcuvmY6o9jEZzNnzCdvBbPO7GM55z1rUR1dFFfKXw313xfcaP8IX1K+R9Ku9VuUWZbyZ7m4w8uVnBG0qCCB8x4A6UAfVtFfMfgbxJcRR+FdaKNC0fhDUrnyrOEuAyXHBWMn5jx0JH1FO0j4u+KptG8QNFqdheyW76Y1pctEj7RcS7HVxHtUkDsOhyMmgD6aoqlo0N9b6bBFq15FfXyg+bcRQeQrnJxhNzbcDA6npV2gAooooAKKKKAGhEDs4VQ7YDMBycdM1U1vSrPW9KudN1SHz7G5Ty5ot7LvXuCVIOD3HccVdooAbFGkUaRxIqRoAqqowFA6AD0p1FFADDFGZRKY0MgGA+OQPTNEcUcRcxxohc7mKqBuPqafRQAU1I0jLGNFUsdzbRjJ9TTqKAGeVH842J8/wB/j73GOfWnKoVQqgBQMADoBS0UAFIQGBBAIPBBpaKAGxosaBI1VEHAVRgClZQylWAKkYIPQilooAbHGkSBIkVEHRVGAK8s+In/ACXb4R/9xf8A9JVr1WvKviJ/yXb4R/8AcX/9JVoA9VooooAKKKKACiiigAooooAKKKKACiiigDlfilcfZfAGtP3aHyv++2C/1rwqFQIh9QPyr2X42OV+Ht6B/FLCv/kRf8K8ciAFlbljz1ryMwf7xLyPsuHo2wrl3l+iMLVQlzLKky7lI6VkeJLG1sNC3W8eJHZQWJyehNa5hS71KSKWQoFXIwcZrnfElzLJprW8nzCOTcH77cY5rly2MlWi29GzpzjFUnRqUlH3krXIfCiymxvmjcAbkDKT1617f4JuJRptraRFAkuTISfuqOprwnwiUAuZZnxGoAIB5Jr1i3drDwmvzmG81oeRbBhykP8AG/4gn8xXt5tWlDD+ypfxKj5Y+r3f/bqu/kfGYaKbu9kTXz3dwl1qCRqhumLRsWA/djhOp9AK4NpJ5riU3FwHZf4Ac112p7Y4lgi1IBEjCjEftXFW9uqao4SfzW2ktW9SjGjhHShtGNl6JHRgnfGU2+skZviNdsVof9ph+lX/AAWBJ4r0IN0+1x/+hVF4sgKadaSn/ntt/MH/AAo8GNjxXon/AF9x/wA6eBl/wk1bfyz/ACZ15xH/AG//AMBKHjhjJ408Qse+ozj8A5FVNSjhiWJYscL+fvVrxuMeMfEQx01Cf/0M10HwusfCb6Nqer+M7i6DWtzHFbRQHLPlST8uOenXpTdFywlCaeihH8kfLZhh3Unz81kj2T9nG1urfQrszoyxfIFz3bkn9CK9irjPh14p8K6xpy2fhi5UCEc28gKyD3IPX6jNdnUHVS5VBKLugooooNAooooAKKKKACiiigAooooAKKKKAOV+LH/JLPGX/YFvf/RD0fCf/klng3/sC2X/AKISj4sf8ks8Zf8AYFvf/RD0fCf/AJJZ4N/7Atl/6ISgDotQsbXUrGey1C3iubSdDHLDMgZHU9QQeCK5Rfh1pSL5Meoa+ll/z6rqs+wD+6Du3hfYNio/i34nvfDPhy2Ok7F1HULtbKCaRdywko8jPt7kLG2B0zjPGa8Ua71lpjO/iXxCbrOfMGpSquf+uQPl/hsx7Vx4qrQi1GrG/wArnnYzNaOBkoVL3fY+l9J02y0fToLDS7WK1s4F2xxRLtVR/jnknuTmrdef/B7xTqHiHStQtdadZtQ0ydYWuUUL56MgZHKjgNyQQOOMjGcDU+Kut6v4b8B6vrGgQ2Ut3ZQPOReMwVUVSSQFB3N0wpIB9RXVGSkk1sd1OpGrBTjs9TrKK8p+IPjnxFoXwq0PxNpUGmPNcx2jXjXBf5DL5Y/doOvLHqwwPWvVqosKKZOJGhkWF1jlKkI7LuCnHBIyM/TIrxfwt8Ttdt9AvdR8QxQavM3iMeHbO20+AWzGQMV3lnkI+YleONuOpzwAe10V4y3xd1q71bQ7LTvC+y4m1i60fULWe4RmSSGIPiNwwXowOSCOCPQ1ej+M9lL4kutPg0W+lsYLi4tPtiMD+8hViSUA+VCVKhieuMgUAesUV5DH8S9U1W+8B3cGm3Gj6PrVy+/7S0UpuIRbNIGXaSVAYDrgn0qnq3xkmufCeoXdjpdxpc11o91qejXUzpKJlh4JdB9xuQcHIx37UAe1UV5Ra/FiW10u/TWtI+zarZWVneIk15GiXUc7BAwccK2ckpgnsuTxTNL+MyalY2LWnhrUJtSutTn0n7Ek0asJoohKSGk2DaVYddpHPHqAetUVHbu8lvE8sRhkZQzRkglCRyMjg49qkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKviJ/yXb4R/wDcX/8ASVa9Vryr4if8l2+Ef/cX/wDSVaAPVaKKKACiiigAooooAKKKKACiiigAooooA8/+OLhfAcgP8VzCv/j+f6V40X/0S1Udhg17D8eZYbX4dXl7cwvPHZuLgxJJ5ZkKhiBuwcc+xrxd9SsH8PQalcz2VtA11HZQ/Ybh7wySOrMEIMUe1+Bgk7cbskHAPl43D1Kk+aHY+qybMcPh6CpVXZ3b8tjC1aR4JWnjwQDhvYVg61eILG4lmcZZSB7mut1SG0sZmXUJb1Ga1a+8pLCR5I7dTtaaVP4EBBGec4yMjmuU8d6bZRRW/wBmZWYqJAUbcrqyhlYexVgR7GufA4epzqFRW1Nc2rYepCVahNNpK69dLjvhlp1vP/aWs6uGOkaWivLGDzPIT+7iH1Ndkl5Pqc8mqazIDcTYCJGxCwRjoijsB+tYE13Z2fhXQvDun7bgqDf6iYjw1w33ELf7K9ce3pVcz3jJsU28SemCSK93LsLVxVSWMlF7tR8orr/289b9rLofMOSpx9n/AFc3dX+xGM/vZjx/f4rE0ERSa0Ps2cCNt+fSq8kVw45mif2Zafo12+lX3nTWwlXaVxGcda9DG4ar7CcVHVo1wVSEMRCcnombHjxMaLbDGCJl/kayvBo/4qrRM9Ptcf8A6FTvFGtLq1vBDBDJGqtvff64wMVW8Os8et6a44ZbmMj/AL6FceCw9SOX1aU1ZtS/I7cyrQrYtTg7rQj8eDHjTxEP+n+Y/wDjxqn4dhJsrmWTi3MpiLHoHKcfyNbPxPiWLx7ryg5BnDn6sik/qa3fgVZ2Ouzat4b1dWNpqn3GXho5Y13KwPrjdSU1PK6DfWEPxSPDxWElioTpx3V392px2gX82k67a3dlKUkikGGX0r7Z8PXp1LRLK8b70sYY/WvDbT9n+5ttVWT+2oZbRWyoMRDY9x0r3nS7KPTtPt7OHPlwoEBPfFYwVlqcmCpTpp85aoooqjtCiiigAooooAKKKKACiiigAooooA5X4sf8ks8Zf9gW9/8ARD0fCf8A5JZ4N/7Atl/6ISj4sf8AJLPGX/YFvf8A0Q9eafD3xf8AEW28A+GoNP8Ahd9usotMtkguv+EgtovPjEShX2FcruGDg8jOKAPWfGXhmy8WaHJpuoGWNd6yxTwkCSCRfuupIIyOeoIIJBBBryz/AIVH4kEvlDxBpTQZx9oaxfzMf7gkwT/wID2ra/4Tb4n/APRI/wDy5bX/AOJo/wCE2+J//RI//Lltf/iazqUYVPjVzmr4OhiGnVinY7PwL4Ts/B+jNZWcktxNNIZ7m6mI3zykAFjjgDAAAHAAA96t+KfDmmeKtIk0vXIZZ7GQ5eKO4kh38EYJjZSRyeCcGuB/4Tb4n/8ARI//AC5bX/4mj/hNvif/ANEj/wDLltf/AImrStojojFRVlsdFqHwz8K6j4dstBvbK7m0mzJaG3bUrnA5B5PmZYAgYBJC44xXV6dZw6fYwWdt5nkQII08yVpWwOmWYlmPuSTXmX/CbfE//okf/ly2v/xNH/CbfE//AKJH/wCXLa//ABNMZ6lPEs8MkUm7ZIpVtrFTgjHBHI+orjdK+F3hHS4hHZ6bOsYv4tTCyX9xKBcxElJfnkPOWOezcbs4Fc//AMJt8T/+iR/+XLa//E0f8Jt8T/8Aokf/AJctr/8AE0AdRd/DvwvdGQzaa2+TUX1YyR3UyOLp1Cs4ZXBGVABUELx0pZfh34Yk1a61H+znS5upGlnWK7mjilkYEM7RK4Qscn5tue+a5b/hNvif/wBEj/8ALltf/iaP+E2+J/8A0SP/AMuW1/8AiaAO1g8HaFbw6BFFY7Y9B/5Bw86Q+R8hT+983ykj5s1mW3ww8HW0WoRQaKiRX1vJaSoJ5dqwudzxxjd+6UnkhNvNc7/wm3xP/wCiR/8Aly2v/wATR/wm3xP/AOiR/wDly2v/AMTQB0EPwu8HxaZe2A0gtDeNE8zyXUzzExf6vErOXXb22sMc+tWNI+HfhfSJrWWw010ltr2TUYne6mkYXEkYjeQlnO4lQBg5HfGea5f/AITb4n/9Ej/8uW1/+Jo/4Tb4n/8ARI//AC5bX/4mgD1WivKv+E2+J/8A0SP/AMuW1/8AiaP+E2+J/wD0SP8A8uW1/wDiaAPVaK8q/wCE2+J//RI//Lltf/iaP+E2+J//AESP/wAuW1/+JoA9Voryr/hNvif/ANEj/wDLltf/AImj/hNvif8A9Ej/APLltf8A4mgD1WivKv8AhNvif/0SP/y5bX/4mj/hNvif/wBEj/8ALltf/iaAPVaK8q/4Tb4n/wDRI/8Ay5bX/wCJo/4Tb4n/APRI/wDy5bX/AOJoA9Voryr/AITb4n/9Ej/8uW1/+Jo/4Tb4n/8ARI//AC5bX/4mgD1WivKv+E2+J/8A0SP/AMuW1/8AiaP+E2+J/wD0SP8A8uW1/wDiaAPVaK8q/wCE2+J//RI//Lltf/iaP+E2+J//AESP/wAuW1/+JoA9Vryr4if8l2+Ef/cX/wDSVaP+E2+J/wD0SP8A8uW1/wDia5W61vxPrPx2+GH/AAlfhH/hG/K/tT7P/wATOK88/Nr833ANu3C9eu72oA9/ooooAKKKKACiiigAooooAKKKKACiiigDzz46pFP8P57W6jlktbqZIJhE4RwjZBKsQwB6dQa+cda8USIZbC7s9a1ODcpM17d2tw2Fzhdj2hRlyd2GBO5VII5z9L/GpC/gC7I/gmhb/wAiCvnOcLJLuKg7s5rycdjJYeokux9Vk+V0sbhXKWjTtf7jk7DWY7aze0h0XVLS2Swl0tWt9Qj3yWkjF3jlMkDAne0jb0VCN5GMYxjJc3us69Ld3EAtrEBI4bZCSscUaKkaAnk4VVGT1xmuz1t4wiWqKF4DSkd/QVhzzZ+SIBFA5PYCveyihKrTWJr9dl+p5GaUqWHrOhRd7bv9Pl+ZMbrYfLt1CgdlFVpLpi2N7E/7IzWt4a0VtXnVMFbUnk95P8BXe3vgK1t7WOWFWC49DXp1sW78sWecodTypbibPymT8v8A69L/AGi6OAzEH0YYrc1+yS1uAqL14FYkdm00rA/MFOK5auJlSjeTNaNKVWfLEtx3ySgBgAa3/B0IvfFejQIM7rlCR7A5P6CuUmtVt5NoGOM13XwYgU+MlvJ2CwWFvLcux7Dbj+p/KssdjpU8tr4j+5K3ray/GxoqfLVUH0f/AATm/HM32nxdr8xbcDfTAH2DFR+gFW/hpfNpWo2N+pI8i/R2I/u5Gf0JrnL6YzGWckkyu0hz7kn+tafhxT/Y8uD1kJH5CufMaf1fAwpL7KivuO3KIqpideqZ9zA5GQcilrl/AviSx1nQdKC3kL372qNJDvG8MAA2R9a6isYyUldHlVKcqcnGXQKKKKogKKKKACiiigAooooAKKKKACiiigDlfix/ySzxl/2Bb3/0Q9Hwn/5JZ4N/7Atl/wCiEo+LH/JLPGX/AGBb3/0Q9Hwn/wCSWeDf+wLZf+iEoA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKGtazpehWi3Wt6lZadbM4jE15OsKFiCQu5iBnAPHsafpOqafrFmt5pF9a39oxIWe1mWVCR1wykivLfjNo+veJ/G3grS9Es4XtbOWbU7i4v7aSWzWRFCxK+3GScv8ALkHkdq4Txb4S8R+CJNNsrS7vJNI1W8utR1e502wuBCLlgoSPyrWRZUiAHGG5bk56AA+mao2mr6feanfada3kE1/Y7PtUCOC8O8ZTcO2RyK8Q8O+HfFusa54Y0LUtf8XwaRp2iS3FzqaebZPdTyykJE+7OXSPbwSWGM8HNcze6zr0NxpMWs3nibS5PEHiW61CWKBbkXUGm242rEI0BkCtuzwOevbNAH0nrmtadoVpHc6vdxWkEkqQI8h+9Ixwqj3NaFfMtn4c8TaxB4T0rW7fxK2iPrl7roe4817mztIkzbRSSckSMS5AJ3Zas8x+P7HwT4Jt9Yk8QRadcG7n1AvDd3E0Tlz5MU3kuk4Xbgj5gMnkECgD6qorwTR9A8W6tqvgvw9e674th0yx0i4vL7VYxLZyXLySbYoZC2f3irj5WJYDJ4PTB8NT+MNb+I/hvU/sHiPSbM3dzJqMUn29/KiiU7YpWkPktvwABGnU9SegB9E6ZrWnapd39tp93FcT2EvkXSJyYpMZ2n3rQryj4NwX3h74Z6rr+uaZqSatql7d6vdWSWzNdbmchUEZGSxVVwPevM9IHjZPCfi3W9Ofx7BrAjSKz0zUftcq20DyqHkXzf8AXThAx+UYXtk4oA+o6K+atRg8Wrp3idPBDeLl0fU5rCw06a8a6a4WUsDcXQ8z95GmAQWO0ZbjgCn6naePNI0D4hTaFL4ne3bWLeztjdGae5S1jBE08AYhmDFhyhHA4IxkAH0lXlXxE/5Lt8I/+4v/AOkq1N8CbHUbfTNYuLzU9Su7Oe5X7LDe2tzAIAEG7yxcu8pUkjknGQcVD8RP+S7fCP8A7i//AKSrQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHIfFuJpfh7q4UZKoj/gHUmvmqABp0BPAPWvqnxvbtd+D9agRdztaS4HqdpIr5PZ8QSuuc+Wx/SvBzWnzVoLvp+J9vwxU5cLV8nf8AD/gHPXs3mySSE/eYmqtnbPf3KwIjNuPOOOPeq91JiIAGuz+E+iPrWpSBUEgR1yHfav4mvvK7VKkoR2SsfF3dSTnLdnp/w38OzWMayzXNrEAAFiGGNd14jEy6LLtWNwF9Otbel6VDZ20SGKzQooyI65X4h34itTHsYxjug6V5CfNIpyTZ4Dq4aa9upnGBAC20/kKTQrMNHuZck8mjxDJwiowP2mQt77R/9etOzItLF5WHEcZb9K8rNq7lVVOPQ+myHDxVOVaXX8kcd4icHWZo4/upha6/wmf7K+H3ijVHIVrtF0+3z1Zm4bH4En/gNeemczXMs0hJZmLGu/8AGBbTvAfhLSiQJJfMvpV78/dz/wB9H8q9TGUv3GGwP/Pycb+kPfl/6Sl8zwpVPaValb1/HT8jgr8hYyB2GK3PDoxo/vuP8q5685Brd8NvnTGHo39KefNuj81+p3ZFb6z8n+h1Pgy8m0+6Oo2XFzZXAlH+0O4PsRkfjX1rpt5FqGn215btuhnjEin2IzXyH4LYC81CNuVfGRXvnwH1Vr3wjPYTtmfTbl4ME87D8yn9SPwrwMBUtWlT76nVnVDmpRrdU7fL/h/zPSaKKK9g+ZCiiigAooooAKKKKACiiigAooooA5X4sf8AJLPGX/YFvf8A0Q9Hwn/5JZ4N/wCwLZf+iEo+LH/JLPGX/YFvf/RD0fCf/klng3/sC2X/AKISgDqqqNqdgt4LRr61F2TjyTKu/wD75zmuN+Md/d2ug6Za2lzLaRalqCWdzcQsUeOIxyPhWHKlmRI8jB+fgg4rzxfDGhLam2Gj6f5J5KmBTk+pOMk+/WsqlVQdj0MHl0sVFyTskfQFFec/Bm8umtdc0uW5mu7LTLtYbWWZy7IrRK5hLHlthbgkkgMB2q78a9R1DSfhprd/pGrrpV5bwPIkxRWZ8KTsXceGPYjJGOBWid1c4qkHTm4PdHc0V4j8QfEtsPhF4d1GbxXqVlrN1YKtmmnXSRve3jRL/rDg/KrHLEkAZOTnFeqeCpbubwho0mp3tvf35tIvtFzbsGjlk2jcyleCM55HFMg2qKK8E8DfFS4tf2fbPW7nUbTVvFEe4TR3M43RhrwxLJMq/MEVWQk4HGORnNAHvdFfP3iXx/r19baXCuoWFtd6f4xttNk1CykkjsruNreR8MN5JUEjchYj5Rz6Pv8A4za3H4ct5LYaM2r/AGvUINyws9veR2xA86JmmjCoc9S7HjgHsAe/UV5P4L+IfiHxZ4i0mzsrDSYLSbR7PVrtpXk3qJWYOkeOD93jOPfNesUAFFFFABRRRQAUUUUAFFFFABVKXSdPl1eHVZLOB9ShiaGK5ZAZEQnJUHsDV2igAooooAKKKKACiiigAooooAK8q+In/JdvhH/3F/8A0lWvVa8q+In/ACXb4R/9xf8A9JVoA9VooooAKKKKACiiigAooooAKKKKACiiigBsih0ZGGVYYIr5D1Oz+w61qOnHkwTywfgrEfyr6+r5z+L2jDSPiD9rxi21ECcH0YYVx/I/jXl5rTbpxmujPpuGa6hXnRf2l+X/AALngd++0N7cV7t8AfDySWCX1zYyTNK3mKzNtUDoOK8abR5tQ8UHS4hlzclD9M19b+EbO40zRrS2SWNEijVAkOMDA9a+nxdTmhHzPnVFwlJdjfvSlpYsWtNnH8BzXk3iq+W988W0kqXH3VRuhrvvEmptFalXmzkYww5zXmt7dRGV7i+Xy47ONp2YHI4GR/SuOHu6sFFvRHm2tRNN4mEYjCiFFjbHIDdT+pqx4mnWz8OXJHVwEH4mrfgGIXUd7POrPJLk5Puc5q/eeF4Nd2289y0durZIzjcfrXzEsVGWK9pU2vc+zo03TwbpQ3tb8DyzQrVtQ1C0s4uZLiVYwPqa6/4p3yXPjW7ghZTBYRx2cYHbaMsP++ia7fRPBGj+HNct723LSm1je4Ls5IXaOv61z+s/D+S6AvvNMV3es1xw24MWO45HbrXpxzzC1cxjVd+WnBrbrJq737RX3ngrK6ypuEWm3rv/AJr1PNLg5U1s6AQunEerHNWrn4feIVkCosDoTw27FbWleFW0i28vU5VlmJzsQ4Vf8a1zfMsLXpJUp3dzsyfB16NdupGys+xF4SimbWZpwCIPL259TmvZ/g3PDYeKtUs1O0XsKOMn7zpn+jH8q8/05BFNGsihIVHOOMVrWN0uk6rZ6jG294bgScfxL3H5Zr5iGK5K8az0S/I9nGYb2lGVFbtfjufSFFRWlxHdW0VxA26KVQ6n1BFS19cnfVHwLVtGFFFFMAooooAKKKKACiiigAooooA5X4sf8ks8Zf8AYFvf/RD0fCf/AJJZ4N/7Atl/6ISj4sf8ks8Zf9gW9/8ARD0fCf8A5JZ4N/7Atl/6ISgDd1nS7LWtMuNP1W2jubOddskTjg9wfUEHBBHIIBFcR/wquzDFE8R+JFtM/wDHuJ4SAPTzDEZfx35962/iJ4hu9A0m0XS44n1PUbpbK1MwJjjYo8jOwBBIVI3OMjJAGRnNcCIteJ86TxfrZvM7vMXyVQH0EXl7MexBPv3rSFB1VdI0hUnT+Bteh6toGjafoGlxadpFsttaRZIQEkkk5LMxyWYnkkkknrU2p6bY6rbC31Sytr2AMH8u4iWRcjocMCM8mua+HHiK+1q11Cy1pYf7U0yZYZZoVKx3CMoZJAp+6SCQVycFTjgirHxL8R3vhLwXqWt6dpo1GWziaVommEaqoUkuSeoGBwOTUNWdmZl+Xwt4fmtYLaXQtKe2tyxhiazjKR7iC20YwM4GcdcVp2drb2VtHbWcEVvbxjakUSBEUegA4FeceOfHGvaP8OdN8VaTbaT5UliLy6ju/OY7mjV1jjEanrlxuYgDAz1JHeeHNQfVvD2majLEkMl3axTvGkgkVCyBioYcMATjI4NIDRrIsvDGg2DStY6JpdsZozDIYbSNN6HGVOByDgcHjitK6laG1mlSJ5nRCwjT7zkDOB7mvF/Bfxq/tKS8uPEU+jabBZ281xd6aVuEvrQJ0BDqFlOMZ2YwT9aAPWZPD2iy6dHp8mkac9hG29LZrZDEjcjIXGAeTz7mnT6Do9xaW1rPpWny21t/qIXtkZIv91SML+FcDY/Gzwxeade3EcGpC5tpbeBbIRxyTXDz58pY9kjIScHgsMY5xVw/FrRxZCb+y9bNydVfRfsS26NP9qWMSFMByuMHGc4z7c0AdxZ6Xp9lIJLKxtbd1iWANFCqERr91MgfdHYdKuV5no3xo8M6miSvb6tYWj2E+oJc3lsEjdIDiZFwxJdDkEAYJGATUNl8cPC91pt/diDU0+x/Zy0PlxySOs77EZQjsOpGQSGHcUAepUV5Lq3xot4PsSWPhzWnu21pNIu7S4iWOaEtGXBADEMzDBUZGQDkjAzuXvxT0Sw8b2nhe+tr6C+up0t4pGMJQuyhlBQSGQDnG4ptz3oA76iuR+EviW88YfDvRde1OK3ivL2N3kS3VljBEjLwCSegHc111ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V8RP8Aku3wj/7i/wD6SrXqteVfET/ku3wj/wC4v/6SrQB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnvxs0Qal4T+2xrm409xMMDkocBh/I/hXoVV75YXtJkulDQshV1IzuB4xWdamqsHB9TowuIlhq0a0ejufKfw+0Zr7xlf6hcQTNG0gEYQfe4GTn0r6CjSO2tFWKBo8LjBFclZJb+GLdLfVtZ0nSUQYWMyKJCM5ycnOa0v+Ek8Pyx7bXxVpk7EcK9yoyfzFdScuSKl0SX3IrEVYVKkpQ2bb+9mPr9xFPK9u8iBm5UEbTn2NeceOtQez8OSWj8zX0gjDY6xrgn9cV1uvSTf2kZbqG3uLOQYSSA7gPxHevNvHtx5+uwWavvis0CgnuW5P6ED8K58ZV5KLfc3wVJzrJfMn8LiWKybadq9/cV2emwebfWeEZo37Vx2n3QtoAvJDDHy1t22vXFnbxm3tXDLwjbepr42peTuj7KNOdrROv8Tpv0a4tYsb7uaOyjwMcZ3P8AoCKl1BltraONo/KOAm5WydvpWLrF1O2uaVak/vLG1864I6CaXk/kB+tQ6jes4DxsXcHA3dPyrhwybg6j+02/lsvwSOShSb1f9dC+JXiYExv5PXLHtWVqBjumEqptOcDvW19mu57OIzSRtEy7mL8Y9hWUVT5t/wAkcRwvqa6O1zopzXNdbleysJbuQRdCW6n0pDDCmriOV8rHjgjrWhp2opAk8sbKWAKIp6jPesjUiZpPMjBZyuQ461m3fY6LylJp6I7fw946k0OUWixfaLHOdh+Up67T/Q16v4f1uy16xF1p8odM7XU/eQ+hFfO1t+6sFeXmZjxkdK2vhT4gfSfFEdrcgpBeMY3bsG/hP+fWvZy7HTpyVKo7p/geDmWWU5wlVpq0l+Pc+gqKKK+lPlQooooAKKKKACiiigAooooA5X4sf8ks8Zf9gW9/9EPR8J/+SWeDf+wLZf8AohKPix/ySzxl/wBgW9/9EPR8J/8Aklng3/sC2X/ohKALvjPw5F4n0hbR53tbmGVbi1uo1DNBMoIDYPBGCykd1YjjOa4b/hF/HCkw7PDbjOBd/ap1OP73k+Ufy8z8a7zxb4itPDGjm/vElmLOsMFvCAZJ5W+6igkDJ55JAABJIANcIPHfi1m84aHoqR5z9la+kL49DII8A/8AASPfvW1L2tn7M56+Lo4dpVZJXOy8EeF08M6fcJJdNe6heS/aLy7ZNnmvtCgKuTtUKoAXJwBySSSZ/Gfhu38W+H7jR766vba0uBtmNpIEZ0IIKEkH5TnmmeDPE9t4p0uS5ghmtbm3lNvdWk4G+CUAEqccEEEEMOCCDUvjDxPpXhDQptX164MFlFwSqF2ZsEhQB3ODWTvfU3UlJXWxzt98MrG88O2Oiya94ljsrWB7XEN/sM0LYHlyALhgAMDjIGRnmuw0XTLTRdIs9M02IQ2VnCsEMeSdqKMAZPJ4HU1g+JPH2geG/B1t4m1a5eHTLlInhwhMknmLuUBepOMkjsAfSuksbmO9sre6gJMM8aypkYO1hkfoaQx1zCtxbywyFtkiFG2sVOCMcEcg+9cKvwp8PzzyS61PquuO1pJZRnU7xpTDDJw4QjBBI/iOW967u4mjt4JJp3CRRqXdm6KAMkmuN8OfEfR9eCT21rqlvpUkcksOqXdsYrSVEJyRIT8vQkbgucUAYmt/CqI+GJ7DSdQvrm8WW3mtJNRvWxatC+VaNkXIYAn5iGJ4zR4G+Fg0qxt5PEWoSXuqx63Jr3mQudomeMR7SWGXGBnPGSe3Sur8YeNdH8LaHd6pezfaY7ZYXeC1dHl2SyLGjhSw+Xcw5z0BxnpVseK/Dp0qTUxr2k/2bFJ5L3f2yPykf+6XzgH2zmgDm7L4UeGraz0+0ZLu4tbK1vLNYppQQ8d05eUNgA5yTgjGKji+FGirpT6bLqOtXFmWgaOOa7DCIRSB0C/L6qBk5OOM11E/izw7b29lPPr+kxQXv/HrI95Gqz84+Qk4b8M1LceI9EttWXS7jWdNi1NioWzkukWY7vu4Qndz245oA5vWPhlomqXN/dST6jBd3epQ6r59vOEeG4ij8tGT5eBtJ4OetQt8KdBPiIautzqiyDU01c24ucwtdKu3eVIJORnPPc4xXRzeL/DUEs0U/iHR45YUaSVHvYgY1U7WZgW4APBJ6Gpb3xNoNjFZyX2t6XbR3oBtWmu40E4PQoSfmzkdM9aAG+DfDll4R8NWOhaUZjZWalIzMwZ8Fi3JAHcntWzWTceJNDttRTT7jWtMiv3kEKW0l1GsrOQCFCk5JwRx15rM0/4geFb6PVpI9dsIo9KuWtbt7iZYljcYGcsQNpLABuhOQDQB1NFcyfG+iya54e02xuBfnXFuXtbqzdJYMQKpfc4b/aAGAeQc4rpqACiiigAooooAKKKKACiiigAooooAKKKKACvKviJ/yXb4R/8AcX/9JVr1WvKviJ/yXb4R/wDcX/8ASVaAPVaKKKACiiigAooooAKKKKACiiigAooooAK5n4kzanbeCdVn0NWbUY4t0W0ZI55IHqBk101YvjPV49C8L6lqMkgjMMLFCT1cjCge+SKTkormfQqMXNqK6nxjJpxvZXmuJHluGO53kOWYnqST3qpPYrE214zg+orprvUJJ2aea3WSQnLSD5ST3JxxVO51kSIIhp6SN0y7En9K2p5xhpx1umddTJsTTlpZlfwfq13pOsQ/ZpHNqTmaAnKMuOeO1K7SX1/LcucySuXNT2OmXNx5m2FYIyMlUGPzPWrUNqLaYquWP9a8HMswhXly0tke/lWXTw6bq7l/S3QFY2Tc3fHWu20tf7RktrQgNmRQcjoAc5J+lcjoqPFdrIUB55zXUrq8Nto9/cRy4unb7HBGik7XYfMxIHULzXzuKclTfJu9F6vT7lueriJ8i8/1LcTW11qGo3ayFzcXDFCV4KL8qn8gKpHTYXuGdrnJByABWPLrOnWcKxfaBKyrzLCwKRqOmT/T2qvbanFqMbC1nLr1d8EDH1Nbqh7OKilorL7iKOvuxkbN/dTRMUJYovC89aqi4kFptbDLIT16ioJ5ra2jXzLqJkJAG1t2T2Ap2pXlnp8QMpZwcAbEJBJ6YPQ/nWUqcuiOuDhFaszNRnMLoIhgnrjvW/o+GjiB6EHcelYFpKt1rEDx27eV94FnX5vwBP51sXuoxWivLcvGkYwGIbGPbnvRyqLS6l1ZqUNCa8nNyQiqEP8ACT2FZF/57W4lgcefAwPHBOPSp7/VNPv4BdxmSJYST++XZvQYBI7HBIFZaapp8XlzG5BZ8lOCRg8c/jV8k00kjkjKDje59CfC7xxB4nsBZzts1S2jHmo3G8dNwrvK+SPBXiK10f4iaZfmXy4fN2THoojfKEn2BOfwr62UhgCpBB6Ed6+pwNeVWl7+6Pj8zw0aFb938LFooortPOCiiigAooooAKKKKAOV+LH/ACSzxl/2Bb3/ANEPR8J/+SWeDf8AsC2X/ohKl+JttPefDbxZa2cMs9zPpN3HFFEhZ5HaFwFUDkkkgACvNfBHxPn0HwXoGkXfw7+Ij3On6fb2krRaISjPHGqkqS4OMg4yBQB6B8TNBvtb0eyl0hY5NQ0y7W+hgkbas+I5I2Td2JSV8E8bsZ4zXnX9o3Ybyn8O+JFuwceQNLmYZ9PNC+V+O/HvW/8A8Lk/6px8Sf8AwR//AGdH/C5P+qcfEn/wR/8A2dbUq8qStE8/GZZRxklOpe67G/8ADDQNQ0q21PUNaiW3v9UmWU2qsH+zxogVEZhwz8EkjI5wCQMm78TtF1TxJ4J1TRdFeyjnv4mtne7LBURlIJG0E7umO1cn/wALk/6px8Sf/BH/APZ0f8Lk/wCqcfEn/wAEf/2dZSbk7s7adONOChHZFDxV8JNS8U+AtMsNQ1YWuuaZpzafbrayA2bghV3OHjL5KqASuD1A4Jr1Hwxpsuj+HdN064upLuW1t0iaaTGXIGM8AD9BxXnv/C5P+qcfEn/wR/8A2dH/AAuT/qnHxJ/8Ef8A9nSLPULuN5bSeOIosjoyqXXcoJHGR3HtXhVl8EL/AM7WGW50nQob/TbiykttHM5guZJFwskkcjYUL1Cr+ddL/wALk/6px8Sf/BH/APZ0f8Lk/wCqcfEn/wAEf/2dAHO6p8JfFetaZrCarqOhfbLvS7DTovISVY1+zXCyktnJOQp5GOTjHc2NU+Ems6lBql7PLo0er3+pw3witXnt4bQRQmJTE6/NvOcsSpByeOhra/4XJ/1Tj4k/+CP/AOzo/wCFyf8AVOPiT/4I/wD7OgDmdS+CetXMWnSXWrWOr3A0v+zb1LozWyOPNeQMphIyPnwQR8xXcSCTWRP4L8QWnjy10qw0t7uxPiaz1ufUntXTYkapvQTMxDIMHaMlsnGOprvf+Fyf9U4+JP8A4I//ALOj/hcn/VOPiT/4I/8A7OgDLsfg3LHrGl3l5/ZM62+p6re3AaIsZUuUZYlOV5KEgnPTHFZE3wN1X+z9Hja90+9aDR10i7tp5riKJgsjOGRoyCR83KkDpnNdX/wuT/qnHxJ/8Ef/ANnR/wALk/6px8Sf/BH/APZ0AZmo/B+6u49ffzdLN7fajp93bTsjFoUt1jDruILAnY2OT15PWn3nwv8AEEMPim30W+0i2h1TWRqscmx0mZCU327OozGvy5DJzn0zWh/wuT/qnHxJ/wDBH/8AZ0f8Lk/6px8Sf/BH/wDZ0AZ/gL4U6r4d8Q6FqF1e2LxWF/ql08cTyudt0kSooZ8sSuw5LEk5HJOa9lryr/hcn/VOPiT/AOCP/wCzo/4XJ/1Tj4k/+CP/AOzoA9Voryr/AIXJ/wBU4+JP/gj/APs6P+Fyf9U4+JP/AII//s6APVaK8q/4XJ/1Tj4k/wDgj/8As6P+Fyf9U4+JP/gj/wDs6APVaK8q/wCFyf8AVOPiT/4I/wD7Oj/hcn/VOPiT/wCCP/7OgD1WivKv+Fyf9U4+JP8A4I//ALOj/hcn/VOPiT/4I/8A7OgD1WivKv8Ahcn/AFTj4k/+CP8A+zo/4XJ/1Tj4k/8Agj/+zoA9Voryr/hcn/VOPiT/AOCP/wCzo/4XJ/1Tj4k/+CP/AOzoA9Vryr4if8l2+Ef/AHF//SVaP+Fyf9U4+JP/AII//s658+IL7xv8Z/h5fW3g/wAXaTZaT/aP2m41bTGgjHm22EwwJHVcc45IxnNAHutFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeKePvDfjLxZ4hlabTSNIgYraRG5iAwP4yN3Jb36dK9rorGvQVaPK20vI6cLiXhp88Um/M+bV+HXi92eM6GkcA4A+1QnP/AI9Utv8ADnxPbFpk0APMBhB9phwD6/er6Norj/suj3f9fI9H+3cR/LH7n/mfPMfgHxgluD/ZSiUnLAXMX/xVZU/w18aGfzE0bvn/AI+of/i6+m6KFlVFO93+H+Q459iI/Zj9z/zPmabwV4ttI1e/0kW0JYKZftMTYJOOgYk/hWlrXg3Wtfvbf+y9DEulWKfZ45jPGhnf+NzlgSMjHPp717zq2mW+q26w3QJVWDqVYggjuCKsWltFZ2sVvboEhjUKqjsK5Xk0ZV/aOT5UtNdbvd7dtF6sJ53VnyycVdeTt+Z87Xvwz8RSCV4/DsBmkC/N58XBHHA3YHQVNpvwv1tCpm8PwR4GCBPEc+3DV9E0V1PK6b+1L71/kJZ7WSsoR+5/5nzyPhVqhCq2hRnaSdz3KNuBGCDluR6elMk+F+vF1K6NCsKKfLgWaLarHqT83PGAPTn1r6JopPK6b+3L71/kL+2638kfuf8AmfMyfCbXoZPMj8OQF85ybiL/AOLqNfhd4yJYz6ZuU/dRJoAqDOe7HPbmvp2ij+yqW7k393+QPO63SEV6J/5nzTN8MfFKBcaH9qU4V1lu4myM5xy/AzzgUyb4U+IWbMfh6NfTNxD8v/j9fTNFP+zKX8z+/wD4ALO6y+xH7n/mfMMPwt8WNK0U+gp5JAAcXUOAB2xur1D4QaZ4s0B7jS9es5BpO3fbSPcRyGFh1ThicEc+gx716dRWtHAwoy54yf8AXyMcRmlTEU/ZzjG3o/8AMB0ooortPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The International Association for the Study of Lung Cancer (IASLC) lymph node map, including the proposed grouping of lymph node stations into \"zones\" for the purposes of prognostic analyses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009; 4:568. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19914=[""].join("\n");
var outline_f19_28_19914=null;
var title_f19_28_19915="Cairo-Bishop define TLS";
var content_f19_28_19915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cairo-Bishop definition of laboratory tumor lysis syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Element",
"      </td>",
"      <td class=\"subtitle1\">",
"       Value",
"      </td>",
"      <td class=\"subtitle1\">",
"       Change from baseline",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uric acid",
"      </td>",
"      <td>",
"       &ge;476 micromol/L  (8 mg/dL)",
"      </td>",
"      <td>",
"       25  percent increase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potassium",
"      </td>",
"      <td>",
"       &ge;6.0 mmol/L (or 6 mEq/L)",
"      </td>",
"      <td>",
"       25 percent increase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phosphorus",
"      </td>",
"      <td>",
"       <p>",
"        &ge;2.1 mmol/L (6.5 mg/dL) for children or",
"       </p>",
"       <p>",
"        &ge;1.45 mmol/L (4.5 mg/dL) for adults",
"       </p>",
"      </td>",
"      <td>",
"       25 percent increase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Calcium",
"      </td>",
"      <td>",
"       &le;1.75 mmol/L (7 mg/dL)",
"      </td>",
"      <td>",
"       25 percent decrease",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Two or more laboratory changes within&nbsp;three days before or&nbsp;seven days after cytotoxic therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767. Copyright &copy;2008 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19915=[""].join("\n");
var outline_f19_28_19915=null;
var title_f19_28_19916="Comparison clinical features epidemic dysentery cholera";
var content_f19_28_19916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of clinical features of epidemic dysentery and cholera",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemic dysentery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cholera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Causative organism",
"        </strong>",
"       </td>",
"       <td>",
"        <em>",
"         Shigella dysenteriae",
"        </em>",
"        type 1",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Vibrio cholerae",
"         </em>",
"         O1",
"        </p>",
"        (",
"        <em>",
"         Vibrio cholerae",
"        </em>",
"        O139)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Infective dose",
"        </strong>",
"       </td>",
"       <td>",
"        10 to 100 organisms",
"       </td>",
"       <td>",
"        1000 to 1,000,000 organisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Clinical features",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Bloody diarrhea",
"        </p>",
"        <p>",
"         Abdominal cramps",
"        </p>",
"        <p>",
"         Fever",
"        </p>",
"        Rectal pain",
"       </td>",
"       <td>",
"        <p>",
"         Watery diarrhea",
"        </p>",
"        <p>",
"         Dehydration",
"        </p>",
"        Vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Complications",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Seizures",
"        </p>",
"        <p>",
"         Rectal prolapse",
"        </p>",
"        <p>",
"         Hemolytic-uremic syndrome",
"        </p>",
"        Sepsis",
"       </td>",
"       <td>",
"        <p>",
"         Severe hypovolemia/shock",
"        </p>",
"        Electrolyte abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        Antibiotics",
"       </td>",
"       <td>",
"        Rehydration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Transmission",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Food and water",
"        </p>",
"        Person-to-person",
"       </td>",
"       <td>",
"        Food and water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Case fatality rate",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         10 to 20 percent (untreated)",
"        </p>",
"        5 percent (treated)",
"       </td>",
"       <td>",
"        <p>",
"         40 percent (untreated)",
"        </p>",
"        &lt;1 percent (treated)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19916=[""].join("\n");
var outline_f19_28_19916=null;
var title_f19_28_19917="Findings associated with time since fetal death";
var content_f19_28_19917=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Good predictors identified in the literature as indicators of intrauterine retention time",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        External fetal and cord examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Placenta and cord histological examination",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histologic fetal gross features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;4 h",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Kidney: cortical tubular nuclear loss of basophilia*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        &ge;6 h",
"       </td>",
"       <td>",
"        Cord discoloration (brown or red)",
"       </td>",
"       <td rowspan=\"2\">",
"        Intravascular karyorrhexis&bull;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desquamation &ge;1 cm",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &ge;12 h",
"       </td>",
"       <td>",
"        Desquamation face, back, abdomen",
"       </td>",
"       <td>",
"        Cord vascular smooth muscle&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        &ge;18 h",
"       </td>",
"       <td>",
"        Desquamation &ge;5 percent of the body",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desquamation 2 or more of 11 zones&loz;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        &ge;24 h",
"       </td>",
"       <td rowspan=\"2\">",
"        Skin color brown or tan",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Liver: hepatocyte, nuclear loss of basophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardium: inner half loss of nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &ge;36 h",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Stem villous vessels luminal abnormalities (5 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        &ge;48 h",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Stem villous vascular lumen abnormalities",
"       </td>",
"       <td rowspan=\"2\">",
"        Myocardium: outer half maximal loss of nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multifocally (25 percent)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &ge;96 h",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Bronchus: loss of epithelial nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        &ge;1 wk",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Liver: maximal loss of nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GI tract: maximal loss of nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trachea: chondrocyte loss of nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal maximal loss of nuclear basophilia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        &ge;2 wk",
"       </td>",
"       <td rowspan=\"3\">",
"        Mummification (any)",
"       </td>",
"       <td>",
"        The stem villous vascular lumen abnormalities",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Extensively\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive villous fibrosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &ge;4 wk",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Kidney: maximal loss of nuclear basophilia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Loss of nuclear basophilia means at least 1 percent of nuclei totally pink.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Because 36 percent of placenta lacked it when the delivery range was 24-36 h, Jacques concluded that the absence of intravascular karyorrhexis cannot exclude time intervals as long as 36 h.",
"      <br>",
"       &Delta; Pyknosis in the smooth muscle cells in the media of the arteries and veins (positive if &gt;1 percent), loss of cohesion with small dark pyknotic or wavy nuclei and eosinophilic cytoplasm, and presence of multilobed nuclei resembling neutrophils (this appearance has been termed",
"       <em>",
"        pseudovasculitis",
"       </em>",
"       .",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Scalp, face, neck, chest, abdomen, back, arms, hands, leg, foot, and scrotum.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marchetti D, Belviso M,&nbsp;Marino M, Gaudio R. Evaluation of the placenta in a stillborn fetus to estimate the time of death. Am J Forensic Med Pathol 2007; 28:38. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19917=[""].join("\n");
var outline_f19_28_19917=null;
var title_f19_28_19918="Pericardial effusion with tamponade long axis";
var content_f19_28_19918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68383/laxpref2_conv.mp4?title=Pericardial+effusion+with+tamponade+long+axis\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD50ooFFABRRRQAUUUUARyQrIQT1pv2VPU1NRQBD9mT1o+zJU1FAEP2ZPWj7MnrU1FAEP2ZPWj7MlTUUAQ/Z0o+zJ61NRQBD9mT1o+zJ61NRQBD9mT1o+zJ61PSHpQBD9mT1o+yp6mpycZzx6H1oKsCQVOQM4oAg+yp6mj7Knqan4PQgj1owaAIfsyUfZkqfdRuoAg+zJSG2TNWN1JmgCD7MnrR9mT1qfNGaAIPsyUfZU9TU9JQBF9mSj7MlT7qN1AEH2ZKPsyetT7qTNAEP2ZPWj7MlTZpd1AEH2ZKFtl3VODk0KTuoAbRRS0AJRRRQAUUUUAFFFFABRRRQAUUUtACUUUtABRSUtACUtFJQAoGTgV6b8Jfh/f+IL9ppYZooChCuFBJORyM/jWJ4N8G3mqo9+zQxW8I34lYgt9MCvon4exSDRLr7FqFvb3Kfetn6ovqeD/k0AeSab8PbPQ5dRn8S2BubK3uo43aSRkCxNHuLZUg8HAqDwx4X8Hy6/ZyXmqWl1p91J5ZjnleNokwcsNvXkdz3r1jx94X1TxZZvFZXlvNBInLt8oyOOMCvnnxl4E1LwpbRTTSxzW0nyxNESS3XPUDjINAHN6xBHaXzwWzK0Kfd2nIqpk0EbTjaygetOUnPFAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV9Hfs4/Dfwp4x8H3F74i0v7ZcpNsV/PkTjnsrAUAfOS9aVfvV9QfHb4W+DfCvw/uNS0TSPst6sgVZPtEr9iejMR2r5VWSTevz5HfigCxRRRQAUUUUAFFFFABRRRQAUUUUALSUtJQAUUUUALSUtJQAtbnhfSF1C5Etw0It4zkrK5UP7ZHNYY689KvW8qbGUEHAyAeOaAPpPwM/hC+N3a6g1nb3PDQus8nltgAYH5+natrTPDt9YPLdWmu6ZdSqQWVGOT6AfLXzdY6hJbsgUFNhyR6108niJ1laW2YwnIcBhknAxQB79quh6pdW1mt3e6bbP5mX3SMNyc5X7vBzg/hXCeLbvTbgnRdZuGvbNpVkuFjAB27SMgjHqK4ibxTPd2TPcT5mjO0EAce9Y88l3cPBLEpdiCrnHXmgDkvFWiRaNcIltNG9vIu5FBJZPZs9+4xnisRDnOK9f0OC007wyL/xFDBMBqqJLG1oszzw+UxMQJxszj7w6daytesoU+H1ld6dYSIZZLrzXSxWb5VZAA8x+ZMDOMUAecEYpKKU0AJRRRQAUUUUAFFFFABRRRQAUUUUAKvWvrn9j458A3v8A18/418jDrX11+yAm34fXRHe5/wAaANX9qqTy/hcwxnddKP8Axx6+JIxkg9OeK+y/2upWj+HNuo/jvFH/AI49fHMa7WAPagCYZIyxy3eiiigAooooAKKKKACiiigAooooAKKKKACiiloAKACegzSqCzBRyTWjHpcgXEreTKfu570ARaXp8+p3Jt7SMySe3rXpmgeCIbOza6vJEc9FjDHeDnrjpjiuEaK50y6W4CoJU53Amug0PxNdxzJG82VJyGZQFFAG9cpYXEzi+01bg7P+WcjADp15FWZ9B06YRyWWnywQ54+ckj25NVl8RWguGkkhLOxHCHIbj61X1HxYktsy4HmNIGyOgwCKANlNK0S101Li+hlR0bLM5wO/oavav4i0P7HAthGEKZJ3Mcs3OB19K8w1XVkvYhHO/mqecLTdM0jVdaH2mxhSdEnEEY81ELSlSwRQSCzEA8DNAGpr1zb3RkkVwSwATccYrAkccNJh0Bz5e8gH8qFsNSuRpzw25k/tKQxWuCD5jhgpX2IJHXHUGoF3qXWTblSVODkZB9RQBlTRNHwy4b0pgwRkN8taUtrI+XZgcdapeSTGZFQ+XnH40AQbl7mlDKe9AjXuKTYvoaAFLD1pNw9aNi+ho2L6UAGR60uR60mxewo2D+7QAuR60ZHrSbB/do2D0oAXI9aMj1pNi+lKFXHQ0AGR619b/shSqngO+UsNouQFPc8GvknavYYNfTv7Ldw9r4K1BmZfLN0uz8jQBsfteSpL8PLEo2Qb1cf98PXyImDLnI54r6q/ajvYZ/h/YoCG3Xqlcf7j18rogLgYO7NAD6KKKACiiigAooooAKKKKACiiigAooooAKcqls4HTvSCteCNUh2uMKfSgDMiUnG04NXbeWQzCO4YBPWhoSkZZPnx/d7VVnmLgB1IoA3pLZ7lY1hkEjZ7VXljntJMMcMO1ZllevbSq8Rxj1rZTVUuXUTRszE8lfSgAiRpVLiYfSopIyF2E5A71ZuYoopFaPcFP8J61HcBSoIyp7g9qAMqfbyNpzXVeC/F1t4e05LW5tXlLaiLh5FRS8UfktHviY/dlUsGU+3WsQrbOgDPgmqF1HEi5G/6nvQB0nhnxRaaRoWo2c0M815HI0+kzgACGV0MUjNzxlCGGM/MorlY5cfL0AqNUbAbYxU966bwn4VutdugkKrsPVySFFAGM1zJJGY1UkEfMoFa/hRrXQtVttR1ywF7ZID/AKMzshPPUEEH9a73xF4U0Hw/pcMNs/m3LH94244xz05+lcDq+0RZQbWX5VPXFAGX4iW0luhNpqJb284+WJWLGPHHOfoTWYc5yQR7GpGiVBkk4b7x74pJhAJSloXaPtvADfiKAGE5pKRegJGM9M0tACqaXIptHNABRRRQAUUUUAKDg56V738BruOHwdMrOebj0+teB9K9a+FF1JD4cZFP/Lbdz+NAHRfH28hn8D6fEuSwuwf/AB168D/5aMTyDXrnxcvGn8NWSsQR9oB/Rq8jThhj60AFFFFABRRRQAUUUUAFFFFABRRRQAUopDwM/wAqD7jFACg8g122nCC+0cSBOVOP51xAOO9dP4PuTGktsWxGxyBQBm3eY7ho0+VfSqs68fKc10Pim2ijkR7ds/L8x9651lGM5+agCttxSq5RgwOD2qRkQdKYRgcDg0AalrqqjC3i59GFaAureZD5Ug59a5pfl6U+KRllGOh60AbRggMqCWXCseSO1XLW1sZbpUuZlMP+0SP5Vj7piyhB8p7VYkkljjzJExFAG3Jpth9pUQPbhR3MjdK7K01jTNHtBFav5rH7yx8/zryeXUJHXy8EDr0qWOa5ul2wgFR1zQB0Gu+IZNQuIyZlK/d4H/1qxpJRcyNI/APH41WkR0PzkA4xxVdnw6j3yaAJJoCcgZxUETJbyo80azRqcFCSP5VYkuCpIU8VSyS2T1zmgBHCH/UxiJSM7FJOPrmkBx1qSO4kg87yiB5qbHz3HHH6VJaWU186paJ5pZtofoCfQUAVqKtahaizuXjSaG4RcYeJiQePcCq3bOce1ACUUUUAFFFFABXf+AbkR6OV3Y/ef41wI611fhO6WLTtuOd2f50Aafj+487RLRM5/fj+TVwQ4c11Xi2cS6ZAMYIkyPrg1y45egCOiiigAooooAKKKKACiiigApaSl7UAJnvz6YFIFAGASfrS0UACgZGelaOiEx3SFpFj9mrPABOD0qzaMrIUmO0/wmgDa1Iu8RZiD9KxJFLjJOF9a2rfd5QUMG/rVW6tgp3kE+woArnTJzoT6t8gtluhaEZ+beUL9PTAq4nhu9eWzUSQeVdWDais247FiUNu3HHBBQqR64HerFlqVhH4cm0jULW6kje8W8WSCdYyCIym0hlbI5zViHxKqeCp9AMClmlJS7LfOkDMrvDj0Z0Rs+xHegDk88AmjJUnnHpUjeXt+UE00plSVU7qAJVuJVAGQDUjXskkZUsSPXAqExSHP97HSoypzjA96AHBsEnknHWtzwXpv9taulrdNcjT41a4u3tY98iwr97aMcsSQB7kViQwySyYgjZm6YHNaun22sJFd21ms6JOF8wKApbacgZHOM8474HpQBo3PhK5tda1u0vruG1t9JmWKW5nVtp3vtjwqgk7h83TgZNYesWdxpeq3en3oVbm0laGVVORuU4OD3Fbqah4kivZAwFzO8EVvNFNAkqukWPL3BhhiuFwx54qnq+k6q1zJd60ZEmuXaV5JfvOxJLMfxoAwTktj+L0oAI5IrTuVs4VSO13SyY5btWc2W5FADeQwI4pvRQq5weRn196UKSKUqV60APKL5KyeapYjO0/eH1qL7yZx1pwG/aDu2Z+bFPnEImDWxkwo6ECgCLtntR3xQoz0YcU5stzQA3mijaaKAFHXnpWro8oSAAsF571k1at5dqHigDQ1aUS20a7g2Gzx6c1kDIkJA4qxcyl4xioFzkCgCOiiigAooooAKKKKACilAJOB1qSWBo/kkVlJGdw7fWgCI9KKKKACiiigApc5680lFAE8E7KwyxA9cVpfaVdMB8t64rGzgYqSLcDlaALsiEIHZW+hpZPJaAhI2V/WljmZ12yqzfSmEFnO3IXHQ0AVowEznpTmkLfMnSpjZt1VgT6Vas9MuJxsQqGbpmgCTQbmKG43XkAdH45YgD8qtvb6XP5kiExD0Y/y5q3a+F9Qd4oZZoEVm6yEhR9SBRrfhdtKuVgn1GzuTjcPJZjt/MCgDo/hNqugaJqNzNfRiWTZ8m5iAOnoayfEfimS41KV4phFAcYCqDjgetcvL5UKZUMSeNxrNcgs3BIFAHfWGuadaR/agsr3A6ucAN+Gawtc1WXV5Gnu8yZG1AAAF/KsuzmWVtsgIh/u961Y1gG1VDIuc4NAGVbW7RjeCAlRmBwpYptU9q3NUSCO3VIc+YecmsaaZpc5cHPYUAVM7Q3TFROxx7VaS2kZWO35ccmq8mAdlAEeOM9qkh8tblGlHyD9ajOG4zjFOHPXpQBJdNDLO7W6kqoGMVC2M/KRg1NBcywOGjYhyNrKQKascjxFwGKKcFj6+lAER4NL1NAOcg0DrxQAo6ZoBIFA+7SUAKSSPpTl4cUzsacv3x9KAG0UUUAFFFFABRRXReFtOt5r6L+0sosg/dBuFY+9AGfZQPAq3BUFuqAj9afdKbqPzAMuK6jWtHksyHiAe2PAwea5gcGQxkgjtQBmOu0c0yrlxGWGVIP0qptI60Ab3gLT7bVvGekWF/GJbWebbIhYqGG1jyRyBx2roNL0/w9fayVRLFhBotxdXQSSZrVblMlSp++VC7MgcZzjiuFtria0uEntpZIZ0OUkjYqynpwRUmn313ptx5+n3M1rPtKeZC5U7T1GR2PpQAl+0bXs5gEIi3naIN2zH+zu+bH15qvU13czXdw891K80znLO5yT9TUNACilQkfdpKVSF6UAXob5uDKBJ7dK6bRrjSn5vLQpnjIY/41xysN4OM1u6bEZeUQZIxyTQB1CWOjzykwvlQPu5P+NNFrZCQC1by39zWXbxyW8nNuT6lTmr4u7Xeu2zuMjrkD/GgDRu7eb7KjPJGVU5LE9K57VbiW5I/1bt0G01cvtVtBF5Z3ox7YrBNzAs5klJZQPlC9aAM6+juY22yIU+o61Syf4qv392twcojDjmsyQHYwwTkGgCxGxQnYKnhu5UGRgE8V1vi3TItR8cLcNeWcej3Rt1e5juYm2oIU3naGyCNrDkdeOpqfxtPpOuLpmq2VxF5m1rKeBYhCyLGcwnZknHlsqbu5j96AOcjSe8QICCzcZq2NHTTMSXTmaUjhE/h+vSptJeGF2VJFCgdWPNUNcvY5nVUcMU70AQ306i3IR1YtwVXnH1rI+Z244qRyzDcwyR39KYFOcnigAEJGdzUxht75p5z1qe3gkmbEaZNAFQAtgFCXY421pRRyWttKkrDaTkJ3B9a0NO0V1/fTsqopzuzVfVChlYx5fPGfagDJaNVi8wTwsTxtBOf5VGevQj2NSS7yu0k7c9MVoaroOoaZZ293dQEWs+dko+6cEg/qDQBlUUEgMRkfX1ozQADrT060wU5TzQA2iiigAooooAPxA+tdZ4ZmtdWh/s69byp04gbpk+n61ygIHJ6ULuXy8HayNuRvQ0Aeh6hJqukr9n1JA8ZPDgda5O+dUlEsQ4zzXUaZ4pi12yl0/wARSrFchg8d0+FTAGMHH19O1Yes6ebc4IYRyfd3d/cUAZPVv3XSoZvv+9S/Mi7OretQE5Y5oAiOc0HrUgx3FMI5JxQA2ilGOc9aQD3oAKKXHoaAPWgAFXbO7nt2yhFUm70tAG9DrEozvcAn2FTQaxNHwGJX/dFc4CQcg1IsrM2CaAOhkuLORS0pcy4+UcAVmTY35VOPrUKws+NjDPvV2ygRztuHjUfU0AZ8smeAuKrYJPNb8+kRyIWtT5mOu2s5rNtpLIEx/eNAFFMpzwaljkJYkDnGKkkhCcKy/nUeGXp83pigB5lYLjHzGmEMuDtzSfOT8ykN6irMUDuwBRm9170ARbS3Xp6UpiaTCgVuWOjyOGMyls/dVOTXR6Z4Mu7tY5Rb+RDIcRyTEgE+nGfQ0Acdpmk3N1MFSMlu1dEmlTWPzXJVDXXeXa6LbfZoVZtRzlyOQo7AfpXPa7BcXZMjoVwOpoAxby93r5an5T0Wsu4PlK3mjDY7VauHjtwGfjPUVkX10snywrtjPJ70AV7iUMrKn3utWr/VLy9to7WZzLDH9xAAMd+vXvVAkscn6UhGQB6UAGBx2PpS4NFJzQAN0pVo6g5pVoAbRQelFABRRRQAo680m3Od5yO2O1FFAAfujAyQc1q2GqmGE2t0PMsmOdg6g+uf/r1lUUAa/kpdtm2kUv8A3R1qL7E8bYYHNUopTE++M7T71eh1Pcm26GVzwV9aAGSQYIqJo9jcc1pAxz48uQfSmXNvjbuU/WgCi6I4wBhqVLWRxheasNbKFLI3QU+CKTqlAFNtPugpYwuQO4qDyXHJU4rprJrqPKncUJ5AArqtJ0/RZ48alZuSe+8j+RoA8scYUk8CjPHXrXs9r8P9D1K5RbaWaZn4xFzj8zWvefAqP7GZLC+CnOCs2R/IGgDwHFOTgn5TmvXz8FtTCkRzQg+gYkn9Kp3nwY1+GPzXUNEO/p+lAHmMEjKxK8Ec81L9slLcHmuvk8CMjFZJEMnoCalj8GhU2sEZj2DGgDlLfVLiE7gCFHBwKkuLp7yIhUGD3Neh2fgaC3RZWtXEvYqxJ/InFXD4USRwPs8m/wBWOD+hoA8qXS7mdgVUbfWtC18NXM8ioksSsTyGJ5+nFep3Xg2KODZM8SMf77MP5U/StKtdDkNyieZKo4YE4X3oA5/R/hjdxAXF5GqW/csSM1sSeG9LtlSb5YrZepLN81dZceL4NStxHerLezp9xtoTb/3yRXK6pfx3cW2/LMy/dXoV+uKAM2/lsLd1OlrGhbjcWJyfxrfu9YvJ9KgS3YpexE5nmUD5STwoGQe3WuYVLedgx+coc7icKv5VS1LxDZ6fHuWVXl/upz/OgDbtYrW0aS4uJuoyXbjJrlPFXiS3kjEFvJ5gPUqK57WPEFxesQoZEx0ZRzWHkscnk0ASXE8k7DzDkVFzn2oooAKKKKACiiigBR0NKvWkHQ0q9aAEPSkpT0pKACiiigAooooAKKKKAA89eaAAD8vFFFACodjblGG9aux6hLwsp3KPaqNKOnPSgDXjuoSMjr6VcjnGAEQ5PpXN4I5HSp4ruaNxskXA7UAdXZ/69TKCBnqK7S08rYpEyj/f4rzO11lVyLuASDPYkGtqHxFpqgLDHPC3+0Bj+dAHfLe29lta2EUcic7g5OfzrQ0zx7rlr5iWV/FHuHO6NT/SvNP7c09oOXw5oh1OCNCUmAPtQB6Vc+P9aikEkksU8g6MFAx+GKnT4leJLqMxvcxiFvvDy1z/ACryj+0TLJxIjD/a4/lV63vTGD88eD2U0Advc61DJztTzD1bJpsGqQxTLNiIsO241wck1uz7m37vap4Nbt7cFXKAe55oA9Hu/FklxCIpXEUB5IwMH8etEHiTKeXbTQsv+wcn9RXmN3rsDrsMiqp55qxper6bbqS93GD/ALJzQB3Euqq0wWT53zxitOLSLjV4yVubaONTjDMc5/KvKbjxTp8aK1tFcyTI2SZVA/kaib4g63GJI7G4W3iYgt8inIx05BoA9U1TSk0a3WS9uFSBuBJ/DXFa7r+h2SPHBP8Abm9YDkH88VwF9rF9qMUcd/MWVDuwVAz+X1rOVNqgBSp9F5/nQBsXviC7mysTLHCeiAAmshyXZmcbmIxmlJz6f1oxQA1RhQDzil6dKWkoAKKKKACiiigAooooAUdaFPNC9aVR81ADEpT1pEpT1oAKKKKAA9KUZx1oAzSAAYJyB6UAAJPWitXUdEubLSNP1GXb9mvVdkxnI2sVOfxFZRxuIUhsenegAowD1q5o2nXOsarb6dYJ5lzO+xB6nGahuYHt5nicjepwQPWgCIgkdcCkwMj2rV8OaPPrV69tCuCqGQs3TAIH9aZd20UMLNGSVHAoAzv4j70DPepLaFp7iGBR88rYUepq94h0e40LVLiwuwDPBt3beQdyhhj8DQBm85yOtGcnnrSN0OOSPStV9IkHhyHWBg20snlqR1zz/wDEmgDKoNHdh3H61agspZbGa8UD7PC4RmPYkZoAgVnXlaeLiUfx4/CovTPGQSM9+at6TYy6lqNtZQELNcPsQPwM0AQm6l4O/p7VG5JbaTknmrGp2klhdPbzsvmrjKiq0hySeFU8bvT60AAx1NK3IrW1DRvsWh6Xf7sxXiOy+vyuV/pWT0NADQOMUY4qW1he5u4oIhmSQ7VHvVvW9Mn0jUprG7KefFjftPAyAR+hoAz6UY/GkzyRg8Vp3GkXEGgWurSKPs1yxVMdcgkf0NAGa3J4pKcflYr3FWYdPnm02W+jANvFKIWb/aIJA/IGgCqKVgBTScZyMYrR0DS5da1OOxtWTzpPu7iQKAM6inMpXOfw96Tjsc4647UAJSgFjtAznjijBpsg3LtZvl6/T2oA37nw3LaS+TqF/Y204+8k7sODz2Wo4/D7zwTyWuoWNzJBEZHSF2J2ZAJ5UdyK6Lx9pl5q3iK5u9NtXuIHVFEsZypwoBxn3FUvDml3mmrrU1/ayWqS6a8Kl8csXQ4/Q0Aci25CQwIPvSoaRmQudg+XsfWlTGaAGJSnrSJSnrQAUUUUAKBkgE4pmQyEseW/lTqXPOe+MfhQB2l9rFhrHhiz0mS5itTYy/JJKSFKtuY4xnnLVgGLSHmZXu7zkjcXjUBhjtg1lKdvT0xQDgD2oA6jwtq+neHdet9Xia+luLY7o8xpjPvz0qHWBot3dzXEN3KIgBtjCgknA6eo69e9c51JPc0uTkEdV5FAHVeFdY0jw5em6tBeySvGYTuRcDJB9faoS9rM+L7zUgfguAMj9a5pOM+9WHuWZGRjlW68UAatidEtNQime4vpPLcOFEaYOPxrT8X6nY+JNVbWJ7rynmUB0jAMuVAUZHTGB61yJYknmm+vv1oA17L+w450edr54QcYVF6fnW8dV0q48NroMF1cW8EEwuA90irk4b0J/vGuLJJOT1pBwMDpQBpNFo6MB51+2DwRGvP61uaLe6TDoepaQk8ym7XfHNcKFWNxgZ4J7Z7VySnaQV4IORSDhSo6GgDfgi0CG5k+3zXcyqNzeWq4k+hyKvxXnh/TtXi1Cx+2sYiHihCqdh/2iW6dfWuRFA4AHYUAdh4rn07W9Xlvkv1iE21miUZfAAXGDxnj1rD8jR2id3ur3lh8vlp0x9azDyMGjcc579KAO11DWbLWPDVnoyXK25tJT5MlyNoKNuZumf4jXOzQ6VE5826u3KnJeGNSh49SQay1+Vdo6Uo4bd3oA3NOudG0+8tbuOS/MsMgcB40Azg+9avi/UNH8Q341NZ5UldcTrgZ3Dhe/wDdFcfmgnJyaANAR6ORmSbUP+ARof5muki1LSdQ8LW2hvdTwJbXHmRvcqqllIYnoT3auKIB60Hr+GKANRo9HSNE87UBIoO6QRoU6/X+la2nX+lR+Gr7SIZJUS5PniS5AUCVflH3SexNcoBwB2FKTksT1brQBsxR6NFG0V1NcyXRIImiUFVGOnJH8q2fCWuaF4bvrbUI01Ke8ifJaSNAuOfRq431z3pT1J7kYNAG9rMekyX811Fes9u5HlxQgNIvHOQeOue9Zd2tgIibKW7kk3Dd5iKE6eoOc1UIBBB6EYoPJBzzjFACYNKCeM/QA9CaTmnKSDkdaADJwF+8g+YAE8UAsFMYkLDr+NJjAGO3IpDyu3tQAoI/hzjsD2pU60AknmlUndQBGlOINRIR608svHNADiKSmlgSOadQAUUUUAFFFFABSg4pKKADqaXgCkooAKKKKACigdaU9KAEooooAKKKKACiiigAooooAdx60U2lXrQAtNPWnU09aACjmgdadQAg96Xj1pDSUAFFFFABSjpSUUAONNoooAVetKv3qRetKv3qAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view from a two-dimensional echocardiogram shows a massive pericardial effusion (PE) surrrounding the right ventricle (RV), left ventricle (LV), and extending behind the left atrium (LA). The patient had severe hemodynamic compromise and tamponade physiology.",
"    <div class=\"footnotes\">",
"     Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19918=[""].join("\n");
var outline_f19_28_19918=null;
var title_f19_28_19919="Rx sexual dys in uremic men";
var content_f19_28_19919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Approach to sexual dysfunction in uremic men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 446px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Palmer, B. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10:1366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_28_19919=[""].join("\n");
var outline_f19_28_19919=null;
